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Thyroid hormone (TH) and glucocorticoid (GC) play critical roles in animal 
development and physiology, particularly the development and function of the central 
nervous system (CNS). These hormones exert their actions by binding to nuclear 
hormone receptors (NRs) that function as ligand-activated transcription factors. 
Cooperative, synergistic gene regulation by NRs is an important mechanism to amplify 
gene expression cascades initiated by hormones during animal development. A good 
example of synergy between TH and GC in development is the acceleration of tadpole 
metamorphosis caused by the synergistic actions of these two hormones. In my 
dissertation work I studied the regulation by TH and GC of Krüppel like factor 9 
(Klf9/Basic Transcription Element Binding Protein 1; Bteb1), a transcription factor 
expressed in the CNS that plays an important role in neuronal development and plasticity. 
The protein product of the Klf9 gene is a member of the Sp1/KLF family of zinc finger 
transcription factors that bind to short genomic sequences that are rich in guanine and 
cytosine nucleotides. In prior work Klf9 was found to be a direct TH receptor (TR) target 
gene. I showed that Klf9 is also directly targeted by the GC receptor (GR), and that 
together TH and GCs cause synergistic induction of Klf9. I also found that this form of 
regulation is phylogenetically ancient; that it was likely present in the earliest tetrapods 
and has been evolutionarily conserved from frogs to mammals. I identified a genomic 
region in the 5’ flanking region of the Klf9 gene that confers synergistic gene regulation 
xvi 
 
by TH and GC (I named this region the ‘Klf9 synergy module’). The Klf9 synergy 
module contains five hexanucleotide NR binding sites, three of which form a composite 
TR/GR response element required for synergistic gene activation. The synergistic effect 
of TH and GC on Klf9 is explained, in part, by a TR-dependent increase in the 
recruitment of the GR and enhanced association of stalled RNA polymerase II at the Klf9 
synergy module, and an interaction between the synergy module and the Klf9 promoter 
by chromosomal looping. I also conducted a genome-wide microarray analysis to identify 
genes that are synergistically regulated by TH and GC in mouse hippocampus-derived 
neurons. This is the first study to investigate transcriptional targets that are coordinately 
regulated by TH and GC in the brain. 
Lastly, my work demonstrated a role for KLF9 in regulating expression of TR 
during tadpole development. I found that KLF9 acts as an accessory transcription factor 
to support TH-dependent expression of TRβ (autoinduction), a gene regulation process 
that is necessary for the progression of amphibian metamorphosis, and normal 
mammalian brain development. Given the synergistic regulation of the Klf9 gene by TR 
and GR, and its role in TRβ autoinduction, my findings support that KLF9 is an 
important intermediate that functions to integrate TH and GC actions, in part by 
enhancing the sensitivity of a cell to hormonal signals. Taken together, my thesis 
broadens our understanding of the molecular mechanisms of NR cooperativity and 
autoinduction, with important implications for animal development. 
 
 
A version of parts of this chapter was published in Bagamasbad, P. and R.J. Denver, 
Mechanisms and significance of nuclear receptor auto- and cross-regulation. Gen Comp 













Thyroid and steroid hormones are powerful signaling molecules that play crucial 
roles in animal development, particularly development of the nervous system. One of the 
first discovered developmental actions of thyroid hormone (TH) was its role in 
controlling amphibian metamorphosis. Thyroid hormone has been shown to play a role in 
the development of all chordates that have been studied thus far. In the developing brain, 
TH shapes neuronal morphology and function, influencing dendritic arborization, 
neuronal differentiation, cell migration, cell proliferation, myelination, and 
synaptogenesis (Rami, Patel et al. 1986; Rami, Rabie et al. 1986; Gould, Allan et al. 
1990; Rami and Rabie 1990; Madeira and Paula-Barbosa 1993; Gilbert and Paczkowski 
2003). Lack of TH during critical periods of early human development leads to a 
condition of severe mental and growth retardation known as cretinism (Porterfield and 
Hendrich 1993).  
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Glucocorticoids (GCs) are steroid hormones produced in response to stress. 
Glucocorticoids play central roles in an organism’s survival, and in physiological and 
behavioral responses to stress. Stress hormones can either accelerate or retard 
development depending on the developmental stage at which they become elevated, and 
are known to be important for determining the timing of birth, and hatching and 
metamorphosis in diverse vertebrate species (Amiel-Tison, Cabrol et al. 2004; Crespi and 
Denver 2005; Denver 2009). The brain is a primary target of GCs during development, 
where they alter neuronal morphology and function, and strongly impact learning and 
memory in adults (McEwen 2008). In juveniles and adults, stress hormones can have 
both positive and negative effects on the brain depending on the type and context of the 
stressor (Joels 2008). Chronic stress leads to atrophy of neurons and impairs performance 
in cognitive tasks, while acute stress may enhance memory consolidation and 
reconsolidation (Watanabe, Gould et al. 1992; Roozendaal and McGaugh 1996; 
Roozendaal, Portillo-Marquez et al. 1996; Magarinos, Verdugo et al. 1997; Magarinos, 
Orchinik et al. 1998; McEwen 1999; Shors 2001; Shors, Chua et al. 2001; Beylin and 
Shors 2003).  
Glucocorticoids and TH exert their actions on animal development by binding to their 
cognate nuclear hormone receptors (NR) which function as ligand-activated transcription 
factors to induce gene regulation programs. A gene that we found to be a common target 
of GC (GR) and TH (TR) receptor is Krüppel-like factor 9 (Klf9; a.k.a. basic 
transcription element binding protein 1 - Bteb1) ((Denver, Ouellet et al. 1999; Hoopfer, 
Huang et al. 2002; Bonett, Hu et al. 2009), Chapter 2). Krüppel-like factor 9 functions in 
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neuronal process formation in the developing frog and rodent brain, and may integrate 
GC and TH-dependent signaling pathways to influence neuronal morphogenesis (Denver, 
Ouellet et al. 1999; Cayrou, Denver et al. 2002; Morita, Kobayashi et al. 2003; Bonett, 
Hu et al. 2009; Scobie, Hall et al. 2009). 
The following thesis introduction focuses on the molecular mechanisms of NR action 
in animal development and physiology. Emphasis is placed on the modulation of GC and 
TH signaling through autoregulation of their cognate NRs, and cooperativity between 
NRs and other constitutively active transcription factors in the regulation of common 
target genes. Portions that focus on NR autoregulation have been published as part of a 
review paper by Bagamasbad and Denver, 2011 (Bagamasbad and Denver 2011).  
 
2. Nuclear Hormone Receptor Superfamily 
 
The NR superfamily can be divided into two types based on evolutionary relatedness, 
cellular localization and receptor function. Type I NRs include the steroid hormone 
receptors: androgen (AR), estrogen (ER), GR, mineralocorticoid (MR) and progesterone 
(PR) receptor. In the unliganded form, type I NRs are localized to the cytoplasm 
associated with molecular chaperones (e.g., heat shock proteins- HSP90, 70, 40) that 
keep the receptors in an inactive but ligand-binding conformation. Upon hormone 
binding, type I NRs change conformation and are released from the chaperone complex. 
They then associate with co-chaperones (FKBP52, PP5) that facilitate translocation to the 
nucleus (Pratt, Galigniana et al. 2004) where they associate with DNA at hormone 
response elements (HRE) (Fig. 1.1A) (Mangelsdorf, Thummel et al. 1995; Germain, 
Staels et al. 2006). Type II NRs include TR, Vitamin D (VDR), retinoic acid (RAR), 
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peroxisome proliferator-activated (PPAR) and retinoid X (RXR) receptor. In contrast to 
type I NRs, type II NRs are located in the nucleus constitutively bound to DNA, and they 
usually act as transcriptional repressors in the absence of hormone (Fig. 1.1B). There are 
other types of NRs called orphan nuclear receptors since only candidate ligands or no 
ligands have been identified thus far (Mangelsdorf, Thummel et al. 1995; Ribeiro, 
Kushner et al. 1995; Aranda and Pascual 2001; Germain, Staels et al. 2006)) . 
All NRs exhibit a modular structure composed of different functional domains. A 
typical NR has six functional domains, designated A-F from the amino to the carboxy 
end of the protein (Fig.1.2). The A/B domain is highly variable in sequence and size, and 
has both ligand- dependent and independent activation function (AF-1). The C domain is  
the DNA binding domain (DBD) composed of two highly conserved zinc finger motifs 
that enables the NRs to bind to HREs. The D domain is highly variable among NRs and  
functions as a hinge between the DBD and ligand binding domain (LBD). The LBD is 
located in the E domain which is also responsible for NR dimerization, ligand- dependent 
transactivation function (AF-2) and association with heat-shock proteins (for Type I NRs) 
(Germain, Staels et al. 2006). The AF-2 domain of NRs is responsible for interaction with 
coactivators that have a NR box (LXXLL motif, where X is any amino acid). Domain F, 
which is highly variable, has yet unknown functions and is not present in some NRs such 











Fig.1.1. Nuclear hormone receptor superfamily. (A) Type I NRs include the steroid 
hormone receptors:   androgen (AR), estrogen (ER), glucocorticoid (GR), 
mineralocorticoid (MR) and progesterone (PR) receptor. In the unliganded form, type I 
NRs are localized to the cytoplasm associated with molecular chaperones (e.g., heat 
shock proteins- HSP90, 70, 40) that keep the receptors in an inactive but ligand-binding 
conformation. Ligand binding induces allosteric changes that allow the Type I NRs to 
translocate into the nucleus and recognize specific hormone response elements (HREs) of 
their target genes.  (B)Type II NRs include thyroid hormone (TR), Vitamin D (VDR), 
retinoic acid RAR), peroxisome proliferator-activated (PPAR) and retinoid X (RXR) 
receptor.  Type II NRs are bound to DNA in the unliganded state and undergo an 
exchange in association of coregulators upon hormone binding. The ligand bound NRs 
recruit coactivators, some of which possess enzymatic activities to modify chromatin 




3. Transcriptional Regulation by Nuclear Hormone Receptors 
 
Nuclear hormone receptors regulate gene transcription by directly binding to DNA or 
by protein-protein interactions, with direct DNA binding as a more common mechanism 
of gene targeting. The NRs activate gene regulation programs that include primary, 
secondary and tertiary responses. These responses are distinguished by the kinetics of 
gene regulation, with early responses generally representing direct regulation of a target 
gene by the NR. Secondary and tertiary responses are mostly due to the protein products 
of the primary response genes, many of which are transcription factors (TFs).  
Transcriptional regulation by NRs is a multistep process that begins with binding of 
the hormone to its cognate NR. For Type I NRs, ligand binding induces allosteric 
changes that exposes the nuclear localization signal and allows the NR to translocate into 
the nucleus and recognize specific DNA sequences in target genes. In contrast, Type II 
NRs are bound to DNA in the unliganded state and undergo an exchange in association of  
coregulators upon hormone binding. The ligand bound NRs recruit coactivators, some of 
which possess enzymatic activities to modify chromatin architecture to promote a  
transcriptionally active environment. This ultimately results in the recruitment of RNA 
polymerase II (Pol II) and the general transcription factors (Roeder 2005; Wolf, Heitzer 












Fig 1.2. Nuclear hormone receptor functional domains . The A/B domain is highly 
variable in sequence and size and has both ligand dependent and independent activation 
function (AF-1). The C domain is the DNA binding domain (DBD) composed of two 
highly conserved zinc finger motifs that enables the NRs to bind to HREs. The D domain 
is highly variable among NRs and functions as a hinge between the DBD and ligand 
binding domain (LBD). The E domain is the LBD that mediates ligand binding, NR 
dimerization, transactivation function (AF-2) and association with heat-shock  proteins 
(for Type I NRs) (Germain, Staels et al. 2006). The AF-2 domain of NRs is responsible 
for interaction with coactivators that have a NR box (LXXLL motif, where X is any 
amino acid). Domain F is highly variable, has yet unknown functions and is not present 




3.1 Nuclear Hormone Receptor-DNA Interaction  
 
 Nuclear receptors bind as dimers to HREs of target genes which are composed of two 
hexanucleotide half sites separated by short spacers. Although more attention has been 
given to HREs that promote transcription upon ligand-NR activation, there are also well 
characterized negative HREs that repress transcription when associated with ligand-
bound NR (Santos, Fairall et al. 2011). Hormone responsive elements are identified 
according to their sequence motif, orientation and length of spacer between half sites. 
Type I NRs mainly function as homodimers that recognize degenerate HREs with 
palindromic half sites separated by three nucleotide spacers. The GR, MR, AR and PR 
bind to half sites with the consensus sequence 5’AGGACA 3’ while the ER recognizes a 
consensus sequence of 5’AGGTCA 3’. Type II NRs bind with higher affinity as 
heterodimers with RXR than as homodimers and recognize HREs of inverted, everted, 
palindromic and direct repeat (DR) half sites of 5’AGGTCA 3’ separated by 1-5 
nucleotide spacers (DR+ 1-5 repeats) (Mangelsdorf, Thummel et al. 1995). The length of 
the spacer between these DRs is an important determinant of which Type II NR is bound. 
For example, TR-RXR heterodimers preferentially bind  DR+4 repeats (Naar, Boutin et 
al. 1991; Umesono, Murakami et al. 1991).   
 
3.2 Transcriptional Activation by Nuclear Hormone Receptors 
 
The NRs influence gene transcription by first binding NR target genes, then 
interacting with nuclear proteins leading to the recruitment of coregulators that promote 
posttranslational modifications of chromatin. Nuclear receptor coactivators can be 
classified into three general classes: histone modifying enzymes (e.g histone 
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acetyltransferases - HATs; histone methyltransferases - HMT; ATP-dependent chromatin 
remodelers - SWI/SNF family) and complexes that interact with the basal transcription 
machinery (Mediator complex, TRAP/DRIP)   (Aranda and Pascual 2001).  
3.2.1  Histone Modifying Coactivators.  
The best characterized HAT coactivators, and the first to be recruited upon hormone 
binding of Type I and II NRs are members of the p160 family (Vo and Goodman 2001; 
McKenna and O'Malley 2002). Members of this protein family include the steroid 
receptor coactivator 1 (SRC-1), SRC-2 (also known as transcriptional 
mediator/intermediary factor 2 - TIF2) (Voegel, Heine et al. 1996) or GR interacting 
protein 1 (GRIP1 (Hong, Kohli et al. 1997)), SRC-3 (also known as receptor-associated 
coactivator 3 - RAC3) (Li, Gomes et al. 1997), ACTR (Chen, Lin et al. 1997), p300/CBP 
interacting protein  (pCIP, (Torchia, Rose et al. 1997)) and TH receptor activator 
molecule (TRAM-1, (Takeshita, Cardona et al. 1997)).  The p160 proteins interact with 
the ligand-bound NR LBD through a highly conserved LXXLL motif (NR box, where X 
is any amino acid) located within the NR interacting domain (RID) of the p160 proteins. 
The SRCs also have a highly conserved activation domain 1 that binds p300/CBP. 
Another conserved activation domain 2 has been shown to interact with the HMTs, 
coactivator associated arginine methyltransferase 1 (CARM1, (Koh, Chen et al. 2001)) 
and protein arginine methyltransferase (PRMT 1,(Bedford 2007)). SRC-1 and SRC-3 
have also been shown to possess an intrinsic HAT activity (York and O'Malley 2010). 
SRC-1 may associate with the basal transcription machinery through TFIIB and TATA-
binding protein (TBP) to promote transcription (Robyr, Wolffe et al. 2000). 
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Apart from the intrinsic HAT activity of some coactivators, a primary role for SRCs 
is to recruit other HATs, primarily  p300/CBP and p300/CBP associated factor (PCAF) to 
hormone regulated genes. Both p300/CBP and PCAF have also been shown to directly 
interact with NRs in a ligand-dependent manner (Chakravarti, LaMorte et al. 1996). The 
HAT activity of these coactivators acetylates lysines in histone tails to neutralize their 
charge and weaken histone-DNA interactions leading to chromatin decompaction and 
greater accessibility of DNA sequences to other transcription factors and RNA 
Polymerase II (Grunstein 1997; Kurdistani and Grunstein 2003).  
In addition to promoting histone acetylation, the SRCs recruit and interact with the 
HMTs, CARM1 and PRMT1. These HMTs catalyze the transfer of methyl group(s) from 
a methyl donor (S-andenosyl-L methionine) to arginine or lysine residues of histone 3 
(H3) or 4 (H4). However, unlike histone acetylation that is associated with transcriptional 
activation, histone methylation can lead to activation or repression depending on which 
histone residues are methylated. For example, PRMT1- and CARM1-mediated 
methylation of H3 at arginine 2, 17 and 26, and lysine 4, 36 and 79 correlates with 
transcriptional activation; whereas, methylation of H3 at lysine 9 (dimethylation) or 27 
(trimethylation) correlates with repression of transcription (Wu and Zhang 2009). The 
precise mechanisms by which histone methylation regulates NR-dependent transcription 
are poorly understood. One proposed mechanism was recently discovered in Xenopus 
where PRMT1 was found to be a coactivator for liganded TR that functions in enhancing 
TR binding, transcription of TR target genes and TH dependent- metamorphosis 
(Matsuda, Paul et al. 2009). Studies conducted in vitro showed that histone methylation 
promotes NR-dependent transcription through recruitment of p300 and subsequent H4 
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acetylation (Wang, Huang et al. 2001). Another study found CARM1 to be associated 
with the nucleosomal methylation activator complex (NUMAC) that includes the ATP-
dependent chromatin remodeler BRG1 (Xu, Cho et al. 2004). 
3.2.2  ATP-dependent Chromatin Remodeling Complex.  
In addition to histone modifying enzymes, the SWI/SNF family of ATP-dependent 
remodeling complexes have been shown to be necessary for, and to promote NR-
dependent transactivation (Trotter and Archer 2007). The vertebrate SWI/SNF complex 
is a multiprotein complex that uses energy derived from ATP hydrolysis to disrupt DNA-
histone interactions, thereby promoting nucleosome eviction and disassembly, and 
enhanced transcription. The SWI/SNF complex includes a DNA-dependent ATPase 
called Brahma (BRM) or Brahma-related gene 1 (BRG-1) and its associated factors 
(BAFS) (Nie, Xue et al. 2000; Eberharter and Becker 2004). The role of BRG-1 in 
steroid-mediated transcription was established using the steroid responsive mouse 
mammary tumor virus (MMTV) promoter and the GR (Archer, Lefebvre et al. 1992). The 
MMTV promoter is a widely used model for steroid-dependent chromatin remodeling 
since, when integrated into chromatin, it acquires a highly organized structure where the 
long terminal repeats of the promoter are arranged into an array of 6 nucleosomes (A-F) 
(Richard-Foy and Hager 1987). Nucleosome A-B contains multiple GREs and binding 
sites for other transcription factors (e.g., nuclear factor-1 - NF-1, octamer transcription 
factor - OTF, TATA box binding protein - TBP) (Richard-Foy and Hager 1987; Archer, 
Lefebvre et al. 1992). Studies have shown the requirement for BRG-1 in GR-mediated 
remodeling of the MMTV promoter, and also for native promoters, such as the 11β 
hydroxysteroid dehydrogenase promoter which is regulated by GCs and has binding sites 
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for the GR (Trotter and Archer 2004). BRG-1 was also found to play a role in AR, TR 
and PR-mediated chromatin remodeling of the MMTV promoter (Fryer and Archer 1998; 
Fryer, Nordeen et al. 1998; Huang, Li et al. 2003), and for ER-mediated transcriptional 
activity of a vitellogenin promoter containing an estrogen response element (Chiba, 
Muramatsu et al. 1994; Kinyamu and Archer 2004; Trotter and Archer 2007).  
The SWI/SNF complex is also important for gene regulation by Type II NRs. For 
example in frogs, BRG-1 expression is increased during metamorphic climax and, 
together with its associated factor BAF57 was shown to enhance transcription of liganded 
TRs (Heimeier, Hsia et al. 2008). The SWI/SNF complex has also been shown to be 
necessary for RAR/RXR and VDR/RXR-dependent transcriptional activation (Trotter 
and Archer 2007). 
3.2.3  Mediator Complex.  
The final step in NR-mediated transcriptional activation is the recruitment of Pol II 
and the general transcription factors to form the preinitiation complex (PIC) at gene 
promoters. In NR-regulated genes, recruitment of Pol II depends on a protein complex 
known as the TR associated protein (TRAP) complex (also known as the SRB- and 
MED-containing cofactor complex - SMCCcomplex) (Ito, Yuan et al. 1999). The TRAP 
complex is a large multisubunit complex initially found to associate with TR at TH 
response element (T3RE) in a ligand-dependent manner, and functions to enhance TR-
dependent transcription (Fondell, Ge et al. 1996; Fondell, Guermah et al. 1999).  A 
second TRAP-related complex was later identified to function with the VDR and was 
named the VDR-interacting complex (DRIP) (Rachez, Lemon et al. 1999). Both the 
TRAP and DRIP complexes are homologous to the yeast Mediator complex that is 
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known to directly recruit and interact with Pol II at gene promoters (Fig1.3; (Myers and 
Kornberg 2000)). In addition to being necessary for TR and VDR function, the 
TRAP/DRIP complexes have been shown to interact with RXR, PPARs, ER and GR in a 
ligand-dependent manner to enhance NR mediated transcription(Yuan, Ito et al. 1998; 
Hittelman, Burakov et al. 1999; Llopis, Westin et al. 2000; Chen and Roeder 2007). 
Among the many proteins that make up the TRAP complex, a 220 kDa subunit 
(TRAP220/DRIP205/MED1) contains two LXXLL motifs that directly associate with the 
AF2 domain of NRs in ligand-dependent manner. The physiological significance of the 
TRAP220/MED1 during development was shown in the TRAP220/MED1 knockout 
mouse that only survives until PND 11.5 and displays defects in NR mediated pathways 
(Ito, Yuan et al. 2000). The association of the TRAP/DRIP complexes with NRs is 
hypothesized to occur after the ligand-dependent recruitment of SRCs, p300/CBP and 
PCAF, and thus constitutes a final step in NR-mediated transcriptional activation (Fig. 
1.3) (Ito and Roeder 2001).  
Earlier studies in yeast showed that the Mediator complex is mostly recruited to gene 
promoters (Malik and Roeder 2010). More recent functional analyses conducted in mouse 
embryonic stem cells and fibroblasts from TRAP220/MED1 knockout mice demonstrate 
that the Mediator complex (i.e TRAP220/MED1 in TR dependent gene expression) plays 
a role in linking NR bound enhancers to gene promoters through chromosomal looping 
(Park, Li et al. 2005; Kagey, Newman et al. 2010).  
3.3 Transcriptional Repression by Nuclear Hormone Receptors 
 
Type II NRs are constitutively bound to HREs of target genes. In the absence of 
ligand, Type II NRs repress gene transcription by recruiting co-repressors. Type II NRs 
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can also regulate gene transcription in a ligand-dependent manner, although this is less 
common (discussed below). Therefore, Type II NRs have a dual function in that they 
repress or activate gene transcription in the absence or presence of ligand, respectively. 
Nuclear hormone receptor co-repressors, that were originally identified to interact with 
Type II NRs but have since been shown to also participate in type I NR function include 
the nuclear receptor corepressor (NCoR) and the silencing mediator of retinoic acid and 
TH receptor (SMRT). These proteins interact with NRs and recruit histone deacetylases 
(HDACs) that catalyze the deacetylation of lysine residues in histone tails, thereby 
promoting a compact chromatin structure that represses transcription (Germain, Staels et 
al. 2006) 
 A dual function model for Type II NRs, where the NR functions to repress or activate 
gene transcription during different developmental periods, was first proposed for TR 
actions in Xenopus and is hypothesized to play an important role in controlling tadpole 
metamorphosis. In this model, the unliganded TR represses expression of adult genes in 
the tadpole prior to the onset of metamorphosis, at which time TH production increases to 
activate gene regulation programs that drive organogenesis and tissue remodeling (Shi 
2009). The repressor function of unliganded TR and its significance during 
developmental transitions is also observed in mice, where TRα was found to repress the 
expression of genes involved in controlling heart function during fetal development when 
TH levels are low. At birth and during early postnatal life when TH levels start to 
increase, TRα loses its repressive functions and activates the expression of some of the 
previously repressed genes in parallel with stimulation of heart rate, suggesting that TRα  
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may act as a molecular switch in controlling the development of the heart at or around the 
time of birth (Mai, Janier et al. 2004).  
Type I and type II NRs can also repress transcription in a ligand-dependent manner. 
This can occur through direct binding of the NR to negative HREs (nHRE). For example, 
repression of the prolactin (PRL) gene by ligand-bound GR depends on a negative GRE 
(nGRE) in the PRL promoter (Sakai, Helms et al. 1988).  Ligand-bound TR has also been 
shown to downregulate the expression of thyroid stimulating hormone α (TSHα) and beta 
subunit (TSHβ) through negative T3REs located in the proximal promoters of these genes 
(Chatterjee, Lee et al. 1989; Wondisford, Farr et al. 1989). Ligand-bound NRs recruited 
to a nHRE repress transcription through several mechanisms that include competitive 
binding with other coactivators at the nHRE, or recruitment of corepressors rather than 
coactivators by the NR when ligand is bound  (Santos, Fairall et al. 2011).   
Transcriptional repression by ligand-bound NRs can also occur independent of DNA 
binding through protein-protein interactions. For example, ligand-bound GR tethered to 
the NF-κB or AP1 transcription factors can confer negative regulation by GCs (De 
Bosscher, Vanden Berghe et al. 2003). Repression by the ligand-bound NR may also 
occur by squelching, whereby the positive actions of NRs on some genes causes 
sequestration of the limiting components of the transcriptional machinery, leading to 
downregulation of other non-NR regulated genes. Ligand-bound NRs can also repress 
gene transcription as a secondary effect of an upregulation of a repressive TF or 








Fig. 1.3. TRAP/DRIP/ Mediator complex. The large multi subunit TR associated 
protein (TRAP)/ VDR-interacting complex (DRIP) complex (also known as the SRB- 
and MED-containing cofactor (SMCC)) is recruited to ligand- activated NR coactivator 
complex.  Both the TRAP and DRIP complexes are homologous to the yeast Mediator 
complex that is known to directly recruit and interact with general transcription factors 
(GTF) and RNA Pol II at gene promoters. The association of the TRAP/DRIP complexes 
with NRs is hypothesized to occur after the ligand-dependent recruitment of SRCs, 















3.4 Other Modes of Transcriptional Regulation 
 
In addition to directly binding to HREs, NRs can modulate gene transcription through 
cooperation with other TFs. A well-studied example is the interaction between TR, RAR 
or GR, and the TFs Fos/Jun at AP-1 binding sites, a highly-conserved enhancer-like 
element recognized by the Fos and Jun family of TFs (Zhang, Wills et al. 1991; Lopez, 
Schaufele et al. 1993; Wondisford, Steinfelder et al. 1993; Benkoussa, Brand et al. 2002; 
De Bosscher, Vanden Berghe et al. 2003; Kassel and Herrlich 2007). Ligand-bound NRs 
are able to repress AP-1 activity, and reciprocally, AP-1 complexes can act as 
transrepressors of NR function. Interaction between NRs and other TFs may involve: (1) 
composite DNA elements that bind both the NR and another TF; (2) overlapping 
response elements wherein the NR and another TF compete for the same binding site, and 
(3) protein-protein interactions where the NR directly or indirectly interacts with another 
TF without binding to DNA. The interaction that occurs between NRs and other TFs can 
lead to positive or negative gene regulation, and in some cases the actions may be 
synergistic such that the combined effect of the interacting TFs is greater than the 
additive effect (Ribeiro, Kushner et al. 1995; Aranda and Pascual 2001; Kassel and 
Herrlich 2007). The importance of interaction between NRs and other TFs is 
demonstrated by findings in a GR knock-in mouse where the wild type GR was replaced 
by a mutant GR incapable of receptor dimerization and DNA binding (Reichardt, 
Kaestner et al. 1998). Whereas, knocking out the GR was embryonic lethal, the GR 
dimerization/DNA binding mutant mice were viable, but with defective GC-dependent 
physiological functions (Reichardt, Kaestner et al. 1998). These findings suggest that the 
life-sustaining actions of GCs mediated by the GR do not depend on the DNA binding 
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function of the GR, but instead may reflect an important role for GR interactions with 
other nuclear proteins.    
 
4. Nongenomic actions of Steroid and Thyroid Hormones 
In addition to their nuclear actions, TH and steroid hormones have rapid effects on 
physiological processes that are too fast to be mediated by classical genomic 
mechanisms. Rapid signaling by steroid hormones, that occur within seconds to minutes, 
are mediated by membrane-associated Type I NRs and G-protein coupled receptors that 
activate several protein kinases (i.e  MAPK, phosphotidylinositol 3-kinase [PI3K], and 
protein kinase C [PKC]), phosphatases, several cyclic amines (cAMP, cGMP) and the 
release of calcium from cells. The activation of these signaling cascades leads to 
posttranslational modification of nuclear proteins that include the classical NRs and NR 
coactivators (Hammes and Levin 2007). Posttranslational modification of NRs and their 
coactivators may augment the transcriptional function of the nuclear NRs and may 
account, at least in part, for the rapid hormone effects. Signaling from membrane 
localized NRs and GPCRs also occurs independent of the transcriptional activity of the 
nuclear NR (Losel, Falkenstein et al. 2003; Hammes and Levin 2007).  
Another mechanism for the rapid effects of TH may be via the αvβ3 integrin plasma 
membrane receptor which has binding domains for TH. Hormone activated αvβ3 integrin 
can initiate TH-directed MAPK, PI3K and phospholipase C signaling. The hormone-
activated kinase cascade also targets the TR for phosphorylation leading to enhanced 
transcriptional activity of the nuclear TR. Nongenomic TH actions may also be mediated 
by the TH-dependent modulation of ion channel function, membrane calcium ATPase 
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and protein kinase A activation. The TRβ was also detected in the cytoplasm in complex 
with TH, and has been shown to interact with PI3K signaling proteins leading to 
downstream gene transcription (Cheng, Leonard et al. 2010). 
 
5. Modulation of Nuclear Hormone Receptor Signaling 
 
Multiple extracellular signals and cellular factors determine whether, and to what 
extent a cell responds to a hormonal signal. First, the cell must express the NR at a 
sufficient level to mediate the hormone response. Variation in NR expression levels in 
part determines the responsiveness of a cell to a hormone. The presence of other 
hormones, or the degree of activation of other signaling pathways, and crosstalk between 
these pathways also play crucial roles in determining a cell’s response to a hormone. 
Crosstalk is a general term that refers to one signaling pathway enhancing or opposing 
the activity of another signaling pathway. Although there are several mechanisms for 
crosstalk among different hormone signaling pathways (Bagamasbad and Denver 2011), 
the following section will primarily focus on the physiological significance and 
molecular mechanisms of three phenomena: (1) how hormones regulate the expression of 
their own receptor (autoregulation, Fig.1.4; in contrast to one NR regulating the 
expression of another NR, or cross-regulation; see Fig. 1.5), (2) how a NR cooperates 
with another  NR to regulate a common target gene, and (3) how a NR cooperates with 
constitutively acting TFs to regulate gene expression. The interactions described in (2) 
and (3) are commonly referred to as ‘cooperativity’, and in some cases, these cooperative 
interactions lead to synergistic transcriptional activation. Transcriptional synergy 
between TFs can be defined as a greater than additive effect of two or more TFs in gene 
regulation (Bonett, Hoopfer et al. 2010). In the following section, emphasis will be 
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placed on mechanisms of signaling by GCs and TH; other hormone systems will be 
discussed based on their significance for understanding generalizable molecular 
mechanisms. 
5.1 Nuclear Receptor Autoregulation 
 
 The regulation of the expression of a NR gene by the liganded NR (autoregulation) is 
an important means for modulating hormone action in developing animals, within the 
reproductive system of adult animals, and for maintaining homeostasis. Autoregulation of 
NR genes can be positive (autoinduction; i.e., homologous upregulation) or negative 
(autorepression; homologous down-regulation). Autoinduction leads to the biosynthesis 
of more NRs by the cell, thus enhancing cellular responsiveness to the hormone. 
Autorepression is a homeostatic mechanism to modulate hormone action by 
downregulating the receptor for the hormone.  
Nuclear hormone receptor autorepression may function as a component of negative 
autoregulatory feedback loops to maintain homeostasis. For example, the GR is 
expressed in the brain in limbic structures involved with fear and anxiety (amygdala, bed 
nucleus of the stria terminalis), and learning and memory (hippocampus), and in 
neurosecretory neurons that regulate the hypothalamo-pituitary-adrenal (HPA) axis. The 
GR plays a central role in mediating negative feedback on the HPA axis, but also may 
facilitate stress-related behaviors through feed-forward actions on limbic structures. A 
physiological means to limit negative feedback of GCs on the HPA axis once the system 
has returned to baseline, and to ‘reign-in’ the facilitating effects of GCs on fear and 
anxiety is to downregulate GR expression in the hypothalamus and limbic structures, 
respectively. Downregulation of GR expression by GCs has been described in mammals 
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and in frogs, and may be a more common form of autoregulation of the GR than 
autoinduction. The GR plays a central role in mediating negative feedback by GCs on the 
activity of the hypothalamic-pituitary-adrenal (HPA) axis (reviewed by (De Kloet, 
Vreugdenhil et al. 1998)). It is expressed in the hypothalamus and limbic structures (e.g., 
amygdala, bed nucleus of the stria terminalis, hippocampus) of the brain, and in the 
anterior pituitary gland. The GR mediates the negative feedback by GCs on the synthesis 
and release of corticotropin-releasing factor (CRF) from the hypothalamus and 
adrenocorticotropic hormone (ACTH) from the anterior pituitary gland (reviewed by 
(Yao, Hu et al. 2008; Denver 2009; Denver 2009). Glucocorticoid receptor expressed in 
these tissues is predominantly negatively regulated by GCs. For example, administration 
of GCs decreased GR protein and/or mRNA throughout the brain of rats and frogs 
(Sapolsky, Krey et al. 1984; Reul, Pearce et al. 1989; Holmes, Yau et al. 1995; Chao, Ma 
et al. 1998; Ghosh, Wood et al. 2000; Spencer, Kalman et al. 2000; Hugin-Flores, 
Steimer et al. 2004; Han, Ozawa et al. 2007; Yao, Hu et al. 2008). In rats, adrenalectomy 
increased GR protein in the hippocampus, hypothalamus, and cortex (O'donnell, Francis 
et al. 1995; Spencer, Kalman et al. 2000; Kalman and Spencer 2002) and GR mRNA in 
the hippocampus; the latter could be reversed by supplementation with GCs (Tornello, 
Orti et al. 1982; Reul, Pearce et al. 1989; Okret, Dong et al. 1991; Holmes, Yau et al. 
1995; Chao, Ma et al. 1998; Hugin-Flores, Steimer et al. 2004; Han, Ozawa et al. 2007).  
 Under physiological conditions, NR autoinduction is often observed when positive 
feedback within the neuroendocrine system increases hormone production, leading to a 
progressive rise in plasma hormone concentrations. Within hormone target tissues, NR 
autoinduction generates a feed-forward response that ends when the positive feedback on 
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hormone production is terminated. For example, during the mammalian ovarian cycle 
gonadotropins secreted by the pituitary gland stimulate estrogen production by the 
ovarian follicle, and rising plasma estrogen concentration causes positive feedback on the 
hypothalamo-pituitary axis. During the mid- to late follicular phase, when plasma 
estrogen titers increase, estrogen stimulates proliferation of uterine endometrial cells; 
estrogen action may be facilitated by the autoinduction of the ER in these cells, a feed-
forward response. These actions are terminated, and plasma estrogen concentration drops 
upon ovulation induced by the surge in plasma luteinizing hormone caused by the 
positive feedback signal of estrogen. Nuclear receptor autoinduction is also seen during 
animal development where it serves as a feed-forward mechanism to drive the 
developmental process. The most studied example of this phenomenon is amphibian 
metamorphosis, where rising plasma TH titers cause autoinduction of TRs in target 
tissues (Tata 2000).  
 There are several mechanisms by which NR expression may be autoregulated that can 
be broadly described as transcriptional or posttranscriptional (Fig. 1.4). At the 
transcriptional level, regulation can be either direct, where the ligand-bound NR 
associates with its own gene to positively or negatively regulate transcription, or indirect, 
where the NR induces expression of a transcription factor(s) that regulates transcription 
of the NR gene (Fig. 1.4 A,B). Both direct and indirect regulation may also occur, where 
the NR binds to and regulates expression of its own gene (demonstrated for ER, GR and 
TR), but full transcriptional regulatory activity depends on the induction of a 
transcription factor(s) that regulates transcription of the NR gene (cooperative regulation; 
Fig. 1.4C). At the posttranscriptional level, the NR may induce expression of genes that 
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influence mRNA stability  (i.e ER and GR) or protein stability via degradation (i.e GR) 
(Fig. 1.4 D,E,F; or perhaps also protein translation or protein bioactivity through 
posttranslational modifications).  
  One of the better understood examples of NR autoinduction and its biological 
significance is the autoinduction of the beta isoform of the TR (TRβ) that occurs during 
amphibian metamorphosis. The transformation of a tadpole into a frog is dependent on 
TH, and TH biosynthesis and secretion increases during metamorphosis reaching a peak 
at metamorphic climax (Denver 2009). The frog X. laevis, like all jawed vertebrates 
studied to date, has two TH receptor subtypes, TRα and TRβ encoded by four genes 
(TRαA and B, TRβA and B) owing to its pseudotetraploidy (Yaoita, Shi et al. 1990). The 
mRNAs for TR subtypes are detected at the time of hatching, and expression of TRα 
increases shortly thereafter to reach peak levels in the tadpole that are sustained through 
metamorphosis (Shi 2000). By contrast, after hatching TRβ mRNA expression is very 
low, but then rises in parallel with the elevation in plasma TH that occurs during 
metamorphosis, reaching a peak at metamorphic climax that coincides with maximal 
production of TH and a period of rapid tissue transformation (Shi 2000). Autoinduction 
of TRβ is also seen in X. laevis tissue culture cells (i.e XTC-2 and XL177), which has 
allowed for detailed investigations of response kinetics and molecular mechanisms of 





Fig. 1.4. Molecular mechanisms for regulation of nuclear receptor (NR) expression. 
The level of functional NRs in a cell can be regulated at transcriptional or 
posttranscriptional levels, or some combination of the two. (A) Direct transcriptional 
regulation involves the hormone (filled oval)–NR complex (NRA; shown as a 
homodimer, but type II NRs also function as heterodimers) directly binding to a hormone 
response element located within the nra gene that activates or represses its expression 
(for cross-regulation the NRA binds to and regulates a different NR gene). Some NRs 
may influence target genes through hormone response elements that are far upstream or 
downstream of the regulated locus. Also, some NRs regulate target genes through 
protein–protein interactions rather than by direct DNA binding. (B) Indirect 
transcriptional regulation involves the hormone–NRA complex inducing the expression 
of a gene that codes for a transcription factor (TF) that then positively or negatively 
regulates nra gene transcription (for cross-regulation the NRA regulates a TF that binds 
to and regulate a different NR gene). (C) Cooperative transcriptional regulation involves 
both direct and indirect transcriptional mechanisms shown in parts (A) and (B). (D) The 
NRA may regulate the expression of a gene that increases or decreases stability of 
the nra mRNA (for cross-regulation, the mRNA for a different NR gene). (E) Hormone 
binding to the NRA can stabilize it, thus increasing its half-life (t½). (F) The NRA may 
induce expression of a ubiquitin ligase that ubiquitinates (Ub) NRs in the cell (either the 
NRA or a different NR) and targets it to the proteasome for degradation. NR protein 


















 The patterns of TRα and TRβ expression in rat brain parallel those seen in the tadpole 
during metamorphosis. For example, TRα expression is high and relatively constant 
throughout late fetal and neonatal periods; whereas, TRβ expression is low at birth and 
shows a dramatic increase during the first 2 weeks postnatally that is coincident with 
rising plasma TH concentrations (Strait, Schwartz et al. 1990). The human TRβ promoter 
has two functional TREs that mediate transactivation in transient transfection assays 
(Suzuki, Miyamoto et al. 1994) (discussed below), but to our knowledge, the occurrence 
and significance of TRβ autoinduction during mammalian development has not been 
investigated. 
5.1.1 Molecular Mechanisms of TR Autoregulation. 
  Autoinduction of TRβ in the tadpole can be explained by the presence of TH 
response elements (TREs) located in the proximal promoter region of the gene (Ranjan, 
Wong et al. 1994); Machuca et al., 1995). The proximal TRβA promoter of X. laevis 
contains three putative TREs, two of which are near optimal direct repeat +4 (DR+4) 
TREs and are located just upstream or proximal to the transcription start site (Ranjan, 
Wong et al. 1994; Machuca, Esslemont et al. 1995). Transfection assays and mutational 
analysis have shown that both DR+4 T3REs support TH-dependent transactivation, and 
also transrepression in the absence of TH. TR-RXR heterodimers, but not TR or RXR 
homodimers bound the DR+4 regions in a ligand-dependent manner (Ranjan, Wong et al. 
1994; Machuca, Esslemont et al. 1995; Ulisse, Esslemont et al. 1996). The human TRβ 
gene has two functional T3REs located in the 5’ flanking region that mediate 
autoinduction in transient transfection assays using the rat pituitary tumor cell line GH3 
(Sakurai, Miyamoto et al. 1992; Suzuki, Miyamoto et al. 1994).  
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 Further support for the functionality of the proximal T3RE in the X. laevis TRβA 
promoter was shown by studies using a promoter-reporter construct transfected into 
living tadpole tail muscle in vivo (Ulisse, Esslemont et al. 1996). Treatment with TH 
activated transcription of a TRβA promoter-reporter construct containing the proximal 
DR+4 T3RE cotransfected with TRβ expression plasmids. This activity was abolished by 
cotransfection of a mutant TRβ capable of binding DNA but not hormone (Ulisse, 
Esslemont et al. 1996). Taken together, both in vitro and in vivo experiments support that 
the frog TRβA gene is a direct TR target. However, TH induction of TRβ was found to be 
partially sensitive to protein synthesis inhibition (Kanamori and Brown 1992; Machuca 
and Tata 1992), suggesting that the synthesis of proteins other than preexisting TRs may 
be required for full TRβ autoinduction.  
 Autoinduction of TRβ was originally thought to be the earliest TH response in 
premetamorphic tadpole tissues (Yaoita and Brown 1990), but it was subsequently 
discovered, through the use of gene expression screens, that other genes respond to TH 
more rapidly than TR (Shi 2000). One of the most rapidly responding TH-induced genes 
in tadpole tissues is the transcription factor Krüppel-like factor 9 (KLF9; also known as 
basic transcription element binding protein 1; BTEB1). In X. laevis tadpole tissues (brain, 
tail, intestine), Klf9 is the most rapidly responding TH-induced gene, and its expression 
parallels the increase in plasma TH that occurs during tadpole metamorphosis (Wang and 
Brown 1993; Gomez, Lahmame et al. 1996; Denver 1997; Shi 2000; Furlow and 
Kanamori 2002; Hoopfer, Huang et al. 2002). In my dissertation work I showed that 
KLF9 functions as an accessory transcription factor for TR autoinduction 
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(Bagamasbad, Howdeshell et al. 2008). Evidence for this role, and the molecular 
mechanisms of KLF9 actions on TR autoinduction are described in chapter 5. 
5.1.2 Physiological Significance of TR Autoinduction. The discovery that TRβ was 
autoinduced in tadpole tissues led to the hypothesis that the increase in TRβ is necessary 
for driving metamorphosis, whereas, the early expression of TRα was necessary to 
establish tissue competence to respond to the hormone  (Tata 2000). There are at least 
two potential mechanisms by which TRβ autoinduction could function to promote 
metamorphosis: 1) Receptor autoinduction could cause a general increase in tissue 
sensitivity to TH, thereby amplifying gene expression responses to TH, or 2) TRα could 
regulate a set of genes/processes that are distinct from those regulated by TRβ. There are 
several lines of evidence that support a role for TRα in establishing tissue competence to 
respond to TH, and in the proliferative actions of the hormone, which are the earliest 
responses to TH that occur in target tissues. Studies of the temporal and spatial 
expression of the different TR subtypes, and the use of TR subtype-specific TH analogs 
support a role for TRα in cell proliferation in the hindlimb and brain. By contrast to TRα, 
the expression pattern of TRβ is dependent on the rise in plasma TH during 
metamorphosis, and findings using the TRβ specific TH analogs GC1 and GC24 support 
the hypothesis that TRβ functions in cell differentiation and apoptosis (reviewed by 
(Furlow and Neff 2006); (Denver, Hu et al. 2009)) 
 Other lines of evidence support a role for TRβ autoinduction during metamorphosis. 
For example, treatment with prolactin, which blocked TH-induced tadpole limb bud 
growth and tail regression, decreased TRβ and completely blocked TRβ autoinduction 
(Tata, Kawahara et al. 1991; Baker and Tata 1992). These correlative data suggest that 
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one mechanism by which prolactin blocks metamorphosis is through inhibition of TRβ 
autoinduction, and therefore that TRβ autoinduction is necessary for tissue 
transformations.   
 Obligate paedomorphic salamanders (they attain reproductive maturity while 
retaining larval characteristics) do not respond to TH by initiating metamorphosis. Safi et 
al. (Safi, Begue et al. 1997) failed to find evidence for expression of TRβ mRNA in the 
mudpuppy Necturus maculosus using reverse transcriptase polymerase chain reaction, 
and suggested that this may be the reason that the animals do not respond to TH by 
metamorphosing. However, this species was found to have genes for both TR subtypes 
that are expressed in some tissues and code for functional proteins as evidenced by DNA 
binding, hormone binding, and transactivation of target genes in in vitro transfection 
assays (Safi, Vlaeminck-Guillem et al. 2006). Contrary to the initial report, Safi et al. 
(Safi, Vlaeminck-Guillem et al. 2006) have since found that both TRs are expressed in 
different tissues at low levels in N. maculosus, but TRβ shows no, or only modest 
responses to high doses of TH in gill and tail fin, two structures that undergo apoptosis in 
metamorphosing salamanders but not in N. maculosus (Safi, Vlaeminck-Guillem et al. 
2006). However, TRβ may be induced in the brain of the mudpuppy where TH responses 
may have been retained to support neurological development (M. Miller and R.J. Denver, 
unpublished). Safi and colleagues suggested that loss of metamorphosis in the lineage of 
salamanders that includes N. maculosus may have depended on the loss of TH-dependent 
control of key genes required for tissue transformation. However, it is also possible that 
the failure to upregulate TRβ in organs that normally undergo metamorphic 
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transformation in metamorphosing species (e.g., the gill, tail, etc.) is responsible for the 
paedomorphic life history.   
5.2 Nuclear Receptor Cross-regulation and Cooperativity 
 
 In addition to hormones autoregulating the expression of their receptors, the 
regulation of expression of other NRs (cross-regulation) and NR cooperativity in 
regulating common target genes are important means for modulating cellular 
responsiveness to different hormonal signals. Nuclear receptor cross-regulation allows for 
simultaneous crosstalk between hormonal signaling pathways, or can modulate in a 
temporal manner the responsiveness of a cell to a subsequent (different) hormonal signal. 
For example, during amphibian metamorphosis cross-regulation between GR/MR and TR 
sensitizes tissues to the TH signal, thereby accelerating metamorphosis. 
 In tadpole tail, corticosteroid treatment accelerated TH-induced tail shrinkage, a 
measure of metamorphic progression (reviewed by (Denver 2009)). Treatment of tadpole 
tail explants with corticosteroids increased nuclear binding capacity for TH (Kikuyama, 
Niki et al. 1983; Suzuki and Kikuyama 1983) and TR mRNAs; similar findings on 
corticosteroid actions on TR mRNA expression were observed in tadpole tail, intestine 
and brain in vivo (Krain and Denver 2004; Bonett, Hoopfer et al. 2010). These findings 
suggest that corticosteroids can enhance sensitivity of target tissues to TH by increasing 
the expression of TRs, thus accelerating metamorphosis. Corticosteroids have also been 
shown to increase expression of type 2 deiodinase in tadpole tissues, which catalyzes the 
conversion of thyroxine (T4) to the more active form T3 (Galton 1990; Bonett, Hoopfer et 
al. 2010). This would increase bioavailability of the ligand for TR, and thus facilitate TH 
action on target tissues. 
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 There is also evidence that TH can regulate GR mRNA in some tadpole tissues. 
Treatment of tadpoles with T3 downregulated GR mRNA in brain and intestine, but 
upregulated it in tail (Krain and Denver 2004; Bonett, Hoopfer et al. 2010). The 
synergistic actions of TH and corticosteroids on tadpole tail shrinkage may be explained, 
in part, by the reciprocal positive cross-regulation of TR and GR, which would sensitize 
the tissue to further hormone action.  
 The molecular basis for GR (or MR) regulation of TR gene expression has not been 
investigated. Therefore, it is not known whether this regulation is direct on TR gene 
transcription, or indirect through induction of other transcription factors, or through 
effects on mRNA transcript or protein stabilization. We recently found that Klf9 is a 
direct GR target gene in frog and mouse brain ((Bonett, Hu et al. 2009); Chapter 2) and 
that it is synergistically induced by TH plus GC (Chapter 3). Thus, in addition to GC-
mediated increases in TR binding, TR expression and TH bioavailability, GCs may 
accelerate development through positive cooperativity between GR and TR on common 
target genes, leading to synergistic gene regulation that serves as a driver for the 
developmental process. 
 In addition to amphibian metamorphosis, there are several examples from the 
mammalian literature of synergy between NRs and other TFs in the regulation of 
developmental and physiological processes. For example, synergy between GR and the 
signal transducer and activator of transcription (STAT) family of proteins  is perhaps one 
of the better studied example of this type of synergy. The STAT proteins are 
phosphorylation targets for Janus kinases (JAK), which are in turn activated by ligand-
bound cytokine receptors. Upon phosphorylation, STATs dimerize and translocate to the 
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nucleus where they bind to response elements in target genes (Pfitzner, Kliem et al. 
2004). The synergy between GR and STAT5 seen in hepatocytes has been shown to play 
a critical role in GC-mediated postnatal growth and maturation (Tronche, Opherk et al. 
2004; Engblom, Kornfeld et al. 2007). The cooperation between GR and cytokine 
signaling-activated STATs (STAT1-3) was also found to be important in the regulation of 
the HPA axis in response to infectious or inflammatory stimuli (Latchoumanin, Mynard 
et al. 2007). Conversely, GC-dependent negative feedback regulation of the HPA axis is 
also partially controlled by GR acting in synergy with the nuclear receptor steroidogenic 
factor-1(SF-1) (Gummow, Scheys et al. 2006).  
 The physiological significance of GR and STAT5 cooperativity is demonstrated in 
liver cells where GR directly interacts with growth hormone (GH)-activated STAT5 to 
induce the expression of genes important for GC-mediated postnatal growth and 
maturation (Tronche, Opherk et al. 2004; Engblom, Kornfeld et al. 2007). The interaction 
between GR and STAT5 is important for postnatal development, since GR also associates 
with STAT5-responsive regions of GH-induced genes (Tronche, Opherk et al. 2004).  In 
addition, targeted deletion of GR or STAT5, or both in hepatocytes led to identical 
impairment of growth curves, and overlapping gene expression changes in single (GR or 
STAT5) and double (GR and STAT5) mutants (Engblom, Kornfeld et al. 2007). Deletion 
of the N-terminal domain of STAT5 that disrupts protein-protein interaction with GR 
lead to growth retardation and dyregulation of target genes, thus supporting that the 
interaction between GR and STAT5 plays a significant role in postnatal development 
(Engblom, Kornfeld et al. 2007).  
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 Glucocorticoids are important modulators of the immune response where they mostly 
have potent immunosuppressive actions, and regulate inflammatory responses through 
crosstalk with cytokine signaling pathways. Glucocorticoids and CRH (which acts via a 
GPCR) act in synergy with cytokine signaling pathways to activate the HPA axis and 
accelerate inflammatory responses. For example, in a corticotropic cell line, the cytokine 
leukemic inhibitory factor (LIF)-mediated activation of STAT 1-3 stimulated pro-
opiomelanocortin (POMC) gene transcription and ACTH secretion (Ray, Ren et al. 1996; 
Chesnokova and Melmed 2002). The GR and STAT 1-3 bound to the POMC promoter 
and cooperated to synergistically increase transactivation of the POMC promoter. These 
results suggest that although GR suppresses POMC expression, when the LIF pathway is 
activated GR loses its repressive actions on POMC transcription and instead facilitates 
STAT signaling (Latchoumanin, Mynard et al. 2007). 
 In contrast, GCs also act in synergy with SF-1, to suppress activation of the HPA 
axis. SF-1 is a monomeric nuclear receptor that regulates the expression of cytochrome 
P450 enzymes, which in turn catalyze the conversion of cholesterol to corticosteroids. In 
adrenocortical cells, GR and SF-1 synergistically activate the expression of Dax-1 (Dose 
sensitive, adrenal hypoplasia congenital determining region on the X-chromosome-1). 
Dax-1 codes for an orphan nuclear receptor that binds to the SF-1 promoter, and recruits 
nuclear receptor corepressors to inhibit SF-1 expression. Therefore, through the 
synergistic induction of Dax-1 by GR and SF-1, a negative feedback loop is formed that 
results in GCs blocking further corticosteroid production (Gummow, Scheys et al. 2006). 
5.2.1  Molecular Mechanisms that Underlie Transcriptional Synergy by Nuclear 
Hormone Receptors. Transcriptional synergy between TFs is defined as a greater than 
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additive effect of two or more TFs on gene regulation (Bonett, Hoopfer et al. 2010), or 
the nonlinear or sigmoidal response of a gene to increasing amounts of two or more 
activators (Carey 1998). Transcriptional synergy is an important means for the cell to use 
a limited number of TFs to link and integrate related signaling pathways (Bonett, Hoopfer 
et al. 2010). Synergy can occur between two NRs (ligand-inducible TFs), or between a 
NR and a constitutively acting TF. The transcriptional synergy between two TFs can take 
different forms. For example, each of the two TFs may individually induce the expression 
of a common target gene, and in combination lead to induction to levels significantly 
greater than their additive contributions. Another common example of synergy is when 
the activity of one or more TFs is insufficient to induce transcription, but when present 
together they induce or further enhance the induction of the target gene. Synergistic 
transrepression and thus downregulation is also observed, but for the present purposes I 
will focus only on synergistic transactivation.  
One of the first and most extensively studied models of transcriptional synergy 
between NRs and other TFs is the synergy that occurs on the MMTV LTR promoter 
between GR, PR and other constitutively active TFs such as Specificity protein 1 (Sp1), 
CAAT-box binding factor, nuclear factor 1 (NF1) and octamer transcription factor (OTF) 
at the (Schule, Muller et al. 1988; Schule, Muller et al. 1988; Bruggemeier, Rogge et al. 
1990). As mentioned earlier, the MMTV LTR promoter (-202 to -59 bp relative to 
transcriptions start site) is a useful model for investigating transcriptional regulation by 
steroid receptors since it contains four HRE half sites of the sequence 5’TGTTCT3’, and 
binding sites for NF1, OTF and TATA binding protein (TBP) (Cato, Skroch et al. 1988; 
Cato and Weinmann 1988; Schule, Muller et al. 1988; Bruggemeier, Rogge et al. 1990). 
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More importantly, when integrated into chromatin it is arranged as an array of 6 
nuclesomes (A-F), and therefore is widely used as a model to investigate NR-mediated 
chromatin remodeling (Pina, Bruggemeier et al. 1990; Archer, Lefebvre et al. 1992). 
Glucocorticoids, progestins and androgens are all capable of inducing MMTV 
transactivation by binding to the HREs present in the promoter, where all four HRE half 
sites contribute to give a maximal response in the presence of all three hormones (Cato, 
Skroch et al. 1988; Cato and Weinmann 1988). Using MMTV promoter-reporter assays, 
Schule and colleagues (Schule, Muller et al. 1988; Schule, Muller et al. 1988) showed 
that the spacing between the HRE half sites and the TF binding sites is a critical 
determinant for synergistic transactivation of the MMTV promoter. Greatest synergy was 
observed in the presence of two GRE/PRE elements (Schule, Muller et al. 1988). The 
presence of multiple HREs in close proximity has been found to be an important 
determinant in synergistic TH and steroid hormone action (Cato, Skroch et al. 1988; 
Klein-Hitpass, Kaling et al. 1988; Liu and Towle 1994). In addition to the steroid 
receptors, TR together with the pituitary-specific factor Pit-1 has also been found to have 
synergistic activity with Sp1, NF1, CP1, OTF-1 and CACC box binding protein in 
transactivation of the human placental lactogen B (hCS-B) promoter in rat pituitary cells 
(Voz, Peers et al. 1991; Voz, Peers et al. 1992). These observations suggest that the 
constitutive TFs, Sp1, NF-1, CP1, OTF-1 and CACC box binding protein may act with 
members of the ligand-inducible NR family to synergistically activate target genes. 
There are several molecular mechanisms that may account for synergy between 
NRs/TFs. At the transcriptional level, this could be due to a combination of: 1) enhanced 
NR/TF expression by autoinduction (Fig. 1.5) or cross-regulation (Fig. 1.5), and thus 
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enhanced recruitment to genomic sites; 2) recruitment of an accessory transcription factor 
at regulatory regions that only occurs in the presence of the synergizing NRs/TFs (Fig. 
1.6A); 3) unidirectional or reciprocal cooperative binding of the synergizing NRs/TFs 
that may be attributed to enhanced decompaction of chromatin, thereby allowing for 
greater DNA-protein contact (Fig. 1.6B); 4) interaction between two regulatory regions 
mediated by protein-protein interactions or chromosomal looping (Fig. 1.6C).  
Examples of mechanism no. 1 involving NR autoinduction and NR cross-regulation were 
described earlier (section 5.1 and 5.2). An example of mechanism no. 2 is the finding that 
ligand- bound PR and GR synergistically activate the MMTV promoter through the PR 
and GR-dependent recruitment of OTF-1, a TF known to interact with TFIID of the basal 
transcription machinery (Bruggemeier, Rogge et al. 1990). A similar mechanism may 
explain the synergy by GR, STAT5 and C/EBP β (CCAAT/ Enhancing Binding Protein 
β) in activating the β-casein gene expression since the recruitment of C/EBP β was 
dependent on GR and STAT5 binding to their respective response elements 






Fig. 1.5. Forms of nuclear receptor (NR) cross-regulation. Hormone-bound NRs can 
regulate the expression of other types of NRs, and NR cross-regulation can take several 
forms. (A) Unidirectional cross regulation involves a NR (NRA) regulating the 
expression of a different NR (NRB) while NRB does not affect the expression of NRA. 
(B) In reciprocal positive cross-regulation, the hormone-bound NR (NRA) positively 
regulates the expression of another type of NR (NRB) and at the same time, hormone-
bound NRB upregulates the expression of NRA. (C) Reciprocal negative cross-regulation 
occurs when a hormone-bound NR (NRA) downregulates expression of another NR 
(NRB), and hormone-bound NRB negatively regulates expression of NRA. (D) In 
another form of cross-regulation, a hormone-bound NR (NRA) positive regulates the 







Fig. 1.6. Molecular mechanisms of transcriptional synergy between nuclear 
hormone receptors (NR) and/ or non-NR transcription factors (TFs.) Nuclear 
hormone receptor A or NRB regulates the expression of Gene X. Combined association 
of NRA and NRB at the Gene X regulatory regions leads to: (A) Recruitment of an 
accessory transcription factor (TF);  
(B) Unidirectional or reciprocal cooperative binding of the synergizing NRA/NRB that 
may be attributed to enhanced decompaction of chromatin thereby allowing for greater 
DNA-protein contact and; (C) Interaction between two regulatory regions mediated by 








Mechanism no. 3, or cooperative DNA association, occurs when a NR/TF facilitates, 
enhances and/or stabilizes the association of the other TF/NR at gene regulatory regions. 
This is observed for the synergistic action of GR and NF-1 at the 11B-hydroxysteroid 
dehydrogenase and MMTV promoters. The association of GR at the MMTV promoter led 
to NF-1, binding which in turn further increased GR association. Synergistic regulation 
by GR and NF-1 did not require protein-protein interactions between the two TFs. It is 
proposed that NF-1 binding facilitates changes that lead to a more open chromatin 
environment allowing for more GR to bind to the GRE (Hebbar and Archer 2007). A 
similar mechanism may account for the synergistic regulation of Dax-1 by GR and SF-1, 
where GC was found to increase SF-1 recruitment to the Dax-1 promoter (Gummow, 
Scheys et al. 2006).   
Other examples of mechanism no. 3 include the synergistic effect of IL-6 and 
dexamethasone (DEX; a glucocorticoid) on α2- macroglobulin (α2-M) gene expression 
that may be explained by the cooperative DNA association of GR and IL-6-activated 
STAT3. Unlike IL-6- activated STAT3, ligand-bound GR does not induce α2-M 
expression. The α2-M gene has STAT3, AP-1 and OTF-1 binding sites at its promoter (-
200 bp from TSS) but there is no GRE within this region. It is hypothesized that GR 
interaction with the α2-M gene occurs through protein-protein interactions at the AP-1 
site. Combined treatment of IL-6 and DEX synergistically induced α2-M mRNA levels 
that may be attributed to the synergistic increase and the prolonged association of GR and 
STAT3 at the promoter (Lerner, Henriksen et al. 2003). This may be due to delayed 
STAT3 dephosphorylation and dissociation, which leads to a more stable protein 
complex to support synergistic transcription. This increase in GR and STAT3 association 
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at the α2-M promoter also correlated with an increased H3 acetylation and recruitment of 
Pol II (Takeda, Kurachi et al. 1998; Lerner, Henriksen et al. 2003). Cooperative DNA 
binding may also explain the synergistic action of GR and LIF-activated STAT1-3 on 
POMC induction, where combined treatment with LIF and DEX led to a prolonged 
association of both STAT3 and GR at the POMC promoter (Latchoumanin, Mynard et al. 
2007). 
An indirect contributing factor in the cooperative increase in NR/TF association at 
gene regulatory regions is the reciprocal enhancement of the nuclear translocation of the 
cooperating NRs/TFs. For example, androgens synergistically enhance STAT5-
dependent activation of STAT5-response elements fused to luciferase (GAS-luciferase) 
and of the endogenous β-casein promoter in prostate cancer cells. Ligand-bound AR and 
active STAT5 led to reciprocal increases in the nuclear localization of AR and STAT5 
(Tan, Dagvadorj et al. 2008). Therefore, cooperative DNA gene association between two 
NRs/TFs may be indirectly attributed to the enhanced, reciprocal increase in NR/TF 
nuclear translocation. 
Transcriptional synergy that occurs by mechanism no. 4 is best exemplified by the 
interaction of GR and STAT5 in the regulation of the β-casein gene in mammary 
epithelial cells. The expression of the β-casein gene is induced by the cytokine PRL 
through STAT5-mediated transcription. The GR alone did not induce β-casein 
expression, but synergistically acted with STAT5 to enhance transcription (Lechner, 
Welte et al. 1997; Stoecklin, Wissler et al. 1997). The synergistic action between GR and 
STAT5 was attributed to two functional STAT5 response elements (STAT5REs) and 
seven GRE half sites at the proximal promoter region (-232 to -24 from TSS), and to two 
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STAT5REs at a distal enhancer region located -6.4 to -6 kb upstream of the TSS of the β-
casein gene (Lechner, Welte et al. 1997; Stoecklin, Wissler et al. 1997; Wyszomierski, 
Yeh et al. 1999; Kabotyanski, Huetter et al. 2006). Mutation of the STAT5REs and GRE 
half sites abolished synergistic induction by GCs and PRL (Kabotyanski, Huetter et al. 
2006). 
Chromatin immunoprecipitation assays revealed that there is a GC-dependent 
recruitment of GR to the proximal promoter and distal enhancer of the β-casein gene that 
was not enhanced with combined GC and PRL treatment. The increase in GR association 
at the enhancer is of interest since there were no GREs identified in this region, 
suggesting that the association of GR at the enhancer may be due to indirect binding 
through protein-protein interactions, and/or through long range chromosomal interactions 
with the promoter. In contrast, there was a PRL-dependent increase in STAT5 association 
at the proximal promoter and enhancer that was synergistically increased in the presence 
of GC and PRL at both regulatory regions. Combined treatment with GC and PRL also 
led to an increase in Pol II association as well as an increase and prolonged p300 
association at the promoter and enhancer of β-casein gene (Kabotyanski, Huetter et al. 
2006).  
The hormone-dependent increase in association of GR, p300 and Pol II at the 
enhancer favors a model for long range interactions between the enhancer and the 
promoter (Kabotyanski, Huetter et al. 2006). Studies of this model demonstrated that 
apart from cooperative DNA binding, NR/TFs can synergistically induce gene expression 
by the interaction of two distant regulatory regions that may be physically associated by 
long range chromosomal looping (Kabotyanski, Huetter et al. 2006). This model is 
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consistent with recent findings that regulatory functions of enhancers are relayed to the 
promoter by long range interactions mediated by chromosomal looping, tracking, 
cohesion and non-coding RNAs (Ong and Corces 2011). 
 
6. Synergistic Transcriptional Regulation of the Krüppel-like factor 9 Gene by 
Thyroid hormone and Glucocorticoids 
 A gene that we discovered to be independently and synergistically upregulated by 
GCs and TH in frogs and rodents is the transcription factor,  Klf9 (also known as Basic 
Transcription Element Binding Protein 1; Bteb1). We found that Klf9 is a direct 
transcriptional target for TR and GR, and we identified an evolutionarily conserved 
enhancer element, we call the Klf9 synergy module, that supports synergistic 
transactivation by TH and GCs (Chapter 3). Our analysis of the hormone-dependent 
transcriptional regulation of Klf9 revealed that synergistic transcription of Klf9 by TR and 
GR may be explained, in part, by several of the molecular mechanisms described above 
(see Chapter 3). 
 Krüppel-like factor 9 was first isolated from rat liver by its ability to bind to the basic 
transcription element (BTE), a GC rich sequence located in the promoter region of the 
cytochrome P450IA1 gene (Imataka, Sogawa et al. 1992). It belongs to the Sp1/Krüppel 
Like Factors (KLF) family of transcription factors. Members of this protein family are 
characterized by a highly conserved carboxy terminal DNA-binding domain composed of 
three tandem repeats of a Cys2His2 zinc finger motif that binds to GC and GT rich 
sequences (Kaczynski, Cook et al. 2003).  In addition to the DNA-binding domain 
(DBD), the N-terminal region of KLF9 that contains two transcription activation domains 
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is also evolutionarily conserved, both in sequence and in transactivation function between 
the frog and mammalian KLF9 proteins (Kobayashi, Sogawa et al. 1995; Furlow and 
Kanamori 2002; Hoopfer, Huang et al. 2002; Bagamasbad, Howdeshell et al. 2007).  
 Analysis of Klf9 expression in X. laevis throughout metamorphosis showed that Klf9 
is expressed in tadpole brain, tail and intestine, and its expression parallels the increase in 
plasma TH and tissue morphogenesis that occurs during metamorphosis (Hoopfer, Huang 
et al. 2002). Similar to X. laevis, the expression of rodent Klf9 (rat – rKlf9; mouse – 
mKlf9) in the brain also parallels the postnatal rise in brain TRβ expression and plasma T3 
concentration (Porterfield and Hendrich 1993; Denver, Ouellet et al. 1999; Morita, 
Kobayashi et al. 2003; Denver and Williamson 2009). The expression of Klf9 in the 
mouse hippocampus and cerebellum increased dramatically at postnatal day 7, a period 
that coincides with the critical window of TH action on the brain (Porterfield and 
Hendrich 1993; Denver, Ouellet et al. 1999; Morita, Kobayashi et al. 2003; Denver and 
Williamson 2009). 
 Consistent with its developmental expression that parallels the rise in TH during 
metamorphosis, gene expression screens in X.laevis identified Klf9 (xKlf9) as one of the 
most rapidly responding, and strongly induced genes in TH-treated tadpole tissue (Shi 
and Brown 1993; Wang and Brown 1993; Brown, Wang et al. 1995; Brown, Wang et al. 
1996; Denver, Pavgi et al. 1997; Shi 2000; Furlow and Kanamori 2002; Hoopfer, Huang 
et al. 2002). Thyroid hormone-dependent regulation of xKlf9 has been attributed to a near 
perfect DR+4 T3RE located ~6.0 kb upstream of the transcription start site of the frog 
gene (Furlow and Kanamori 2002). Two T3REs have also been identified in the mKlf9 
gene to account for its TH-dependent regulation ((Denver and Williamson 2009), Chapter 
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3). Analysis of the TH-dependent regulation of mKlf9 gene showed that TRβ associated 
with the identified T3REs, as shown by ChIP assay, and this DNA sequence exhibited 
strong enhancer activity in transient transfection assays. Treatment with TH, both in vitro 
and in vivo, caused hyperacetylation of histones at the upstream T3REs of the mouse Klf9 
promoter (Denver and Williamson 2009) (Chapter 3).   
 Support for a role for KLF9 in neural development and plasticity comes from studies 
in the rodent and frog central nervous system (CNS). Thyroid hormone-dependent 
expression of Klf9 was shown in primary neonatal rat cortical neurons and astrocytes, but 
not in oligodendrocytes (Denver, Ouellet et al. 1999). Overexpression of KLF9 in a 
mouse neuroblastoma cell line (Neuro2a) caused a dose-dependent increase in the 
number and length of neurites (Denver, Ouellet et al. 1999). The same morphological 
changes were seen by T3 treatment of a Neuro2a cell line engineered to stably express 
TRβ1 (N2a[TRβ1]) (Denver, Ouellet et al. 1999), suggesting that the TH-mediated 
increase in KLF9 expression promotes neurite outgrowth. The effect of TH on neurite 
branching in primary rat embryonic neuronal cultures was abolished by knocking down 
KLF9 with antisense oligonucleotides (Cayrou, Denver et al. 2002). Mice deficient for 
KLF9 exhibited decreased dendritic arborization in the Purkinje cells of the cerebellum 
(Morita, Kobayashi et al. 2003), and delayed neuronal maturation and reduced 
neurogenesis-dependent LTP in the dentate gyrus (Scobie, Hall et al. 2009). In addition, 
mutant mice showed significantly reduced activity in behavioral tests that define 
functions of  the cerebellum, hippocampus and amygdala, which may be indicative of 
impaired synapse formation in these regions of the brain (Morita, Kobayashi et al. 2003). 
Analysis of KLF9 protein in the tadpole brain by immunohistochemistry (IHC) showed 
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that KLF9 is not expressed in proliferating cells, suggesting that it plays a role in cell 
differentiation (Hoopfer, Huang et al. 2002). Consistent with these findings, we found 
that forced expression of KLF9 in tadpole brain led to an increase in the number of Golgi 
stained cells, that may reflect enhanced neuronal differentiation (Bonett, Hu et al. 2009). 
Taken together, these findings suggest that KLF9 may be involved in changes in neuronal 
morphology such as dendritic branching, axonogenesis and synaptogenesis that is 
induced by TH in the developing brain. 
In addition to the TH-mediated expression of Klf9, we have shown that GCs can also 
induce Klf9 expression in the CNS of X. laevis. Expression Klf9 mRNA was upregulated 
in the brain of GC-treated tadpoles and juvenile frogs and in XTC-2 cells (a X. laevis 
embryonic fibroblast cell line). The GC-dependent expression of xKlf9 was found to be a 
direct transcriptional effect of GR (Bonett, Hu et al. 2009). These findings are intriguing, 
since the mammalian hippocampus (and frog homolog – the medial pallium (Yao, Hu et 
al. 2008)) expresses high levels of GR/MR and thus is a target for GCs, which influence 
memory consolidation and retrieval (Roozendaal 2002). The hippocampus undergoes 
structural and functional reorganization, also known as neural plasticity, in response to 
acute and chronic stress (McEwen 2008). Adaptive changes in the hippocampus that 
occur in response to stress include dendrite remodeling, neurogenesis, and synaptogenesis 
(McEwen 2007). Structural plasticity of the hippocampus is regarded to be the basis for 
learning and memory (Leuner and Gould 2010). Given that Klf9: (1) is regulated by TH 
and GCs, (2) is highly expressed in the hippocampus, a brain region targeted by TH and 
GCs, and (3) functions in neurite outgrowth and dendritic arborization, we hypothesize 
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that KLF9 functions as an important intermediate that may coordinate TH and stress 
hormone action on hippocampal plasticity and subsequent memory consolidation.  
 
7. Thesis Summary 
 
In this thesis I describe studies that investigated the molecular mechanisms behind the 
evolutionarily conserved, synergistic regulation of Klf9 by TH and GC in the brain. I also 
describe a study that investigated a role for KLF9 in regulating the expression of TRβ, 
whose upregulation is necessary for the progression of amphibian metamorphosis and 
mammalian brain development. My findings have important implications for 
understanding how TH and GCs cooperate to control animal development and 
physiology.  
The TH-dependent regulation of the Klf9 gene is well established, and was shown to 
be conserved between frog and rodent. Based on our previous work in Xenopus, I 
investigated if the molecular mechanism behind GC-dependent regulation of Klf9 is 
evolutionarily conserved between frog and rodents. Studies to address this question are 
described in Chapter 2 where I found GC-dependent expression of Klf9 in mouse 
hippocampus that is mediated by the direct transcriptional activity of the GR. I identified 
two GRE/MREs (GRE/MRE-6.1 and GRE/MRE-5.3) in the mouse and human Klf9 gene 
that confer GC-dependent regulation, and I discovered that one of these GRE/MREs 
(GRE/MRE-5.3) is evolutionarily conserved between frog and mammals, and can also 
support GC regulation of the frog Klf9 gene.   
In addition to the individual actions of TH and GC on Klf9 expression, I found that 
GC and TH synergistically induce Klf9 expression in both frog and rodent brain. The 
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conserved GRE/MRE-5.3 is located within an evolutionarily conserved ~180 bp 
sequence that also contains the putative T3RE initially identified in frog Klf9 gene. In 
Chapter 3, I explored the molecular mechanisms behind the synergistic action of TH and 
GC on Klf9 expression. Located within the ~180 bp synergy module is the GRE/MRE-
5.3 that I identified in Chapter 2, and a composite response element composed of 3 HRE 
half sites (T3RE identified in (Furlow and Kanamori 2002) and another HRE half site) 
that is critical for the synergistic regulation of the Klf9 gene by TH and GC. I found that 
the synergy module was sufficient to support synergistic transactivation of the frog and 
mouse Klf9 gene. I then investigated the molecular mechanism behind the transcriptional 
synergy that occurs between TR and GR in Klf9 regulation. I tested several hypotheses 
based on the different mechanisms to explain NR/TF cooperativity in Klf9 gene 
transcription. 
 I found that TR association peaks at the synergy module, which is independent of 
hormone treatment, consistent with TRs being constitutively bound to DNA in the 
unliganded state. On the other hand, TH plus GC treatment led to an enhanced 
recruitment of GR to the synergy module, suggesting that hormone-bound TR may 
function as a transcriptional switch that derepresses the Klf9 locus by promoting histone 
acetylation and chromatin decompaction, leading to a more transcriptionally active 
chromatin environment. This allows for an enhanced and synergistic recruitment of GR 
in the presence TH and GC. The presence of ligand-bound TR, and enhanced recruitment 
of GR at the synergy module was also accompanied by a synergistic association of stalled 
Pol II at the synergy module, which may indicate that the presence of TH and GC keeps 
the Klf9 locus poised for a rapid transcriptional response. The association of Pol II at the 
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synergy module was also accompanied by transcription at the synergy module and 
flanking region, and RNA transcripts produced at this region also showed synergistic 
expression with TH plus GC treatment that was ~10-30 times greater than the Klf9 
mRNA. Work from our collaborators found that the Xenopus Klf9 synergy module 
interacts with the Klf9 promoter region in a TH-dependent manner by chromosomal 
looping. Thus, synergistic transcription of the Klf9 gene by TR and GR may be attributed 
to the synergistic association of GR and stalled Pol II, and chromosomal looping that 
allows transcriptional information at the synergy module to be relayed to the promoter, 
resulting in synergistic gene transcription.         
In Chapter 4, I investigated whether hormone synergy is a general phenomenon in 
hippocampal cells by determining if there are other genes synergistically regulated by TH 
and GC. For this study, I conducted microarray analysis on hormone-treated mouse 
hippocampal neuronal cells, HT-22. I found 69 genes that are synergistically upregulated, 
and 80 genes synergistically downregulated by TH plus GC in HT-22 cells. To my 
knowledge, this is the first study that has looked at coordinate gene regulation by TH and 
GC in hippocampal cells. Among genes that are synergistically upregulated by TH plus 
GC, there was an overrepresentation of genes that are involved in remodeling of the 
cytoskeleton, suggesting that TH and GC may have synergistic effects in shaping 
neuronal morphology and function. 
 In Chapter 5, I tested the hypothesis that the coordinate upregulation of Klf9 and 
TRβ that occurs during tadpole metamorphosis was functionally linked. Specifically, I 
tested whether Klf9, which is induced by TH with faster kinetics than TRβ, functions as 
an accessory TF for TR in promoting TRβ autoinduction. The discovery that Klf9 is a 
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rapidly responding TH-induced gene, and that the TRβA promoter has several potential 
binding sites for KLF9 (Ranjan, Wong et al. 1994) led to the hypothesis that TRβA is a 
target gene for KLF9. Studies to test this hypothesis are described in Chapter 5 
(Bagamasbad, Howdeshell et al. 2008). Analysis of the kinetics of expression of TRβA 
and Klf9 mRNAs showed that Klf9 is upregulated earlier than TRβA in XTC-2 cells and 
in the brain of premetamorphic tadpoles treated with TH. Electrophoretic mobility shift 
assays showed that KLF9 can bind to GC-rich regions of the proximal TRβA promoter, 
and ChIP assays found that KLF9 associates with this region in vivo in a TH and 
developmental stage-dependent manner. Furthermore, forced expression of KLF9 in 
XTC-2 cells or tadpole brain in vivo accelerated and enhanced TRβA autoinduction 
((Bagamasbad, Howdeshell et al. 2008), Hu and Denver, unpublished data). These 
findings support the hypothesis that the immediate early gene KLF9 functions as an 
accessory transcription factor necessary for TRβ autoinduction.  
 In summary, findings of this thesis describe mechanisms for how two NRs cooperate 
to synergistically regulate gene expression. My studies also demonstrate how the protein 
product of the immediate early gene Klf9 functions in a transcriptional network to 
enhance the autoinduction of TRβ, a NR known to be essential for postembryonic animal 
development. Results of my thesis demonstrate that through the synergistic actions of 
liganded GR and TR in inducing the expression of Klf9, and together with the role of 
KLF9 in TRβ autoinduction, a positive feed forward loop is formed that, in part, may 
account for the increased sensitivity to hormone signals, and the amplification of gene 
expression cascades that control animal development (Fig. 1.7). Together, my findings 
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Fig. 1.7. KLF9 functions as an intermediate that enhances sensitivity to thyroid 
hormone. Ligand-bound GR, TR-retinoid X receptor (RXR) heterodimers bind to and 
synergistically induce the expression of the Klf9 gene. KLF9 associates with the promoter 
region of TRβ and enhances TRβ autoinduction. The synergistic action of glucocorticoids 
and thyroid hormone in upregulating Klf9 expression creates a positive, feed forward 
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MOLECULAR BASIS FOR GLUCOCORTICOID INDUCTION OF THE 




Stress has complex effects on hippocampal structure and function, which 
consequently affects learning and memory. These effects are mediated in part by 
circulating glucocorticoids (GCs) acting via the intracellular GC receptor (GR) and 
mineralocorticoid receptor (MR). The molecular mechanisms by which GCs influence 
hippocampal neurons are poorly understood. Here we investigated GC regulation of 
Krüppel-like factor 9 (Klf9), a transcription factor implicated in neuronal development 
and plasticity. Injection of corticosterone (CORT) into postnatal day 6 and 30 mice 
increased Klf9 mRNA in the hippocampal region. Treatment of the mouse hippocampal 
cell line HT-22 with CORT caused a time and dose-dependent increase in Klf9 mRNA. 
The CORT induction of Klf9 was resistant to protein synthesis inhibition, suggesting that 
Klf9 is a direct CORT response gene. In support of this hypothesis, we identified two GC 
response elements (GRE/MRE) located -6.1 and -5.3 kb relative to the transcription start 
site, and we verified their functionality by promoter-reporter, gel shift and chromatin 
immunoprecipitation assays. The -5.3 kb GRE/MRE is largely conserved across 
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tetrapods, but conserved orthologs of the -6.1 kb GRE/MRE were only detected in therian 
mammals. Glucocorticoid treatment caused recruitment of the GR, histone 
hyperacetylation, and nucleosome removal at Klf9 upstream regions. Our findings 
support that GR/MR can directly induce Klf9 expression acting via two GC response 
elements located in the 5’ flanking region of the mouse Klf9 gene. Krüppel-like factor 9 








The hippocampus, a neural structure involved with learning and memory, among 
other functions, is an important target for the actions of circulating glucocorticoids (GCs) 
produced basally and in response to stress. Glucocorticoid actions on the hippocampus 
are complex: they may facilitate or impair hippocampal function by influencing cell 
survival, dendritic remodeling and synaptic transmission (Joels, Pu et al. 2006; McEwen 
2008). The nature of these effects depends on the concentration and duration of elevation 
in plasma GCs  (e.g. severity or duration of the stressor) and the physiological or 
behavioral context (Joels 2008). In rodents, chronic stress, or repeated exposure to high 
levels of GCs caused retraction and atrophy of dendrites, neuronal cell death, inhibited 
long term potentiation (LTP), and impaired hippocampal-dependent cognitive tasks 
(Watanabe, Gould et al. 1992; Magarinos, Verdugo et al. 1997; McEwen 1999). By 
contrast, moderate acute stress, mediated in part by GCs, enhanced hippocampal neuronal 
function and hippocampal-dependent processes (Shors 2001; Shors, Chua et al. 2001; 
Roozendaal 2002; Beylin and Shors 2003; Karst and Joels 2005; Joels, Pu et al. 2006). 
Also, basal circulating GCs are required for normal hippocampal function. For example, 
adrenalectomy in rats caused cell death, reduced cell body area, and decreased dendritic 
branching in dentate gyrus granule cells, while replacement with CORT prevented these 
changes (Gould, Woolley et al. 1990). Adrenalectomy also impaired memory in a spatial 
water-maze task (Roozendaal, Portillo-Marquez et al. 1996; Oitzl, Reichardt et al. 2001).   
The actions of GCs are mediated in large part by two nuclear receptors that function 
as ligand-activated transcription factors - the mineralocorticoid receptor (MR) and the 
glucocorticoid receptor (GR) (Reul and de Kloet 1985); both are highly expressed in the 
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mammalian hippocampus (Puymirat 1992; De Kloet, Vreugdenhil et al. 1998). The MR 
and GR bind to DNA at hormone response elements comprised of two hexanucleotide 
half sites (Ribeiro, Kushner et al. 1995; Aranda and Pascual 2001) and they recruit 
coactivator or corepressor complexes that contain histone modifying enzymes. The 
histone modifications promote an open or closed chromatin environment, thereby 
influencing the rate of transcription (Aoyagi and Archer 2008).      
 Stress hormones cause biochemical, physiological and structural changes in neurons, 
but relatively little is known about the transcriptional mechanisms that underlie these 
cellular changes (McEwen 2010). Although direct transcriptional targets of the GR have 
been identified in hippocampal neurons (Datson, van der Perk et al. 2001; Morsink, 
Steenbergen et al. 2006; Datson, Morsink et al. 2008; Datson, Speksnijder et al. 2010; 
Datson, Polman et al. 2011) the mechanisms by which GCs influence neuronal structure 
and function are poorly understood. Earlier we found that the transcription factor 
Krüppel-like factor 9 (KLF9; or Basic Transcription Element Binding Protein 1; BTEB1) 
is a direct thyroid hormone (TH) target gene that is strongly upregulated during postnatal 
brain development (Denver, Ouellet et al. 1999; Denver and Williamson 2009). Krüppel-
like factor 9 belongs to the Sp/KLF family of transcription factors that bind to GC and 
GT rich sequences in the genome (Kaczynski, Cook et al. 2003). Krüppel-like factor 9 
plays a key role in TH-dependent actions on neuronal morphology (Denver, Ouellet et al. 
1999; Cayrou, Denver et al. 2002). For example, expression of KLF9 in Neuro-2a cells 
increased neurite extension and branching (Denver, Ouellet et al. 1999), while 
suppression of KLF9 in primary embryonic rat neuronal cultures inhibited TH-induced 
neurite branching (Cayrou, Denver et al. 2002). Expression of Klf9 in the rodent brain 
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increases in parallel with the postnatal rise in plasma TH (Morita, Kobayashi et al. 2003; 
Denver and Williamson 2009). Krüppel-like factor 9 deficient mice exhibited reduced 
dendritic arborization of cerebellar Purkinje cells (Morita, Kobayashi et al. 2003), 
delayed neuronal maturation and reduced neurogenesis-dependent LTP in the dentate 
gyrus (Scobie, Hall et al. 2009), and behavioral deficits consistent with abnormal 
functions of the amygdala, hippocampus and cerebellum (Morita, Kobayashi et al. 2003).  
We recently reported that Klf9 mRNA and protein were strongly induced in Xenopus 
brain by exposure to confinement/shaking stressor (Bonett, Hu et al. 2009). This stressor-
induced increase was blocked by treatment with RU486, or mimicked by injection of 
CORT. Datson et al. (Datson, Polman et al. 2011) recently found Klf9 to be induced by 
CORT in primary rat hippocampal neurons, and they provided evidence for two putative 
GR/MR binding sites in the Klf9 5’ flanking region. In the current study we investigated 
the molecular basis for CORT regulation of Klf9 in mouse hippocampal neurons. We 
looked at whether CORT could induce Klf9 expression in mouse hippocampus in vivo, 
and in mouse hippocampal tissue culture cells, and we identified two evolutionarily 
conserved hormone response elements in the Klf9 5’ flanking region to which the 
GR/MR bind to regulate Klf9 expression.  
 
Materials and Methods 
Animal care. We purchased adult wild type C57/BL6J mice from Jackson Laboratories, 
and Dr. Fujii-Kuriyama kindly provided Klf9 mutant mice (Klf9 locus disrupted by 
insertion of the LacZ gene) (Morita, Kobayashi et al. 2003). Mice were maintained on a 
12:12 photoperiod, given food and water ad libitum, and bred in the laboratory. We 
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conducted histochemical staining for  galactosidase using brains from 7 week old 
heterozygous Klf9 mutant mice. Wild type mice at postnatal day 6 (PND 6) or 30 (PND 
30) were given intraperitonial (i.p.) injections of corticosterone (CORT; Sigma Chemical 
Co., St. Louis, MO) dissolved in corn oil vehicle at a dose of 14 mg/ kg body weight; 
control animals received corn oil vehicle or were unhandled. This dose of CORT 1is in 
the midrange of CORT doses (3-50 mg/kg CORT) reported in the literature to increase 
plasma CORT within the physiological range (Quadrilatero and Hoffman-Goetz 2005). 
One hour after injection the animals were killed and brains were collected for analysis. 
We microdissected the hippocampal region for measurement of Klf9 mRNA and 
heteronuclear RNA (hnRNA) by RTqPCR. All experiments were conducted in 
accordance with the guidelines of the University Committee on the Use and Care of 
Animals at the University of Michigan. 
 
RNA Extraction, Reverse Transcription and Quantitative PCR. We extracted total RNA 
from HT-22 cells or the hippocampal region of PND 6 and PND 30 mice using Trizol 
reagent (Invitrogen) following the manufacturer’s protocol.  One microgram of total 
RNA was used for cDNA synthesis using the High Capacity Reverse Transcription kit 
(Life Technologies Corp., Carlsbad, CA). For quantitative PCR we designed Taqman 
assays and conducted real time PCR using Absolute qPCR low ROX Mix (ABgene). The 
primers and Taqman probe used to analyze Klf9 mRNA expression (Table 1) spanned an 
exon/intron boundary. Standard curves were constructed using a cDNA pool generated 
from HT-22 cell RNA to compare relative expression levels.  Klf9 mRNA was 
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normalized to GAPDH mRNA (Applied Biosystems), the expression of which did not 
change with treatment. 
 
Plasmid Constructs. A chromatin immunoprecipitation (ChIP)-promoter DNA chip 
(ChIP-chip) assay for MR conducted on a chromatin isolated from HEK293 cells 
engineered to express myc-tagged human MR (HEK293-hMR+; for methods see (Ziera, 
Irlbacher et al. 2009) identified two regions of the upstream region of the human Klf9 
gene (T. Ziera and S. Borden, unpublished data). Subsequent bioinformatic analysis 
revealed that both loci contain putative glucocorticoid/mineralocorticoid response 
elements (GRE/MRE). These regions were isolated by PCR using human genomic DNA 
as template; one was 632 bp from -5771 to -5139 bp (fragment 1, centered at ~5.5kb), a 
second was 336 bp from -4211 to -3875 bp (fragment 2, centered at ~4 kb) relative to the 
transcription start site (TSS). The DNA fragments were subcloned into the pGL4.23 
reporter vector (Promega) at the Xho I and Hind III sites for testing in HEK293-hMR+ 
cells (Supplemental Materials and Methods). The two orthologous regions of the mouse 
Klf9 gene, a 634 bp fragment (fragment 1) located -5776 to -6410 bp upstream of the 
transcription start site (TSS) and a 336 bp fragment (fragment 2) located -4566 to -4892 
bp upstream of the TSS, were isolated by PCR using mouse genomic DNA as template 
and cloned into pGL4.23. An evolutionarily conserved 179 bp mouse genomic region 
(from -5333 to -5154 bp upstream of TSS) that contained a GRE/MRE identified by 
DNAse I footprinting (described below) was also isolated by PCR and cloned into 
pGL4.23. Plasmid constructs containing genomic DNA fragments with mutated 
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GRE/MRE half sites were generated using the QuickChange site directed mutagenesis kit 
(Stratagene) following the manufacturer’s protocol (primers in Table 2). 
 
Cell Culture and Transient Transfection Assays. HT-22 is a cell line derived from 
mouse hippocampus immortalized with the SV40 T antigen (Morimoto and Koshland 
1990; Morimoto and Koshland 1990) with properties of differentiated neurons (Morimoto 
and Koshland 1990; Morimoto and Koshland 1990; Maher and Davis 1996; Sagara, 
Dargusch et al. 1998). HT-22 expresses functional GR, but has no detectable MR, as 
3
H-
corticosterone binding in HT-22 lysates is completely displaced by RU486 (A. 
Rozeboom and A. Seasholtz, unpublished data). HT-22/MR16 cells were engineered to 
express mouse MR by stably transfecting the HT-22 parent cell line with CMV-MR and 
pPGKpuro plasmids, and selection in 2.5 g/ml puromycin. The CMV-MR construct 
contains the full-length mouse MR cDNA (clone pMR-2A; (Rozeboom, Akil et al. 2007) 
in a CMV expression vector (pCMVneo). The HT-22/MR16 cells exhibit functional MR 
binding and transcriptional activation of GRE-luciferase constructs with 1-10 nM 
aldosterone (A. Rozeboom and A. Seasholtz, unpublished data). 
       We cultured HT-22 and HT-22/MR16 cells in Dulbecco’s modified Eagle’s medium 
(DMEM; Invitrogen) supplemented with sodium bicarbonate (2.2 g/L), penicillin G (100 
units/mL), streptomycin sulfate (100 g/mL) and 10% fetal bovine serum (FBS) stripped 
of thyroid (Samuels, Stanley et al. 1979) and steroid hormones (Yao, Schulkin et al. 
2008). Cells were cultured under a humidified atmosphere of 5% CO2 at 37
o
C. For gene 
expression analysis we seeded cells at a density of 2.5 x10
6
 cells per well in 6-well plates; 
for transient transfection assays we seeded cells at 6.5 x10
4
 cells per well in 24-well 
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plates. When cells reached 80% confluency, and immediately before hormone treatments, 
we replaced the growth medium with serum-free DMEM. Corticosterone (CORT; Sigma 
C2505), dexamethasone (DEX; Sigma D1756), or aldosterone (ALDO; Sigma A9477) 
were dissolved in 100% ethanol and added to the media to the final concentrations 
indicated below. Mifepristone (RU486; a GR antagonist; Sigma M8046) was dissolved in 
ethanol and added to wells to a final concentration of 1 M 1 h before addition of 
hormone. 3,5,3’-triiodothyronine (T3; Sigma T2752) was dissolved in dimethylsulfoxide 
(DMSO). Control treatments received an equivalent concentration of vehicle (0.001% 
ethanol and 0.03% DMSO). All hormone treatments were continued for 4 h before cell 
harvest. Hormone treatment experiments were conducted at least two times with 
comparable results. 
To determine if hormone-dependent induction of Klf9 mRNA requires ongoing 
protein synthesis we treated cells with 100 g/ml of the protein synthesis inhibitor 
cycloheximide (CHX; Sigma). This dose of CHX reduced protein synthesis by 98% in 
HT-22 cells (P. Bagamasbad and R. Denver, unpublished data. We treated cells with 
CHX for 1 h before and for 4 h during treatment with hormone.  
For luciferase reporter assays we plated HT-22 cells in DMEM with hormone-
stripped FBS, and transfected at 50-60% confluency with 300 ng of the pGL4.23 reporter 
constructs plus 20 ng of pRenilla plasmid (for normalization of transfection efficiency) 
using the Fugene 6 transfection reagent (Roche, Indianapolis, IN) following the 
manufacturer’s protocol. Immediately before transfection the growth medium was 
replaced with medium containing hormone-stripped FBS without penicillin/streptomycin, 
and cells were incubated with the transfection mixture overnight. Twenty four h after 
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transfection cells were  treated in serum free medium with 100 nM CORT or vehicle for 4 
h before harvest for luciferase activity using the dual luciferase assay kit (Promega). Each 
transfection experiment was conducted at least three times with 4-5 wells per treatment. 
Electrophoretic mobility shift assay (EMSA). We conducted EMSA as described by 
Hoopfer et al. (2002) (Hoopfer, Huang et al. 2002) with recombinant human GR 
generated using the TnT SP6 quick-coupled translation system (Promega) following the 
manufacturer’s protocol. We programmed the reaction with 1 g of CMV-hGR 
expression plasmid (OriGene) and confirmed protein expression by [
35
S]-labeled amino 
acid incorporation, SDS-PAGE and autoradiography (Hoopfer, Huang et al. 2002). 
Duplex oligonucleotides corresponding to the predicted GRE/MREs located 6.1 kb and 
5.3 kb upstream of the transcription start site (Table 2) were labeled with 
32
P-dCTP by 
Klenow fill-in for use as probes in the EMSA. Competitive EMSA using 1.5 M 
radioinert wild type or mutant GRE/MRE oligo (Table 2) was done to examine 
specificity of binding. A 
32
P-labeled mouse mammary tumor virus (MMTV) probe 
containing a well characterized GRE was used as a positive control for GR binding 
(Table 2). 
 
Fluorescent DNAse I footprinting. We conducted DNAse I footprinting as described by 
Blauwkamp et al. (Blauwkamp, Chang et al. 2008) using the Promega Core Footprinting 
System protocol. We generated FAM or HEX fluorescent-labeled double stranded DNA 
probes corresponding to the mouse Klf9 5’ flanking region (-5333 to -5154 bp; 179 bp). The 
region corresponding to the DNA binding domain (DBD) of the human GR was PCR-
amplified and subcloned it into the TOPO/pET151/D vector (Invitrogen) to make 
TOPO/pET151/D-hGR-DBD. Bacterially-expressed GR-DBD was purified using the 
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ProBond system (Invitrogen) following the manufacturer’s protocol. We combined 1 g of 
GR-DBD with 150 ng HEX(green)-labeled probe in a 50 μl digestion reaction. The 
FAM(blue)-labeled probe (150 ng) was digested in a 50 μl reaction without added GR-DBD. 
The two probe digestion reactions were then combined, extracted with phenol/ chloroform, 
concentrated by ethanol precipitation, and analyzed by Big Dye Terminator Cycle sequencing 
(Applied Biosystems). Peaks in the chromatograms were assigned to specific nucleotides 
using FAM-labeled ddATP, ddCTP, ddGTP or ddTTP in a manual sequencing reaction.  
 
Chromatin immunoprecipitation assay. We plated HT-22 cells in 100 mm plates in 
DMEM with hormone-stripped FBS. Cells were grown to 90% confluency before 
treatment with 100 nM CORT or EtOH vehicle in serum free medium for 4 h before 
harvest for chromatin extraction. We also isolated chromatin from the hippocampal 
region of PND 6 mice 1 h after injection of CORT (14 mg/kg); control animals were left 
unhandled. Five micrograms of sheared chromatin was used for each reaction, and ChIP 
assay was conducted as described by Denver and Williamson (Denver and Williamson 
2009).  Polyclonal rabbit antiserum to mouse GR (5 g; M-20X; Santacruz 
Biotechnology) or anti-acetylated histone 3 (AcH3; 5 l; Millipore) were used for ChIP 
assay. ChIP samples were analyzed by quantitative real time PCR using Taqman 
primer/probe sets (Table 1) that were targeted to different regions of the mouse Klf9 
gene.  
 
Data Analysis and Statistics. We analyzed data by one-way ANOVA or Student’s t-test 
using the SYSTAT computer program (v.10; SPSS Inc., Chicago, IL). Data from dual 
luciferase assays (firefly luciferase counts divided by Renilla luciferase counts) and ChIP 
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assays (the ratio of ChIP signal to input) were log10 transformed before statistical 
analysis. P<0.05 was accepted as statistically significant. Gene expression data are 
reported as the mean+SEM. To predict putative GRE/MRE sites we used the online 
programs Transcription Element Search System (TESS; www.cbil.upenn.edu/tess) and 
Match (www.gene-regulation.com/pub/ programs.html#match) using a library of matrices 
from TRANSFAC 6.0 (www.gene-regulation.com) with core and matrix similarity of 
transcription factor binding sites set higher than 0.85. The conservation of the identified 
GRE/MREs and flanking sequences was assessed using BLAT (http://genome.ucsc.edu/). 
Extracted sequences were aligned using Clustal W. The percent similarity to mouse was 
calculated for the GRE/MRE half sites, and nucleotide frequency diagrams were 
produced with Weblogo (http://weblogo.berkeley.edu/logo.cgi).    
 
Results 
Exogenous corticosterone increased Klf9 mRNA in mouse hippocampus in vivo  
Immunohistochemical staining for betagalactosidase on coronal brain sections of 
LacZ-Klf9 heterozygous mice confirmed that the Klf9 gene is highly expressed in all 
regions of the hippocampus (Fig. 1A) (Morita, Kobayashi et al. 2003). Intraperitoneal 
injection of CORT in PND6 or PND30 mice significantly increased Klf9 mRNA in the 
region of the hippocampus 1 h after injection compared with vehicle injected or 
unhandled controls (Fig. 1B; PND6: F( 2, 26)=17.084, p<0.0001; PND30:  
F( 2, 14)=6.937, p<0.01; ANOVA). We also observed a significant increase in Klf9 hnRNA 




Corticosterone caused a rapid and dose-dependent increase in Klf9 mRNA in HT-22 
cells  
Treatment of HT-22 cells with CORT increased Klf9 mRNA in a time- and dose-
dependent manner (Fig. 2A,B; time: F(5,23)=22.06, p<0.0001; dose: F(7,30)=37.69, 
p<0.0001; ANOVA). The level of Klf9 hnRNA was also greater after CORT treatment 
(Fig 2C; p<0.05; Student’s t test). The mean Klf9 mRNA level was higher at 30 minutes 
after CORT exposure, and this reached statistical significance at 1 h; a maximal response 
was reached by 2 h. The EC50 for CORT induction of Klf9 mRNA (tested at 4 h of 
hormone exposure) was 5.7 nM, and maximal response was reached at 30 nM. Earlier, 
we reported that Klf9 is a TR target gene in rodent and frog brain, and in mouse 
neuroblastoma cells (Denver, Pavgi et al. 1997; Denver, Ouellet et al. 1999; Hoopfer, 
Huang et al. 2002; Denver and Williamson 2009). For comparison, we show similar 
upregulation of Klf9 mRNA by T3 in HT-22 cells that was both time and dose-dependent 
(Supplemental Fig. 1). 
Hormone induction of Klf9 mRNA in HT-22 cells was largely resistant to protein 
synthesis inhibition. Although CHX tended to reduce basal and hormone-induced 
(measured after 4 h) Klf9 mRNA, it did not block the hormone response (Fig. 3A; 
Control (-CHX): F(2,11)= 81.63, p<0.0001; CHX: F(2,11)=151.8; p<0.001; ANOVA).   
 
Both GR and MR can regulate the Klf9 gene, but the GR may predominate 
Treatment of HT-22 cells with CORT (100 nM) or the GR-selective agonist DEX (10 
nM) caused robust (~3 fold) and similar increases in Klf9 mRNA measured at 4 h (Fig. 
3B; –RU486: F(2,11)=42.40, p<0.001; ANOVA). Responses to both CORT and DEX were 
blocked by co-treatment with the GR receptor antagonist RU486 (Fig. 3B; +RU486: 
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F(2,11)= 3.128; ANOVA). These data clearly show that GC regulation of Klf9 can be 
mediated by the GR in HT-22 cells. However, the findings do not rule out a role for the 
MR in regulating Klf9 in other cell types because HT-22 cells do not express functional 
MR protein (A.M. Rozeboom and A.F. Seasholtz, unpublished data). Consistent with a 
lack of functional MR, HT-22 cells did not respond to ALDO (10 nM; Fig. 3C). 
To determine if the MR can mediate corticosteroid actions on Klf9 gene expression 
we analyzed hormone responses in HT-22/MR16 cells. Doses of ALDO as low as 1 nM 
activated a GRE/MRE containing promoter in a transient transfection reporter assay in 
these cells (A. Rozeboom and A.F Seasholtz unpublished data; the Kd for ALDO binding 
to the MR is 0.5 - 2.6 nM; (Veldhuis, Van Koppen et al. 1982; Reul and de Kloet 1985; 
de Kloet, Reul et al. 1990). Treatment of HT-22/MR16 cells with 10 nM ALDO caused a 
small, but statistically significant increase in Klf9 mRNA (Fig. 3C; F(8, 27)=26.45, 
p<0.001; ANOVA). However, the increase observed with 10 nM ALDO was only 25% 
of the level induced by 10 nM DEX or 100 nM CORT. In a subsequent experiment we 
found that ALDO caused a dose-dependent increase in Klf9 mRNA in HT-22/MR16 cells 
with an EC50 of 25 nM (Fig. 3D; F(8, 35)= 26.45, p<0.001; ANOVA). This EC50 is 
approximately five times greater than the EC50 for CORT in HT-22 cells, and high 
concentrations of ALDO (>30 nM) can activate GR as well as MR (Arriza, Simerly et al. 
1988). Together, these results suggest that MR can mediate induction of Klf9 
transcription in HT-22/MR16 cells, but significantly less than the activation by GR alone 
(i.e., with DEX) or by GR and MR together (i.e., with CORT).    
 
Identification of functional GRE/MREs in the human and mouse Klf9 genes 
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A ChIP-chip assay for MR on chromatin from HEK293-hMR+ cells identified two 
MR binding sites in the 5’ flanking region of the human Klf9 gene (T. Ziera and S. 
Borden, unpublished data). One region (fragment 1) was centered at ~-5.5kb, and a 
second (fragment 2) at ~-4 kb relative to the TSS. Both regions were cloned into the 
pGL4.23 reporter plasmid to determine whether these MR binding regions support 
corticosteroid-dependent transcriptional activation. Promoter-reporter assays conducted 
in HEK293-hMR+ cells showed that only fragment 1 was activated by ALDO, and this 
response was blocked by the MR specific antagonist RU26752 (Supplemental Fig.2). 
This genomic region is highly conserved between human and mouse. In silico analysis of 
the human Klf9 fragment 1 using TESS and Match identified a near perfect palindromic 
GRE/MRE full site that is completely conserved between mouse (mKlf9 GRE/MRE 6.1) 
and human (-5474 bp in human; hKlf9 GRE/MRE 5.5; Fig. 4A, partial sequence of the 
600 bp fragment shown). The GR bound the mouse Klf9 GRE/MRE-6.1 in EMSA, and 
this binding was abolished by mutation of the half sites (Fig. 4B).  
 We cloned the region of the mouse Klf9 gene (mKlf9 634 bp fragment: -6410 to -
5776 bp) orthologous to the human fragment 1, and compared the ability of the mouse 
and human sequences to support CORT-dependent transactivation in transient 
transfection assays. The Klf9 promoter-reporter constructs were transfected into HT-22 
cells, and the cells treated with 100 nM CORT for 4 h before harvest for dual luciferase 
assay. Both the human and mouse Klf9 gene fragments supported CORT-dependent 
transactivation (Fig. 4C; hKlf9 GRE/MRE-5.5, 3.3 fold activation, p<0.0001; mKlf9 
GRE/MRE-6.1, 2.6 fold activation, p<0.0001; Student’s t test). Mutation of each half site 
of mouse Klf9 GRE/MRE-6.1 abolished CORT responsiveness (Fig. 4C).   
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Earlier we found stressor and CORT-dependent regulation of the Klf9 gene in 
Xenopus (Bonett, Hu et al. 2009), but we were unable to identify a GRE/MRE in a 
similar region of the frog gene by comparative sequence analysis using the Xenopus 
tropicalis genome (version 4.1). In a separate study looking for CORT-responsive 
regions of the frog Klf9 gene, we used promoter-reporter assays to screen fragments of 
the frog Klf9 5’ flanking region, and we discovered that the region -6 to -5 kb relative to 
the TSS was CORT-responsive (P. Bagamasbad and R.J. Denver, unpublished data). 
Within this fragment sequence comparison revealed a ~180 bp sequence highly 
conserved between frog and mammalian Klf9 genes. This region of the frog Klf9 gene 
was previously reported to possess a TH response element (T3RE) (Furlow and Kanamori 
2002). Through DNAse I footprinting with GR-DBD of the orthologous mouse genomic 
region (179 bp fragment) we identified a GRE/MRE full site that is highly conserved 
across tetrapods (centered at -5285 bp in mouse, -4634 bp in human, and -5957 bp in frog 
Klf9 genes; Fig. 5A, B). We designated this the mouse GRE/MRE-5.3, and confirmed 
that the GR bound this sequence in EMSA (Fig. 5C). Binding of GR to the GRE/MRE-
5.3 probe was competed by unlabeled wildtype, but not by mutated GRE/MRE-5.3 (Fig. 
5C). The 179 bp fragment of the mouse Klf9 gene supported CORT-dependent 
transactivation in promoter-reporter assay conducted in HT-22 cells (Fig. 5D). Mutation 
of both half sites of the GRE/MRE-5.3 significantly reduced, but did not eliminate 
CORT-dependent transactivation (Fig. 5D; p<0.05, Student’s t test).    
Chromatin-immunoprecipitation assay conducted with chromatin extracted from the 
hippocampal region of PND6 mice showed GR association at both the GRE/MRE-6.1 
and GRE/MRE-5.3 regions, and this signal was increased by CORT injection (Fig. 6A. 
80 
 
p<0.05, Student’s t test). By comparison, we saw no significant GR ChIP signal at the 
Klf9 intronic region (+11 kb from the TSS). In HT-22 cells, acetylation of histone 3 
(AcH3) was substantially greater at the two GRE/MRE regions compared to the intron. 
Treatment of cells with CORT for 4 h increased H3 acetylation at the GRE/MRE-5.3 
(p<0.01, Student’s t test) but not at the GRE/MRE- 6.1 or at the intron (Fig. 6B top 
panel). Treatment with CORT decreased the H3 ChIP signal, but only at the GRE/MRE-
5.3 (Fig. 6B bottom panel; p<0.01, Student’s t test).   
 
Evolutionary conservation of the GRE/MREs in vertebrate Klf9 genes 
Bioinformatic analysis of the two GRE/MREs identified in this study (-5.3 and -6.1 
kb in mouse) showed that these sequences are highly conserved across species. Both half 
sites of the mouse GRE/MRE-5.3 are identical across several orders of mammals, a 
representative lizard and a frog (Fig. 7). There are two nucleotide substitutions in one of 
the half sites in zebra finch. We located an orthologous region in the galliform genomes 
(chicken and turkey), but the putative GRE/MRE sequences were highly divergent, and 
included an insertion mutation in the half site spacer region. We were unable to identify a 
region orthologous to GRE/MRE-5.3 in ray finned fishes. The GRE/MRE-6.1 is highly 
conserved across therian mammals, with only a single base substitution in a half site 
between marsupials and eutherians (Fig. 7). This GRE/MRE occurs within a ~150 base 
region that is also mostly conserved across therians. We could not identify an orthologous 
region, nor a GRE/MRE-6.1 in the genomes of a monotreme (platypus), birds (zebra 





Glucocorticoids exert profound and complex actions on the central nervous system 
(CNS), many of which are mediated by the GR and MR. However, the genes regulated by 
GR and MR, and roles for the protein products of these genes in CNS development and 
function are poorly understood. Here we describe the identification and functional 
characterization of two GRE/MREs in the Klf9 gene, a GC-inducible gene in 
hippocampal neurons that codes for a transcription factor known to play a role in 
neuronal structure and function (Denver, Ouellet et al. 1999; Cayrou, Denver et al. 2002; 
Morita, Kobayashi et al. 2003; Lin, Bloodgood et al. 2008; Bonett, Hu et al. 2009; 
Scobie, Hall et al. 2009). We found that the mouse Klf9 gene is induced by GCs, both in 
vivo and in the hippocampal-derived cell line HT-22. The GR is recruited to the Klf9 gene 
in a hormone-dependent manner, and this leads to increased histone acetylation and 
nucleosome eviction at the GRE/MRE-5.3, which is consistent with GCs promoting an 
open chromatin structure at the Klf9 locus. These results agree with our prior findings in 
Xenopus, where exposure to handling/shaking stressor or injection of CORT caused rapid 
and robust increases in Klf9 mRNA and protein in frog brain (Bonett, Hu et al. 2009).  
Injection of CORT increased Klf9 mRNA in the mouse hippocampal region in vivo. 
Similarly, CORT increased Klf9 mRNA in HT-22 cells in a time and dose-dependent 
manner. Increased levels of Klf9 hnRNA in mouse brain in vivo and in HT-22 cells show 
that CORT increased transcription of the Klf9 gene. Also, the rapid kinetics of CORT-
dependent upregulation of Klf9 mRNA in HT-22 cells, and the resistance to protein 
synthesis inhibition support that CORT regulation of Klf9 transcription is direct. 
Regulation of Klf9 by the GR is supported by induction of Klf9 mRNA in HT-22 cells by 
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the GR specific agonist DEX, and blockade of DEX and CORT responses by the GR-
specific antagonist RU486. These findings parallel our data in Xenopus where we found 
that stressor-induced increases in Klf9 mRNA in frog brain in vivo, or CORT-dependent 
responses in XTC-2 cells were completely blocked by RU486 (Bonett, Hu et al. 2009).  
Our findings in mouse and frog support that Klf9 is regulated by the GR. We also 
provide evidence that mammalian Klf9 genes can be regulated by the MR, although in 
HT-22 cells the GR may predominate. For example, the GRE/MRE located at -5.5 in 
human (-6.1 in mouse) was identified by ChIP-chip assay on chromatin from HEK293-
hMR+ cells. Promoter-reporter assays conducted in HEK293-hMR+ cells showed that 
ALDO (10 nM) could induce Klf9, which was blocked by the MR-selective antagonist 
RU26752. ALDO caused a small but significant increase in Klf9 mRNA in HT-22/MR16 
cells; however, this induction was significantly less than the CORT-mediated increase. 
Taken together, we conclude that while the MR may contribute to the regulation of Klf9, 
this action may be less important than the GR, and may be dependent on the sequence of 
the GRE/MRE, the cell type, and perhaps the MR:GR ratio.  
Krüppel-like factor 9 is directly regulated by GCs in hippocampal neurons via two 
GRE/MREs located in the 5’ flanking region of the gene. ChIP-chip assay identified a 
GRE/MRE located at -5.5 kb in human Klf9, and we confirmed its presence in an 
orthologous region of the mouse genome (at -6.1 kb), and the functionality of this 
response element in both species. This sequence, comprising a GRE/MRE of two half 
sites with a three base spacer (see Fig. 3B) was earlier found by So et al. (So, Cooper et 
al. 2008) to be bound by GR in mouse C3H10T1/2 mesenchymal stem-like cells. 
Comparative sequence analysis showed that the GRE/MRE-6.1 is conserved among 
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several orders of therian mammals, but it is not found in monotremes, or other 
vertebrates. Datson et al. (Datson, Polman et al. 2011) recently found that the GR binds 
to this region in rat hippocampal cells. We extend their findings by showing that this 
sequence supports hormone-dependent transactivation, which is abolished by point 
mutation of the half sites; that GR binds to this sequence in vitro; and that GR associates 
with this genomic region in a hormone-dependent manner in vivo. We also show the 
therian origin of this response element and conservation over more than 160 million years 
in mammals (Fig. 7).  
We identified a second GRE/MRE located at -5.3 kb in the mouse Klf9 gene (~800 bp 
downstream of the GRE/MRE-6.1). This region was not bound by MR in a ChIP-chip 
assay of chromatin isolated from HEK293-hMR+ cells (T. Ziera and S. Borden, 
unpublished data); we identified it when doing a promoter-reporter scan of the Xenopus 
Klf9 5’ flanking region (P. Bagamasbad and R.J. Denver, unpublished data). The 
orthologous region of the mouse gene supported GC-dependent transactivation, so we 
conducted DNAse I footprinting and subsequently identified a GRE/MRE comprised of 
two half sites with a three base spacer. The GRE/MRE-5.3 half sites are 100% conserved 
across several mammalian orders, a lizard, and a frog. Datson et al. (Datson, Polman et 
al. 2011) recently found evidence for a GRE/MRE in this region of the rat Klf9 gene. We 
extend their findings by confirming its functionality and high degree of conservation over 
370 million years of tetrapod evolution. 
The GRE/MRE-5.3 is found within an evolutionarily conserved genomic region of 
~180 bp located -5 to -6 kb relative to the TSS in vertebrate Klf9 genes. Outside of the 
coding region and the core promoter, there is no evolutionary conservation between frog 
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and mammal Klf9 genes, suggesting that this ~180 bp sequence has been subject to strong 
stabilizing selection owing to the presence of essential cis regulatory elements. In 
Xenopus this ~180 bp region was earlier found to contain a functional T3RE to which TR 
binds to induce Klf9 expression during tadpole metamorphosis (Furlow and Kanamori 
2002); we confirmed that the mouse has a homologous T3RE (P. Bagamasbad and R.J. 
Denver, unpublished data; in addition to a T3RE located at -3.8 kb relative to the TSS; 
(Denver and Williamson 2009). The ~180 bp sequence also contains an evolutionarily 
conserved, predicted GRE/MRE half site adjacent to the T3RE. However, this region was 
not protected by the GR-DBD in the DNAse I footprint assay. It is possible that the GR 
associates with the region of the T3RE through low affinity DNA binding, or though 
protein-protein interactions, which could account for the residual CORT response 
observed when the GRE/MRE-5.3 was mutated. 
Chromatin immunoprecipitation assay showed greater GR association at the mouse 
GRE/MRE-5.3 compared to the GRE/MRE-6.1. This was accompanied by hormone-
induced H3 acetylation at the GRE/MRE-5.3 but not at the GRE/MRE-6.1. Histone 3 
acetylation is a marker for transcriptionally active chromatin (Aoyagi and Archer 2008), 
and is necessary to promote nucleosome eviction and chromatin disassembly (Luebben, 
Sharma et al. 2010). Consistent with this action, we observed hormone-dependent 
nucleosome eviction (depletion of H3) at the region of the GRE/MRE-5.3 but not at the 
GRE/MRE-6.1. Although the GR associates with the GRE/MRE-6.1 in vivo and in vitro, 
and this sequence can support hormone-dependent transactivation, our findings of GR 
recruitment and histone modification suggest that the GRE/MRE-5.3 may be a stronger, 
more important hormone response element in vivo. This likely reflects the location of the 
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GRE/MRE-5.3 within the conserved ~180 bp genomic region, where transcription factors 
binding to cis regulatory elements such as the T3RE promote an open chromatin structure, 
thereby allowing for greater GR recruitment and action (P. Bagamasbad and R.J. Denver, 
unpublished data).  
Glucocorticoid actions on the hippocampus require new protein synthesis achieved though 
transactivation of GC target genes by liganded GR or MR. Recently, some GR/MR genomic 
targets have been identified in hippocampal neurons (e.g., (Datson, Polman et al. 2011), but 
little is known about the function of their gene products in hippocampal cell physiology and 
structure. Earlier we showed that KLF9 is in the pathway induced by TH that promotes 
differentiation of neuronal cells (Denver, Ouellet et al. 1999; Cayrou, Denver et al. 2002), 
(Bonett, Hu et al. 2009). Morita et al. (Morita, Kobayashi et al. 2003) found that Klf9 null 
mice had reduced dendritic arborization of cerebellar Purkinje cells, and behavioral 
abnormalities consistent with defects of the hippocampus, cerebellum and amygdala. These 
mice also displayed impaired late-phase adult hippocampal neurogenesis (Scobie, Hall et al. 
2009), a critical component of hippocampal-dependent learning and memory (Toni, Laplagne 
et al. 2008). Taken together, the findings support a role for KLF9 in mediating corticosteroid 
and thyroid hormone actions in neuronal development and plasticity.  





Table 2.1. Taqman assays used for quantitative real time PCR analysis of gene 






Probe – 5’ 6FAM-AAAGTCTATGGAAAATCC 3’ 
Forward: 5’ GCACAAGTGCCCCTACAGT 3’ 
Reverse: 5’ TGTATGCACTCTGTAATGGGCTTT 3’ 
 
For ChIP assay 
 
mKlf9 GRE/MRE-6.1 (-6134 to -6022 relative to the TSS): 
Probe – 5’ 6FAM- TTCTGACTCACCCAGAGGGCCG 3’ 
Forward: 5’ AAGGACAAACTGTTCCACAACAAC 3’ 
Reverse: 5’ CCCCCCGAGTATGGTTCTG 3’ 
 
mKlf9 GRE/MRE-5.3 (-5232 to -5143 relative to the TSS): 
Probe – 5’ 6FAM- ACCTGCCTCCTCCGGCTGCTG 3’ 
Forward: 5’ AGAACTGGGACTGTCCTCAAATG 3’ 
Reverse: 5’ TGGCATCGCCCTTTTAAAAA 3’ 
 
mKlf9 intron (+11503 to +11569 relative to the TSS): 
Probe – 5’ 6FAM-CTTCTGCACTGGTTTTAG 3’ 
Forward: 5’ CGTATAGCTGTTTGAGGTCCATAGTT 3’ 








Table 2.2 Oligonucleotides used for construction of pGL4.23 promoter plasmids, 
DNAseI footprinting and electrophoretic mobility shift assay (EMSA). 
______________________________________________________________________________ 
 
PCR primers to amplify promoter fragments cloned into pGL4.23 vector 
mKlf9 GRE/MRE-6.1 
Forward:  5’ atactcgagGACTAGGGGCTTAAG 3’ 
Reverse: 5’ ataaagcttCGGCCAGGCTGTGCGA 3’ 
 
mKlf9 GRE/MRE-5.3 
Forward: 5’ atactcgagTCCTTGCACGAGTTTGGG 3’ 
Reverse: 5’ ataaagcttATCGCCCTTTTAAAAATCT 3’ 
 
PCR primers for site-directed mutagenesis of pGL4.23 promoter plasmids 
mKlf9 GRE/MRE 1-6.1 mut: AGGACAaacTGTTCA mutated to GAATTCaacTGTTCA 
Forward: 5’ GGAGACGGGTGGGAGGGGGGTAAAAGAATTCAACTGTTCCACAACAACCACAG 3’ 
Reverse: 5’ CCTGTGGTTGTTGTGGAACAGTTGAATTCTTTTACCCCCCTCCCACCCGTCTCCA 3’ 
 
mKlf9 GRE/MRE 2-6.1 mut: AGGACAaacTGTTCA mutated to AGGACAaacGAAAAA 
Forward: 5’ GGAGGGGGGTAAAAAGGACAAACGAAAAAACAACAACCACAGGAAACACAGC 3’ 
Reverse: 5’ AGGGCTGTGTTTCCTGTGGTTGTTGTTTTTTCGTTTGTCCTTTTTACCCCCCTCCC 3’ 
 
 
mKlf9 GRE/MRE-5.3 mut: AGGGCAgttTGTTCA mutated to ACCTCAgttGAATCA 
Forward:5’GCGGATTCCTCGTCCCCCAATCTACCTCAGTTGAATCAACTGCAGCAAAGAGAG 3’ 
Reverse: 5’AGCTCTCTTTGCTGCAGTTGATTCAACTGAGGTAGATTGGGGGACGAGGAATCC 3’ 
 
PCR primers to amplify fluorescent labeled DNA for  DNAseI footprinting  
Forward: FAM or HEX 5’ TCCTTGCACGAGTTTGGG 3’;  




Sense:  5’ gatcAAAAGGACAAACTGTTCCACA 3’ 
Antisense: 5’ gatcTGTGGAACAGTTTGTCCTTTT 3’  
 
mKlf9 GRE/MRE-6.1 mut 
Sense:  5’ gatcAAAGAATTCAACGAAAAAACA 3’ 
Antisense: 5’ gatcTGTTTTTTCGTTGAATTCTTT 3’  
 
mKlf9 GRE/MRE-5.3 
Sense:  5’ gatcAATCTAGGGCAGTT TGTTCAACTGCAGCAAA 3’ 
Antisense: gatcTTTGCTGCAGTTGAACAAACTGCCCTAGATT 3’ 
 
mKlf9 GRE/MRE-5.3 mut 
Sense:  5’ gatcAATCTACCTCAGTTGAATCAACTGCAGCAAA 3’ 
Antisense: 5’ gatcTTTGCTGCAGTTGATTCAACTGAGGTAGATT 3’ 
 
MMTV 
Sense: 5’ gatcGTTGGGTTACAAACTGTTCTAACCA 3’ 
Antisense: 5’ gatcTGGTTAGAACAGTTTGTAACCCAAC 3’  
____________________________________________________________________________ 
PCR primers for site directed were designed using QuickChange Primer Design tool (Agilent) 
Shaded nucleotides represent introduced mutations in the GRE/MRE halfsites.  
Lower case letters represent restriction sites for subcloning into the pGL4.23 vector or non- 







Fig. 2.1. Injection of corticosterone increased Klf9 mRNA and hnRNA levels in the 
hippocampal region of the postnatal mouse brain. (A) A representative coronal section 
of the hippocampal region of a LacZ-Klf9 heterozygous mouse generated by insertion of 
LacZ within the coding region of the Klf9 gene (Morita, Kobayashi et al. 2003). 
Histochemistry was conducted for beta-galactosidase with immunofluorescent detection 
using Cy3. (B) Postnatal day 6 (PND 6) and day 30 (PND 30) wild type C57/BL6J mice 
were injected with vehicle (oil), corticosterone (CORT) at a dose of 14 mg/kg 
bodyweight, or left unhandled. One hour after injection animals were killed, the 
hippocampal region was dissected and RNA extracted for measurement of Klf9 mRNA 
by RTqPCR (n=8 at PND 6, and n=5 at PND 30). (C) Postnatal day 6 mice were injected 
with CORT as described above, and Klf9 hnRNA was measured by RTqPCR (n= 8). Klf9 
mRNA and hnRNA were normalized to the mRNA level of the housekeeping gene 
GAPDH. Bars represent the mean + SEM and letters above the means indicate significant 
differences among treatments (means with the same letter are not significantly different; 







Fig. 2.2. Treatment with corticosterone caused dose and time-dependent increases in 
Klf9 mRNA in the mouse hippocampal-derived cell line HT-22. HT-22 cells were 
treated with 100 nM corticosterone (CORT) for different times (A) or with increasing 
doses of CORT for 4 h (B) before harvest and analysis of Klf9 mRNA. (C) HT-22 cells 
were treated with 100 nM CORT for 4 h before harvest and analysis of Klf9 hnRNA. In 
each experiment HT-22 cells were treated with the hormone doses for the times indicated 
before cell harvest, RNA extraction and analysis by RTqPCR. Klf9 mRNA and hnRNA 
were normalized to the mRNA level of the housekeeping gene GAPDH. Bars represent 
the mean + SEM (n=4) and letters above the means indicate significant differences 
among hormone concentrations or time point (means with the same letter are not 

















Fig. 2.3. Induction of Klf9 mRNA by corticosterone in HT-22 cells is resistant to 
protein synthesis inhibition. Klf9 can be regulated by the GR or by the MR. (A) HT-
22 cells were treated with or without cycloheximide (CHX; 100 g/ml) for 30 min before 
addition of corticosterone (CORT; 100 nM) or 3,5,3’ triiodothyronine (T3; 30 nM). 
Treatment with CHX plus hormones was continued for 4 h before cell harvest for 
analysis of Klf9 mRNA. We used T3 as a positive control since earlier we showed that 
Klf9 is a direct TR target gene (Denver and Williamson 2009). (B) HT-22 cells were 
cultured in the presence or absence of the GR-selective antagonist RU486 (1 M) for 1 h 
before the addition of vehicle (100% EtOH), 100 nM CORT, or 10 nM of the GR-
selective agonist dexamethasone (DEX). Hormone treatment was continued for 4 h 
before cell harvest and analysis of Klf9 mRNA. (C) HT-22 and HT-22/MR16 cells were 
treated with vehicle (100% EtOH), 100 nM CORT, 10 nM DEX or 10 nM ALDO for 4 h 
before cell harvest for analysis of Klf9 mRNA. (D) HT-22/MR16 were treated with 
increasing concentrations of the MR-selective agonist aldosterone (ALDO) for 4 h before 
cell harvest for analysis of Klf9 mRNA. In each experiment  cells were treated with the 
hormone doses for the times indicated before cell harvest, RNA extraction and gene 
expression analysis by RTqPCR. Klf9 mRNA was normalized to the mRNA level of the 
housekeeping gene GAPDH. Bars represent the mean + SEM (n=4) and letters above the 
means indicate significant differences among hormone concentrations or time point 
(means with the same letter are not significantly different; Tukey’s multiple comparison 






Fig. 2.4. Identification and functional analysis of a GRE/MRE located at -5.5 kb in 
the human, and -6.1 kb in the mouse Klf9 genes. (A) A ChIP-chip promoter assay 
conducted on chromatin isolated from HEK293-hMR+ cells identified a fragment of 
~600 bp in the human Klf9 5’ flanking region that contains a functional GRE/MRE (T. 
Ziera and S. Borden, unpublished data). The sequence alignment is of a portion of this 
genomic region of human and mouse Klf9 showing the presence of putative GRE/MRE 
sites in the two genes (half sites are boxed) predicted by the TESS and Match programs. 
The numbers to the left of the alignment indicate the positions upstream of the TSS. The 
GRE/MRE in the human gene is centered at ~-5.5 kb, and the GRE/MRE in the mouse 
gene is centered at ~-6.1 kb. (B) The ability of the GR to bind to the mouse Klf9 
GRE/MRE-6.1 was tested in vitro by electrophoretic mobility shift assay (EMSA). Each 
reaction contained [
32
P]-labeled GRE/MRE-6.1 oligo as probe (lanes 1-5) and 2 l of in 
vitro synthesized luciferase protein (control, lane 2) or human GR protein (lanes 3-5). 
The GR binding to the probe was competed with 1.5 M radioinert GRE/MRE-6.1 (lane 
4) or mutated GRE/MRE-6.1 oligonucleotides (lane 5). We conducted EMSA with a 
MMTV GRE probe as a positive control for GR binding (right panel). Each reaction 
contained [
32
P]-labeled MMTV oligonucleotide as probe (lanes 6-9) and 2 l of in vitro 
synthesized luciferase protein (control, lane 7) or human GR protein (lanes 8 and 9). The 
GR binding to the MMTV probe was competed with 1.5 M radioinert MMTV 
oligonucleotide (lane 9). The supershifted bands indicated by the arrows are the GR-
bound probe. (C) Promoter luciferase constructs containing the human GRE/MRE-5.5, 
mouse GRE/MRE-6.1, and corresponding half site mutants (X; A- 5’half site, B- 3’half 
site) of the mouse GRE/MRE-6.1 were transfected into HT-22 cells. Cells were treated 
with CORT for 4 h before harvest and analysis by dual luciferase assay. Bars represent 
the mean + SEM (n=5). Asterisks indicate statistically significant differences between 
vehicle (Control) and CORT treated cells for each promoter-reporter construct 































Fig. 2.5. Identification and functional analysis of an evolutionarily conserved 
GRE/MRE located at -5.3 kb in the mouse (-4.6 kb in the human) Klf9 gene. (A) 
DNase I protection assay with the human GR-DBD of the evolutionary conserved 179 bp 
fragment of the mouse Klf9 gene identified a GRE/MRE located ~-5.3 kb relative to the TSS (see 
Materials and Methods). The green traces are from the probe incubated with the GR-DBD, while 
the blue traces are from the probe incubated without the GR-DBD. Areas where there is a blue 
peak but no green peak indicate nucleotides protected from DNAse I digestion by the GR-DBD. 
The nucleotide sequence is shown beneath the traces. (B) Sequence alignment showing 
conservation of the GRE/MREs (mouse GRE/MRE-5.3) in human, mouse and frog Klf9 genes 
(GRE/MRE half sites are boxed). The numbers to the left of the alignment indicate the positions 
upstream of the TSS. The GRE/MRE in the human gene is centered at ~-4.6 kb and in the frog 
gene at ~-5.9 kb. (C) The ability of the GR to bind to the mouse Klf9 GRE/MRE-5.3 was tested in 
vitro by electrophoretic mobility shift assay. Each reaction contained [
32
P]-labeled GRE/MRE-5.3 
oligo as probe (lanes 1-5) and 2 l of in vitro synthesized luciferase protein (control, lane 2) or 
human GR protein (lanes 3-5). The GR binding to the probe was competed with 1.5 M 
radioinert GRE/MRE-5.3 (lane 4) or mutated GRE/MRE-5.3 oligonucleotides (lane 5). The 
supershifted bands indicated by the arrow are the GR-bound probe. (D) Promoter luciferase 
constructs containing the mouse GRE/MRE-5.3 and corresponding GRE/MRE-5.3 mutant (X) 
were transfected into HT-22 cells. Cells were treated with CORT for 4 h before harvest and 
analysis by dual luciferase assay. Bars represent the mean + SEM (n=5). Asterisks indicate 
statistically significant differences between vehicle (Control) and CORT treated cells for each 






Fig. 2.6. Corticosterone promotes GR association, histone 3 acetylation and 
nucleosome eviction at the 5’ flanking region of the mouse Klf9 gene. (A) Wild type 
PND6 mice were injected with corticosterone (CORT) at a dose of 14 mg/kg bodyweight 
or left unhandled. One hour after injection animals were killed, the hippocampal region 
was dissected and chromatin extracted for GR ChIP assay. ChIP samples (n=9) were 
analyzed by RTqPCR using Taqman assays that targeted the GRE/MRE-6.1, GRE/MRE-
5.3 or a distal intronic region (negative control) of the mouse Klf9 gene. Bars represent 
the mean ChIP signals expressed as a percentage of input. Statistical analysis was 
conducted on log10 transformed data, and the asterisks indicate statistically significant 
differences between unhandled and CORT injected animals (P<0.05; Student’s t test). (B) 
HT-22 cells were treated with EtOH vehicle or 100 nM CORT for 4 h before harvest for 
chromatin extraction and ChIP assay for acetylated histone 3 (AcH3, top panel) and 
histone 3 (H3, bottom panel). ChIP samples (n=4) were analyzed by RTqPCR using 
Taqman assays that target the GRE/MRE-6.1, GRE/MRE-5.3 or a distal intronic region 
(negative control) of the mouse Klf9 gene. Bars represent the mean ChIP signals 
expressed as a percentage of input. Statistical analysis was conducted on log10 
transformed data, and the asterisks indicate statistically significant differences between 








Figure 2.7. Origin and evolution of two GRE/MREs in vertebrate Klf9 genes. 
Phylogeny of vertebrate relationships with branch lengths scaled to average divergence 
time estimates (www.timetree.org). Arrows indicate the minimum origin of the Klf9 
gene, and Klf9 GRE/MREs-5.3 and 6.1 (based on distance from mouse TSS). GRE/MRE 
sequences for each taxon are shown to the right of the tree (when present). Half sites are 
highlighted in yellow and their percent similarities to mouse are listed. The frequency of 
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DECIPHERING THE REGULATORY LOGIC OF AN ANCIENT, 





Different hormones may cooperate to regulate physiology and development. A 
striking example is the acceleration of tadpole metamorphosis by the synergistic actions 
of thyroid hormone (T3) and glucocorticoid (GC). Krüppel-like factor 9 (KLF9) is a 
transcription factor that mediates hormone action during development; the Klf9 gene is 
directly regulated by T3 receptor (TR) and GC receptor (GR). We investigated whether 
the Klf9 gene is synergistically activated by T3 plus GC. Gene expression analysis in frog 
and mouse cell lines, and in tadpole and mouse brain showed that treatment with T3 plus 
GC synergistically activated Klf9. Kinetic analysis of mRNA and heteronuclear RNA 
accumulation supported that synergy occurred at the transcriptional level. Transfection 
assays with reporter constructs containing 1 kb fragments of the 5’ flanking region of the 
frog Klf9 gene identified a region between -5 and -6 kb that supported synergistic 
transactivation. Comparative sequence analysis showed an evolutionarily conserved 
region of ~180 bp within the -5 to -6 kb fragment. The frog and mouse ~180 bp 
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sequences conferred synergistic transactivation, supporting that this region comprises an 
enhancer module; we therefore designated this as the Klf9 synergy module. In silico 
analysis identified three putative hormone response element (HRE) half sites for TR and 
GR, and a NFB site that overlaps with the middle and the 3’ half sites. Using gel shift, 
DNAseI footprinting and chromatin immunoprecipitation (ChIP) assays we found that 
TR and GR associate with specific sequences within the enhancer module. Site-directed 
mutagenesis of the HRE half sites support that these sequences form a composite TR/GR 
HRE; mutation of the half sites attenuated or abolished the synergistic response, 
supporting that direct DNA binding by TR and/or GR are necessary for synergistic 
transactivation. Using a series of ChIP assays, we found that T3 plus GC treatment caused 
synergistic recruitment of GR and stalled RNA polymerase II at the Klf9 synergy module 
and surrounding region. Association of RNA pol II also correlated with transcription at 
the Klf9 synergy module. These findings support that the synergistic action of GC and T3 
in development may be mediated by the synergistic upregulation of immediate early 
genes like Klf9, and that synergistic gene regulation by T3 and GC may be a general, and 






 The hormones produced by the thyroid (HPT) and adrenocortical (HPA; stress) 
endocrine axes play critical roles in animal development, physiology and behavior. 
Recent findings show that thyroid hormone (T3) and corticosteroids (primarily 
glucocorticoids – GCs) cooperate during organogenesis, and may act synergistically to 
regulate tissue formation and remodeling. The broader significance of this interaction is 
that stress hormones, whose production changes in response to variation in the internal 
and external environment, may modulate tissue responses to T3, a potent developmental 
signaling molecule. This is perhaps best exemplified in amphibians, where GCs have 
been shown to accelerate T3-dependent metamorphosis by increasing tissue sensitivity to 
the T3 signal (Kikuyama, Niki et al. 1983; Galton 1990; Kikuyama, Kawamura et al. 
1993; Denver 2009; Bonett, Hoopfer et al. 2010).  In mammals, T3 and GC act in synergy 
during fetal lung maturation by promoting alveolar epithelial differentiation, which is 
essential for air exchange immediately after birth (Smith and Sabry 1983; Metzger, Klein 
et al. 2008; Pei, Leblanc et al. 2011). Thyroid hormone and GC were found to 
synergistically regulate the activity of intestinal enzymes required for intestinal 
maturation at a period that coincides with weaning in rodents. This is hypothesized to be 
an important adaptative physiological response as the animal switches from liquid to 
solid food (McDonald and Henning 1992). Synergistic regulation by T3 and GC is also 
observed in the expression of the growth hormone (GH) and GH-releasing hormone 
(GHRH) receptor gene in rat pituitary and somatotropic cell lines (Martial, Seeburg et al. 
1977; Shapiro, Samuels et al. 1978; Nogami, Yokose et al. 1995), and may play an 
important role in controlling body growth in juvenile animals.  In humans, stress 
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hormones and a stressful uterine environment accelerates fetal brain maturation and 
development, a process which is also developmentally regulated by T3 (Porterfield and 
Hendrich 1993; Challis, Sloboda et al. 2001; Welberg and Seckl 2001; Amiel-Tison, 
Cabrol et al. 2004). The actions of stress hormones and T3 on organ formation and 
maturation leads to accelerated fetal development in conditions of intrauterine stress, 
which is associated with earlier parturition, and may represent an adaptive response that 
improves postnatal survival (Challis, Sloboda et al. 2001; Amiel-Tison, Cabrol et al. 
2004). Thus, through the coordinated action of T3 and GC in promoting the development 
of common target tissues, environmental signals may be transduced into developmental 
responses that enable an organism to modulate its rate of development.  
 The synergistic actions of T3 and GC during development are mediated by their 
cognate nuclear hormone (NR) receptors: thyroid hormone (TR) and the 
mineralocorticoid (MR) and glucocorticoid (GR) receptors (Reul and de Kloet 1985; 
Aranda and Pascual 2001). The MR, GR and TR function as ligand-activated 
transcription factors by binding to DNA at hexanucleotide half sites; NRs typically 
function as dimers, and therefore bind to two half sites that form a hormone response 
element (HRE)  (Ribeiro, Kushner et al. 1995; Aranda and Pascual 2001). In the 
unliganded state the TRs are typically bound to DNA where they recruit corepressors that 
in turn recruit histone deacetylases (HDACs) and other histone modifying enzymes that 
create a compact, repressive chromatin structure (Cheng, Leonard et al. 2010) Upon 
hormone binding the corepressors are exchanged for coactivators that acetylate lysine 
residues on histone tails, among other histone modifications, thereby promoting an open, 
transcriptionally active chromatin structure (Roeder 2005; Wolf, Heitzer et al. 2008; 
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Cheng, Leonard et al. 2010) . By contrast, the MR and GR are found in the cytosol in the 
unliganded state, but translocate to the nucleus and bind to DNA when hormone is 
present (Aranda and Pascual 2001; Germain, Staels et al. 2006). Depending on the tissue 
type and target gene, the MR and GR recruit  coactivators or corepressors that promote 
chromatin modifications leading to transactivation or transrepression, respectively 
(Robyr, Wolffe et al. 2000; Aoyagi and Archer 2008).  
The synergistic interaction between transcription factors is a common phenomenon 
observed during development and allows for a rich array of transcriptional responses to 
ensure genes are expressed at the appropriate time and place (Courey 2001).  The 
competence of a cell to synergistically respond to T3 and GC-dependent signaling may 
depend on GC-dependent enhancement of tissue sensitivity to T3 and vice versa, resulting 
from enhanced TR/GR expression by autoinduction or cross-regulation, or the synergistic 
expression of common TR and GR target genes, most of which are transcription factors. 
The combined effects of these mechanisms results in an amplification of gene regulation, 
leading to enhanced responses to T3 and GC.  
   Krüppel-like factor 9 (Klf9; or Basic Transcription Element Binding Protein 1; 
Bteb1) is a gene that we found to be a direct TR and GR/MR target (Chapter 2; (Denver, 
Ouellet et al. 1999; Bagamasbad, Howdeshell et al. 2008; Bonett, Hu et al. 2009; Denver 
and Williamson 2009). Krüppel-like factor 9 belongs to the Sp/KLF family of 
transcription factors that bind to GC and GT rich sequences in the genome (Kaczynski, 
Cook et al. 2003). It is strongly upregulated in the brain during postnatal development in 
frog and rodents (Denver, Ouellet et al. 1999; Denver and Williamson 2009), and its 
expression is dependent on T3 (Denver, Pavgi et al. 1997; Denver, Ouellet et al. 1999; 
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Furlow and Kanamori 2002; Hoopfer, Huang et al. 2002; Denver and Williamson 2009). 
In both the tadpole and rodent brain, Klf9 mRNA exhibits a coordinate increase with TR 
mRNA and protein (Porterfield and Hendrich 1993; Denver, Ouellet et al. 1999; Shi 
2000; Morita, Kobayashi et al. 2003; Bagamasbad, Howdeshell et al. 2008; Denver and 
Williamson 2009). We showed that KLF9 function as an intermediary in T3-dependent 
neuronal morphologenesis (Denver, Ouellet et al. 1999; Cayrou, Denver et al. 2002). A 
KLF9-deficient mouse line exhibited decreased dendritic branching of cerebellar Purkinje 
cells, that was accompanied by reduced activity in behavioral tests that define functions 
of the cerebellum, hippocampus and amygdala (Morita, Kobayashi et al. 2003). Scobie 
and colleagues [27] recently showed that these mice have delayed neuronal maturation 
and reduced neurogenesis-dependent LTP in the dentate gyrus (Scobie, Hall et al. 2009).  
In a pilot experiment using frog tissue culture cells we found evidence that Klf9 
mRNA is synergistically upregulated by combined treatment with T3 and GC. In the 
present study, we report that synergistic regulation of Klf9 is observed in frog and mouse 
brain in vivo and in tissue culture cells. This synergy depends on an evolutionarily 
conserved enhancer module located ~6 kb upstream of the transcription start site which 
we designate the ‘Klf9 synergy module’. We also provide evidence that hormone synergy 
is mediated by a composite HRE located within the Klf9 synergy module, that liganded 
TR creates an open chromatin environment allowing for enhanced recruitment of the GR, 
that stalled RNA polymerase II (Pol II) is enriched at the synergy module, and that the 





Materials and Methods 
Animal care. Xenopus tropicalis tadpoles at Nieuwkoop-Faber (NF; REF) stage 52-54 
were treated with 3,5,3’- triiodothyronine (T3 Sigma, St. Louis, MO; 1, 5, or 50 nM), 
CORT (100 nM), T3 plus CORT or an equivalent volume of ethanol (0.001%) as vehicle 
control. Tadpoles were maintained in 4L aquaria and hormone was added to their rearing 
water. Hormone treatment was done for 24 h, with hormones replenished at 12h. At 
sacrifice, the brain was collected for subsequent RNA isolation and gene expression 
analysis by RTqPCR (see below).  
Adult wild type C57/BL6J mice were purchased from Jackson Laboratories. Mice 
were maintained on a 12L:12D photoperiod, given food and water ad libitum, and bred in 
the laboratory to generate offspring for analysis. Wild type mice at postnatal day 6 (PND 
6) were given intraperitonial (i.p.) injections of (T3; Sigma) dissolved in 100% DMSO at 
a dose of 25 ug/kg body weight (Denver and Williamson 2009), corticosterone (CORT; 
Sigma Chemical Co., St. Louis, MO) dissolved in corn oil vehicle at a dose of 14 mg/ kg 
body weight (Chapter 2) or T3 plus CORT; control animals received corn oil plus DMSO 
as vehicle or were left unhandled. One hour after injection the animals were killed and 
brains were collected for gene expression analysis. We microdissected the brains to 
recover the hippocampal region for measurement of Klf9 mRNA by RTqPCR (described 
below). All experiments were conducted in accordance with the guidelines of the 
University Committee on the Care and use of Animals at the University of Michigan. 
 
RNA Extraction, Reverse Transcription and Quantitative PCR. Total RNA was 
extracted from tadpole and mouse brain, and tissue culture cells using Trizol reagent 
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(Invitrogen) following the manufacturer’s protocol.  One microgram of total RNA was 
used for cDNA synthesis using the High Capacity Reverse Transciption kit with RNAse 
inhibitors from Applied Biosystems (Life Technologies Corp., Carlsbad, CA). For 
quantitative PCR we designed Taqman assays and conducted real time PCR using an ABI 
7500 fast real time PCR machine with Absolute qPCR low ROX Mix (ABgene). The 
primers and Taqman probes used to analyze Klf9 mRNA expression spanned an 
exon/intron boundary (see Table 1). Standard curves were constructed using cDNA pools 
to compare relative expression levels. Klf9 mRNA was normalized to GAPDH mRNA 
(mouse, Applied Biosystems assay # 4331182) and ribosomal protein L8 (frog). 
Expression of GAPDH or rpL8 mRNAs did not change with any of the treatments (data 
not shown). 
 
Plasmid Contructs. One kilobase fragments from -7 kb to 0 kb upstream of the X. 
tropicalis Klf9 transcription start site (TSS) and the evolutionarily conserved ~180 bp 
genomic region of the mouse and frog Klf9 gene (Klf9 synergy module - described in 
Results; mouse: from -5333 to -5154 bp; frog: from -6000 to -5836 bp upstream of TSS) 
were PCR-amplified. The fragments were cloned into the pGL4.23 promoter-luciferase 
reporter vector at the XhoI and HindIII sites. Plasmid constructs containing the mouse 
Klf9 synergy module (a 179 bp fragment) with mutated TRE and GRE/MRE half sites 
were generated using the QuikChange site directed mutagenesis kit (Stratagene) 




Cell Culture and Transient Transfection Assays. Xenopus laevis embryonic fibroblast 
(XTC-2) and renal epithelium (A6)-derived cell lines were cultured in Leibovitz L-15 
medium (diluted 1:1.5 for amphibian cells) supplemented with sodium bicarbonate (2.2 
g/L), penicillin G (100 units/mL), streptomycin sulfate (100 g/mL) and 10% fetal 
bovine serum (FBS) that had been stripped of thyroid (Samuels, Stanley et al. 1979) and 
steroid hormones (Yao, Schulkin et al. 2008). Amphibian cells were cultured under a 
humidified atmosphere of 5% CO2 at 25
o
C. 
HT-22 is a cell line derived from mouse hippocampus immortalized with the SV40 T 
antigen (Morimoto and Koshland 1990; Morimoto and Koshland 1990). This cell line 
exhibits properties of differentiated neurons; e.g., they express neuron specific markers 
such as enolase and the neurofilament triplet, but not the glial cell marker, glial fibrillary 
acidic protein (Morimoto and Koshland 1990; Morimoto and Koshland 1990; Maher and 
Davis 1996; Sagara, Dargusch et al. 1998). ). HT-22 expresses functional GR, but has no 
detectable MR, as 
3
H-corticosterone binding in HT-22 lysates is completely displaced by 
RU486 (A. Rozeboom and A. Seasholtz, unpublished data; see Chapter 2). We cultured 
HT-22 cells in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) sodium 
bicarbonate (2.2 g/L), penicillin G (100 units/mL), streptomycin sulfate (100 g/mL) and 
10% fetal bovine serum (FBS) that had been stripped of thyroid (Samuels, Stanley et al. 
1979) and steroid hormones (Yao, Schulkin et al. 2008). Cells were cultured under a 
humidified atmosphere of 5% CO2 at 37
o
C.  
For gene expression analysis we seeded cells at a density of 2.5 x10
6
 cells per well in 
6-well plates; for transient transfection assays we seeded cells at 6.5 x10
4
 cells per well in 
24-well plates. When cells reached 80% confluency, and immediately before hormone 
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treatments, we replaced the growth medium with serum-free L-15 (XTC-2 and A6) or 
DMEM (HT-22). Corticosterone (CORT; Sigma C2505) was dissolved in 100% ethanol 
and added to the medium to the final concentrations indicated below. Triiodothyronine 
was dissolved in dimethylsulfoxide (DMSO). Control treatments received an equivalent 
concentration of vehicle (0.001% ethanol and 0.03% DMSO). All hormone treatments 
were continued for 4 hr before cell harvest. 
 For luciferase reporter experiments, we plated cells in L-15 (XTC-2 and A6) or 
DMEM (HT-22) with hormone stripped FBS and transfected at 50-60% confluency with 
250 ng of the pGL4.23 reporter constructs plus 20 ng of pRenilla plasmid (for 
normalization of transfection efficiency by dual luciferase assay) using the Fugene 6 
transfection reagent (Roche, Indianapolis, IN) following the manufacturer’s protocol. 
Immediately before transfection the growth medium was replaced with medium 
containing hormone-stripped FBS without penicillin/streptomycin, and cells were 
incubated with the transfection mixture overnight. Cells were then treated in serum free 
media with vehicle (0.03 % DMSO, 0.001% ethanol), T3 (30 nM), CORT (100 nM), or 
T3 plus CORT for 4 h before harvest for luciferase activity using the dual luciferase 
assay kit (Promega). Luciferase activity was quantified using a luminometer (Femtometer 
FB 12; Zylux Corp., Maryville, TN). Each transfection experiment was conducted at least 
three times with 4-5 wells per treatment. 
To determine if hormone-dependent induction of Klf9 mRNA requires ongoing 
protein synthesis we treated cells with the protein synthesis inhibitor cycloheximide 
(CHX; Sigma). We first determined the dose of CHX to be used to block protein 





S]-ExPress protein labeling mix ([
35
S]- methionine plus [
35
S]cysteine; Perkin Elemer) 
and measuring radioactivity incorporated into trichloroacetic acid (TCA)-precipitable 
protein. We plated XTC-2 and HT-22 cells in 6-well plates and grew them to 80% 
confluency in growth medium (L-15 for XTC-2 and DMEM for HT-22 supplemented 
with pen/strep and 10% FBS). We then replaced the medium with methionine and 
cysteine-deficient L-15 or DMEM supplemented with penicillin/streptomycin and 10% 
FBS, and cultured cells for 2 hr before adding 10 Ci/well of [
35
S]-ExPress protein 
labeling mix. Simultaneously, we added CHX (10 g for XTC-2 cells; 100 g for HT-22 
cells) dissolved in ethanol or ethanol vehicle (final concentration 0.001%). After a 6 hr 
incubation we harvested cells and precipitated proteins with 10% ice-cold TCA. The 
precipitates were suspended in scintillation cocktail and radioactivity measured by liquid 
scintillation counting.  
 
Electrophoretic mobility shift assay (EMSA). We conducted EMSA as described by 
Hoopfer et al. (2002) with recombinant X. laevis TRβ and RXRα, and human GR that we 
synthesized in vitro using the TnT SP6 quick-coupled translation system (Promega) 
following the manufacturer’s protocol. We programmed the reactions with 1 g of the 
pSP76-xTRβ, pSP76-xRXRα (gifts of Yun Bo Shi) or CMV-hGR (OriGene) plasmids 
and confirmed protein expression by [
35
S]-labeled amino acid incorporation, SDS-PAGE 
and autoradiography (see Hoopfer et al., 2002). Duplex oligonucleotides corresponding 
to the predicted T3 response element (T3RE) and the GRE/MRE located within the Klf9 
synergy module (mouse GRE/MRE-5.3; Chapter 2) both located within the synergy 





P-dCTP by Klenow fill-in for use as probes in the EMSA. Competitive EMSA for 
TR/RXR or GR binding to [
32
P]-labeled probes was conducted with 1.5 M duplex 
oligonucleotides corresponding to the wild type and mutant forms of the predicted T3RE 
located within the Klf9 synergy module; wild type and mutant upstream GRE/MRE 
(mouse GRE/MRE-6.1), or PCR-generated full length mouse Klf9 synergy module. A 
[
32
P]-labeled T3RE probe from the X. laevis TRβ gene (Machuca, Esslemont et al. 1995)  
and a mouse mammary tumor virus (MMTV) GRE probe (Yao, Schulkin et al. 2008) 
were used as positive controls for TR/RXR and GR binding, respectively. 
 
Chromatin Immunoprecipitation assay. We isolated chromatin from HT-22 cells treated 
with vehicle (ethanol and DMSO), T3 (30 nM), CORT (100 nM) or T3 plus CORT. We 
also isolated chromatin from the hippocampal region of PND 6 mice 1 hr after injection 
of vehicle (oil), or CORT (14 mg/kg); a group of control animals were left unhandled. 
Five micrograms of sheared chromatin were used for each reaction, and ChIP assay was 
conducted as described by Denver and Williamson (Denver and Williamson 2009).  
Polyclonal rabbit antiserum to X. laevis TR (PB, 5 l; gift of Yun Bo Shi), mouse GR (5 
g; M-20X, Santacruz Biotechnology), RNA polymerase II Ser5 (2 g, abcam 5131-50), 
RNA polymerase II Ser2 (2 g, Abcam 5095), histone 3, anti-acetylated histone 3 
(AcH3) or histone (AcH4) (5 l, Millipore) were used for ChIP assay. ChIP samples that 
were prepared previously by Denver and Williamson (Denver and Williamson 2009) 
from PND5 T3-injected mouse brain and T3-treated N2a[TRβ] cells were also used. ChIP 
samples were analyzed by quantitative real time PCR using Taqman primer/probe sets 
that were targeted to different regions of the mouse Klf9 gene (Table 3.1).  
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Data Analysis and Statistics. Data were analyzed by one-way ANOVA or Student’s t-
test using the SYSTAT computer program (version 10; SPSS Inc., Chicago, IL). Data for 
dual luciferase   assays (firefly luciferase counts divided by pRenilla luciferase counts) 
and ChIP assays (expressed as the ratio of ChIP signal to input) were log10 transformed 
before statistical analysis. P<0.05 was accepted as statistically significant. Gene 
expression data are reported as the mean + SEM. A synergistic effect of T3 and CORT on 
gene expression and ChIP signal is defined as: (1) a greater than additive effect by one 
standard deviation with combined hormone treatment, or (2) no effect with T3 or CORT 




Treatment with thyroid hormone plus corticosterone produced a synergistic 
increase in Klf9 mRNA in tadpole and mouse brain in vivo 
Treatment with T3 or CORT alone by addition to the aquarium water caused a 
significant increase in Klf9 mRNA in the tadpole brain, while combined treatment with 
T3 and CORT led to a synergistic increase in Klf9 mRNA (1nM T3: 2.67 fold change; 100 
nM CORT: 2 fold change; T3 plus CORT: 5.75 fold change; F( 6, 41)=47.99, p<0.001; Fig. 
3.1A; ANOVA). Similarly in the mouse, intraperitoneal injection of T3 or CORT alone 
caused a significant increase in Klf9 mRNA in the hippocampus 1 hr after injection 
compared with vehicle injected or unhandled controls. Combined treatment with T3 plus 
CORT caused a synergistic increase in Klf9 mRNA (T3: 3 fold change; CORT: 1.5 fold 




Treatment with thyroid hormone plus corticosterone caused a synergistic increase 
in Klf9 mRNA in frog and mouse tissue culture cells 
Treatment of frog XTC-2 or A6 cells with T3 or CORT increased Klf9 mRNA, while 
combined treatment of T3 plus CORT caused a synergistic increase in Klf9 mRNA (XTC-
2; T3: 1.6 fold change; CORT: 1.6 fold change; T3 plus CORT: 5 fold change F(3,15)= 
85.01, p< 0.01; A6; T3: 4 fold change; CORT: 12 fold change; T3 plus CORT: 53 fold 
change;  F(3,15)= 93.59, p< 0.01; Fig. 3.1C; ANOVA). In HT-22 cells T3 and CORT also 
independently and synergistically increased Klf9 mRNA. The synergistic effect of T3 plus 
CORT on Klf9 gene expression in HT-22 cells was seen after 1, 2, 4 and 6 h of hormone 
treatment (T3: 2.4 fold change; CORT: 2.7 fold change; T3 plus CORT: 6.5 fold change; 1 
h: F(3,15)= 216.5, p< 0.001; 2 h: F(3,15)= 17.6, p< 0.01; 4 h: F(3,15)= 68.26, p< 0.001; 6 h: 
F(3,15)= 42.36, p< 0.001; Fig. 3.1D; ANOVA). We also observed a synergistic increase in 
Klf9 hnRNA in HT-22 cells, which shows that Klf9 transcription was synergistically 
increased by T3 plus CORT (F(3,11)= 13.78, p< 0.01, Supplemental Fig. 3.1; ANOVA). 
We did not measure Klf9 hnRNA in the frog cell lines. 
 
Synergistic activation of  Klf9 transcription by T3 plus CORT is resistant to protein 
synthesis inhibition. 
The protein synthesis inhibitor cycloheximide effectively reduced protein synthesis at 
the two doses tested in XTC-2 and HT-22 cells by 92% and 96% , respectively (XTC-2: 
F(2,14)= 37.46, p< 0.001, Fig.2A; HT-22: F(2,17)= 102.8, p< 0.001, Fig. 3.2B; ANOVA). 
Hormone-dependent induction of Klf9 mRNA was resistant to protein synthesis inhibition 
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in both XTC-2 and HT-22 cells, which supports that the independent and synergistic 
effects of T3 and CORT on Klf9 transcription are mediated by TR and GR/MR directly 
regulating the Klf9 gene (XTC-2 (-CHX): F(3,15) = 85.01 , p<0.01; XTC-2(+CHX): F(3,15) 
=109.8, p<0.01; Fig. 2C; HT-22 (-CHX): F(3,15) = 120.7 , p<0.01; HT-22 (+CHX): F(2,15) 
=359.3, p<0.01; Fig. 3.2D; ANOVA).  
 
Identification of an evolutionarily conserved region of ~180 bp that confers 
synergistic hormone regulation on vertebrate Klf9 genes  
To identify the genomic region that confers hormone dependent regulation of 
vertebrate Klf9 genes we used promoter-reporter assays in XTC-2 cells to screen a series 
of 1 kb fragments of the frog Klf9 5’ flanking region covering 0 to 7 kb upstream of the 
TSS. We found the -6 to -5 kb fragment to be T3 and CORT-responsive, and this region 
supported synergistic transactivation by T3 plus CORT (F(3,15) = 89.44 , p<0.001; Fig 3A; 
ANOVA). A similar pattern of synergistic transactivation of the -6 to -5 kb frog Klf9 
promoter fragment was seen in HT-22 cells (F(3,19) = 245.2 , p<0.001; Supplemental Fig. 
3.2; ANOVA).  
Several of the other frog Klf9 gene fragments showed individual T3 or CORT-
dependent transactivation but not synergy; these effects tended to be small and were cell 
line-dependent For example, in XTC-2 cells the -7 to -6 kb and -1 to 0 kb fragments 
showed small responses to CORT and T3 (-7 to -6 kb TSS: F(3,15) = 11.64 , p<0.05; -1 to 0 
kb TSS: F(3,15) =14.9, p<0.05; Fig. 3.3A; ANOVA) . In HT-22 cells the -3 to -2 kb and -1 
to 0 kb fragments showed CORT responsiveness (-3 to -2 kb TSS: F(3,19) = 48.1 , p<0.05; 
-1 to 0 kb TSS: F(3,19) = 42.64 , p<0.05; Supplemental Fig. 3.2; ANOVA). 
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Since the -6 to -5 kb frog Klf9 fragment consistently showed independent and 
synergistic transactivation by T3 and CORT in frog and mouse cell lines, we conducted in 
silico comparative genomic analysis to attempt to identify conserved regions that might 
explain the hormone regulation. Computer analysis revealed a ~180 bp region that is 
evolutionarily conserved among tetrapod Klf9 genes (frog: -6000 to -5836 bp relative to 
the TSS; mouse: -5333 to -5154 bp relative to the TSS; human -4634 to -4505 bp relative 
to the TSS;  Fig. 3.4A, Supplemental Fig. 3.3). We were unable to identify a similar 
genomic region in fishes (zebrafish and pufferfish). In frogs, this Klf9 genomic region 
was previously reported to possess a T3RE (yellow; comprised of two half sites - HRE h2 
and HRE h3; mouse Klf9 T3RE at -5.23 relative to the TSS; frog Klf9 T3RE at -6.0 
relative to the TSS) (Furlow and Kanamori 2002). We also previously identified a 
functional GRE/MRE (GRE/MRE-5.3, blue) in this region of the mouse Klf9 gene that is 
conserved from frog to human (Chapter 2). In silico analysis of this conserved ~180 bp 
fragment using Match and Transcription Element Search System (TESS) identified 
another highly conserved HRE half site (HRE h1, green, Fig. 3.4A) that was predicted to 
be a GRE/MRE half site. However, the HRE h1 was not protected by the GR-DBD in a 
DNAseI footprinting assay (Chapter 2). In addition to TR and GR/MR response elements, 
TESS also identified estrogen response elements and Sp1 binding sites within the ~180 
bp conserved region (Supplementary Fig. 3.3).  
To determine if the evolutionarily conserved ~180 bp region supported synergistic 
transactivation we cloned the mouse Klf9 fragment (179 bp) and conducted promoter-
luciferase assays in HT-22 cells. This showed that this region of the mouse genome 
supported independent and synergistic transactivation by T3 and CORT (F(3,15) = 145.3 , 
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p<0.001; Fig. 3.4B; ANOVA;), and we therefore designated this region the ‘Kf9 synergy 
module’. The frog Klf9 synergy module also supported independent and synergistic 
transactivation by T3 and CORT in XTC-2 cells (xKlf9 synergy module: F(3,15) = 515.4 , 
p<0.001; mKlf9 synergy module: F(3,15) = 178.3 , p<0.001; Supplemental Fig. 3.4B; 
ANOVA).  
 Mutation of both half sites of the GRE/MRE-5.3 attenuated but did not eliminate the 
CORT response, attenuated the T3 response, but eliminated synergistic transactivation 
(GRE/MRE-5.3 mut: F(3,15) = 29.54, p<0.001; Fig. 3.4B; ANOVA). Mutation of both half 
sites of the predicted T3RE (HRE h2 and HRE h3) eliminated T3-dependent 
transactivation, greatly reduced CORT-dependent transactivation and abolished 
synergistic transactivation (HRE h2 and HRE h3 mut: F(3,15) = 3.664 , p<0.05; Fig. 3.4B; 
ANOVA). Mutation of the HRE h1 abolished the CORT response (even with the 
GRE/MRE-5.3 remaining intact) and reduced, but did not eliminate the T3 and synergistic 
responses (HRE h1 mut: F(3,15) = 42.20 , p<0.001; Fig. 3.4B; ANOVA). When the HRE 
h2 was mutated, all hormone responses were eliminated (HRE h2 mut: F(3,15) = 2.294;  
Fig. 3.4B; ANOVA). However when the HRE h3 was mutated the independent and 
synergistic transactivation by T3 and CORT were reduced but not eliminated (HRE h3 
mut: F(3,15) = 77.1 , p<0.001; Fig. 3.4B; ANOVA;).  
 
TR and GR bind to the Klf9 synergy module in vitro 
The orthologous T3RE of the frog Klf9 T3RE-6.0 in the mouse Klf9 gene (T3RE-5.23) 
was bound by TR-RXR heterodimers in EMSA (Fig. 3.5A). Binding could be competed 
by radioinert wild type but not by mutated oligonucleotide (Fig. 3.5A).  The GR can also 
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bind to GRE/MRE-5.3 within the mKlf9 synergy module in gel shift assays and that was 
eliminated by mutation of the GRE/MRE (Chapter 2). Competition binding analysis 
showed that the binding of GR to the previously identified GRE/MRE-6.1 (Chapter 2) 
could be competed by the ~180 bp mKlf9 synergy in gel shift assays (Fig. 3.5B). 
 
TR and GR bind to the Klf9 synergy module in vivo 
Chromatin-immunoprecipitation assay conducted with chromatin extracted from the 
hippocampal region of T3-injected PND5 mice (chromatin from study by Denver and 
Williamson, 2009; Fig. 3.5C) showed TR association at the Klf9 synergy module. The TR 
ChIP signal was significantly greater than the control (normal rabbit serum ChIP signal) 
at the Klf9 synergy module but not at the distal intron (Fig. 3.5C; p<0.001, Student’s t 
test). Chromatin-immunoprecipitation assay conducted with chromatin extracted from 
Neuro2a[TRβ] cells treated with T3 also showed TR association at the Klf9 synergy 
module  (Supplementary Fig. 3.5 ; *p<0.01, **p<0.001. Student’s t test).   
Chromatin-immunoprecipitation assay conducted with chromatin extracted from the 
hippocampal region of  CORT injected PND6 mice showed GR association at the 
GRE/MRE- 6.1 and Klf9 synergy module, and the GR association was increased 1 hr 
after CORT injection (Fig. 3.5D. p<0.05, Student’s t test, data as seen in Chapter 2). By 
comparison, there was no significant GR ChIP signal at the Klf9 distal intronic region 






Hormone-dependent recruitment of TR and GR across the Klf9 locus 
We conducted ChIP assays for TR and GR using chromatin from hormone-treated 
HT-22 cells to determine if the synergistic effect of T3 plus CORT on Klf9 transcription 
can be attributed to an enhanced recruitment of TR or GR. Looking across the mouse 
Klf9 locus TR association peaked at the Klf9 synergy module, but was unchanged by 
hormone treatment, consistent with TRs being constitutively bound to DNA (Fig. 3.6A). 
The ChIP signal for the NRS control was low (maximum 0.06% of input) across the Klf9 
locus and was not affected by hormone treatment (data not shown). 
Scanning of GR association across the mKlf9 locus by ChIP assay revealed an 
enhanced recruitment of GR at the GRE/MRE-6.1 and Klf9 synergy module with T3 plus 
CORT treatment (Fig. 3.6C). There was a synergistic recruitment of GR at the 
GRE/MRE-6.1 and Klf9 synergy module in response to T3 plus CORT treatment 
(GRE/MRE-6.1 kb: F(3,21)= 7.4555, p<0.05;  synergy module -5.3 kb: F(3,21)= 8.631, 
p<0.001; Fig. 3.6D; ANOVA). 
 
Hormone-dependent histone modifications across the Klf9 locus 
To determine if the synergistic effect of T3 plus CORT on Klf9 gene transcription can 
be observed at the level of chromatin modification, we conducted ChIP assays for histone 
3 (H3), acetylated H3 (AcH3) and acetylated H4 (AcH4). All hormone treatments 
decreased H3 levels at the GRE/MRE-6.1 and at the synergy module (Fig. 3.7A), but this 
effect was not enhanced by combined treatment with T3 and CORT (GRE/MRE-6.1 kb: 




Histone 3 (Fig. 3.7C) and H4 (Fig. 3.7E) acetylation was increased by T3 or CORT 
alone at the GRE/MRE-6.1 and at the Klf9 synergy module, but there was no synergistic 
effect of T3 plus CORT on AcH3 (AcH3 GRE/MRE- 6.1 kb: F(3,13)= 16.92, p<0.001; 
AcH3  Klf9 synergy module -5.3 kb: F(3,14)= 25.97, p<0.001; Fig. 3.7D; ANOVA) or 
AcH4  (AcH4 GRE/MRE- 6.1 kb: F(3,13)= 4.705; AcH4 Klf9 synergy module -5.3 kb: 
F(3,14)= 13.99, p<0.001; Fig. 3.7E; ANOVA). Hormone treatment did not alter the H3, 
AcH3 or AcH4 signal at the -3.8 kb region, nor at the distal intron in HT-22 cells.  
 
Hormone-dependent recruitment of RNA polymerase II across the Klf9 locus 
Using ChIP assay, we looked at the recruitment of two phosphorylated forms of RNA 
polymerase II  (the stalled RNA pol II S5P and the elongating RNA pol II S2P) across the 
mouse Klf9 locus in HT-22 cells. The stalled RNA pol II signal peaked at the Klf9 
synergy module and at the TSS (Fig. 3.8A). There was enhanced, synergistic recruitment 
of stalled RNA pol II S5P at the Klf9 synergy module by treatment with T3 plus CORT 
(Klf9 synergy module- 5.3 kb: F(3,18)= 10.6, p<0.001; Fig. 3.8B; ANOVA). There were no 
hormone-dependent changes in stalled RNA pol II S5P recruitment at any of the other 
genomic regions analyze. The ChIP signal for elongating RNA pol II S2P was increased 
by T3 at both the synergy module and at -3.8 kb, but was not enhanced by T3 plus CORT 







Detection of transcripts at the Klf9 synergy module 
Since there was a peak in the stalled and elongating RNA pol II at the Klf9 synergy 
module, we determined if this genomic region is transcribed by conducting RTqPCR on 
RNA from hormone-treated HT-22 cells. We detected transcripts at the Klf9 synergy 
module (we refer to this RNA as the Klf9 enhancer RNA – Klf9 eRNA). In an initial 
attempt to determine the limits of transcription at this region we conducted RTqPCR 
assays at regions flanking the Klf9 synergy module. In addition to the Klf9 synergy 
module (~-5.3 kb relative to the TSS), we detected transcript at -3.8 kb, but not at -6.1 kb 
and -2 kb relative to the TSS (Supplementary Fig. 3.6), suggesting that the transcript is at 
least 1.5 kb, but smaller than 4 kb in length. The pattern of hormone response of the Klf9 
eRNA was similar to that of the Klf9 mRNA. However, the magnitude of increase in Klf9 
eRNA by combined hormone treatment was significantly greater than the Klf9 mRNA 
(153 fold increase for the Klf9 eRNA vs. 6 fold increase for the Klf9 mRNA; Klf9 eRNA: 
F(3,11)= 15.16, p<0.01; Klf9 mRNA: F(3,11)= 276, p<0.001; Fig. 3.9A; ANOVA ). Similar 
to the mRNA, the expression of the Klf9 eRNA was not affected by cycloheximide 
treatment (-CHX: F(3,15)= 54.31, p<0.001; +CHX: F(3,14)= 54.87, p<0.001; Fig. 3.9B; 
ANOVA).   
 
Discussion  
Cooperativity among transcription factors allows a cell to integrate multiple inputs 
and generate an appropriate transcriptional response (Herschlag and Johnson 1993; Carey 
1998; Courey 2001). Synergistic transcriptional responses, in part due to TF 
cooperativity, provide a means for two or more simultaneous signals to generate a 
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response greater than additive, or for one signal to increase the sensitivity of the cell to a 
second, perhaps temporally delayed signal. Here we report synergistic regulation of the 
Klf9 gene by T3 and GC that is explained by an evolutionarily conserved NR enhancer 
module located in the 5’ flanking region of the gene. This module contains a composite 
TR and GR/MR HRE, in addition to a separate GRE/MRE. We show that the liganded 
TR functions as a transcriptional ‘switch’ to create a chromatin environment that allows 
recruitment of the stress-activated GR (and perhaps MR), thereby increasing 
transcription. Together the TR and GR/MR generate a synergistic transcriptional 
response. We also show a synergistic increase in stalled RNA pol II at the Klf9 synergy 
module, that correlates with transcription at the synergy module, leading to the generation 
of an eRNA. Lastly, in collaboration with our colleagues in Paris, France, we report that 
the upstream region interacts with the Klf9 promoter through chromosomal looping.  
 
 Discovery of hormone synergy on Klf9 
Earlier we reported that frog and mouse Klf9 genes are independently regulated by T3 
and GC ((Denver, Ouellet et al. 1999; Bonett, Hu et al. 2009; Denver and Williamson 
2009), Chapter 2). In this study we found that the Klf9 gene is synergistically induced by 
T3 plus CORT in the tadpole and mouse brain, further supporting that hormone regulation 
of this gene arose very early in tetrapod evolution and has been conserved. The 
synergistic response was also seen in frog and mouse tissue culture cells, thus allowing us 
to investigate the molecular mechanisms for hormone synergy. The synergistic increase 
in Klf9 mRNA was accompanied by a coordinate increase in heteronuclear RNA, which 
supported that the synergy occurred at the level of transcription. Moreover, the 
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synergistic increase in Klf9 mRNA was resistant to protein synthesis inhibition, 
supporting that hormone action was due to a direct transcriptional action on the Klf9 
gene.  
 
Identification of an evolutionary conserved genomic region that supports hormone 
synergy 
We conducted a promoter-reporter scan of the 5’ flanking region of frog Klf9 gene to 
search for a region(s) that supports synergistic transactivation by T3 and CORT. We 
found a 1 kb fragment located between 5 and 6 kb upstream of the TSS that supported 
hormone synergy, and comparative genomic sequence analysis showed that this region 
possessed a sequence of ~180 bp that was conserved among tetrapods. There is no 
evolutionary conservation between the frog and mammalian Klf9 genes outside of the 
coding region, the core promoter and the Klf9 synergy module. We cloned this region of 
the frog and mouse Klf9 genes and showed that it is sufficient to support synergistic 
transactivation by T3 plus CORT.  
Located within the Klf9 synergy module are five hexanucleotide half sites that could 
support NR action. Earlier we showed that the HRE located at -5.3 kb in the mouse Klf9 
gene was a bonafide GRE/MRE; this GRE/MRE is conserved from frog to human 
(Chapter 2). Located at ~-5.2 kb are three half sites, two of which were identified 
previously by Furlow and Kanamori (Furlow and Kanamori 2002) in the frog Klf9 gene 
and predicted to form a DR+4 T3RE. We confirmed that TR associates with the 
orthologous T3RE in the mKlf9 gene (mKlf9 T3RE-5.23) by EMSA and ChIP assay. We 
also identified a third half site, predicted to be a GRE/MRE half site, located 5 
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(mammals) or 6 (nonmammals) nucleotides downstream of the predicted T3RE . All three 
half sites are completely conserved from frog to mammals. 
  In silico also analysis revealed highly conserved binding sites for Sp1, Nuclear 
factor 1 (NF-1), NFκB and the estrogen receptor (ER) within the Klf9 synergy module 
(Supplemental Fig. 3.3). Apart from these predicted transcription factor binding sites, the 
Klf9 synergy module contains stretches of highly conserved sequences which may be 
important binding sites for other proteins that function in Klf9 transcriptional regulation. 
Thus, the Klf9 synergy module is enriched with evolutionarily conserved regulatory 
elements suggesting that the Klf9 synergy module has been subject to strong stabilizing 
selection due to the presence of important cis regulatory elements sufficient to support 
the conserved hormone- dependent transcriptional regulation of the Klf9 gene.   
 
Mutagenesis of the predicted HRE half sites identifies a composite TR and GR/MR 
response element 
Since the hormone-dependent transcriptional regulation of the Klf9 gene is conserved 
between frog and mouse, and because there are more tools available to analyze the mouse 
genome, we used the mouse Klf9 gene as a model to analyze the molecular mechanisms 
behind the synergistic gene regulation  Mutational analysis of the HRE halfsites showed 
that although the T3RE-5.23 and GRE/MRE-5.3 are both required for the synergistic 
activation by T3 and CORT, the T3RE-5.23 is necessary for T3-dependent activation, 
while the GRE/MRE-5.3 only partly contributes to CORT-dependent response. Mutation 
of the Klf9 synergy module T3RE- 5.23 also increased basal T3 response compared to the 
wild type Klf9 synergy module (Supplemental Fig. 3.2B), consistent with the repressive 
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role of unliganded TR (Germain, Staels et al. 2006; Shi 2009). Mutation of the HRE half 
sites suggest that the residual CORT responsiveness of the GRE/MRE-5.3 mutant could 
be attributed to HRE h1 and HRE h2 acting as composite response element for GR 
association. More importantly, the absence of any hormone response with the HRE h2 
mutant suggests that it is composite HRE half site that plays a central role for synergistic 
activation by TR and GR. A similar configuration of  three hexanucleotide half sites was 
identified to confer T3 plus GC synergistic regulation of  the rat growth hormone 
releasing hormone (GHRH)  receptor  gene in somatotropic cell lines ((Nogami, Hiraoka 
et al. 2002), Supplemental Fig. 3.7).  
Taken together, these data suggest that all of the HRE half sites we tested are 
important to achieve full synergistic gene by T3 plus CORT. However, HRE h3 with 
HRE h2, and HRE h1 and GRE/MRE-5.3, may function to confer independent T3 and 
CORT responses, respectively; whereas, HRE h2 functions as part of a composite 
response element that is critical for synergistic regulation of the Klf9 gene by T3 and GC.  
    It is possible that ligand bound TR and GR association at the HREs within the Klf9 
synergy module is necessary to promote the recruitment of another TF needed to confer 
synergistic transactivation of the gene; the presence of conserved stretches outside of the 
identified HREs suggests that multiple TFs can be recruited to this genomic region. A 
similar example was observed in the synergistic regulation of the MMTV promoter by the 
progesterone receptor (PR) and GR where OTF-1, a TF known to interact with TFIID of 
the basal transcription machinery, was only recruited to the promoter in the presence 
ligand bound PR and GR (Bruggemeier, Kalff et al. 1991). This may also be a potential 
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mechanism for how the composite GRE/MRE (HRE h1  and HRE h2) functions to confer 
GC-dependent regulation.  
The region of the synergy module was not protected by the GR-DBD in a DNAseI 
footprint assay (Chapter 2) and therefore the GR may associate with the composite 
response element with low affinity DNA binding, or through protein-protein interactions 
(or both). In support of this hypothesis, we identified a highly conserved NFκB binding 
site that encompasses HRE h1 and HRE h2 (see Supplemental. Fig. 3.3). The interaction 
between GR and NFκB has been a subject of extensive research owing to their 
antagonistic roles in the immune-inflammatory response. NFκB is comprised of a family 
of constitutively expressed TFs that are activated by the proinflammatory cytokine tumor 
necrosis factor alpha (TNF), and bind to NFκB response elements (NFκB RE) of target 
genes as dimers (p50 and p65 dimers) (Vallabhapurapu and Karin 2009).The  most 
extensively studied mechanism is mutual antagonism of GR and NFκB, most often 
occuring via a tethering mechanism where the GR is recruited, via protein-protein 
interactions, by DNA-bound NFB dimers (De Bosscher, Vanden Berghe et al. 2003). 
However, recent studies show that GR and p65 are both recruited to genes that are 
synergistically upregulated by NFκB and GC signaling (Rao, McCalman et al. 2011). 
Thus, the interaction between TR, GR and NFκB at the Klf9 gene merits further 
investigation in the context of hormone synergy to determine if the GR (or the TR) is 
tethered to the composite response element via interaction with NFkB dimers. There are 
several examples where the GR dimerization and DNA binding capacity is dispensable 
for GC-dependent regulation (Reichardt, Kaestner et al. 1998); reviewed in (De Bosscher, 
Vanden Berghe et al. 2003; Kassel and Herrlich 2007) indicating that tethering by 
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protein-protein interaction plays a significant role in GR-dependent gene regulation.  We 
also identified a highly conserved NF-1 binding site within the synergy module. Nuclear 
factor-1 is a constitutively active TF and their binding sites are often found adjacent to 
clusters of HREs where they have been shown to synergistically enhance thyroid and 
steroid receptor transcriptional activity (Cato, Skroch et al. 1988; Schule, Muller et al. 
1988; Bruggemeier, Rogge et al. 1990; Voz, Peers et al. 1992). Therefore it is likely that 
the NF-1 binding site within the synergy module also plays a role for synergistic 
regulation of Klf9 TH and GC.  
 
Molecular basis for hormone synergy: TR  and GR recruitment and marks of active 
transcription across the Klf9 locus 
 Results of our ChIP assays for TR and GR confirmed our hypothesis that TR acts as a 
transcriptional switch that, upon ligand-binding opens up the chromatin to unmask HREs 
and/or facilitate the access of the GR. In further support of this hypothesis, we have 
preliminary evidence showing that overexpression of a dominant negative TR that is 
unable to bind hormone and recruit coactivators, dampens the CORT-dependent 
expression of Klf9 (J. Knoedler, unpublished data).   
 Although a T3RE located at -3.8 kb from the TSS of the mouse Klf9 gene was earlier 
identified in the mouse Klf9 gene and shown by ChIP assay to recruit TR in hippocampus 
and neuroblastoma cells (Denver and Williamson 2009), we did not find a significant 
association of TR at the -3.8 kb TRE in HT-22 cells. The -3.8 kb TRE in the mouse Klf9 
gene is only conserved among mammals, and this suggests that there has been stronger, 
stabilizing selection for the T3RE-5.23 of the Klf9 synergy module. The T3RE-5.23 is in 
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close proximity with other highly conserved HREs and TF binding sites indicating that 
T3RE-5.23 is within a transcriptionally active chromatin environment and may therefore 
play a more ubiquitous and significant role in the TH -regulation of the Klf9 gene, while 
the -3.8 kb T3RE may function in a cell type-specific manner. 
 Histone 3 (H3) and histone 4 (H4) acetylation are markers of transcriptionally active 
chromatin (Aoyagi and Archer 2008), and acetylation is necessary to promote 
nucleosome eviction and chromatin disassembly (Luebben, Sharma et al. 2010). 
Consistent with the peak of TR and GR association at the synergy module and at the 
GRE/MRE-6.1, we also found lower levels of H3 (representative of nucleosome 
eviction), and higher levels of acetylated H3 and H4 (representing chromatin 
decompaction) in these regions.  However, these changes were not enhanced by 
combined treatment with T3 and GC at any of the Klf9 regions that we analyzed, 
suggesting that hormone-dependent nucleosome eviction and histone acetylation may be 
maximal induced by the individual hormones and cannot be enhanced by combined 
treatment. 
 
Molecular basis for hormone synergy: RNA polymerase II association and hormone- 
dependent transcription at Klf9 synergy module.  
Transcription is a multistep process that involves assembly of the preinitiation 
complex (PIC), composed of general transcription factors (GTF elongation and RNA 
polymerase II (Pol II), followed by transcriptional initiation, promoter escape, proximal 
promoter pausing, elongation and termination (Saunders, Core et al. 2006). Each of these 
steps can be rate limiting, and the stepwise transitions tightly regulated. The C-terminal 
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domain (CTD) of the largest subunit of Pol II is composed of heptad repeats (YSPTSPS) 
that undergoes dynamic phosphorylation at Ser2 and Ser5 during transcription and, the 
different phosphorylation patterns correlate with Pol II function and cofactor recruitment 
(Komarnitsky, Cho et al. 2000; Phatnani and Greenleaf 2006). The CTD of Pol II is 
hypophosphorylated upon assembly of the PIC and it undergoes hyperphosphorylation as 
it transitions into transcriptional elongation. Phosphorylation at Ser5 predominantly peaks 
at the 5’ end of a gene and decreases or remains constant towards the 3’ end of the gene 
while Ser2 phosphorylation is found mostly at the center and at the 3’ end of the gene 
(Komarnitsky, Cho et al. 2000; Morris, Michelotti et al. 2005). The phosphorylation of 
the CTD at Ser5 is a characteristic marker of Pol II stalling predominantly at proximal 
promoters and released upon phosphorylation of the CTD at Ser2, enabling the transition 
to productive elongation (Komarnitsky, Cho et al. 2000; Morris, Michelotti et al. 2005; 
Saunders, Core et al. 2006).  
Although we did not see an enhancement of transcriptionally active chromatin marks 
by combined hormone treatment, we found that the peak of TR and GR association was 
accompanied by a peak, and synergistic association of stalled Pol II at the synergy 
module with T3 plus GC treatment. There was a smaller peak of stalled Pol II at the 
promoter. Pol II stalling is hypothesized to be an important regulatory step in 
transcription. In Drosophila, stalled Pol II is highly enriched among genes implicated in 
development and response to stimuli suggesting that Pol II stalling keeps the gene poised 
and ready to afford a rapid transcriptional response to developmental and environmental 
signals (Muse, Gilchrist et al. 2007; Zeitlinger, Stark et al. 2007; Margaritis and Holstege 
2008). Although Pol II stalling is hypothesized  to keep Pol II in a poised state for active 
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transcription, Pol II stalling is also observed in genes that are actively transcribed, which 
indicates that modulating the residence time of Pol II at transcribed genes provides an 
additional regulatory step in transcription (O'Brien and Lis 1991; Nechaev and Adelman 
2008).  
These findings suggest that the synergistic association of stalled Pol II at the synergy 
module with T3 plus CORT may keep the locus poised to initiate a faster and synergistic 
response to hormone treatment. There are several possibilities to account for the 
synergistic association of stalled Pol II at the synergy module that need to be tested. 
Enhanced association of stalled Pol II may be due to synergistic recruitment of 
hypophosphorylated Pol II, enhanced phosphorylation of Ser5 or increased stability and 
time of association of stalled Pol II at the synergy module. Kinetic analysis by ChIP 
assays for hypophosphorylated, stalled and elongating pol II, and kinases that function in 
Pol II phosphorylation may be done to address these possibilities.   
Results of our Pol II ChIP assays are consistent with recent findings that the PIC is 
not only recruited to core promoters but also to enhancers, and that Pol II-bound 
enhancers may function in promoter targeting and regulation (Szutorisz, Dillon et al. 
2005). For example, in the prostate specific antigen (PSA) gene, androgen induces 
recruitment of the androgen receptor (AR) and Pol II at an enhancer element located ~5 
kb upstream of the TSS of the PSA gene (Louie, Yang et al. 2003). There was also greater 
Pol II recruitment at the enhancer than at the PSA promoter (Louie, Yang et al. 2003), 
which may be an additional step of transcriptional regulation that keeps the gene in a 
potentiated state without the risk of premature gene transcription (Szutorisz, Dillon et al. 
2005). Recruitment of the PIC and other chromatin modifying proteins were also 
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observed at enhancer elements of the mouse λ5-VpreBI (Szutorisz, Canzonetta et al. 
2005) and α and β-globin (Vieira, Levings et al. 2004) loci in embryonic stem cells, and 
in the locus control region of the growth hormone gene in pituitary and liver cells (Ho, 
Elefant et al. 2006). 
The peak in Pol II association at the Klf9 synergy module was accompanied by 
transcription at the synergy module and surrounding region. We detected eRNA 
transcripts by RTqPCR of hormone-treated HT-22 cells and XTC-2 (Supplemental Fig. 
3.8), where the pattern of eRNA expression was similar and correlated with the hormone-
dependent regulation of Klf9 mRNA. Furthermore, eRNA levels were induced by 
combined hormone treatment to a significantly higher level compared to the mRNA 
(~150x greater in HT-22 and ~10x greater in XTC-2). Our preliminary analysis by 
RTqPCR suggests that the eRNA is probably transcribed towards the direction of the Klf9 
promoter.  
Our discovery of eRNA transcripts at the synergy module is consistent with studies 
that found noncoding RNA transcripts at the Pol II-associated enhancer elements of the α 
and β-globin and growth hormone gene (Vieira, Levings et al. 2004; Ho, Elefant et al. 
2006).  Genome wide ChIP-seq analysis also recently found GTF (CBP) and Pol II to be 
recruited at ~3,000 activity-regulated enhancers in mouse cortical neurons, and  ~2,000 of 
these Pol II-bound activity-regulated enhancers are transcribed into short noncoding 
transcripts of <2 kb (Kim, Hemberg et al. 2010). Enhancer RNA synthesis was dependent 
on the presence of the promoter of the associated gene and correlated with induction of 
nearby genes (Kim, Hemberg et al. 2010). Coincidentally, others have shown Klf9 is also 
an activity regulated gene (Lin, Bloodgood et al. 2008; Scobie, Hall et al. 2009). More 
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recent studies suggest that noncoding RNA transcripts detected at the enhancer elements 
also have important functions in transcription. For example, the β globin and the human 
growth hormone noncoding enhancer transcripts are hypothesized to play important roles 
in enhancer-promoter dynamics. Insertion of transcription termination sequences in the 
region between the enhancer and promoter to block synthesis of noncoding RNA 
transcripts significantly reduced the transcription of the β globin and the human growth 
hormone gene (Ling, Ainol et al. 2004; Ho, Elefant et al. 2006). In addition, siRNA-
mediated depletion of long noncoding RNAs, identified through the GENCODE 
annotation of the human genome, decreased the expression of the neighboring protein 
coding gene (Orom, Derrien et al. 2010) indicating that transcripts produced at enhancer 
elements play a functional role in the target gene transcription.  
 
Chromosomal looping brings the Klf9 synergy module in contact with the core 
promoter. 
Using a genome wide analysis by chromatin interaction analysis with paired end tag 
sequencing (ChIA-PET) (Li, Fullwood et al. 2010) to look at T3 dependent genomic 
interactions, Laurent Sachs and colleagues have shown that there is a T3-dependent 
interaction between the Klf9 synergy module and the core promoter (and several other 
genomic regions; Fig. 3.10) which supports the role of the synergy module as a bona fide 
enhancer that functionally communicates with the Klf9 promoter to mediate synergistic 
transcription. Whether the Klf9 eRNA is a byproduct of Pol II association and 




The assembly of activators and the PIC at enhancers needs to be relayed or 
transferred to gene promoters for gene transcription to occur. For example, association of 
PIC at the enhancer elements of the α and β globin was found to be required for the PIC 
to bind to the promoters (Vieira, Levings et al. 2004; Vernimmen, De Gobbi et al. 2007). 
Through chromosome conformation capture (3C) assay, a technique used to detect 
physical long range chromosomal  interaction (Hagege, Klous et al. 2007),  physical 
interactions were found between the enhancer elements and promoter of the α globin 
indicating that PIC transfer from the enhancer to the promoter may occur by chromosome 
looping. The PIC at enhancers could also be transferred to the promoter by tracking from 
the enhancer towards the target gene promoters or through a combination of tracking that 
leads to chromosomal looping (Zhu, Ling et al. 2007). The interaction of enhancer and 
promoter by chromosomal looping can also be facilitated by cohesin complexes (Ong and 
Corces 2011) and the multisubunit Mediator complex (Kagey, Newman et al. 2010).   
The Mediator complex directly recruits and interacts with Pol II at gene promoters 
(Myers and Kornberg 2000). Among the many proteins that make up the Mediator 
complex, a 220 kDa subunit called TR associated protein 220 (TRAP220)/Vitamin D 
receptor interacting protein (DRIP205)/ MED1 was found to associate with TR (Ito and 
Roeder 2001) and GR (Hittelman, Burakov et al. 1999; Chen and Roeder 2007) in a 
ligand-dependent manner. Recent evidence showed that TRAP220/MED1 plays a role in 
linking enhancers to gene promoters by chromosomal looping (Park, Li et al. 2005; 
Kagey, Newman et al. 2010). Since both TR and GR are known to recruit TRAP220 
(DRIP205/ MED1), it would be interesting to determine if TRAP220 is recruited to the 
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Klf9 synergy module and if it facilitates the interaction of the synergy module with the 
promoter in regulating Klf9 transcription.  
In this study we identified an evolutionarily conserved enhancer (synergy module) in 
the Klf9 gene that contains functional HREs and we elucidated the molecular mechanisms 
that lead to the synergistic transcription of Klf9 gene. We propose a model (Fig. 3.11) 
whereby TR is bound to the synergy module in the unliganded state and associates with 
corepressors to repress Klf9 transcription. Upon T3 binding, TR releases exchanges 
corepressors for coactivators that promote histone acetylation and chromatin 
decompaction, which leads to a more transcriptionally active chromatin environment. 
This allows for an enhanced and synergistic recruitment of GR in the presence T3 and 
CORT. The presence of ligand-bound TR, and enhanced recruitment of GR at the 
synergy module leads to a synergistic association of stalled Pol II at the synergy module 
maintaining the Klf9 locus poised for a rapid transcriptional response. Association of 
hormone bound TR, GR and Pol II at the synergy module leads to transcription at that 
region, and to chromosomal looping that allows the regulatory information at the synergy 
module to be relayed to the promoter, ultimately resulting in synergistic gene 
transcription.         
The coordinate  and synergistic actions of GC and T3 in common target tissues is 
observed during critical periods of vertebrate development, and is regarded to allow for 
important adaptive responses to changing environments (Smith and Sabry 1983; 
McDonald and Henning 1992; Bonett, Hu et al. 2009; Denver 2009; Bonett, Hoopfer et 
al. 2010; Pei, Leblanc et al. 2011). However, the molecular basis behind the synergistic 
actions of T3 and GC in regulating these developmental transitions is poorly understood.  
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In this study, we report the synergistic action of TR and GR/MR in upregulating the 
expression of a transcription factor KLF9, which is plays an important role in amphibian 
and mammalian development. We hypothesize that through the synergistic regulation of 
common T3 and GC target genes, physiological and developmental processes are 









Table 3.1. Taqman assays used for quantitative real time PCR analysis of gene 






Probe – 5’ 6FAM-AAAGTCTATGGAAAATCC 3’ 
Forward: 5’ GCACAAGTGCCCCTACAGT 3’ 
Reverse: 5’ TGTATGCACTCTGTAATGGGCTTT 3’ 
 
mKlf9 eRNA 
Probe – 5’ 6FAM- TTCTGACTCACCCAGAGGGCCG 3’ 
Forward: 5’ AAGGACAAACTGTTCCACAACAAC 3’ 
Reverse: 5’ CCCCCCGAGTATGGTTCTG 3’ 
 
mKlf9 hnRNA 
Probe – 5’ 6FAM-CTTCTGCACTGGTTTTAG 3’ 
Forward: 5’ CGTATAGCTGTTTGAGGTCCATAGTT 3’ 
Reverse: 5’ CCTGGCCTCGTCTCAGAAATT 3’ 
 
 
For ChIP assay 
 
mKlf9 GRE/MRE-6.1 (-6134 to -6022 relative to the TSS): 
Probe – 5’ 6FAM- TTCTGACTCACCCAGAGGGCCG 3’ 
Forward: 5’ AAGGACAAACTGTTCCACAACAAC 3’ 
Reverse: 5’ CCCCCCGAGTATGGTTCTG 3’ 
 
mKlf9 synergy module-5.3  (-5232 to -5143 relative to the TSS): 
Probe – 5’ 6FAM- ACCTGCCTCCTCCGGCTGCTG 3’ 
Forward: 5’ AGAACTGGGACTGTCCTCAAATG 3’ 
Reverse: 5’ TGGCATCGCCCTTTTAAAAA 3’ 
 
mKlf9 -3.8(-3861 to -3777 relative to the TSS): 
Probe – 6FAM-ACCTCACTTCACCTCTCC 3’ 
Forward primer – 5’ TCCAGTCCGCAGATAAGAAAATGG 3’ 
Reverse primer – 5’ GGCCTCTTCTGCCTTAAATGAGAT 3’ 
 
mKlf9 -2.0 (-2097 to -2025 relative to the TSS) 
Probe – 6FAM- TGT CTC AAA AAA CCC CCC AAA AAG GC 3’ 
Forward primer – 5’ CAG CCA AGG ATA CAC AGA GAA ACC 3’ 
Reverse primer – 5’ GGGAAGCCATCTTGGAAATCT3’ 
 
mKlf9 promoter (-973 to -903 relative to the TSS) 
Probe – 6FAM- CCA GCC CTC AAA CAG T 3’ 
Forward primer – 5’ AGC GTT TGC AGG AAG TCA CTT A 3’ 








mKlf9 TSS (+164 to +230 relative to the TSS) 
Probe – 6FAM- CTT TCT CTG GGA CTC CGA CAC GTT TGC3’ 
Forward primer – 5’ CGC CTG GCT CGC AGT T 3’ 
Reverse primer – 5’ GCG GTC GCA AGT TTA TTC GA 3’ 
 
 
mKlf9 + 2kb (+1934 to +2018 relative to the TSS) 
Probe – 6FAM- CAG CGG GCC TTA CCT TGT CCT GAG A 3’ 
Forward primer – 5’ GGG TCG TTT GTA ACT GTT GTT ATG A 3’ 
Reverse primer – 5’ CAC GAT GCC AAC AAC TCT GAA3’ 
 
mKlf9 intron (+11503 to +11569 relative to the TSS): 
Probe – 5’ 6FAM-CTTCTGCACTGGTTTTAG 3’ 
Forward: 5’ CGTATAGCTGTTTGAGGTCCATAGTT 3’ 








Table 3.2 Oligonucleotides used for construction of pGL4.23 promoter plasmids and 
electrophoretic mobility shift assay (EMSA). 
______________________________________________________________________________ 
 
PCR primers to amplify promoter fragments cloned into pGL4.23 vector 
xtKlf9 -7 to -6 kb 
Forward:  5’ ata ctcgag ATG GTG TAC CTT TGG CAC TGA CA 3’ 
Reverse: 5’ ata aagctt GAC GAA ACT GTG GAG CTC ACG ATC 3’ 
 
xtKlf9 -6 to -5 kb 
Forward:  5’ ata ctcgag AGC TCC ACA GTT TCG TCC CTG  3’ 
Reverse: 5’ ata aagctt CTG CCA TGC TGG TTA CGT TAT TTA AT 3’ 
 
xtKlf9 -5 to -4 kb 
Forward:  5’ ata ctcgag TAA ATA ACG TAA CCA GCA TGG CAG AA 3’ 
Reverse: 5’ ata agatct  CTG TGG TTG GTG ATG TCA TTT ATG T 3’ 
 
xtKlf9 -4 to -3 kb 
Forward:  5’ ata ctcgag CCA ACC ACA GGA TAT AAC TTA TGA T 3’ 
Reverse: 5’ ata aagctt TCT TAT CCA AGA ATC AAT GCT TGA 3’ 
 
xtKlf9 -3 to -2 kb 
Forward:  5’ ata ctcgag TCA AGC ATT GAT TCT TGG ATA AGA  3’ 
Reverse: 5’ ata aagctt CAC TTT GAC TCA TTA GTG TGA GTG T 3’ 
 
xtKlf9 -2 to -1 kb 
Forward:  5’ ata ctcgag TGA GTC AAA GTG AAC AAT AGC ACA T 3’ 
Reverse: 5’ ata aagctt GAT CCA TAG AGT AAC CAA TGG TGT C 3’ 
 
xtKlf9 -1 to 0 kb 
Forward:  5’ ata ctcgag GAC ACC ATT GGT TAC TCT ATG GAT C 3’ 
Reverse: 5’ ata agatct GAC AAA GCT GCA TAT GAG ACA CTC 3’ 
 
xKlf9 synergy moldule -6.0 
Forward: 5’ ata ctcgag CCC TGT ACC ATTTAGGGC c 3’ 
Reverse: 5’ ataaagctt    AGC GCC GCT TTAAGAAAT 3’ 
 
mKlf9 synergy moldule -5.3 
Forward: 5’ atactcgagTCCTTGCACGAGTTTGGG 3’ 
Reverse: 5’ ataaagcttATCGCCCTTTTAAAAATCT 3’ 
 
PCR primers for site-directed mutagenesis of pGL4.23 mKlf9 synergy module 
mKlf9 GRE/MRE- 5.3 mut: AGGGCAgttTGTTCA mutated to ACCTCAgttGAATCA  
Forward:5’GCGGATTCCTCGTCCCCCAATCTACCTCAGTTGAATCAACTGCAGCAAAGAGAG 3’ 
Reverse: 5’AGCTCTCTTTGCTGCAGTTGATTCAACTGAGGTAGATTGGGGGACGAGGAATCC 3’ 
 
mKlf9 T3RE- 5.23 mut: TGTCCT caaa TGA ACC mutated to TAACCT caaa ATAACC 
Forward: 5' ATTTCTGAGAACTGGGACTAACCTCAAAATAACCTGCCTCCTCCGGCTG 3' 
Reverse: 5' CAGCCGGAGGAGGCAGGTTATTTTGAGGTTAGTCCCAGTTCTCAGAAAT 3' 
 
mKlf9 HRE h2 mut: TGTCCT caaa TGA ACC mutated to TAACCT caaa TGA ACC  
Forward: 5'GGGATTTCTGAGAACTGGGACTAACCTCAAATGAACCTGC3' 







mKlf9 HRE h3 mut: TGTCCT caaa TGA ACC mutated to TGTCCT caaa ATAACC 
Forward: 5' CTGGGACTGTCCTCAAAATAACCTGCCTCCTCCG 3' 
Reverse: 5' CGGAGGAGGCAGGTTATTTTGAGGACAGTCCCAG 3' 
 
mKlf9 HRE h1 mut: AGAACT mutate to ACCAAA 
Forward: 5'GATGTTCCAGCAGGGAAGGGATTTCTGACCAAAGGGACTGTCCTCAAA 3' 





mKlf9 T3RE- 5.23 
Sense:  5’ gatc TCTG AGAACT GGGAC TGTCCT CAAA TGAACCTGC  3’ 
Antisense: 5’ gatc GCA GGT TCA TTT GAG GAC AGT CCC AGT TCT CAGA 3’  
 
mKlf9 T3RE- 5.23 mut 
Sense:  5’gatc TCTG AGAACT GGGAC TAACCT CAAA ATAACCTGC  3’ 
Antisense: 5’ gatc GCAGGTCATTTTGAGGTTAGTCCCAGTTCTCAGA 3’  
 
xTRβ T3RE 
Sense: 5’ gatc CGTCCTCCCTAGGCAGGTCATTTCAGGACAGCCCAGCGCCC  3’ 
Antisense: 5’ gatc ACCAGGGCGCTGGGCTGTCCTGAAATGACCTGCCTAGGGAG 3’  
____________________________________________________________________________ 
PCR primers for site directed were designed using QuickChange Primer Design tool (Agilent) 
Shaded nucleotides represent introduced mutations in the GRE/MRE halfsites.  
Lower case letters represent restriction sites for subcloning into the pGL4.23 vector or non- 

















Fig. 3.1. Corticosterone (CORT) synergizes with 3,5,3’-triiodothyronine (T3) to 
induce Klf9 mRNA in frog and mouse brain. (A) Nieuwkoop- Faber stage 52-54 X. 
tropicalis tadpoles were treated with T3 and CORT at the doses indicated and brain was 
collected for RNA isolation 24h post hormone treatment.  (B) The X.laevis embryonic 
fibroblast (XTC-2) and renal epithelium(A6) derived cell line were treated with 5 nM T3, 
100 nM CORT or T3 plus CORT for 4h before harvest and RNA isolation. (C) Postnatal 
day 6 (PND 6) wild type C57/BL6J mice were injected with vehicle (oil and DMSO),  T3 
( 25 ug/kg bodyweight) , CORT (14 mg/ kg bodyweight), T3 plus CORT or left 
unhandled. One hour after injection animals were killed, the hippocampal region was 
dissected and RNA extracted (n=5-6/ treatment group). (D) HT-22 cells were treated with 
30 nM T3, 100 nM CORT or T3 plus CORT for different times before harvest and RNA 
extraction. All RNA samples were used to measure Klf9 mRNA by RTqPCR using 
Taqman assay.  Frog and mouse Klf9 mRNA were normalized to the mRNA level of the 
housekeeping gene rpL8 and GAPDH, respectively. Bars represent the mean + SEM and 
letters above the means indicate significant differences among treatments (means with the 
same letter are not significantly different; Tukey’s multiple comparison test; P<0.05). 







Fig. 3.2. Induction of Klf9 mRNA by corticosterone (CORT) and 3,5,3’-
triiodothyronine (T3) in XTC-2 and HT-22 cells is resistant to protein synthesis 
inhibition. XTC-2 (A) and HT-22 (C) cells were grown to 80% confluency in growth 
medium (L-15 for XTC-2 and DMEM for HT-22 supplemented with pen/strep and 10% 
FBS), after which it was replaced with methionine and cysteine-deficient L-15 or DMEM 
supplemented with penicillin/streptomycin and 10% FBS, Cells were cultured for 2 hr 
before addition 10 Ci/well of [
35
S]-ExPress protein labeling mix. Different doses of 
cycloheximide (CHX) or ethanol as vehicle (final concentration 0.001%) were added 
simultaneously to the protein labeling mix. Cells were harvested after a 6h incubation and 
proteins were precipitated  with 10% ice-cold TCA. Radioactivity of the precipitated 
proteins was measured by liquid scintillation counting.  XTC-2 (B) and (D) HT-22 cells 
were treated with or without CHX (10 g/ml in XTC-2; 100 g/ml in HT-22) for 30 min 
before addition of 3,5,3’ triiodothyronine (T3; 5 nM in XTC-2; 30 nM in HT-22),  
corticosterone (CORT; 100 nM) or T3 plus CORT. Treatment with CHX plus hormones 
was continued for 4 h before cell harvest for analysis of Klf9 mRNA by RTqPCR. Frog 
and mouse Klf9 mRNA were normalized to the mRNA level of the housekeeping gene 
rpL8 and GAPDH, respectively. Bars represent the mean + SEM (n=4) and letters above 
the means indicate significant differences among treatments (means with the same letter 
are not significantly different; Tukey’s multiple comparison test; P<0.05). Dashed lines 






Fig. 3.3. Identification of the Klf9 genomic region that supports corticosterone 
(CORT) and 3,5,3’-triiodothyronine (T3) synergistic transactivation. A series of 1 
kilobase fragments covering from -7 kb to 0 kb upstream of the X. tropicalis Klf9 
transcription start site were cloned into a luciferase vector and transfected into XTC-2 
cells.  Cells were treated with T3, CORT or T3 plus CORT for 4 h before harvest and 
analysis by dual luciferase assay. Bars represent the mean + SEM (n=4-5) fold induction 
and letters above the means indicate significant differences among hormone 
concentrations or time point (means with the same letter are not significantly different; 
Tukey’s multiple comparison test; P<0.05). Dashed lines represent the additive effects of 




























Fig.3.4. Identification and functional analysis of an evolutionarily conserved ~180 bp 
synergy module  located -6 kb of the mouse Klf9 gene. (A). Comparative sequence 
analysis of the -6 to -5 kb X.tropicalis Klf9 genomic region that supported 3,5,3’-triiodothyronine 
(T3) plus corticosterone (CORT) synergistic activation revealed a ~180 bp fragment (partial 
sequence shown), containing five hormone response element (HRE) half sites that are 
evolutionarily conserved across vertebrates. Sequence alignment showing conservation of the 
T3RE (yellow; HRE h2 and HRE h3), GRE/MRE (blue; mouse GRE/MRE-5.3) and a hormone 
response element half site (HRE h1; green) across several vertebrate species. The conserved 180 
bp fragment, we call the Klf9 synergy module is centered at ~-4.6 kb in human, ~-5.3 kb in mouse 
and  ~-5.9 kb in the frog Klf9 gene. (B) Promoter luciferase constructs containing the mouse Klf9 
179 bp synergy module, and corresponding site mutants (*) were transfected into HT-22 cells. 
Cells were treated with T3, CORT or T3 plus CORT for 4 h before harvest and analysis by dual 
luciferase assay. Bars represent the mean + SEM (n=4) and letters above the means indicate 
significant differences among treatments (means with the same letter are not significantly 
different; Tukey’s multiple comparison test; P<0.05). Dashed lines represent the additive effects 







Fig. 3.5. The thyroid hormone receptor (TR) and glucocorticoid receptor GR 
associate with the synergy module in vitro and in mouse hipppocampus in vivo. (A) 
The ability of the TR to bind to the mouse Klf9 synergy module TRE was tested in vitro 
by electrophoretic mobility shift assay. Each reaction contained [
32
P]-labeled synergy 
module T3RE oligo as probe (lanes 1-5) and 2 l of in vitro synthesized luciferase protein 
(control, lane 2) or frog TRβ plus frog RXRα protein (lanes 3-5). The TRβ/RXRα 
binding to the probe was competed with 1.5 M radioinert synergy module T3RE (lane 4) 
or mutated synergy module T3RE oligonucleotides (lane 5). We conducted EMSA with a 
probe containing the previously identified T3RE in the frog TRβ promoter as a positive 
control for TRβ/RXRα binding. Each reaction contained [
32
P]-labeled xTRβ T3RE 
oligonucleotide as probe (lanes 6-9) and 2 l of in vitro synthesized luciferase protein 
(control, lane 7) or TRβ/RXRα (lanes 8 and 9). The TRβ/RXRα binding to the xTRβ TRE 
probe was competed with 1.5 M radioinert xTRβ TRE oligonucleotide (lane 9). The 
supershifted bands indicated by the arrows are the TRβ/RXRα -bound probe. (B) The 
ability of the GR to bind to the mouse Klf9 GRE/MRE-5.3 within the synergy module 
was tested in vitro by electrophoretic mobility shift assay. Each reaction contained [
32
P]-
labeled GRE/MRE-5.3 oligo as probe (lanes 1-5) and 2 l of in vitro synthesized 
luciferase protein (control, lane 2) or human GR protein (lanes 3-5). The GR binding to 
the probe was competed with 1.5 M radioinert GRE/MRE-5.3 (lane 4) or mutated 
GRE/MRE-5.3 oligonucleotides (lane 5). The supershifted bands indicated by the arrow 
are the GR-bound probe. (C) Wild type PND5 mice were injected with T3 at a dose of 25 
µg/kg bodyweight. Four hours after injection animals were killed, the hippocampal 
region was dissected and chromatin extracted for TR ChIP assay. ChIP samples (n=4-5) 
were analyzed by RTqPCR using Taqman assays that targeted the synergy module or a 
distal intronic region (negative control) of the mouse Klf9 gene. Bars represent the mean 
ChIP signals expressed as a percentage of the input for TR serum (anti-TR) or normal 
rabbit serum (NRS) as negative control. Statistics were conducted on the normalized TR 
(the mean ChIP signals expressed as a percentage of the input minus the NSB where NSB 
was assessed by ChIP using NRS). Statistical analysis was conducted on log10 
transformed data, and the asterisks indicate statistically significant differences between 
anti-TR and NRS ChIP signal (P<0.01; Student’s t test).   (D) Wild type PND6 mice were 
injected with corticosterone (CORT) at a dose of 14 mg/kg bodyweight or left unhandled. 
One hour after injection animals were killed, the hippocampal region was dissected and 
chromatin extracted for GR ChIP assay. ChIP samples (n=9) were analyzed by RTqPCR 
using Taqman assays that targeted the GRE/MRE-6.1,synergy module or a distal intronic 
region (negative control) of the mouse Klf9 gene. Bars represent the mean ChIP signals 
expressed as a percentage of input. Statistical analysis was conducted on log10 
transformed data, and the asterisks indicate statistically significant differences between 
unhandled and CORT-injected animals (P<0.05; Student’s t test). Dashed lines represent 





























Fig. 3.6. Hormone- dependent recruitment of TR and GR across the Klf9 locus. HT-
22 cells were treated with T3 (30 nM), CORT (100 nM) or T3 plus CORT for 4 h before 
harvest for chromatin extraction and ChIP assay for TR (A, B) and GR (C,D). ChIP 
samples (n=6) were analyzed by RTqPCR using Taqman assays that target different 
genomic regions of mouse Klf9 gene indicated by their distance from the Klf9 
transcription start site (TSS). Line plots represent the hormone dependent association of 
TR (A) or GR (C) across the Klf9 genomic locus expressed as percentage of input. 
Asterisks indicate  a statistically significant synergistic effect of T3 plus CORT on TR or 
GR association.  Representative bar graphs of ChIP signals expressed as a percentage of 
input of a subset of data points for TR with T3 plus CORT treatment (B) and GR (D) are 
also shown. Statistical analysis was conducted on log10 transformed data, and the letters 
above the means indicate significant differences among treatments (means with the same 












Fig. 3.7. Corticosterone (CORT) or 3,5,3’-triiodothyronine (T3)  promotes 
nucleosome eviction, histone 3 and histone 4 acetylation at the synergy module of the 
mouse Klf9 gene. HT-22 cells were treated with T3 (30 nM), CORT (100 nM) or T3 plus 
CORT for 4 h before harvest for chromatin extraction and ChIP assay for histone 3(H3) 
(A, B), acetylated histone 3 (AcH3) (C,D) or acetylated histone 4 (AcH4) (E,F). ChIP 
samples (n=4) were analyzed by RTqPCR using Taqman assays that target different 
genomic regions of mouse Klf9 gene indicated by their distance from the Klf9 
transcription start site (TSS). Line plots represent the hormone dependent ChIP signals 
for H3 (A), AcH3 (C) or AcH4 (E) across the Klf9 genomic locus expressed as 
percentage of input. Asterisks indicate a statistically significant effect of T3 or CORT.   
Representative bar graphs of ChIP signals expressed as a percentage of input of a subset 
of data points for H3 (B), AcH3 (D) or AcH4 (F) are also shown. Statistical analysis was 
conducted on log10 transformed data, and the letters above the means indicate significant 
differences among treatments (means with the same letter are not significantly different; 




















Fig. 3.8. Hormone-dependent recruitment of stalled RNA polymerase II (S5P) and 
elongating RNA polymerase II (S2P) across the Klf9 locus. HT-22 cells were treated with 
T3 (30 nM), CORT (100 nM) or T3 plus CORT for 4 h before harvest for chromatin extraction and 
ChIP assay for stalled RNA pol II S5P (A, B) and elongating RNA pol II S2P (C,D). ChIP 
samples (n=6) were analyzed by RTqPCR using Taqman assays that target different genomic 
regions of mouse Klf9 gene indicated by their distance from the Klf9 transcription start site (TSS). 
Line plots represent the hormone dependent association of stalled (S5P) (A) or elongating (S2P) 
(C) RNA polymerase II across the Klf9 genomic locus expressed as percentage of input. Asterisks 
indicate a statistically significant synergistic effect of T3 plus CORT on stalled RNA polymerase 
II association.  Representative bar graphs of ChIP signals expressed as a percentage of input of a 
subset of data points for stalled (S5P) (B) or elongating (S2P) (D) RNA polymerase II are also 
shown. Statistical analysis was conducted on log10 transformed data, and the letters above the 
means indicate significant differences among treatments (means with the same letter are not 
significantly different; Tukey’s multiple comparison test; P<0.05). Dashed lines represent the 








Fig. 3.9. Corticosterone (CORT) synergizes with 3,5,3’-triiodothyronine (T3) to 
induce transcription at the Klf9 synergy module. (A) HT-22 cells were treated with30 
nM T3, 100 nM CORT or T3 plus CORT and (B) with or without cycloheximide (CHX) 
for 30 min before addition of 30 nM T3, 100 nM CORT or T3 plus CORT for 4h before 
harvest and RNA extraction. RNA samples were treated with DNAseI and were 
measured by RTqPCR using Taqman assay targeted to the synergy module (eRNA) and 
an exon-exon boundary of the Klf9 gene (mRNA). RTqPCR without reverse transcriptase 
was used as a negative control and did not yield any amplicons. RNA transcripts at were 
normalized to the mRNA level of the housekeeping gene GAPDH. Bars represent the 
mean + SEM and letters above the means indicate significant differences among 
treatments (means with the same letter are not significantly different; Tukey’s multiple 













Fig. 3.10. The synergy module interacts with the Klf9 promoter as shown by 
Chromosomal interaction analysis by paired end tag sequencing (ChIA-PET). (A) 
The frog Klf9 locus shown as reference to locate genomic regions identified by  RNA- 
paired end tag sequencing (RNA- PET) (B), or RNA-Seq to identify and measure Klf9 
mRNA transcript levels across the locus produced with (E) or without (F) T3 treatment of 
tadpole tail fin tissue.  (C) Thyroid hormone receptor (TR) binding sites and the 
corresponding levels of TR bound across the Klf9 locus, indicated as red peaks, were 
identified by TR ChIP- Seq using chromatin from T3-treated tadpole tail fin tissue.. 
Within the genomic region shown, highest levels of TR binding were found in a region 
corresponding to the synergy module (blue arrow) (D) Thyroid hormone-dependent long- 
range chromosomal interactions across the Klf9 locus were identified by (ChIA-PET). 
Long range interaction between genomic regions are shown as two purple bars connected 







Fig. 3.11. Klf9 is synergistically regulated by corticosterone (CORT) and 3,5,3’-
triiodothyronine (T3) at the transcriptional level. In the absence of T3, thyroid hormone 
receptor (TR) is bound to the Klf9 synergy module and is associated with corepressors to 
maintain a compact chromatin environment that is not permissive for Klf9 transcription. Upon T3 
binding, TR releases the corepressors in exchange for coactivators that promote histone 
acetylation, chromatin decompaction, looping and RNA polymerase II mediated transcription of 
the synergy module (eRNA) and Klf9 gene (mRNA). On the other hand, CORT treatment 
activates the glucocorticoid receptor (GR) located in the cytoplasm followed by translocation to 
the nucleus where it associates with the synergy module and other GRE/MRE  and  recruits 
coactivators leading to possible chromatin looping and RNA pol II mediated transcription or Klf9 
eRNA and mRNA.  Combined treatment with T3 plus CORT leads to T3 dependent depression of 
the Klf9 locus that allows an enhanced and synergistic recruitment of GR. The presence of ligand 
bound TR and enhanced recruitment of GR at the synergy module leads to a synergistic 
association of stalled RNA polymerase II (pol2) at the synergy module maintaining the Klf9 locus 
poised for a rapid transcriptional response. Association of hormone bound TR, GR and pol2 at the 
synergy module leads to transcription at that region and to chromosomal looping that allows the 
regulatory information at the synergy module to be relayed to the promoter ultimately resulting in 
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IDENTIFICATION  OF  GENES  SYNERGISTICALLY  REGULATED  BY 
THYROID  HORMONE  AND  GLUCOCORTICOIDS  IN  HIPPOCAMPAL 




The hippocampus is a well-known target of thyroid hormone (T3) and glucocorticoid 
action. Deficiency in T3 during neonatal development results in morphological and 
functional changes in the hippocampus such as reduced dendritic arborization, delayed 
synaptogenesis and impaired synaptic transmission. Glucocorticoids (e.g., corticosterone 
- CORT) both facilitate and inhibit hippocampal development and function depending on 
their level and duration of elevation. Despite evidence that these two hormones play 
critical roles in neural development and function, few studies have looked at whether 
these hormones interact to regulate similar or different sets of target genes, or if they may 
cooperate to regulate gene expression.  In this study we investigated gene regulation by 
T3 or CORT alone, or the two hormones together in the mouse hippocamapal-derived cell 
line HT-22. We treated cells with T3 (30 nM) or CORT (100 nM), or T3 plus CORT for 4 
hr before cell harvest and RNA isolation for microarray analysis. We identified 425 genes 
that were regulated by CORT, 293 induced and 132 repressed.  There were 203 genes 
regulated by T3, 116 induced and 87 repressed. We found 69 genes synergistically up-
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regulated, and 80 genes synergistically down-regulated by T3 plus CORT treatment. 
Among the synergistically up-regulated genes, gene ontology analysis identified a group 
of genes involved with cytoskeletal remodeling, supporting that a major synergistic 




The hippocampus, a neural structure important for learning and memory, is strongly 
influenced by the actions of thyroid hormone (T3) and glucocorticoids (GCs; stress 
hormones; e.g., corticosterone - CORT) A deficienty of T3 during neonatal and postnatal 
life results in morphological and functional changes in the hippocampus that include 
delayed neuronal migration, reduction in cell body size and dendritic arborization of 
granular and pyramidal neurons, delayed synaptogenesis in the dentate gyrus, reduction 
of synapses between mossy fibers and CA3 pyramidal neurons, impaired synaptic 
transmission in the CA1 region and impaired performance in  behavioral tasks related to 
hippocampal function (Rami, Patel et al. 1986; Rami, Rabie et al. 1986; Gould, Allan et 
al. 1990; Rami and Rabie 1990; Akaike, Kato et al. 1991; Madeira and Paula-Barbosa 
1993; Gilbert and Paczkowski 2003; Darbra, Balada et al. 2004; Gilbert 2004; Dong, Yin 
et al. 2005; Gilbert and Sui 2006; Gilbert and Sui 2008). Glucocorticoids also play 
important roles in hippocampal development and function, but they may have facilitatory 
or inhibitory effects depending on the physiological and behavioral context and, severity 
and duration of the stressor (Joels 2008). For example, in rodents, chronic stress, or 
prolonged treatment with GC causes retraction and atrophy of  dendrites in the CA3 
region of the hippocampus (Watanabe, Gould et al. 1992; Magarinos, Verdugo et al. 
1997; McEwen 1999), neuronal loss, inhibits long term potentiation (LTP) and impairs 
hippocampal-dependent cognitive tasks (McEwen 1999).  In contrast, moderate acute 
stress, mediated in part by GCs, has been shown to enhance hippocampal neuronal 
function and hippocampal-dependent processes (Shors 2001; Shors, Chua et al. 2001; 
Roozendaal 2002; Beylin and Shors 2003; Karst and Joels 2005; Joels, Pu et al. 2006).  
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Although several studies have established that T3 and GCs influence structure and 
function of hippocampal neurons (Porterfield and Hendrich 1993; McEwen 1999; 
Porterfield 2000), few have investigated the interaction between, and combined effects of 
T3 and GC (Gould, Woolley et al. 1991). Several gene expression analyses have been 
conducted to identify GC-induced genes in hippocampal neurons (Datson, van der Perk et 
al. 2001; Morsink, Steenbergen et al. 2006; Datson, Morsink et al. 2008; Royland, Parker 
et al. 2008; Datson, Speksnijder et al. 2010; Datson, Polman et al. 2011). However, to my 
knowledge, no gene expression analysis has been done on hippocampus to identify genes 
that are coordinately regulated by T3 and GC. A gene that we found to be independently 
and synergistically regulated by T3 and GC in hippocampal neurons is Krüppel-like factor 
9 (Klf9) (Denver, Pavgi et al. 1997; Denver, Ouellet et al. 1999; Furlow and Kanamori 
2002; Bagamasbad, Howdeshell et al. 2008; Bonett, Hu et al. 2009; Denver and 
Williamson 2009), Chapter 2,3). This transcription factor is known to influence neuronal 
structure and function(Denver, Ouellet et al. 1999; Cayrou, Denver et al. 2002; Morita, 
Kobayashi et al. 2003; Lin, Bloodgood et al. 2008; Scobie, Hall et al. 2009). The 
synergistic regulation of Klf9 by T3 and GC is marked (see Chapter 3), but this is the only 
gene identified to be regulated in this manner in the hippocampus. We therefore sought to 
determine if the synergistic regulation of Klf9 was an isolated phenomenon, or if there are 
other genes that are similarly regulated. If other genes show similar synergistic induction 
by hormones, this might point to similar transcriptional mechanisms, and perhaps related 
functions in hormone action on hippocampal cells. We identified 69 synergistically up-
regulated and 80 genes synergistically down-regulated by T3 and GC. Gene ontology 
analysis of the synergistically up-regulated genes showed that there is an enrichment of 
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genes involved in organization of the actin cytoskeleton, and in cell growth and 
proliferation, suggesting that T3 and GCs may coordinately regulate genes involved in 
neuroprogenitor proliferation, and neuronal morphology. 
 
Materials and methods 
Cell Culture and Transient Transfection Assays. HT-22 is a cell line derived from 
mouse hippocampus immortalized with the SV40 T antigen (Morimoto and Koshland 
1990; Morimoto and Koshland 1990). This cell line exhibits properties of differentiated 
neurons; e.g., they express neuron specific markers such as enolase and the neurofilament 
triplet, but not the glial cell marker, glial fibrillary acidic protein (Morimoto and 
Koshland 1990; Morimoto and Koshland 1990; Maher and Davis 1996; Sagara, Dargusch 
et al. 1998). HT-22 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
Invitrogen) supplemented with sodium bicarbonate (2.2 g/L), penicillin G (100 
units/mL), streptomycin sulfate (100 g/mL) and 10% fetal bovine serum (FBS) that had 
been stripped of thyroid (Samuels, Stanley et al. 1979) and steroid hormones (Yao, 
Schulkin et al. 2008). Cells were cultured under a humidified atmosphere of 5% CO2 at 
37
o
C. For gene expression analysis we seeded cells at a density of 1 x10
7
 cells per well in 
100 cm
2
 plates. When cells reached ~90-95% confluency, and immediately before 
hormone treatments, we replaced the growth medium with serum-free DMEM. 
Corticosterone (CORT; Sigma C2505) was dissolved in 100% ethanol and added to the 
media to a final concentration of 100 nM. 3,5,3’-triiodothyronine (T3; Sigma T2752) was 
dissolved in dimethylsulfoxide (DMSO) and added to a final concentration of 30 nM. 
Control treatments received an equivalent concentration of vehicle (0.001% ethanol and 
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0.03% DMSO). All hormone treatments were continued for 4 h before cell harvest. Each 
hormone treatment was performed in triplicate for RNA extraction and microarray 
analysis. 
 
RNA Extraction, Reverse Transcription and Quantitative PCR. We extracted total RNA 
from HT-22 cells using the Trizol reagent (Invitrogen) following the manufacturer’s 
protocol. The extracted RNA was further purified using the RNAeasy Kit (Qiagen) to 
obtain a UV absorbance ratio at A260/280 to be between 1.8 to 2.0. We conducted RTqPCR 
for Klf9 expression (as described in Chapter 2) to verify that the hormone treatments 
worked before microarray analysis.   
 
Microarray analysis. Total RNA (175 ng per sample) was amplified using the Illumina 
Totalprep RNA Amplification Kit (Ambion, Inc.) to generate biotinylated amplified 
RNA. The biotinylated RNA (2 µg) was hybridized at 55° C for 22 hr to Illumina Bead 
Chips (Illumina Mouse WG-6 v2.0). Microarrays were washed and scanned for data 
collection as directed by the manufacturer. Microarray data was normalized (Rank 
Invariant), and analysed with Illumina Genome Studio software. The mean array values 
of three replicates per treatment were used to compute fold change over control.  
 
Data Analysis and Statistics. We filtered the microarray data set using the Statisical 
Analysis Program SAS (version 9.5, SAS Institute, Inc). Gene expression fold change 
was computed as the ratio between the average of the hormone treatment hybridization 
signal intensity (n=3/ hormone treatment) and average of the control treatment 
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hybridization intensity. Hormone-dependent regulation was identified based on a cut-off 
P value <0.05, and a 1.2 fold change for T3 treated samples; and P<0.02, and a 1.5 fold 
change for CORT, and T3 plus CORT-treated samples. The P value cutoff was set higher 
and fold change cutoff was set lower for the T3 data set  than the CORT and T3 plus 
CORT data set since we only found 10 genes to be regulated by T3 at a P <0.02, 1.5 fold 
change. The HT-22 cells are differentiated neurons and may have a weak T3 response. 
Genes considered to be synergistically regulated by T3 plus CORT are , those that were 
not regulated by T3 or CORT alone but were regulated with T3 plus CORT based on a 
P<0.02 and a 1.5 fold change, or genes that were regulated by T3 and/or CORT alone that 
showed a greater than additive effect of positive or negative regulation with T3 plus 
CORT treatment. Whether the combined effect of T3 and CORT on gene expression was 
greater than the additive effect of either hormone alone was determined by unpaired 
Student’s t-test. This compared the combined hormone treatment array signal to the sum 
of the T3 alone and the CORT alone array signals. Gene ontology analysis was conducted 
using the Ingenuity Pathway Analysis (IPA) Software (Illumina). 
 
Results 
Identification of genes differentially regulated by T3, CORT and T3 plus CORT.  
Genome wide expression analysis of hormone treated HT-22 cells identified 116 genes to 
be up-regulated (Table 4.1; Supplemental Table 4.3) and 87 genes to be down-regulated 
(Table 4.2; Supplemental Table 4.4) by T3. Treatment with CORT up-regulated the 
expression of 293 genes regulated (Table 4.4; Supplemental Table 4.5) and down-
regulated the expression of 132genes (Table 4.4; Supplemental Table 4.6). Treatment 
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with T3 plus CORT treatment up-regulated the expression of 252 genes (Table 4.5; 
Supplemental Table 4.7) and down-regulated the expression of 148 genes (Table 4.6; 
Supplemental Table 4.8). A summary of the number of genes differentially regulated by 
each of the hormone treatments is shown in Table 4.7. The number of genes commonly 
regulated by the individual or combined hormone treatments is depicted in Fig. 4.1 as a 
Venn diagram.  
 Genes regulated by T3 plus CORT treatment, but not by treatment with T3 or CORT 
alone were considered to be synergistically regulated. In addition to this group of genes, 
we conducted statistical analysis to determine which genes that were regulated by one or 
both hormones alone showed a greater than additive effect of combined hormone 
treatment (either positive or negative); i.e., genes found at the intersections of sectors in 
the Venn diagram in Fig 4.1.) By these criteria we found 69 genes to be synergistically 
up-regulated (Table 4.8), and 80 genes to be synergistically down-regulated (Table 4.9) 
by T3 plus CORT treatment. 
 
Gene ontology (GO) analysis of genes differentially regulated by T3, CORT and T3 
plus CORT in HT-22 cells. We used the Ingenuity Pathway Analysis Program to identify 
pathways and biological functions that are enriched in our microarray dataset. The top 
associated networks and biological functions, subdivided into disease and disorders, 
molecular and cellular functions and physiological system development and function, 
identified by GO analysis are presented in Table 4.10 to 4.14 (T3-regulated GO analysis, 
Table 4.10; CORT-regulated GO analysis, Table 4.11; T3 plus CORT-regulated GO 
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analysis, Table 4.12; synergistically up-regulated GO analysis, Table 4.13; synergistically 
down-regulated GO analysis, Table 4.14). 
 
Discussion 
The hippocampus is a well-known target for T3 and GC action, where both hormones 
influence basic developmental processes such as neurogenesis, dendritic arborization, 
synaptogenesis and synaptic plasticity. Here we report results of  a microarray analysis 
for genes that are regulated by T3 or CORT, and with combined treatment of the two 
hormones. We placed emphasis on finding genes that were synergistically up- or down-
regulated by T3 plus CORT. Using the Ingenuity Knowledgebase Pathway Interaction 
Analysis, which identifies direct and indirect transcriptional targets, and other molecules 
known to interact with hormone-dependent pathways, we found ten of the T3-regulated 
genes to be in the T3 and T3 receptor interaction pathways (Supplemental Table 4.7). 
Eighteen CORT-regulated genes were in the GC and GC receptor interaction pathways 
(Supplemental Table 4.8).  
Gene ontology analysis of genes regulated by T3 revealed an enrichment of genes 
involved in gene expression (transcription factors), cell death, and cell growth and 
proliferation. Among the CORT-regulated genes, there is an enrichment of genes 
involved in apoptosis, cell movement (migration and invasion), and differentiation of 
various cell types (blood cells, hematopoietic progenitor cells, connective tissue cells and 
endothelial cells). There was also an enrichment of genes involved in nervous system 
development and function, particularly those related to the development of neurological 
diseases such as encephalopathy, Huntington’s disease and neuromuscular disease. 
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Among the genes regulated by T3 plus CORT, we found an enrichment of genes involved 
in cellular development and differentiation of cells (blood cells, hematopoietic progenitor 
cells, connective tissue cells, muscle cells), cell movement and cell homing, and 
apoptosis. 
 Among the genes synergistically up-regulated by T3 plus CORT, 12 of the 69 genes 
were found to be related to cellular assembly and reorganization. There was also an 
enrichment of genes involved in DNA replication and repair, and post-translational 
modification. It is noteworthy that the gene synergistically induced by T3 plus CORT 
with the highest fold change (~10 fold) is cytochrome b-561 (Cyb561), a transmembrane 
electron transport protein that is found in catecholamine and neuropeptide secretory 
vesicles in the adrenal medulla, pituitary gland and other neuroendocrine tissues 
(McBride, Yi et al. 1994). This may indicate that one of the physiological processes 
affected by hormone synergy is the formation of secretory vescicles, or the process of 
neurotransmitter secretion. In the brain, this could impact synaptic strength and signaling, 
and may represent an important component of hormone action on synaptic 
function/plasticity. Cytochrome b-561 was also identified as a senescence-associated 
gene in human keratinocytes (Kang, Kameta et al. 2003).  Genes that were synergistically 
down-regulated by T3 plus CORT were enriched for genes involved in proliferation of 
embryonic, mesenchymal and neuronal cells, and in differentiation of muscle cells.  
 Since we found Klf9 to be synergistically up-regulated in the mouse hippocampus in 
vivo and in HT-22 cells, and KLF9 has been shown to influence neuronal morphology, 
we were interested to discover that among the genes synergistically up-regulated by T3 
plus CORT, there was an overrepresentation of genes (12 of the 69 genes) related to 
167 
 
cellular assembly and reorganization, with 5 of the 12 genes (ARFIP2, CALR, PI3K 
signaling complex, Rac, SLC3A2) involved in remodeling of the cytoskeleton. This 
suggests that similar to Klf9, other genes involved in shaping neuronal structure are 
synergistically regulated by T3 and CORT. I hypothesize that through the synergistic 
gene regulation by T3 and CORT, cell biological processes such as dendritic elaboration, 
axonogenesis and synaptogenesis may be accelerated or enhanced. To my knowledge, 
our microarray dataset represents the first of its kind to identify genes that are 
coordinately regulated by T3 and CORT in any cell type. These results need to be further 
validated by RTqPCR, and compared with other published microarray datasets of genes 
















Table 4.1. Top 25 genes upregulated by 4h of T3 treatment in HT-22 cells.  
PROBE ID SYMBOL DEFINITION P value Fold 
change 
ILMN_1254031 Klf9 Mus musculus Kruppel-like factor 9 (Klf9), mRNA. 0 3.09 
ILMN_1220280 Tas1r1 Mus musculus taste receptor, type 1, member 1 (Tas1r1), 
mRNA. 
0 2.68 
ILMN_1232601 Cyb561 Mus musculus cytochrome b-561 (Cyb561), mRNA. 0 2.61 
ILMN_2430906 2310051E17
Rik 
PREDICTED: Mus musculus RIKEN cDNA 
2310051E17 gene (2310051E17Rik), mRNA. 
0.00009 2.23 
ILMN_1229547 Spon2 Mus musculus spondin 2, extracellular matrix protein 
(Spon2), mRNA. 
0 1.93 





 0 1.74 
ILMN_3127391 Npr3 Mus musculus natriuretic peptide receptor 3 (Npr3), 
transcript variant 1, mRNA. 
0 1.59 
ILMN_1217117 Cdon  0 1.51 
ILMN_2420341 9629514_325  0.02144 1.5 
ILMN_2457585 Trp53inp2 Mus musculus transformation related protein 53 inducible 
nuclear protein 2 (Trp53inp2), mRNA. 
0 1.49 
ILMN_1243564 Plekha1 Mus musculus pleckstrin homology domain containing, 





 0 1.48 
ILMN_2708877 Plekha1 Mus musculus pleckstrin homology domain containing, 
family A (phosphoinositide binding specific) member 1 
(Plekha1), mRNA. 
0 1.47 
ILMN_2812215 Plekhg5 Mus musculus pleckstrin homology domain containing, 
family G (with RhoGef domain) member 5 (Plekhg5), 
mRNA. 
0.00009 1.46 
ILMN_2918002 Gbp3 Mus musculus guanylate nucleotide binding protein 3 
(Gbp3), mRNA. 
0.00276 1.46 





 0.01358 1.42 
ILMN_1255967 B430216N15
Rik 
 0.01463 1.41 
ILMN_2772155 LOC1000457
80 
PREDICTED: Mus musculus similar to metalloprotease-
disintegrin meltrin beta (LOC100045780), mRNA. 
0.005 1.41 
ILMN_2966104 Htra1 Mus musculus HtrA serine peptidase 1 (Htra1), mRNA. 0 1.38 
ILMN_2746738 Htra1 Mus musculus HtrA serine peptidase 1 (Htra1), mRNA. 0 1.37 
ILMN_2433213 Klf7  0 1.37 
ILMN_2482756 Usf2 Mus musculus upstream transcription factor 2 (Usf2), 
mRNA. 
0.00049 1.36 











Table 4.2. Top 25 genes downregulated by 4h of T3 treatment in HT-22 cells.  
PROBE ID SYMBOL DEFINITION P value Fold 
change 
ILMN_2606667 Ddx6 Mus musculus DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 6 (Ddx6), mRNA. 
0.0318 
-1.72 
ILMN_2654822 Chd4 Mus musculus chromodomain helicase DNA 
binding protein 4 (Chd4), mRNA. 
0.0072 
-1.49 
ILMN_1230786 5730588I11Rik  0.01204 
-1.47 
ILMN_1253178 Aldh3a1 Mus musculus aldehyde dehydrogenase family 3, 
subfamily A1 (Aldh3a1), mRNA. 
0 
-1.47 
ILMN_2543842 2810417K24Rik  0.03291 
-1.46 
ILMN_1230788 Tle1 Mus musculus transducin-like enhancer of split 1, 
homolog of Drosophila E(spl) (Tle1), mRNA. 
XM_984202 XM_984240 XM_984277 
XM_984316 XM_984359 XM_984397 




ILMN_1237565 EG626367 PREDICTED: Mus musculus predicted gene, 
EG626367 (EG626367), misc RNA. 
0 
-1.44 
ILMN_1256844 EG668850 PREDICTED: Mus musculus predicted gene, 
EG668850 (EG668850), misc RNA. 
0 
-1.42 








ILMN_1243988 LOC269251  0.00022 
-1.41 
ILMN_3031781 Arid5b Mus musculus AT rich interactive domain 5B 
(MRF1-like) (Arid5b), mRNA. 
0.01249 
-1.39 








ILMN_1219839 mtDNA_ND6  0 
-1.35 




ILMN_3038404 Tcf25 Mus musculus transcription factor 25 (basic helix-
loop-helix) (Tcf25), transcript variant 3, mRNA. 
0.0094 
-1.34 
ILMN_2710678 Nfic  0.04947 
-1.34 
ILMN_1255731 Dnm3os Mus musculus dynamin 3, opposite strand 
(Dnm3os), non-coding RNA. 
0.01697 
-1.33 




ILMN_2874853 Eef1b2 Mus musculus eukaryotic translation elongation 
factor 1 beta 2 (Eef1b2), mRNA. 
0.04617 
-1.31 
ILMN_1259322 Pdk4 Mus musculus pyruvate dehydrogenase kinase, 
isoenzyme 4 (Pdk4), mRNA. 
0 
-1.31 
ILMN_1230726 5430406J06Rik  0.01611 
-1.31 
ILMN_2529519 LOC230592  0.02703 
-1.3 










Table 4.3. Top 25 genes upregulated by 4h of CORT treatment in HT-22 cells. 
PROBE ID SYMBOL DEFINITION P 
value 
Fold change 
ILMN_2701664 Tsc22d3 Mus musculus TSC22 domain family, member 3 
(Tsc22d3), transcript variant 2, mRNA. 
0 8.82 
ILMN_3150811 Tsc22d3 Mus musculus TSC22 domain family, member 3 
(Tsc22d3), transcript variant 1, mRNA. 
0 5.41 
ILMN_1259322 Pdk4 Mus musculus pyruvate dehydrogenase kinase, 
isoenzyme 4 (Pdk4), mRNA. 
0 5.02 
ILMN_2813484 Per1 Mus musculus period homolog 1 (Drosophila) (Per1), 
mRNA. 
0 4.64 
ILMN_2588249 S3-12 Mus musculus plasma membrane associated protein, S3-
12 (S3-12), mRNA. 
0 4.48 
ILMN_2987862 Per2 Mus musculus period homolog 2 (Drosophila) (Per2), 
mRNA. 
0 4.21 
ILMN_2770894 Map3k6  0 3.82 
ILMN_2768972 Fam107a Mus musculus family with sequence similarity 107, 
member A (Fam107a), mRNA. 
0 3.8 
ILMN_1232601 Cyb561 Mus musculus cytochrome b-561 (Cyb561), mRNA. 0 3.78 
ILMN_2712075 Lcn2 Mus musculus lipocalin 2 (Lcn2), mRNA. 0 3.74 
ILMN_2638923 Rn18s Mus musculus 18S RNA (Rn18s), non-coding RNA. 0 3.69 
ILMN_1226935 Orm1 Mus musculus orosomucoid 1 (Orm1), mRNA. 0 3.44 
ILMN_1219154 Mt2 Mus musculus metallothionein 2 (Mt2), mRNA. 0 3.4 
ILMN_2654074 Sesn1 Mus musculus sestrin 1 (Sesn1), mRNA. 0 3.35 
ILMN_1232884 Sphk1 Mus musculus sphingosine kinase 1 (Sphk1), transcript 
variant 1, mRNA. 
0 3.24 
ILMN_2813487 Per1 Mus musculus period homolog 1 (Drosophila) (Per1), 
mRNA. 
0 3.06 
ILMN_2987863 Per2 Mus musculus period homolog 2 (Drosophila) (Per2), 
mRNA. 
0 3.03 
ILMN_2822000 Slc10a6 Mus musculus solute carrier family 10 (sodium/bile acid 
cotransporter family), member 6 (Slc10a6), mRNA. 
0 3.03 
ILMN_3136744 Sesn1 Mus musculus sestrin 1 (Sesn1), mRNA. 0 3.02 





 0 2.98 
ILMN_1226712 Ccdc134 Mus musculus coiled-coil domain containing 134 
(Ccdc134), mRNA. 
0 2.92 
ILMN_2637714 Rasa3 Mus musculus RAS p21 protein activator 3 (Rasa3), 
mRNA. 
0 2.87 
ILMN_1255287 Mela  0 2.71 










Table 4.4. Top 25 genes downregulated by 4h of CORT treatment in HT-22 cells. 
PROBE ID SYMBOL DEFINITION Pvalue Fold 
change  




ILMN_2754985 Phlda1 Mus musculus pleckstrin homology-like domain, 
family A, member 1 (Phlda1), mRNA. 
0 
-3.09 






























ILMN_2752569 Paip1 Mus musculus polyadenylate binding protein-








ILMN_1253178 Aldh3a1 Mus musculus aldehyde dehydrogenase family 3, 
subfamily A1 (Aldh3a1), mRNA. 
0 
-2.01 
ILMN_2551741 0610010I05Rik  0 
-1.98 
ILMN_2868220 Inhba Mus musculus inhibin beta-A (Inhba), mRNA. 0 
-1.92 




ILMN_2937735 Irak2 Mus musculus interleukin-1 receptor-associated 
kinase 2 (Irak2), mRNA. 
0 
-1.87 
ILMN_2451115 1500001E21Rik  0 
-1.83 




ILMN_2507810 mtDNA_ND5  0 
-1.79 
ILMN_2988299 Srf Mus musculus serum response factor (Srf), mRNA. 0 
-1.79 
ILMN_2683593 Fubp1  0 
-1.79 




ILMN_2550570 Fibp  0.00095 
-1.76 
ILMN_2937738 Irak2 Mus musculus interleukin-1 receptor-associated 












Table 4.5. Top 25 genes upregulated by 4h of T3 plus CORT treatment in HT-22 
cells.  
PROBE ID SYMBOL DEFINITION P value Fold 
change 
ILMN_1232601 Cyb561 Mus musculus cytochrome b-561 (Cyb561), mRNA. 0 10.52 
ILMN_2701664 Tsc22d3 Mus musculus TSC22 domain family, member 3 
(Tsc22d3), transcript variant 2, mRNA. 
0 7.25 
ILMN_1254031 Klf9 Mus musculus Kruppel-like factor 9 (Klf9), mRNA. 0 5.518 
ILMN_2430906 2310051E17
Rik 
PREDICTED: Mus musculus RIKEN cDNA 
2310051E17 gene (2310051E17Rik), mRNA. 
0 5.245 
ILMN_1259322 Pdk4 Mus musculus pyruvate dehydrogenase kinase, 
isoenzyme 4 (Pdk4), mRNA. 
0 4.71 
ILMN_3150811 Tsc22d3 Mus musculus TSC22 domain family, member 3 
(Tsc22d3), transcript variant 1, mRNA. 
0 4.506 
ILMN_2813484 Per1 Mus musculus period homolog 1 (Drosophila) (Per1), 
mRNA. 
0 4.291 
ILMN_2987862 Per2 Mus musculus period homolog 2 (Drosophila) (Per2), 
mRNA. 
0 3.917 
ILMN_2524986 Ear3 Mus musculus eosinophil-associated, ribonuclease A 
family, member 3 (Ear3), mRNA. 
0 3.793 
ILMN_2638923 Rn18s Mus musculus 18S RNA (Rn18s), non-coding RNA. 0 3.65 
ILMN_1220280 Tas1r1 Mus musculus taste receptor, type 1, member 1 
(Tas1r1), mRNA. 
0 3.196 
ILMN_2770894 Map3k6   0 3.102 
ILMN_2822000 Slc10a6 Mus musculus solute carrier family 10 (sodium/bile 
acid cotransporter family), member 6 (Slc10a6), 
mRNA. 
0 3.064 
ILMN_2813487 Per1 Mus musculus period homolog 1 (Drosophila) (Per1), 
mRNA. 
0 3.008 
ILMN_2622983 Dusp1 Mus musculus dual specificity phosphatase 1 (Dusp1), 
mRNA. 
0 2.93 
ILMN_2738345 Lims2 Mus musculus LIM and senescent cell antigen like 
domains 2 (Lims2), mRNA. 
0 2.913 
ILMN_2712075 Lcn2 Mus musculus lipocalin 2 (Lcn2), mRNA. 0 2.821 
ILMN_2588249 S3-12 Mus musculus plasma membrane associated protein, 
S3-12 (S3-12), mRNA. 
0 2.805 
ILMN_2768972 Fam107a Mus musculus family with sequence similarity 107, 
member A (Fam107a), mRNA. 
0 2.783 
ILMN_2654074 Sesn1 Mus musculus sestrin 1 (Sesn1), mRNA. 0 2.765 
ILMN_2637714 Rasa3 Mus musculus RAS p21 protein activator 3 (Rasa3), 
mRNA. 
0 2.758 
ILMN_2987863 Per2 Mus musculus period homolog 2 (Drosophila) (Per2), 
mRNA. 
0 2.683 
ILMN_1219154 Mt2 Mus musculus metallothionein 2 (Mt2), mRNA. 0 2.571 
ILMN_2517483 D15Bwg0759
e 
  0 2.552 











Table 4.6. Top 25 genes downregulated by 4h of T3 plus CORT treatment in HT-22 
cells.  
PROBE ID SYMBOL DEFINITION P value Fold 
change 
ILMN_2754985 Phlda1 Mus musculus pleckstrin homology-like domain, 
family A, member 1 (Phlda1), mRNA. 
0 
-2.883 




ILMN_2771176 Ccl7   0 
-2.687 














  0 
-2.259 
ILMN_1253178 Aldh3a1 Mus musculus aldehyde dehydrogenase family 3, 
subfamily A1 (Aldh3a1), mRNA. 
0 
-2.244 
ILMN_2662926 Egr1 Mus musculus early growth response 1 (Egr1), mRNA. 0 
-2.137 








ILMN_2759365 Angptl4 Mus musculus angiopoietin-like 4 (Angptl4), mRNA. 0 
-2.099 
ILMN_2752569 Paip1 Mus musculus polyadenylate binding protein-








ILMN_2479290 Fas Mus musculus Fas (TNF receptor superfamily member 
6) (Fas), mRNA. 
0 
-2.014 












  0.00001 
-1.993 












ILMN_2902979 Fas Mus musculus Fas (TNF receptor superfamily member 
6) (Fas), mRNA. 
0 
-1.89 
ILMN_2996648 Prl2c4 Mus musculus prolactin family 2, subfamily c, member 
4 (Prl2c4), mRNA. 
0 
-1.823 












Table 4.7 Summary of the representative number of genes independently and 
synergistically regulated by T3 and CORT treatment in HT-22 cells. 
 
 
UP DOWN TOTAL 
T3 116 87 203 
CORT 293 132 425 
T3 plus CORT 252 148 400 
Synergistic upregulation 69   69 







































Table 4.8. Genes synergistically upregulated by 4h of T3 plus CORT treatment in 
HT-22 cells. The probe IDs highlighted in grey are genes that were found to be regulated 
by T3 and/ or CORT alone and synergistically upregulated by T3 plus CORT. 









Mus musculus cytochrome b-561 
(Cyb561), mRNA. 2.61 3.78 10.52 
ILMN_1254031 Klf9 
Mus musculus Kruppel-like factor 9 




PREDICTED: Mus musculus 
RIKEN cDNA 2310051E17 gene 
(2310051E17Rik), mRNA. 2.23 2.19 5.25 
ILMN_1253191 
E230024B1
2Rik   1.48 1.2 2.28 
ILMN_2868480 Ear4 
Mus musculus eosinophil-
associated, ribonuclease A family, 
member 4 (Ear4), mRNA. 1.08 1.75 2.21 
ILMN_2714031 Errfi1 
Mus musculus ERBB receptor 
feedback inhibitor 1 (Errfi1), 
mRNA. 1.21 1.46 2.1 
ILMN_2509988 Lbr   1.13 1.46 1.85 
ILMN_1256943 Ear3 
Mus musculus eosinophil-
associated, ribonuclease A family, 
member 3 (Ear3), mRNA. -1.05 1.37 1.76 
ILMN_1221494 Ubtd2 
Mus musculus ubiquitin domain 
containing 2 (Ubtd2), mRNA. 1.15 1.43 1.74 
ILMN_2602597 Sh3rf1 
Mus musculus SH3 domain 
containing ring finger 1 (Sh3rf1), 
mRNA. 1.02 1.48 1.73 
ILMN_2595359 Slc3a2 
Mus musculus solute carrier family 
3 (activators of dibasic and neutral 
amino acid transport), member 2 
(Slc3a2), mRNA. 1.2 1.48 1.73 
ILMN_2752010 Mcm4 
Mus musculus minichromosome 
maintenance deficient 4 homolog 
(S. cerevisiae) (Mcm4), mRNA. 1.09 1.49 1.65 
ILMN_1215803 Slc38a4 
Mus musculus solute carrier family 
38, member 4 (Slc38a4), mRNA. 1.11 1.46 1.65 
ILMN_1229416 
1110034A24
Rik   1.03 1.29 1.64 
ILMN_2682945 Psmd2 
Mus musculus proteasome 
(prosome, macropain) 26S subunit, 
non-ATPase, 2 (Psmd2), mRNA. -1.03 1.42 1.63 
ILMN_1233813 Ss18 
Mus musculus synovial sarcoma 
translocation, Chromosome 18 
(Ss18), mRNA. 1.06 1.4 1.63 
ILMN_2633777 Rab34 
Mus musculus RAB34, member of 
RAS oncogene family (Rab34), 
mRNA. 1.02 1.42 1.62 
ILMN_1232055 
9330175B01
Rik   1.08 1.45 1.6 
ILMN_1230422 BC018507 
PREDICTED: Mus musculus 
cDNA sequence BC018507, 
transcript variant 5 (BC018507), 
mRNA. 1.05 1.46 1.6 
ILMN_1257772 BC026590 
Mus musculus cDNA sequence 






Mus musculus RIKEN cDNA 
B230342M21 gene 
(B230342M21Rik), mRNA. 1.02 1.47 1.59 
ILMN_1228557 Id2 
Mus musculus inhibitor of DNA 
binding 2 (Id2), mRNA. -1.12 1.27 1.59 
ILMN_2648937 Pdzrn3 
Mus musculus PDZ domain 
containing RING finger 3 (Pdzrn3), 
mRNA. 1.14 1.32 1.59 
ILMN_3160881 Vrk3 
Mus musculus vaccinia related 
kinase 3 (Vrk3), mRNA. 1.08 1.48 1.59 
ILMN_2944646 Cope 
Mus musculus coatomer protein 
complex, subunit epsilon (Cope), 
mRNA. 1.01 1.44 1.58 
ILMN_1228245 Prickle1 
Mus musculus prickle like 1 
(Drosophila) (Prickle1), mRNA. -1.05 1.43 1.58 
ILMN_2682947 Psmd2 
Mus musculus proteasome 
(prosome, macropain) 26S subunit, 
non-ATPase, 2 (Psmd2), mRNA. 1.01 1.34 1.58 
ILMN_1243908 Sh3gl1 
Mus musculus SH3-domain GRB2-




PREDICTED: Mus musculus 
RIKEN cDNA 4732460K03 gene, 
transcript variant 1 
(4732460K03Rik), mRNA. 1.08 1.4 1.57 
ILMN_2955806 Arfip2 
Mus musculus ADP-ribosylation 
factor interacting protein 2 (Arfip2), 
mRNA. 1 1.43 1.57 
ILMN_2636832 Cyb5r3 
Mus musculus cytochrome b5 
reductase 3 (Cyb5r3), mRNA. 1.03 1.49 1.57 
ILMN_2490548 Tspan4 
Mus musculus tetraspanin 4 
(Tspan4), mRNA. 1.18 1.32 1.57 
ILMN_1226366 Uck1 
Mus musculus uridine-cytidine 
kinase 1 (Uck1), mRNA. 1.06 1.42 1.57 
ILMN_1257501 Pet112l 
Mus musculus PET112-like (yeast) 
(Pet112l), mRNA. -1.05 1.43 1.56 
ILMN_2644920 Plekhf1 
Mus musculus pleckstrin homology 
domain containing, family F (with 
FYVE domain) member 1 
(Plekhf1), mRNA. 1.08 1.49 1.56 
ILMN_2776585 Slc1a5 
Mus musculus solute carrier family 
1 (neutral amino acid transporter), 
member 5 (Slc1a5), mRNA. 1.05 1.44 1.56 
ILMN_2764205 Tor1a 
Mus musculus torsin family 1, 
member A (torsin A) (Tor1a), 
mRNA. 1.01 1.36 1.56 
ILMN_2511971 Whsc1l1 
Mus musculus Wolf-Hirschhorn 
syndrome candidate 1-like 1 
(human) (Whsc1l1), transcript 




Mus musculus RIKEN cDNA 
1700065O13 gene 
(1700065O13Rik), mRNA. 1.06 1.43 1.55 
ILMN_2489314 
2500002G2




Mus musculus DNA segment, Chr 
15, ERATO Doi 682, expressed 
(D15Ertd682e), mRNA. -1.06 1.39 1.55 
ILMN_1250036 Tmem201 
Mus musculus transmembrane 
protein 201 (Tmem201), transcript 




Mus musculus zinc finger CCCH 
type containing 13 (Zc3h13), 
mRNA. 1.02 1.33 1.55 
ILMN_2861176 Calr 
Mus musculus calreticulin (Calr), 
mRNA. -1.05 1.4 1.54 
ILMN_2709681 Hdlbp 
Mus musculus high density 
lipoprotein (HDL) binding protein 
(Hdlbp), mRNA. -1.03 1.45 1.54 
ILMN_2455637 Top1mt 
Mus musculus DNA topoisomerase 
1, mitochondrial (Top1mt), nuclear 
gene encoding mitochondrial 
protein, mRNA. 1.06 1.48 1.54 
ILMN_2631192 Vps26b 
Mus musculus vacuolar protein 
sorting 26 homolog B (yeast) 




Mus musculus RIKEN cDNA 
2410025L10 gene 
(2410025L10Rik), mRNA. 1.16 1.32 1.53 
ILMN_3051252 BC026590 
Mus musculus cDNA sequence 
BC026590 (BC026590), mRNA. 1.05 1.33 1.53 
ILMN_2933399 Ppp1r10 
Mus musculus protein phosphatase 
1, regulatory subunit 10 (Ppp1r10), 
mRNA. 1.02 1.49 1.53 
ILMN_1216116 Smarcd2 
Mus musculus SWI/SNF related, 
matrix associated, actin dependent 
regulator of chromatin, subfamily d, 
member 2 (Smarcd2), mRNA. 1.09 1.47 1.53 
ILMN_1217144 Tbc1d5 
Mus musculus TBC1 domain 
family, member 5 (Tbc1d5), 
mRNA. 1.07 1.36 1.53 
ILMN_1228501 Tob2 
Mus musculus transducer of 
ERBB2, 2 (Tob2), mRNA. 1.03 1.42 1.53 
ILMN_2497581 Uhrf1 
Mus musculus ubiquitin-like, 
containing PHD and RING finger 
domains, 1 (Uhrf1), mRNA. -1.11 1.42 1.53 
ILMN_1214918 LOC546015 
PREDICTED: Mus musculus 
similar to ribosomal protein S9 
(LOC546015), misc RNA. -1 1.44 1.52 
ILMN_1234112 Tomm70a 
Mus musculus translocase of outer 
mitochondrial membrane 70 
homolog A (yeast) (Tomm70a), 
mRNA. 1.16 1.35 1.52 
ILMN_2443831 Uba1 
Mus musculus ubiquitin-like 
modifier activating enzyme 1 
(Uba1), mRNA. 1.02 1.36 1.52 
ILMN_2746328 BC003993 
Mus musculus cDNA sequence 




Mus musculus RIKEN cDNA 
C730025P13 gene 
(C730025P13Rik), mRNA. -1.01 1.45 1.51 
ILMN_1243679 Cep55 
Mus musculus centrosomal protein 
55 (Cep55), mRNA. 1.06 1.45 1.51 
ILMN_2985111 Chfr 
Mus musculus checkpoint with 
forkhead and ring finger domains 




Mus musculus RIKEN cDNA 
E430025E21 gene 
(E430025E21Rik), mRNA. 1.03 1.38 1.51 
ILMN_2794686 Fam152b 
Mus musculus family with 







PREDICTED: Mus musculus 
hypothetical protein 
LOC100044204 (LOC100044204), 
mRNA. -1.12 1.36 1.51 
ILMN_2820379 Rnf135 
Mus musculus ring finger protein 
135 (Rnf135), mRNA. 1.04 1.26 1.51 
ILMN_2515982 Ugt1a6b 
Mus musculus UDP 
glucuronosyltransferase 1 family, 
polypeptide A6B (Ugt1a6b), 
mRNA. 1.06 1.43 1.51 
ILMN_1223015 Dedd2 
Mus musculus death effector 
domain-containing DNA binding 
protein 2 (Dedd2), mRNA. -1.01 1.27 1.5 
ILMN_2695150 Smc5l1   -1.05 1.25 1.5 
ILMN_2480463 Trim25 
Mus musculus tripartite motif-



































Table  4.9. Genes synergistically downregulated by 4h of T3 plus CORT treatment in 
HT-22 cells. The probe IDs highlighted in grey are genes that were found to be regulated 
by T3 and/ or CORT alone and synergistically downregulated by T3 plus CORT. 






T3 plus CORT 
Fold Change 
ILMN_2759365 Angptl4 
Mus musculus angiopoietin-like 4 
(Angptl4), mRNA. 1.15 -1.39 -2.1 
ILMN_2996648 Prl2c4 
Mus musculus prolactin family 2, 
subfamily c, member 4 (Prl2c4), 
mRNA. -1.01 -1.2 -1.82 
ILMN_2623793 Zfhx3 
Mus musculus zinc finger 
homeobox 3 (Zfhx3), mRNA. 1.07 -1.27 -1.82 
ILMN_2741096 Timp3 
Mus musculus tissue inhibitor of 
metalloproteinase 3 (Timp3), 
mRNA. 1.06 -1.34 -1.79 
ILMN_2506727 
9430052C07
Rik   -1.26 -1.22 -1.78 
ILMN_2875585 Prl2c3 
Mus musculus prolactin family 2, 
subfamily c, member 3 (Prl2c3), 
mRNA. -1.03 -1.3 -1.76 
ILMN_2937136 Tceal1 
Mus musculus transcription 
elongation factor A (SII)-like 1 
(Tceal1), mRNA. -1.21 -1.32 -1.72 
ILMN_1217489 LOC671878 
PREDICTED: Mus musculus 
similar to spermine synthase 




PREDICTED: Mus musculus 
similar to aquaporin 5 
(LOC100046616), mRNA. -1.04 -1.05 -1.68 
ILMN_3115472 Aqp5 
Mus musculus aquaporin 5 (Aqp5), 
mRNA. -1.09 1 -1.66 
ILMN_2816180 Lbh 
Mus musculus limb-bud and heart 
(Lbh), mRNA. -1 -1.2 -1.65 
ILMN_2806159 Tmsb4x 
Mus musculus thymosin, beta 4, X 
chromosome (Tmsb4x), mRNA. -1.01 -1.45 -1.64 
ILMN_2474666 
4933411D12
Rik   1.01 -1.38 -1.64 
ILMN_3007428 Sox9 
Mus musculus SRY-box containing 
gene 9 (Sox9), mRNA. -1.05 -1.12 -1.64 
ILMN_2775937 Plat   1.13 -1.34 -1.62 
ILMN_2617996 Prl2c2 
Mus musculus prolactin family 2, 
subfamily c, member 2 (Prl2c2), 
mRNA. 1 -1.1 -1.62 
ILMN_1236123 Tomm6 
Mus musculus translocase of outer 
mitochondrial membrane 6 homolog 
(yeast) (Tomm6), nuclear gene 
encoding mitochondrial protein, 
mRNA. -1.04 -1.49 -1.62 
ILMN_2643241 Accn2 
Mus musculus amiloride-sensitive 
cation channel 2, neuronal (Accn2), 
mRNA. 1.1 -1.35 -1.62 
ILMN_2696592 C77080   -1.07 -1.26 -1.62 
ILMN_1230152 Adamts4   -1.08 -1.38 -1.62 
ILMN_1250075 Dpysl3 
Mus musculus dihydropyrimidinase-
like 3 (Dpysl3), mRNA. -1.06 -1.35 -1.62 
ILMN_2653207 Tead2 Mus musculus TEA domain family -1.07 -1.48 -1.6 
180 
 




PREDICTED: Mus musculus 
RIKEN cDNA A930002H24 gene 
(A930002H24Rik), mRNA. 1.02 -1.07 -1.6 
ILMN_2760979 Tgfbr2 
Mus musculus transforming growth 
factor, beta receptor II (Tgfbr2), 
transcript variant 1, mRNA. 1.05 -1.17 -1.6 
ILMN_1216381 Nfic 
Mus musculus nuclear factor I/C 
(Nfic), transcript variant 2, mRNA. 1.02 -1.32 -1.6 
ILMN_2841720 Ttc3 
Mus musculus tetratricopeptide 
repeat domain 3 (Ttc3), mRNA. -1.02 -1.3 -1.59 
ILMN_2623776 Eps8 
Mus musculus epidermal growth 
factor receptor pathway substrate 8 
(Eps8), mRNA. 1.08 -1.4 -1.59 
ILMN_1228031 Dusp8 
Mus musculus dual specificity 
phosphatase 8 (Dusp8), mRNA. 1.1 -1.28 -1.59 
ILMN_1213376 Cfl1 
Mus musculus cofilin 1, non-muscle 
(Cfl1), mRNA. 1.16 -1.42 -1.59 
ILMN_1244343 
B230369L08
Rik   -1.04 -1.5 -1.57 
ILMN_2495703 Clip2 
Mus musculus CAP-GLY domain 
containing linker protein 2 (Clip2), 




PREDICTED: Mus musculus 
similar to Deltex3 
(LOC100045005), misc RNA. -1.07 -1.44 -1.57 
ILMN_2828916 Frmd6 
Mus musculus FERM domain 
containing 6 (Frmd6), mRNA. 1.11 -1.48 -1.56 
ILMN_1246841 Relb 
Mus musculus avian 
reticuloendotheliosis viral (v-rel) 
oncogene related B (Relb), mRNA. 1.11 -1.37 -1.56 
ILMN_2617265 Ipo13 
Mus musculus importin 13 (Ipo13), 
mRNA. -1.03 -1.42 -1.56 
ILMN_2757870 Psmb10 
Mus musculus proteasome 
(prosome, macropain) subunit, beta 
type 10 (Psmb10), mRNA. -1.02 -1.43 -1.55 
ILMN_2642913 Emp1 
Mus musculus epithelial membrane 
protein 1 (Emp1), mRNA. 1.09 -1.37 -1.55 
ILMN_1219807 Hoxd4 
Mus musculus homeo box D4 
(Hoxd4), mRNA. 1.03 -1.36 -1.55 
ILMN_1223697 Cd44 
Mus musculus CD44 antigen 
(Cd44), transcript variant 2, mRNA. -1.11 -1.31 -1.55 
ILMN_1227131 Ehbp1l1 
Mus musculus EH domain binding 
protein 1-like 1 (Ehbp1l1), mRNA. 1.17 -1.49 -1.55 
ILMN_2747381 Ddx24 
Mus musculus DEAD (Asp-Glu-
Ala-Asp) box polypeptide 24 
(Ddx24), mRNA. -1.06 -1.38 -1.54 
ILMN_1235173 LOC386218   -1.02 -1.47 -1.54 
ILMN_1213200 Med16 
Mus musculus mediator complex 
subunit 16 (Med16), mRNA. 1.03 -1.36 -1.54 
ILMN_1225835 Mfap5 
Mus musculus microfibrillar 
associated protein 5 (Mfap5), 
mRNA. -1.18 -1.08 -1.54 
ILMN_2449019 Tnk2 
Mus musculus tyrosine kinase, non-




Mus musculus RIKEN cDNA 
2900024O10 gene 




Mus musculus SH3 domain binding 
glutamic acid-rich protein-like 3 
(Sh3bgrl3), mRNA. -1.04 -1.27 -1.53 
ILMN_2440530 Vat1 
Mus musculus vesicle amine 
transport protein 1 homolog (T 
californica) (Vat1), mRNA. 1.01 -1.21 -1.53 
ILMN_2760254 Mrgprf 
Mus musculus MAS-related GPR, 
member F (Mrgprf), mRNA. 1.1 -1.14 -1.53 
ILMN_1249547 Zfp292 
PREDICTED: Mus musculus zinc 
finger protein 292, transcript variant 
4 (Zfp292), mRNA. -1.13 -1.47 -1.53 
ILMN_3161105 Ahnak2 
Mus musculus AHNAK 
nucleoprotein 2 (Ahnak2), mRNA. 1.06 -1.08 -1.52 
ILMN_2656422 BC028528 
Mus musculus cDNA sequence 
BC028528 (BC028528), mRNA. -1.18 -1.35 -1.52 
ILMN_1238535 
4832420L08
Rik   -1.14 -1.29 -1.52 
ILMN_2974720 Igf2bp2 
Mus musculus insulin-like growth 
factor 2 mRNA binding protein 2 
(Igf2bp2), mRNA. -1.02 -1.38 -1.52 
ILMN_2629601 Slc4a7   1.03 -1.42 -1.52 
ILMN_2441921 Trim56 
Mus musculus tripartite motif-
containing 56 (Trim56), mRNA. -1.05 -1.33 -1.52 
ILMN_1259610 Cd276 
Mus musculus CD276 antigen 
(Cd276), mRNA. 1.08 -1.36 -1.52 
ILMN_1252222 Hectd2 
Mus musculus HECT domain 
containing 2 (Hectd2), mRNA. 1.02 -1.47 -1.52 
ILMN_1235732 Cdsn 
Mus musculus corneodesmosin 
(Cdsn), mRNA. 1.09 -1.14 -1.51 
ILMN_2658815 Tmem98 
Mus musculus transmembrane 
protein 98 (Tmem98), mRNA. -1.13 -1.35 -1.51 
ILMN_1228441 
C230043G09
Rik   -1.12 -1.44 -1.51 
ILMN_1225373 C1qbp 
Mus musculus complement 
component 1, q subcomponent 
binding protein (C1qbp), nuclear 
gene encoding mitochondrial 
protein, mRNA. 1.06 -1.4 -1.51 
ILMN_2689307 Spnb2 
Mus musculus spectrin beta 2 
(Spnb2), transcript variant 2, 
mRNA. -1.13 -1.26 -1.5 
ILMN_2731057 Psme2 
Mus musculus proteasome 
(prosome, macropain) 28 subunit, 
beta (Psme2), transcript variant 1, 
mRNA. -1.1 -1.41 -1.5 
ILMN_1259967 Prl2c2 
Mus musculus prolactin family 2, 
subfamily c, member 2 (Prl2c2), 
mRNA. -1.04 -1.01 -1.5 
ILMN_2759365 Angptl4 
Mus musculus angiopoietin-like 4 
(Angptl4), mRNA. 1.15 -1.39 -2.1 
ILMN_2776603 Ccl9 
Mus musculus chemokine (C-C 
motif) ligand 9 (Ccl9), mRNA. 1.1 -1.52 -1.9 
ILMN_2996648 Prl2c4 
Mus musculus prolactin family 2, 
subfamily c, member 4 (Prl2c4), 
mRNA. -1.01 -1.2 -1.82 
ILMN_2741096 Timp3 
Mus musculus tissue inhibitor of 
metalloproteinase 3 (Timp3), 
mRNA. 1.06 -1.34 -1.79 







PREDICTED: Mus musculus 
RIKEN cDNA A930002H24 gene 
(A930002H24Rik), mRNA. 1.02 -1.07 -1.6 
ILMN_2828916 Frmd6 
Mus musculus FERM domain 
containing 6 (Frmd6), mRNA. 1.11 -1.48 -1.56 
ILMN_2449019 Tnk2 
Mus musculus tyrosine kinase, non-
receptor, 2 (Tnk2), mRNA. 1.17 -1.44 -1.53 
ILMN_2760254 Mrgprf 
Mus musculus MAS-related GPR, 
member F (Mrgprf), mRNA. 1.1 -1.14 -1.53 
ILMN_3161105 Ahnak2 
Mus musculus AHNAK 
nucleoprotein 2 (Ahnak2), mRNA. 1.06 -1.08 -1.52 
ILMN_2520249 Hspg2   1.28 -1.31 -1.52 
ILMN_1235732 Cdsn 
Mus musculus corneodesmosin 
(Cdsn), mRNA. 1.09 -1.14 -1.51 
ILMN_1229547 Spon2 
Mus musculus spondin 2, 
extracellular matrix protein (Spon2), 
mRNA. 1.93 -1.23 -1.51 
ILMN_2778151 Sox9   1.04 1.02 -1.51 
ILMN_1259967 Prl2c2 
Mus musculus prolactin family 2, 
subfamily c, member 2 (Prl2c2), 






























Table 4.10. Gene ontology analysis of genes differentially regulated by T3. The top 
biological functions that are over represented in T3 regulated genes are listed based on P 
value of statistical significance of enrichment and the total number of molecules involved 
in a biological pathway  out of the total 203 T3 regulated genes. 
Top networks 
  Drug Metabolism, Endocrine System Development and Function, Lipid 
Metabolism  
   Gene Expression, Cell Cycle, Cellular Growth and Proliferation  
  Cell Death, Cellular Growth and Proliferation, Cell-To-Cell Signaling and 
Interaction  
  
   Top Biological Functions 
Diseases and Disorders P value 
No. of 
molecules 
Cancer  2.43E-05 - 1.63E-02 48 
Gastrointestinal Disease  4.42E-04 - 1.34E-02 26 
Genetic Disorder   4.42E-04 - 1.34E-02 14 
Neurological Disease  4.42E-04 - 1.34E-02 11 
  
Molecular and Cellular Functions   
Gene Expression  3.22E-07 - 4.48E-04  36 
Cell Death  1.90E-05 - 1.57E-02 34 
Cellular Growth and Proliferation  1.03E-04 - 1.72E-02 46 
Cellular Development  1.96E-04 - 1.72E-02 38 
Cell Cycle  2.65E-04 - 1.62E-02 20 
  
Physiological System Development and Function   
Hematological System Development and Function  4.48E-05 - 1.70E-02 20 
Organismal Development 4.48E-05 - 1.51E-02 20 
Tissue Development   4.48E-05 - 1.72E-02 39 
Organismal Survival  5.37E-05 - 4.63E-03 22 
Skeletal and Muscular System Development and 












Table 4.11. Gene ontology analysis of genes differentially regulated by CORT. The 
top biological functions that are over represented in CORT regulated genes are listed 
based on P value of statistical significance of enrichment and the total number of 
molecules involved in a biological pathway  out of the total 425 CORT regulated genes. 
Top networks 
  Gene Expression, Free Radical Scavenging, Cell Death  
  Cell Death, Cellular Function and Maintenance, Hematological System 
Development and Function  
  Cell-To-Cell Signaling and Interaction, Nervous System Development 
and Function, Cellular Disassembly and Organization  
  
   Top Biological Functions 
Diseases and Disorders P value 
No. of 
molecules 
Neurologic Disease 2.08E-08 – 2.74E-03 58 
Inflammatory Response  5.27E-08 – 3.66E-03 57 
Cancer  1.13E-07 – 3.86E-03 107 
Reproductive System Disease  4.04E-07 – 1.20E-03 57 
  
Molecular and Cellular Functions   
Cell Death 6.11E-14 – 3.90E-03  109 
Cellular Movement 4.08E-13 – 2.77E-03 76 
Cellular Development 2.80E-11 – 3.57E-03 89 
Cellular Growth and Proliferation 6.56E-11 – 3.25E-03 107 
Cellular Function and Maintenance 1.70E-07 – 3.81E-03 69 
  
Physiological System Development and 
Function   
Tissue Development  3.09E-08 – 3.14E-03 91 
Cardiovascular System Development and 
Function 3.35E-08 – 3.25E-03 51 
Organismal Survival   4.36E-08 – 1.26E-04 53 
Organismal Development 5.54E-08 – 3.73E-03 62 
Hematological System Development and 










Table 4.12. Gene ontology analysis of genes differentially regulated by T3 plus 
CORT. The top biological functions that are over represented in T3 plus CORT regulated 
genes are listed based on P value of statistical significance of enrichment and the total 
number of molecules involved in a biological pathway  out of the total 400 T3 plus  
CORT regulated genes. 
Top networks 
  Lipid Metabolism, Small Molecule Biochemistry, Cell Death 
  Cell Morphology, Organismal Function, Cellular Movement  
  Cellular Development, Cell Cycle, Cancer  
  
   Top Biological Functions 
Diseases and Disorders P value 
No. of 
molecules 
Cancer 1.96E-07 – 7.37E-03 105 
Inflammatory Response  1.73E-06 – 6.83E-03 55 
Reproductive System Disease 4.74E-06 – 7.37E-03 71 
Genetic Disorder 2.86E-05 – 4.79E-03 73 
  
Molecular and Cellular Functions   
Cellular Development  1.26E-09 – 7.46E-03  84 
Cellular Movement 1.46E-09 – 7.26E-03 66 
Cell Death 2.57E-08 – 7.51E-03 94 
Cellular Growth and Proliferation 1.18E-07 – 7.40E-03 105 
Gene Expression 3.15E-06 – 7.51E-03 68 
  
Physiological System Development and Function   
Tissue Development  1.30E-07 –7.46E-03 85 
Cardiovascular System Development and 
Function 5.66E-07 – 7.46E-03 40 
Organismal Development 5.66E-07 – 7.46E-03 65 
Embryonic Development 1.09E-05 – 7.46E-03 57 












Table 4.13. Gene ontology analysis of genes synergistically upregulated regulated by 
T3 plus CORT. The top biological functions that are over represented in T3 plus CORT 
regulated genes are listed based on P value of statistical significance of enrichment and 
the total number of molecules involved in a biological pathway  out of the total 69 genes 
synergistically upregulated by T3 plus CORT treatment. 
Top Networks 
  Cellular Development, Cellular Assembly and Organization, Skeletal and Muscular 
System Development and Function  
  Drug Metabolism, Cellular Development, Hematological System Development and 
Function  
  Infectious Disease, Post-Translational Modification, Hematological Disease  
  
   Top Biological Functions 
Disease and Disorders P value 
No. of 
Molecules 
Cancer  2.96E-03 - 4.21E-02 19 
Connective Tissue Disorders  2.96E-03 - 2.34E-02 3 
Developmental Disorder  2.96E-03 - 2.96E-03 3 
 Molecular and Cellular Functions 
  Cellular Assembly and Organization  8.56E-06 - 4.91E-02 12 
DNA Replication, Recombination, and Repair  1.27E-04 - 4.26E-02 5 
























Table 4.14. Gene ontology analysis of genes synergistically downregulated regulated 
by T3 plus CORT. The top biological functions that are over represented in T3 plus 
CORT regulated genes are listed based on P value of statistical significance of 
enrichment and the total number of molecules involved in a biological pathway  out of 
the total 80 genes synergistically downregulated by T3 plus CORT treatment. 
Top networks 
  Cellular Movement, Cellular Assembly and Organization, Cellular Function 
and Maintenance 
  DNA Replication, Recombination and, Repair, Molecular Transport, Cell Death 
  Cell to Cell Signaling and Interaction, Cellular Growth and Proliferation, 
Connective Tissue Development and Function  
  
   Top Biological Functions 
Diseases and Disorders P value 
No. of 
molecules 
Cancer 3.97E-04 – 4.86E-02 22 
Gastrointestinal Disease 7.88E-04 – 2.17E-02 10 
Infectious Disease 8.58E-04 – 4.81E-02 9 
Cardiovascular Disease 1.49E-03 – 4.81E-02 4 
  
Molecular and Cellular Functions   
Cellular Growth and Proliferation  1.19E-04 – 4.81E-02  17 
Cellular Development  1.28E-04 – 4.81E-02 16 
Cell to Cell Signaling and Interaction 2.11E-04 – 4.81E-02 14 
Cellular Movement 3.25E-04 – 4.81E-02 14 
Molecular Transport 5.61E-04 – 4.81E-02 8 
  
Physiological System Development and Function   
Digestive System Development and Function 2.19E-05 –4.55E-02 6 
Embryonic Development 1.19E-04 – 4.03E-02 17 
Skeletal and Muscular System Development and 
Function 2.88E-04 – 4.29E-02 10 
Tissue Development 5.89E-04 – 4.81E-02 19 













Fig. 4.1. Representative number of genes  regulated by T3, CORT, T3 plus CORT in 
cultured mouse hippocampal cells by microarray analysis. Genes that are 
differentially based on a p value of <0.01 (n=3/ hormone treatment) and 1.2 fold change 
for T3; 1.5 fold change for CORT and T3 plus CORT. Fold change is calculated as the 
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A ROLE FOR KRÜPPEL-LIKE FACTOR 9 (KLF9) IN THE AUTOINDUCTION 
OF THYROID HORMONE RECEPTOR BETA 
 
Abstract  
Thyroid hormone (T3) induces gene regulation programs necessary for tadpole 
metamorphosis. Among the earliest responses to T3 are the up-regulation of T3 receptor 
beta (TRautoinduction) and the Krüppel-like factor 9 (Klf9/ also known as Basic 
transcription element binding protein 1 (BTEB1)). KLF9 is a member of the Krüppel 
family of transcription factors that bind to GC-rich regions in gene promoters. The 
proximal promoter of the Xenopus laevis Tr gene has seven GC-rich sequences, which 
led us to hypothesize that KLF9 binds to and regulates Tr. In tadpoles and the frog 
fibroblast-derived cell line XTC-2, T3 upregulated Klf9 mRNA with faster kinetics than 
Trand Klf9 mRNA correlated with increased KLF9 protein expressionKLF9 bound 
to GC-rich sequences in the proximal Tr promoter in vitro. Using chromatin 
immunoprecipitation assay we show that KLF9 associates with the Tr promoter in 
vivo in a T3 and developmental stage-dependent manner. Induced expression of KLF9 in 
XTC-2 cells caused accelerated and enhanced autoinduction of the Tr  
gene. This enhancement was lost in N-terminal truncated mutants of KLF9.  However, 
point mutations in the zinc fingers of KLF9 that destroyed DNA binding did not alter the 
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protein’s activity on Tr  autoinduction, suggesting that KLF9 can function in this 
regard through protein-protein interactions. Our findings support the hypothesis that 
KLF9 associates with the Tr promoter in vivo and enhances autoinduction, but this 
action does not depend on its DNA binding activity.  Cooperation among the protein 
products of immediate early genes may be a common mechanism for driving 





















 Autoinduction of nuclear hormone receptors is a common, although poorly 
understood phenomenon in animal development (Tata 2000). The autoinduction of 
thyroid hormone (T3) receptor genes (Tr) during amphibian metamorphosis is a dramatic 
example of this form of gene regulation (Tata 2000). All vertebrates possess two Tr genes 
designated Tr and Tr (also known as NR1A1 and NR1A2, respectively; Xenopus 
laevis has two Tr and two Tr genes each designated A or B owing to its 
pseudotetraploidy (Yaoita, Shi et al. 1990). Thyroid hormone is the primary morphogen 
controlling tadpole metamorphosis and TRs are ligand-dependent transcription factors. 
One of the earliest gene regulation events during amphibian metamorphosis is the 
upregulation of Tr by T3 (Yaoita and Brown 1990). This regulation depends on TRs 
binding to thyroid hormone response elements (TREs) present in the Tr promoter 
(receptor autoinduction; (Yaoita, Shi et al. 1990; Machuca, Esslemont et al. 1995). It is 
hypothesized that autoinduction of Tr genes is essential for metamorphosis (Tata 2000). 
The gene regulation programs induced by the T3-TR complex that lead to tissue 
morphogenesis have been characterized in several tadpole tissues (Wang and Brown 
1991; Buckbinder and Brown 1992; Shi and Brown 1993; Brown, Wang et al. 1996; 
Denver, Pavgi et al. 1997; Veldhoen, Crump et al. 2002; Helbing, Werry et al. 2003; Das, 
Cai et al. 2006).  
 Krüppel-like factor 9 (Klf9) is an immediate early gene induced by T3 in most tadpole 
tissues during metamorphosis (there are two Klf9 genes in X. laevis designated ‘a’ and 
‘b’; (Brown, Wang et al. 1996; Furlow and Kanamori 2002; Hoopfer, Huang et al. 2002). 
The direct regulation of the X. laevis Klf9 genes by T3 is explained by one or more TREs 
195 
 
located upstream of the transcription initiation sites (Brown, Wang et al. 1996; Furlow 
and Kanamori 2002). KLF9 is a member of the Krüppel family of transcription factors 
(KLF; also known as Basic transcription element binding protein 1 (BTEB1) (Kaczynski, 
Cook et al. 2003)) first isolated in a screen for proteins that bind to a GC-rich (GC box) 
sequence in the promoter of the rat cytochrome P-450IA1 gene (designated the basic 
transcription element or BTE; (Yanagida, Sogawa et al. 1990; Imataka, Sogawa et al. 
1992). KLF9 possesses a DNA binding domain (DBD) consisting of three Cys2-His2 
zinc finger domains (Philipsen and Suske 1999; Dang 2000). Krüppel-like proteins are 
distantly related to the specificity protein (Sp) family members, including Sp1 (Philipsen 
and Suske 1999; Dang 2000). The KLF9 DBD shares 72% sequence similarity with rat 
Sp1 (Imataka, Sogawa et al. 1992) and the two proteins bind with similar affinity to the 
BTE sequence (Sogawa, Kikuchi et al. 1993). While Sp1 and KLF9 have very similar 
DNA binding domains, and they bind to similar or identical consensus DNA sequences, 
the two proteins are completely different outside of the DBD. In addition to other KLF 
family members, three proteins designated KLF2, 3 and 4 have been identified in 
mammals, although the KLF2 appears to be more distantly related to KLF9 than the other 
two proteins (Sogawa, Imataka et al. 1993; Dang 2000; Martin, Cooper et al. 2000; 
Kaczynski, Conley et al. 2002). As with KLF9 and Sp1, the KLF proteins share almost 
identical DNA binding domains, but are divergent in their N-terminal regions that harbor 
domains necessary for their transactivation, and in some cases transrepression functions 
(Kaczynski, Cook et al. 2003). 
 Krüppel-like factor 9 mRNA and protein are strongly upregulated by T3 in tadpole 
tissues ((Hoopfer, Huang et al. 2002)), but the genes that KLF9 regulates, and thus its 
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functions in tadpole development are unknown. It is noteworthy that KLF9 is the only 
KLF/Sp 1-like family member known to be upregulated by T3 in tadpole tissues (Wang 
and Brown 1991; Buckbinder and Brown 1992; Shi and Brown 1993; Brown, Wang et al. 
1996; Denver, Pavgi et al. 1997; Veldhoen, Crump et al. 2002; Helbing, Werry et al. 
2003; Das, Cai et al. 2006). Earlier, we and others showed that KLF9 is also regulated by 
T3 in developing rodent brain where it promotes neurite outgrowth (Denver, Ouellet et al. 
1999; Cayrou, Denver et al. 2002; Morita, Kobayashi et al. 2003). KLF9 is expressed in 
uterine endometrial cells where it transactivates the uteroferrin gene, and may influence 
cell proliferation by regulating cell cycle and growth-associated genes (Simmen, Chung 
et al. 1999; Simmen, Zhang et al. 2000; Simmen, Zhang et al. 2002). The actions of 
KLF9 in endometrial cells appear to involve direct protein-protein interactions with the 
progesterone receptor (Zhang, Zhang et al. 2002). We found that X. laevis KLF9 is 
capable of activating synthetic promoter constructs containing multiple or single GC 
boxes (Hoopfer, Huang et al. 2002). Mammalian KLF9 also has transactivation function 
on several synthetic and native promoters (Imataka, Sogawa et al. 1992; Imataka, Mizuno 
et al. 1993; Sjottem, Anderssen et al. 1996; Foti, Stroup et al. 1998; Simmen, Chung et al. 
1999; Chen and Davis 2000). KLF proteins have been reported to activate or repress 
transcription depending on the number of GC boxes present in the promoter construct 
tested, the target gene analyzed and the cell type (Imataka, Mizuno et al. 1993; Sjottem, 
Anderssen et al. 1996; Foti, Stroup et al. 1998; Imhof, Schuierer et al. 1999; Simmen, 
Chung et al. 1999; Chen and Davis 2000; Furlow and Kanamori 2002; Hoopfer, Huang et 
al. 2002; Hsiang and Straus 2002; Zhang, Zhang et al. 2002; Kaczynski, Cook et al. 
2003). Whether these proteins function as transcriptional activators or repressors may 
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depend on the architecture of the specific promoter and the chromatin environment 
(Kaczynski, Cook et al. 2003).  
 Based on the early response kinetics of the Klf9 and Trgenes, the observation that 
the protein products of these genes are expressed in the same cells (Hoopfer, Huang et al. 
2002) and the identification of seven GC rich regions in the proximal X. laevis Tr 
promoter, we hypothesized that Tr may be a target gene for KLF9. We further 
hypothesized that the upregulation of KLF9 plays a role in the autoinduction of Tr, 
perhaps functioning as an accessory transcriptional activator. Here we show that the 
kinetics of Klf9 mRNA upregulation in response to T3 are faster than Trand that 
KLF9 binds to regions of the proximal Tr promoter that contain GC boxes. Using 
chromatin immunoprecipitation (ChIP) assay we show that KLF9 associates with the 
Tr promoter in vivo in a T3– and developmental stage-dependent manner. Forced 
expression of BTEB1 in the X. laevis fibroblast cell line XTC-2 (Pudney, Varma et al. 
1972) accelerates the activation of the Tr promoter and expression of endogenous 
Tr mRNA in response to T3. This action depends on the first 30 amino acids of KLF9, 
but not on its DNA binding capacity, since point mutations in the zinc fingers did not 
alter the activity. Taken together, our findings support the hypothesis that the 
upregulation of KLF9 by T3 plays a role in the transcriptional regulation of the Tr 







Materials and Methods 
Animals and hormone treatments. Tadpoles of X.laevis were reared in dechlorinated tap 
water (water temperature, 20-22 C) and fed pulverized frog brittle (Nasco, Fort 
Atkinson, WI). Developmental stages were assigned according to Nieuwkoop and Faber 
(NF; (Nieuwkoop and Faber 1956). Tadpoles were treated with 3,5,3'-L-triiodothyronine 
(T3; sodium salt; Sigma, St. Louis, MO) by adding it to the aquarium water to a final 
concentration of 10 nM for various times; water was changed and hormone replenished 
daily over the treatment period. Tadpoles were then euthanized by immersion in 0.01% 
benzocaine (Sigma), and whole brains and tails were collected for RNA or ChIP analyses 
(see below). Animal care was in accordance with institutional guidelines. 
 
RNA extraction and reverse transcriptase-PCR (RT-PCR) analysis. Total RNA was 
isolated from tadpole brains or XTC-2 cells using the Trizol reagent (Invitrogen, 
Carlsbad, CA) following the manufacturer’s instructions. The RNA was treated with 
DNase I (Roche, Indianapolis, IN) prior to reverse transcription to remove genomic DNA 
contamination following the methods of Manzon and Denver (Manzon and Denver 
2004). The DNase-treated RNA was reverse transcribed using SuperScript II (0.5 l, 200 
U/l; Invitrogen) and 0.2 to 2 microliters of the resulting cDNA was used for PCR.  
Semi-quantitative RT-PCR: Standard PCR reactions were initiated in 25 l containing 
10X PCR buffer, 1.5 mM MgCl2, dNTP mix (1.25 mM each), forward and reverse 
primers for each gene of interest (10 uM), and Taq DNA polymerase (1.25 U; Promega, 
Madison, WI). Each thermal cycle consisted of 94 C for 1 min, 55 C for 1 min and 72 
C for 2 min. The number of cycles for each gene was determined empirically by 
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constructing linear amplification curves. We used 32 cycles for Bteb1, 36 for Tr and 
28 for ribosomal protein L8 (rpL8; a housekeeping gene used to normalize for RNA 
loading and cDNA synthesis). Oligonucleotide primer sequences for Klf9 are given in 
Table 5.1. Primer sequences used for rpL8 and Tr were as described by Manzon and 
Denver (Manzon and Denver 2004). PCR products were electrophoresed on 1% agarose 
gels, stained with ethidium bromide, and densitometry conducted using Scion Image 
Software (version 3.0, Scion Corporation). The band densities of Klf9 and Tr 
amplicons for each sample were normalized to the densities of the rpL8 bands. 
Quantitative, real time PCR (qPCR): For quantitative RT-PCR (RTqPCR) we developed 
TaqMan assays and analyzed samples on an ABI 7500 fast real time PCR machine using 
TaqMan Universal PCR Master Mix (Applied Biosystems, Inc., Foster City, CA). The 
primer/probe sets used are given in Table 5.1 and were designed to span exon/intron 
boundaries. Standard curves were generated using cDNAs from the time point that 
exhibited the highest expression level for each gene to provide for a relative quantitation. 
Trand Klf9 mRNAs were normalized to the level of rpL8 mRNA. 
 
Plasmid Constructs. The pCMV-xKLF9 expression plasmid was described by Hoopfer et 
al. (Hoopfer, Huang et al. 2002). The X. laevis Tr promoter-luciferase plasmid 
(Ranjan, Wong et al. 1994) was a generous gift of Dr. Yun-Bo Shi. Full-length and N-
terminal truncated mutants of KLF9 were generated by PCR (primers in Table 5.2) and 
cDNA fragments were directionally cloned into the pCS2 vector. The choice of deletions 
was based on the location of two putative transactivation domains (A and B) located in 
rat KLF9 (Kobayashi, Sogawa et al. 1995) that are highly conserved in Xenopus KLF9 
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(Hoopfer, Huang et al. 2002). The plasmid pCS2-xKLF9Δ30 has a deletion of the first 30 
amino acids that includes transactivation domain A; pCS2-xKLF9Δ99 has both 
transactivation domains A and B removed; and pCS2-xKLF9Δ120 represents only the 
DNA binding domain. 
  The plasmid construct  pCS2-xKLF9 C2AH harbors histidine to alanine substitutions 
(H211A, H241A, H296A)  in the first histidine residues of each of the three zinc fingers 
of KLF9. This construct was generated using the QuikChange Multi Site-Directed 
Mutagenesis Kit (Stratagene) with pCS2-xKLF9 as template and three primers shown in 
Table 5.2.  
 
Electrophoretic mobility shift assay. We conducted electrophoretic mobility shift assay 
(EMSA) as described by Hoopfer et al. (Hoopfer, Huang et al. 2002) with minor 
modifications. The BTE and mutated BTE (mBTE) probes used were as described by 
Yanagida et al. (Yanagida, Sogawa et al. 1990). Bacterial cell lysate containing the fusion 
protein GST-xKLF9[DBD] was prepared as described by Hoopfer et al. (Hoopfer, Huang 
et al. 2002). Recombinant wild type KLF9 or KLF9 C2AH mutant were produced in vitro 
using the TnT SP6 Quick Coupled Translation System (Promega). For EMSA, one 
microliter of a 1:512 dilution of GST-xKLF9[DBD] lysates or varying volumes of the in 
vitro translated proteins  were incubated in a volume of 35 l with 20,000 cpm [
32
P]-BTE 
and 1.4 g double-stranded poly(deoxyinosinic-deoxycytidylic)acid [poly (dI-dC)] in 
buffer containing 20 mM HEPES (pH 7.8), 1 mM dithiothreitol (DTT), 0.1% Nonidet P-
40, 50 mM KCl and 20% glycerol. For antibody supershifts, proteins were pre-incubated 
for 20 min prior to the addition of 
32
P-BTE with 1 g normal rabbit serum IgG or affinity 
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purified anti-xKLF9 IgG that recognizes only the N-terminal region of the protein (see 
below). The reaction continued at room temperature for 40 min before fractionation by 
non-denaturing 6% polyacrylamide gel electrophoresis in 0.25X Tris-borate-EDTA 
(TBE).  Gels were fixed in 30% methanol/10% acetic acid, dried and processed for 
autoradiography.   
 The ability of regions of the proximal X. laevis Tr promoter (Genbank Accession 
#U04675) to displace GST-xKLF9[DBD] binding to the [
32
P]-BTE was tested by 
competitive EMSA (1.89 M for each competitor DNA). The X. laevis tr promoter 
fragments were generated by PCR and gel-purified using QIAEX II (Qiagen, Valencia, 
CA). The regions of the promoter that we analyzed are shown in Fig. 2 and Supplemental 
Table 5.1, and the oligonucleotides used to amplify the sequences by PCR are given in 
Table 5.3.  
 We then synthesized short oligonucleotide probes for EMSA containing predicted GC 
boxes in the Tr promoter fragments that demonstrated competitive binding to GST-
xKLF9[DBD] (see above). Oligonucleotides (24 bp) were synthesized, each of which 
encompassed one or two GC boxes within each Tr promoter region (see Fig. 2 and 
Table 5.4). Each GC-box containing oligonucleotide was labeled with [
32
P]-dCTP and 
used as a probe in EMSA. 
 
Cell culture and transfection assays. We plated XTC-2 cells at a density of 2 x 10
5 
cells 
per well in 6 well plates for gene expression and transfection assays. For ChIP assays, we 
plated cells at a density of 1 x 10
6
 cells per 100 mm plate. Before transfections or 
hormone treatments cells were cultured overnight in a humidified atmosphere of 5% CO2 
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at 25C. Cells were cultured in Leibovitz-15 medium (L-15; diluted 1:1.5 for amphibian 
cells; Invitrogen Life Technologies, Carlsbad, CA) supplemented with sodium 
bicarbonate (2.47 g/L), penicillin G sodium (100 U/ml), streptomycin sulfate (100 
g/mL) and 10% fetal bovine serum that had been stripped of thyroid hormone following 
the method of Samuels et al. (Samuels, Stanley et al. 1979). For gene expression, 
transfection and ChIP assays, cells were treated for different times with or without 5 nM 
T3 before harvest.  
 For the luciferase reporter assay experiments, we transfected cells using the 
polyethylenimine (pEi; Sigma) method (Meunier-Durmort, Grimal et al. 1997). The total 
amount of DNA per well was normalized by adding empty vector (pCMVneo). All cells 
were cotransfected with the pRenilla-luciferase plasmid for normalization of cell 
transfection by dual reporter luciferase assay following the manufacturer’s instructions 
(Promega, Madison, WI). Just prior to transfection the cells were washed twice with 
serum-free L-15, and the pEi/DNA solution was added directly to the wells. After 1 hr 
the transfection medium was replaced with growth medium and the cells were incubated 
overnight. Cells were then treated with or without T3 for different times before harvest 
and analysis of luciferase activity.  Luciferase activity was quantified (measured as 
relative light units) using a luminometer (Femtomater FB 12; Zylux Corp., Maryville, 
TN). Each transfection experiment was conducted three times with 4-5 wells per 
treatment. 
 For analysis of the effects of forced expression of wild type or mutant KLF9 on 
endogenous Tr mRNA we used the pCS2-based expression vectors described above, 
and transfected XTC-2 cells using Fugene 6 Transfection Reagent (Roche). Each well of 
203 
 
a 6 well plate received 1 g of plasmid DNA and the total amount of DNA per well was 
normalized by adding empty vector (pCS2). Forty eight hours after transfection cells 
treated with or without T3 for different times before harvest and RNA extraction. Each 
transfection experiment was done two to three times with 6 replicates per treatment.   
 
Western blotting and Immunocytochemistry. We prepared Western blots following the 
methods of Ranjan et al. (Ranjan, Wong et al. 1994) with protein extracts of XTC-2 cells 
transfected with pCS2-xKLF9, or pCS2 and extracts of XTC-2 cells treated +/- T3. Forty 
micrograms of total protein for each sample were separated by electrophoresis on 10% 
denaturing SDS-polyacrylamide gels. Proteins were transferred to nitrocellulose 
membranes and probed with an affinity-purified antiserum to X. laevis KLF9 (Hoopfer, 
Huang et al. 2002). The antiserum was generated in a rabbit against the full-length X. 
laevis KLF9 protein, and affinity-purified such that the IgGs recognize only the N-
terminal region of the frog KLF9 protein (Hoopfer, Huang et al. 2002); 0.2 g purified 
IgG/ml). These antibodies do not recognize the DNA binding domain (DBD) of xKLF9 
(Hoopfer, Huang et al. 2002), which is critical to the specificity of the reagent given the 
high degree of conservation of the DBDs among Krüppel and Sp 1-like family members. 
This purified antiserum was also used for ChIP assays (described below). 
 We conducted immunocytochemistry for KLF9 protein following the methods that we 
described previously (Hoopfer, Huang et al. 2002). Briefly, NF stage 52 tadpoles were 
treated with or without T3 (10 nM) for 24 hr before sacrifice. Brains were fixed for 24 hr 
at 4
o
C in 4% paraformaldehyde and then saturated in 30% sucrose for 24 hr. Tissues were 
embedded in M-1 embedding matrix (Shandon Lipshaw Inc., Pittsburgh, PA), frozen and 
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cryosectioned saggitally at 20 m. We used five brains per treatment in the analyses. 
Cryosections were blocked, incubated with anti-X. laevis KLF9 IgG and immune 
complexes detected with either a goat anti-rabbit horseradish peroxidase secondary 
antibody (Vectastain elite ABC and Vector VIP kits; Vector Laboratories Inc., 
Burlingame, CA) or with a goat anti-rabbit Cy3-conjugated fluorescence secondary 
antibody (Jackson Immunoresearch Laboratories, West Grove, PA). To test for the 
specificity of the immunohistochemical reaction we preabsorbed the antibody with E. coli 
expressed GST-xKLF9 (10 g/ml; (Hoopfer, Huang et al. 2002). Tissue sections were 
analyzed using an Olympus IX81 inverted fluorescence microscope. 
 
Chromatin immunoprecipitation assay. We conducted ChIP assays as described 
previously for tadpole tissues (Sachs and Shi 2000). We used the Upstate Biochemicals, 
Inc. ChIP assay kit (Lake Placid, NY) following the manufacturer’s instructions. The 
negative controls included: no primary antibody, replacement of the primary antibody 
with normal rabbit serum, and the analysis of regions outside of the proximal Tr 
promoter (Ef1 promoter, Tr exon 3/4, Tr exon 5, intestinal fatty acid binding 
protein [Ifabp] promoter). For ChIP we used affinity-purified IgGs against X. laevis 
KLF9; 4 g purified IgG/reaction). The PCR reactions for ChIP on tadpole brain or tail 
included [
32
P]-dCTP (1 Ci/reaction) and the PCR products were analyzed on 6% 
polyacrylamide gels followed by autoradiography, or using an Agilent Technologies 
2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA). ChIP assays on XTC-2 
cells were analyzed using quantitative, real-time PCR using the iCycler iQ real time PCR 
detection system from Bio-Rad (Hercules, CA). We used iQ Syber Green Supermix (Bio-
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Rad) following the manufacturer’s protocol with annealing temperatures adjusted for 
each primer set. Oligonucleotide PCR primers used for ChIP analyses are in Table 5.3.  
 
Results 
Klf9 mRNA is upregulated by T3 in premetamorphic tadpole brain 
with faster kinetics than Tr mRNA  
 Exposure of premetamorphic (NF Stage 52) tadpoles to T3 (10 nM in the aquarium 
water) resulted in significant time-dependent increases in brain Klf9b (F=222.35, 
P<0.0001; ANOVA) and Tr (F=74.03, P<0.001) mRNA levels (Fig. 1). The earliest 
time point at which a significant increase in Klf9b mRNA was detected was 8h 
(P<0.0001; Scheffe’s test) and the mRNA level continued to increase up to 16 h. By 
contrast, a significant increase in Tr mRNA expression was not detected until 16 h.  
  
Thyroid hormone upregulates KLF9 protein in premetamorphic tadpole brain 
 Similar to results that we reported earlier (Hoopfer, Huang et al. 2002) we observed a 
strong increase of KLF9 protein expression in premetamorphic tadpole brain (NF stage 
52) following treatment with T3 (10 nM for 24 h; representative brain sections shown in 
Fig. 1B, panels 1 & 2). The strong nuclear staining for KLF9 was completely abolished 
by preabsorption with GST-xKLF9 (Fig. 1B, panels 3 & 4).  
 Western blot analysis with affinity purified anti-xKLF9 IgG on protein extracts of 
transfected XTC-2 cells showed that the antiserum detected the overexpressed KLF9 
protein but did not crossreact with endogenous cellular proteins (Fig. 1C upper panel). 
Native KLF9 protein was increased in untransfected XTC-2 cells by 24 h treatment with 
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T3 (Fig. 1C lower panel).   We routinely detected two bands by Western blot that 
corresponded to the KLF9 protein. The basis for KLF9 protein heterogeneity is currently 
unknown, but likely reflects posttranslational modifications (X. laevis KLF9 is predicted 
to have up to four phosphorylation and two N-linked glycosylation sites; (Hoopfer, 
Huang et al. 2002)).  
 
KLF9 binds to the proximal Tr promoter in vitro 
 Computer analysis of the proximal X. laevis Tr promoter sequence showed the 
presence of seven GC-rich regions commonly characterized as Sp1 binding sites (based 
on (Ranjan, Wong et al. 1994). The approximate locations of these GC-rich regions are 
shown in schematic in Fig. 2, and the precise locations are given in Supplemental Table 
5.1. We used EMSA to determine if KLF9 can bind to the Tr promoter in vitro. We 
generated ~200-300 bp fragments of the Tr promoter by PCR (Fig. 2, Supplemental 
Table 5.1, Table 5.3) and used them as competitors in EMSA for binding of bacterially 
expressed GST-xKLF9[DBD] (Hoopfer, Huang et al. 2002) to a [
32
P]-labeled probe 
consisting of the BTE sequence of the rat CYP1A1 gene (Imataka, Sogawa et al. 1992).  
Each of the Tr gene promoter fragments with GC-rich sequences competed for 
binding in the EMSA, and the degree of competition correlated with the number of GC 
boxes contained within the fragment. By contrast, promoter fragments that did not 
possess GC boxes exhibited no competition in the EMSA (Fig. 3A).   
 We next synthesized short oligonucleotide probes (24 bp) encompassing one or two 
GC boxes within the proximal Tr promoter region (to include all seven predicted GC 
boxes; Fig. 2 and Table 5.4) and tested for KLF9 binding to these DNA elements by 
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EMSA. Radioinert oligonucleotides were used as competitors to verify the specificity of 
binding. This experiment showed that KLF9 bound to all but one of these GC box 
sequences, and that the binding could be competed with unlabeled probe (Fig. 3B). We 
observed no binding with probe #5 which contains one GC box of identical sequence to 
the GC box elements found in other regions. As a positive control for the quality of the 
oligonucleotide probes we conducted EMSAs with nuclear extracts from X. laevis tadpole 
brain, which has abundant GC box binding activity (Hoopfer, Huang et al. 2002). This 
showed that nuclear proteins formed complexes to an equal extent with each of the 
radiolabeled DNAs (including probe #5; data not shown.)  
 
KLF9 associates with the proximal Tr promoter in vivo in a T3 and 
developmental stage-dependent manner 
 To determine if KLF9 associates with the proximal Tr promoter in vivo we 
conducted ChIP assays on brain and tail of premetamorphic X. laevis tadpoles that had 
been treated with or without T3 for 48 hr before sacrifice. We found KLF9 associated 
with the proximal Tr promoter in vivo and the signal was increased in a T3-dependent 
manner in both brain and tail on most regions (not region G in brain or tail, nor region B 
in tail; Fig. 4). As controls for the ChIP assays we included the elimination of the primary 
antibody or the replacement of the primary antibody with normal rabbit serum. In each 
case the ChIP signal was below or at the limit of detection in the assay (data not shown). 
Another important control was the analysis of regions outside of the proximal Tr 
promoter (Ef1 promoter, Tr exon 3/4, Tr exon 5, Ifabp promoter) which showed 
little or no association of KLF9. It should be noted that although we analyzed the 
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promoter by targeting relatively small regions for PCR (~200-300 bp), the nature of the 
ChIP assay, in which genomic fragments ranging from 500-1000 bp are produced by 
sonication, does not allow us to determine with precision where within the promoter 
KLF9 is associating. Nevertheless, our data show that KLF9 associates with the proximal 
Tr promoter in vivo and that the signal is increased following T3 treatment.  
 We found no KLF9 associated with control DNA sequences that included an intronic 
region of the Tr gene that is at least 30 kb downstream from the start site (Tr exon 
3/exon 4), the Ef1 or the Ifabp promoters (an indirect T3 response gene that is 
downregulated by T3; (Shi and Hayes 1994).   
 Earlier we showed that Klf9 mRNA and protein exhibit dramatic increases in tadpole 
brain during spontaneous or T3–induced metamorphosis (Hoopfer, Huang et al. 2002). 
We therefore tested whether the increased KLF9 protein expression in brain during 
spontaneous metamorphosis resulted in increased association of KLF9 with the proximal 
Tr promoter. As predicted, we found that the amount of KLF9 associated with the 
Tr promoter (regions A/B were analyzed) was increased in animals at metamorphic 
climax (NF stage 62) when T3 production and KLF9 protein is highest (Hoopfer, Huang 
et al. 2002) compared with premetamorphic tadpoles (NF stage 54) when T3 and KLF9 
are low (Fig. 4B).  
 
Klf9 and TrmRNAs are coordinately upregulated and KLF9 associates with the 
proximal Trpromoter in XTC-2 cells  
 We found statistically significant, time-dependent effects of T3 on Klf9 (F=11.255, 
P<0.0001; ANOVA) and Tr (F=36.936, P<0.0001) mRNA expression in XTC-2 cells 
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(Fig. 5A). Significant upregulation of Klf9 mRNA occurred by 3 hr (P=0.009; Scheffe’s 
test), which was the maximum level of induction observed, and was maintained through 
48 hr of treatment. By contrast, Tr mRNA was not significantly increased until 6 hr 
(P=0.001), then reached a maximum by 12 hr that was maintained through 48 hr.  
 Using ChIP assay on XTC-cells that had been treated with T3 for 24h, we observed 
association of KLF9 with two regions of the proximal Tr promoter. Real-time PCR 
analysis of the ChIP assay showed significantly greater association of KLF9 with the 
upstream region of the Tr promoter (region A/B; see Fig. 2 and 3), compared with the 
region located in the 5’ UTR (region G; Fig. 5B; F=12.957, P<0.0001; ANOVA). The 
KLF9 signal at exon 5 of the Tr gene (which is far downstream from the transcription 
start site) was not significantly different from background (i.e., ChIP with NRS, data not 
shown; Fig. 5B). We observed a small but statistically significant (P=0.043; t-test) T3-
dependent increase in KLF9 association with the upstream region of the Tr promoter 
(region A/B) in XTC-2 cells (Fig. 5C). Note that the level of KLF9 induction by T3 was 
lower in XTC-2 cells (~2.5 fold) compared with the brain in vivo (~10.5 fold).  
 
Induced expression of KLF9 in XTC-2 cells accelerates autoinduction of the Tr 
gene.  
 We used XTC-2 cell transfection and promoter-reporter assays to test the hypothesis 
that KLF9 enhances autoinduction of the Tr gene. Treatment with T3 caused 
significant time-dependent increases in luciferase activity in cells transfected with empty 
vector (ANOVA: F=55.564, P<0.0001) and pCMV-xKLF9 (F=601.043, P<0.0001; 
luciferase activity was significantly elevated by 2 hr in both treatments; P<0.05; 
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Scheffe’s test; Fig. 6A). Forced expression of KLF9 had no effect on basal promoter 
activity, but resulted in a significant acceleration of Tr promoter autoinduction. 
Luciferase activity in pCMV-xKLF9 transfected cells was significantly greater than 
empty vector controls at 2 hr and 6 hr  of T3 treatment (P<0.0001 for both; unpaired t-
test; Fig. 6A).  
  We also used XTC-2 cells to determine if forced expression of KLF9 could alter the 
autoinduction of the endogenous Tr gene. Treatment with T3 caused a time-dependent 
increase in endogenous Tr mRNA in cells transfected with empty vector (pCS2; 
ANOVA: F=86.02, P<0.0001) and pCS2-xKLF9 (ANOVA: F=215.2, P<0.0001; Fig. 
6B). At all time points measured, Tr mRNA was significantly greater in pCS2-xKLF9 
transfected cells  compared with empty vector controls   (P<0.05 for  0h; P<0.01 for 2, 4, 
and 6h; unpaired t-test). Furthermore, the increase in Tr mRNA caused by forced 
KLF9 expression occurred in a dose dependent manner, with 0.3 g and 1 g of pCS2-
xKLF9 plasmid increasing Tr mRNA 1.2 and 1.4 fold, respectively, over empty vector 
controls (data not shown). 
 
KLF9 transactivation domain is required for Tr autoinduction. 
 Two N-terminal transactivation domains in rodent  KLF9 that were identified by 
mutagenesis are highly conserved with the frog proteins (Kobayashi, Sogawa et al. 1995; 
Hoopfer, Huang et al. 2002). We constructed truncated xKLF9 mutants in which one or 
both of these transactivation domains were removed to determine if they  are necessary 
for the action of KLF9 on Tr autoinduction in XTC-2 cells. Removal of 
transactivation domain A (pCS2-xKLF9Δ30) or both domains A and B (pCS2-
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xKLF9Δ99 or pCS2-xBTEB1Δ120) abolished the activity of KLF9 on Tr 
autoinduction (compare to cells transfected with pCS2-xKLF9; Fig. 7A; P<0.001). 
Deletion of only transactivation domain A (pCS2-xKLF9Δ30) resulted in apparent 
dominant negative activity, for it also reduced the T3-induced Tr mRNA as compared 
with the empty vector control  (P<0.001; Fig 7A). 
 
DNA binding capacity of KLF9 is not required for Tr autoinduction. 
 We introduced point mutations into the zinc fingers of KLF9 to disrupt its DNA 
binding capacity. Histidine to alanine substitutions of the first histidine residue in each of 
the three Cys2His2 zinc fingers were generated by site-directed mutagenesis. The histidine 
to alanine substitution was previously shown to eliminate the DNA binding capacity of 
KLF1 (Pandya and Townes 2002) and another zinc finger protein JAZ (Yang, May et al. 
1999).  The mutant KLF9 (pCS2-xKLF9 C2AH) retained full activity on Tr 
autoinduction compared with wildtype KLF9 (Fig 7B). The loss of DNA binding 
capacity in the KLF9 C2AH mutant was confirmed by EMSA (Fig. 7C). Similar amounts 
of wildtype KLF9 and KLF9 C2AH mutant were used in the EMSA as verified by 
Western blotting (data not shown). 
  
Discussion   
 Thyroid hormone initiates programs of gene expression in diverse tadpole tissues that 
underlie the dramatic transformation that occurs during amphibian metamorphosis (Shi 
2000). Several of the early T3 response genes that were identified through gene 
expression screens code for transcription factors (Buckbinder and Brown 1992; Kanamori 
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and Brown 1993; Shi and Brown 1993; Brown, Wang et al. 1996; Denver, Pavgi et al. 
1997; Das, Cai et al. 2006). These proteins are hypothesized to regulate a secondary 
response program of genes necessary for adult phenotypic expression (Brown, Wang et 
al. 1995). The transcription factor KLF9, whose hormone-dependent expression depends 
on one or more TREs located upstream of the transcription start site, is the earliest 
responding gene thus far identified in the tadpole (Wang and Brown 1993; Denver, Pavgi 
et al. 1997; Furlow and Kanamori 2002; Hoopfer, Huang et al. 2002). The Tr gene is 
strongly upregulated by T3, which requires direct binding of the T3-TR complex to the 
Tr promoter (a phenomenon referred to as autoinduction; (Machuca, Esslemont et al. 
1995). Here we show that KLF9 associates with the promoter region of the Tr gene 
and can enhance T3–dependent transcription. Our findings support the hypothesis that the 
early upregulation of KLF9 during tadpole metamorphosis plays a role in the 
autoinduction of Trgeneswhich is hypothesized to be essential for metamorphosis 
(Brown, Wang et al. 1995). Therefore, the protein products of two primary response 
genes regulate each other’s promoter. Crossregulation among primary response 
transcription factors is likely to be an important means for developmental gene regulation 
causing robust gene expression responses necessary for driving tissue morphogenesis.   
 The autoinduction of Trgenes was originally thought to be the earliest molecular 
response to T3 in tadpole tissues (Yaoita and Brown 1990; Tata 2000). Previous studies 
that relied on Northern blotting suggested that the upregulation of Tr and Klf9 mRNAs 
by T3 was, by and large, coordinate (Furlow and Brown 1999; Furlow and Kanamori 
2002). However, several lines of evidence support the view that the Klf9 genes are the 
most rapidly responding genes yet identified in tadpole tissues (Wang and Brown 1993; 
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Furlow and Kanamori 2002). Using RT-PCR we clearly show that KLF9 is induced by T3 
with faster kinetics than TR, both in the tadpole in vivo and in the X. laevis fibroblast-
derived cell line XTC-2. We found detectable accumulation, and maximal induction of 
KLF9 transcripts several hours earlier than TR (the precise timing depends on whether 
tissues or cultured cells are analyzed; see also (Hoopfer, Huang et al. 2002; Krain and 
Denver 2004). Also, KLF9 protein is upregulated during spontaneous metamorphosis or 
by exogenous T3 in tadpoles (see Fig. 1B; (Hoopfer, Huang et al. 2002), and KLF9 and 
TR are expressed in the same cells (Hoopfer, Huang et al. 2002). These findings are 
consistent with the hypothesis that KLF9 is present within the cell, either commensurate 
with or prior to the upregulation of TR, and could thus influence transcription of the 
Trgene.  
 The presence of GC-rich sequences in the proximal Tr promoter (commonly 
referred to as Sp1 sites; (Ranjan, Wong et al. 1994)), and the early and robust T3 response 
kinetics of KLF9 led us to hypothesize that this protein binds to and regulates the Tr 
gene. We used EMSA to test whether regions of the proximal Tr promoter possess 
binding sites for KLF9. We found that KLF9 could directly bind to the GC boxes located 
in the Tr promoter. However, while the binding of protein to DNA in an EMSA is 
suggestive of the presence of a transcription factor binding site, it does not determine 
whether the DNA binding protein actually associates with the gene of interest in vivo. To 
test this for KLF9 and Tr, we used ChIP assay, that depended on a specific, affinity 
purified antiserum directed against the unique N-terminal region of the frog KLF9 
protein. Our ChIP experiments clearly show that KLF9 associates with the proximal 
Tr promoter in vivo in a hormone and developmental stage-dependent manner. Earlier, 
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we showed that KLF9 protein is strongly induced by T3 in tadpole brain in vivo and is 
highly expressed during metamorphic climax (compared with premetamorphosis; 
(Hoopfer, Huang et al. 2002). The enhanced association of KLF9 with the Tr promoter 
with T3 treatment and at metamorphic climax could be due to the increased expression of 
KLF9 and/or an active T3-dependent recruitment of KLF9 to the promoter.  
 Similar to our findings in the tadpole in vivo we found that Klf9 and Tr mRNAs 
are upregulated in XTC-2 cells, and that Klf9 exhibits faster kinetics than Tr We also 
found that KLF9 associates with the proximal Tr promoter in XTC-2 cells by ChIP 
assay, and that the degree of association was higher at an upstream region (region A/B 
with multiple GC boxes) vs. a region in the 5’ UTR (region G with one GC box; and vs. 
the TrA exon 5 where there are no identifiable GC boxes; see Fig. 5B). Furthermore, 
association of KLF9 with region A/B in XTC-2 cells was T3-dependent.  
 Given that KLF9 and TRs are expressed in the same cells (Hoopfer, Huang et al. 
2002) and KLF9 associates with the proximal Tr promoter in vitro and in vivo, and 
frog KLF9 possesses transactivation function (Hoopfer, Huang et al. 2002), we 
hypothesized that KLF9 positively regulates the Tr gene. In support of this hypothesis 
we found that induced expression of KLF9 in XTC-2 cells resulted in faster kinetics and 
greater absolute magnitude of induction by T3 of the Tr gene, as determined by 
promoter-reporter transfection assay and by analysis of the endogenous mRNA 
expression.  
 By contrast to the full-length KLF9, forced expression of N-terminal truncated 
mutants of KLF9 in which one or both transactivation domains were removed eliminated 
activity on Trautoinduction. Kobayashi et al. (Kobayashi, Sogawa et al. 1995) 
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identified two transactivation domains in rat KLF9 by mutagenesis. Earlier we showed 
that frog KLF9 has transactivation activity, and the identified transactivation domains are 
very similar among the frog and rodent proteins, suggesting conserved functions 
((Hoopfer, Huang et al. 2002). Our present findings point to an essential role for these 
regions of KLF9 for activity on Trautoinduction. 
 Up to this point our results were consistent with KLF9 binding to GC rich regions of 
the frog Trgene leading to enhanced autoinduction. We were therefore surprised to 
discover that this DNA binding capacity was dispensable for KLF9 action. Subsitution of 
alanines for each of the zinc-chelating histidine residues in the three zinc fingers of KLF9 
destroyed DNA binding but did not alter activity of the protein on TrThus, while 
KLF9 associates with chromatin at the Trpromoter in vivo, binding to DNA is not 
required for it to enhance Trautoinduction, suggesting that KLF9 functions in this 
regard through protein-protein interaction. The GC boxes present in the Trpromoter 
could facilitate the targeting of the protein to this genomic region.  
 Members of the KLF and Sp factor families have been found to synergize with 
nuclear hormone receptors through protein-protein interactions. For example, Sp1 
interacts with the estrogen receptor to regulate several promoters (Porter, Saville et al. 
1997; Duan, Porter et al. 1998; Sun, Porter et al. 1998). KLF9 was shown to interact with 
progesterone receptor (PR) in the regulation of PR target genes in endometrial epithelial 
cells (Zhang, Zhang et al. 2002). However, in a preliminary study we found no direct 
interaction between KLF9 and TRs using co-immunoprecipitation assays (K.L. 
Howdeshell and R.J. Denver, unpublished data.) To our knowledge, other than the PR, 
KLF9 interactions with nuclear proteins have not been studied. KLF9 is a member of a 
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family of proteins (KLF/Sp 1-like) that bind to GC or GT rich regions in gene promoters 
(Kaczynski, Cook et al. 2003). It is possible that other KLFs or Sp-like factors regulate 
the TrA promoter, and this deserves further study. However, it is noteworthy that KLF9 
is the only KLF identified in several gene expression screens of tadpole tissues that is 
strongly upregulated by T3 during metamorphosis (Wang and Brown 1991; Buckbinder 
and Brown 1992; Kanamori and Brown 1993; Shi and Brown 1993; Brown, Wang et al. 
1996; Denver, Pavgi et al. 1997; Veldhoen, Crump et al. 2002; Helbing, Werry et al. 
2003; Das, Cai et al. 2006). Also, to our knowledge, KLF9 is the only KLF/Sp 1-like 
family member found to be regulated by T3 in mammalian cells (Denver, Ouellet et al. 
1999). Thus, if other KLFs participate in Tr gene regulation they would likely do so as 
basal, or constitutive factors. We propose here that the strong upregulation of KLF9 by T3 
is critical to the role that KLF9 plays in regulating the Tr promoter in vivo. 
 In conclusion, our results support the hypothesis that the protein product of the 
immediate early gene Klf9 associates with the Trgenomic region in vivo, and can 
enhance autoinduction; i.e., it forms a positive regulatory loop. The surge in plasma T3 
that occurs during metamorphic climax in the tadpole is accompanied by a dramatic 
autoinduction of Trgenes (Shi, Yaoita et al. 1992)The autoinduction of Tr genes is 
thought to be essential for metamorphosis, especially for later developmental events such 
as cell differentiation and programmed cell death (e.g., tail resorption; (Tata 2000). Thus, 
to achieve maximal TR expression to initiate tissue transformation may require that TRs 
bind to and activate the Tr promoters (Machuca, Esslemont et al. 1995), and induce the 
expression of KLF9 which cooperates with TRs in the autoinduction of their genes. Such 
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cooperativity among the protein products of immediate early genes may be a common 






















































 Forward 5'-CGTGGCAAAGTTTATGGG-3'  





Forward                  5’-GGAAGCCACTGGAAACAGAAAA-3’  
Reverse      5’-CATTAACTATGGGAGCTTGTCCAA-3’  
Probe      FAM-AAAATTTTTGCCAGAGGAC-MGBNFQ 
 
Klf9b: 
 Forward      5’-CCAGTCAGGTCAACCAATGAAA-3’  
Reverse      5’-AAACTTTGCCACACCCAGTGT-3’ 
Probe      FAM-AGG CAC AGG TGT CC-MGBNFQ 
 
rpL8: 
 Forward  5’-TTTGCTGAAAGAAATGGCTACATC-3’ 
 Reverse 5’-CAC GGC CTG GAT CAT GGA-3’ 
      Probe      VIC-AGG GTA TTG TGA AAG ACA-MGBNFQ 
_____________________________________________________________________ 
Oligonucleotide primers for semi-quantitative RT-PCR and TaqMan assays were designed to 
span exon/intron boundaries. The primers for semi-quantitative RT-PCR amplified mRNAs 





Table 5.2. Oligonucleotide primers used to generate truncated mutants and point 
mutations in the three zinc fingers of X. laevis KLF9.  
_____________________________________________________________________ 
 
Primers used to generate N-terminal truncated xKLF9 mutants: 
 
30 xKLF9 For           5'-ATAGGATCCGCCGCCATGGAAGTGGAGCAGCCC-3' 
99 xKLF9 For  5'-ATAGGATCCGCCGCCATGGAGTTAAACAAGTACC-3' 
120 xKLF9 For  5'-ATAGGATCCGCCGCCATGGACAGCGATGTCACCA-3' 
xKLF9 Rev   5'-ATACTCGAGTCAGGTGAATGATGAATTGGAC-3' 
 
Primers used to generate point mutations in the three zinc finger domains of xKLF9: 
 
xKLF9 H211A  5'-GTCTTCCCATCTCAAAGCCGCTTACAGAGTCCATACAGGT-3' 
xKLF9 H241A  5'-CCGATGAGTTAACTCGCGCCTACAGAACCCACACAG-3' 
xKLF9 H269A  5'-TGAGAAGCGATCACTTGACCAAAGCTGCACGTCGCCA-3' 
_____________________________________________________________________ 
The  indicates deletion of the first 30-120 amino acids. Primers used for point mutations 
generated a histidine  alanine substitution in each of the three zinc fingers. 
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Table 5.3.  Oligonucleotide primers used for the analysis of the X. laevis TrA 
promoter. 
__________________________________________________________________________________ 
TrA promoter region  
    -1138/-823 (A) 5'-CAG TGG AGT AAC TAC CAG-3'  
5’-GTA CAC ATG CCT GCA CTA-3'  
    -841/-604 (B) 5'-TAG TGC AGG CAT GTG TAC-3'  
5'-GAG CAG GTG CAG CAT CTA-3'  
    -622/-414 (C) 5'-TAG ATG CTG CAC CTG CTC-3'  
5'-ACT ATG GCA TGT TAC AGC-3'  
    -432/-266 (D) 5'-GCT GTA ACA TGC CAT AGT-3'  
5'-GCC TGA GTG AAG ACC CAT-3'  
    -283/-92 (E)          5'-ATG GGT CTT CAC TCA GGC-3'  
5'-GTC ATG AAA CTC CTC GGT-3'  
    -109/+182 (F)       5'-ACC GAG GAG TTT CAT GAC-3'  
5’-TAT AGA CAC AGG CAG CTT A-3'  
    +164/+366 (G)      5’-TAA GCT GCC TGT GTC TAT A-3'  
5’-TGA CAG TCA GAG GAA CTG A-3'  
    exon 3/exon 4           5'-CAG AAA CCT GAA CCC ACA CAA-3'  
5'-CAC TTT TCC ACC CTC GGG CGC ATT-3' 
    qPCR -885/-752  5'-TTG TGC CTG CTT GCT TGC TA-3'   
5'-ACT ATA ATA GGC GGG CCA AGC TGA-3'  
   qPCR +165/+322    5'-AGC TGC CTG TGT CTA TAC TGA TGG-3’  
5'-ACA GGG AGA TCT ACA GCT GAT CGT-3'  
   qPCR  exon 5  5'-CCC CGA AAG TGA AAC TCT AAC GT-3'   
5'-AAA CCA CTC CAA GTC CTC CAT TTT-3'  
Ef1 promoter   5’-TGC ACA GTT GGC GCA GTG-3’   
5’-TGA GGA AGA GAG CGA ACC-3’ 
Ifabp promoter  5’-ATA GCA GCA GGT GGT TGC G-3’   
5’-GGC CAC AAG ATC TAC TCG-3’  
__________________________________________________________________________________ 
For each pair of oligonucleotides the top sequence is the forward primer, the bottom sequence is 
the reverse primer. Capital letters in parentheses correspond to promoter regions given in Figure 2 
and Supplemental Table 1.  
qPCR – indicates primer sets that were used for quantitative real-time PCR using SYBR green. 




Table 5.4. Short oligonucleotides corresponding to GC-rich regions (bold, 
underlined) of the X. laevis TrA promoter used as probes and competitors in 
EMSA. 
_____________________________________________________________________ 
GC box  Region of     
number*  TrA promoter    Oligonucleotide sequence 
_____________________________________________________________________  
     1,2              -1032/-1013        5’gatcGGGGGCGGGGGGCCCGCCCT3’   
                                                                               3’-CCCCGCCCCCCGGGCGGGActag-5’ 
     3  -978/-957        5’-gatcAGATAGGCGGGGGGGTGGTG-3  
                              3’-TCTATCCGCCCCCCCACCACctag-5’ 
     4  -770/-751        5’-gatcTGGCCCGCCTATTATAGTTT-3’                     
                                    3’-ACCGGGCGGATAATATCAAActag-5’ 
     5  -723/-704       5’-gatcTCTGGCGGGGCCCTGTTATC-3’  
                      3’-AGACCGCCCCGGGACAATAGctag-5’ 
     6  -545/-526           5’-gatcGGATGCGGGCGGGCGCGGGC-3’  
                      3’-CCTACGCCCGCCCGCGCCCGctag-5’ 
     7  +228/+247        5’-gatcCTCCCCGCCCCCCCTATCCT-3’  
                      3’-GAGGGGCGGGGGGGATAGGActag-5’  
_____________________________________________________________________ 
* Numbering based on position within the TrA gene as depicted in Figure 2. 
For each pair of oligonucleotides the top sequence is the forward primer, the bottom 







Fig 5.1.  Thyroid hormone upregulates Klf9 mRNA in tadpole brain with faster kinetics 
than Tr mRNA. Increased Klf9 mRNA correlates with elevated KLF9 protein. (A) 
Upregulation of Klf9 (top) and Tr (bottom) mRNAs in premetamorphic X. laevis tadpole brain 
(NF Stage 52) following exposure to T3 (10 nM) added to the aquarium water (n=4/time point). 
Gene expression was analyzed by RTqPCR. Asterisks designate significant differences from the 
zero time point (P<0.0001; Scheffe’s test). (B) Treatment with T3 increases KLF9 protein 
expression in X. laevis tadpole brain. Panel 1: KLF9 protein is expressed at a very low level in NF 
stage 52 tadpole brain (optic tectum shown) but is increased dramatically by T3 treatment (panel 
2; 10 nM in aquarium water for 24 h). Panel 3: Representative saggital brain section 
(hypothalamic region) from a NF stage 52 tadpole treated with T3 in the aquarium water (10 nM; 
24 h). Strong KLF9 staining was restricted to cell nuclei. Panel 4: Immunostaining for KLF9 was 
eliminated by preabsorption with GST-xKLF9. KLF9 immunoreactivity was detected by Cy3 
immunofluorescence (panels 1, 2) or by horseradish peroxidase staining (panels 3, 4). (C) 
Western blot analysis of xKLF9 in protein extracts from pCS2 or pCS2-xKLF9 transfected XTC-
2 cells  (upper panel); endogenous KLF9 in protein extracts of XTC-2 cells treated with or 
without T3 (30 nM) for 24h (lower panel). This dose of T3 causes a maximal response in Tr 
and Klf9 mRNA (data not shown). Immunoblotting was conducted using affinity purified IgG that 


















Fig 5.2.  Schematic representation of the X. laevis TrA gene with locations of GC boxes and 
regions analyzed by EMSA and ChIP assay. The bars with letters underneath indicate the 
general regions of the TrA gene targeted for analysis by EMSA and in the ChIP assay, and 
correspond to the specific sequences given in Supplemental Table 1. The numbering of the seven 
GC boxes corresponds to that given in Table 4. The dark grey filled box represents the upstream 
region, the ‘S’ indicates the transcription start site, the light grey filled box represents the 5’ UTR, 
and the asterisk indicates a TRE that has been characterized and proposed to mediate T3-







































Fig 5.3. (A) Binding of GST-xKLF9[DBD] to regions of the proximal X. laevis Tr 
promoter in vitro. We used electrophoretic mobility shift assay (EMSA) to test the ability of 
radioinert DNA fragments (1.89 M/reaction) corresponding to different regions of the proximal 
Tr promoter (generated by PCR; see Fig. 2 and Supplemental Table 1) to displace GST-
xKLF9[DBD] binding to the [
32
P]-BTE probe. BTE – basic transcription element; mBTE – 
mutated BTE. (B) Binding of GST-xKLF9[DBD] to GC-rich regions of the proximal Tr 
promoter. We used EMSA to test whether GST-xKLF9[DBD] could bind to short, [
32
P]-labeled 
oligonucleotides encompassing one or two GC boxes in the Tr promoter. The numbering of 
the GC boxes included in each oligonucleotide probe is based on that given in Fig. 2 and Table 4. 
In each case homologous, radioinert competitors (1.89 M) were used to displace binding. BTE – 




















Fig 5.4. KLF9associates with the proximal Tr promoter in vivo in a T3 and developmental 
stage-dependent manner. ChIP assay was conducted using an affinity purified IgG directed 
against the N-terminal region of X. laevis KLF9. (A) T3-dependent association of KLF9 with the 
proximal Tr promoter in tadpole brain and tail. Premetamorphic (NF stage 52) X. laevis 
tadpoles were treated with 10 nM T3 added to the aquarium water for 48 hours prior to tissue 
collection for ChIP assay (see Materials and Methods). The lettered TrA promoter regions 
analyzed correspond to those given in Fig. 2 and Supplemental Table 1. The Tr exon 1/exon 2, 
and the Ef1 and Ifabp promoters were used as negative controls. (B) Developmental stage-
dependent association of KLF9 with the proximal Tr promoter in early prometamorphic (NF 
stage 54) and climax stage (NF stage 62) X. laevis tadpole brain. Only region A of TrA 
promoter, which showed robust T3-dependent association of KLF9 was targeted for ChIP analysis 






















Fig 5.5. Klf9 and Tr mRNAs are upregulated by T3, and KLF9 associates with the proximal Tr 
promoter in XTC-2 cells. (A) T3 upregulates Klf9 mRNA in XTC-2 cells with faster kinetics than TR. 
XTC-2 cells were treated with T3 (5 nM) for various times before harvest for RNA isolation and semi-
quantitative RT-PCR analysis of Klf9 and Tr mRNA expression. Gene expression was normalized to the 
level of rpL8 expression (a housekeeping gene). Klf9 mRNA was maximally induced at 3 hr (P=0.009; 
Scheffe’s test) and maintained through 48 hr of treatment. Tr mRNA was significantly induced at 6 hr 
(P=0.001), reached a maximum by 12 hr and was maintained through 48 hr. Bars represent the mean + 
SEM (n=6 wells/time point) and letters above the means indicate significant differences among time points 
(i.e., means with the same letter are not significantly different; P<0.05; Scheffe’s test). (B) KLF9 associates 
with the proximal Tr promoter in XTC-2 cells. XTC-2 cells were treated with T3 (5 nM) for 24h, and we 
used ChIP assay coupled with quantitative real time PCR to detect BTEB1 association with the Tr gene. 
We found significantly greater association of KLF9 at an upstream region of the promoter (overlapping 
with regions A and B shown in Fig. 2; -885 to -752) which contains multiple GC boxes compared with a 
region in the 5’ UTR (region G; +166 to +322) that has only one GC box, or the exon 5 of the Tr gene 
which has no GC boxes. Letters indicate significant differences among gene regions (i.e., means with the 
same letter are not significantly different; P<0.05; Scheffe’s test). (C) Treatment of XTC-2 cells with T3 (5 
nM, 24 h) increases KLF9 association with the upstream TRA promoter (region A/B) as analyzed by ChIP 














































Fig 5.6. Expression of KLF9 enhances Tr autoinduction in XTC-2 cells. (A) Forced 
expression of KLF9 accelerates and enhances autoinduction of the Tr promoter. XTC-2 cells 
were cotransfected with the X. laevis Tr promoter-luciferase plasmid, pCMV-xKLF9 and 
pRenilla (to normalize for transfection efficiency using a dual reporter luciferase assay; see 
Experimental Procedures). Cells were treated with 5 nM T3 for 0, 2 or 6 h before harvest. Bars 
represent the mean + SEM. The data shown are the means + SEM from one transfection 
experiment (n=4/treatment group) and the experiment was repeated three times with similar 
results. The T3-dependent activation of the Tr promoter was not altered by transfection with 
empty vector (pCMVneo; data not shown.) Asterisks denote significant differences from empty 
vector controls (* P<0.01; ** P<0.001; Student’s unpaired t-test). (B) Forced expression of KLF9 
increases the expression of endogenous Tr mRNA. XTC-2 cells were cotransfected with 1 g 
pCS2-xKLF9 or pCS2 empty vector plus pRenilla. Forty eight hr after transfection the cells were 
treated with 5 nM T3 for 0, 2, 4, or 6h before harvest. Gene expression analysis was done by 
RTqPCR. Data shown are the means + SEM from one transfection experiment (n=6/treatment) 
and the experiment was repeated four times with similar results. Asterisks denote significant 








Fig. 5.7. The N-terminal transactivation domains, but not the DNA binding capacity of the 
zinc fingers of KLF9 are required for Tr autoinduction. (A) N-terminal truncated forms of 
xKLF9 fail to enhance Tr autoinduction in XTC-2 cells.  XTC-2 cells were transfected with 
the indicated expression vectors and 48 hr later cells were treated with 5 nM T3 for 6h. Gene 
expression analysis was done by RTqPCR. Data shown are the means + SEM for the T3 –treated 
cells only; n=6/treatment. Letters indicate significant differences among treatments (i.e., means 
with the same letter are not significantly different; P<0.05; Bonferroni’s multiple comparison 
test). (B) Mutations in the three zinc fingers of KLF9 do not affect activity on Tr 
autoinduction. The first histidine residue in each of the Cys2His2  zinc finger DNA binding 
domain  of KLF9 was mutated to alanine to generate pCS2-xKLF9 C2AH. XTC-2 cells were 
transfected with the indicated expression vectors and 48h later cells were treated with 5 nM T3  
for 6h. Data shown are the means + SEM from one transfection experiment (n=6/treatment) and 
the experiment was repeated twice with similar results. Letters indicate significant differences 
among treatments (i.e., means with the same letter are not significantly different; P<0.05; 
Bonferroni’s multiple comparison test). (C) Electrophoretic mobility shift assay showed that the 
KLF9 C2AH mutant does not bind to DNA. Recombinant wildtype KLF9 and KLF9 C2AH 
mutant proteins were generated by coupled in vitro transcription/translation and varying amounts 
were tested for their ability to bind to the [
32
P]-BTE probe in vitro. Radioinert BTE 
oligonucleotide was added to some reactions as a competitor, and antibody supershift was used to 
verify the presence of KLF9 protein in the protein-DNA complexes formed. Western blot analysis 
confirmed that equal amounts of wildtype and mutant KLF9 proteins were used in the EMSA 
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 Chapter 6 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Synergistic gene regulation by nuclear hormone receptors is an important mechanism 
for amplifying gene regulatory cascades that are initiated by hormones. We have 
identified the transcription factor (TF), Krüppel like factor 9 (Klf9) as an important 
intermediate for the synergistic effect of GC on TH action during vertebrate 
development. In this thesis, I describe the molecular mechanisms of GC (GR/MR) and 
TH (TR) receptor transcriptional synergy in regulating the expression of an immediate 
early TF, Krüppel like factor 9 (Klf9) in the brain. I further demonstrate a functionally 
significant role for KLF9 in TRβ autoinduction, which has important implications for 
understanding the function of immediate early transcriptional responses in 
morphogenesis.  
 
Conserved hormone-dependent regulation of the Klf9 gene 
Hormone-dependent regulation of Klf9 was first discovered in X. laevis where it was 
found to be the most rapidly and strongly induced gene in TH-treated tadpole tissue 
(Denver, Pavgi et al. 1997). Frog Klf9 expression also parallels the increase in plasma TH 
that occurs during tadpole metamorphosis (Shi and Brown 1993; Wang and Brown 1993; 
Brown, Wang et al. 1995; Brown, Wang et al. 1996; Denver, Pavgi et al. 1997; Shi 2000; 
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Furlow and Kanamori 2002; Hoopfer, Huang et al. 2002).  Similar to X .laevis, the 
expression of rat and mouse Klf9 in the brain is upregulated by TH, and also 
coincides with the postnatal rise in brain thyroid hormone receptor (TRβ) expression 
and plasma T3 concentration (Porterfield and Hendrich 1993; Denver, Ouellet et al. 
1999; Morita, Kobayashi et al. 2003; Denver and Williamson 2009). Thyroid 
hormone-dependent regulation of Klf9 has been attributed to a near perfect DR+4 
T3RE located ~6.0 kb and ~3.8 kb upstream of the transcription start site of the frog 
and mouse Klf9 gene, respectively (Furlow and Kanamori 2002; Denver and 
Williamson 2009). Comparative sequence analysis showed that the T3RE-3.8 in the 
mouse Klf9 gene is not conserved between frogs and rodents. As part of the studies 
conducted in Chapter 3, I found the T3RE previously identified in frog Klf9 (T3RE-
6.0) to be evolutionarily and functionally conserved across tetrapods (T3RE-5.23 in 
mouse Klf9, T3RE-4.6 in human Klf9), and that TR associates with the conserved 
T3RE- 5.23. Comparative functional analysis of the mouse Klf9 T3RE-5.23 and T3RE-
3.8 by ChIP scan showed a higher association of TR and transcriptionally active 
histone marks at the mouse Klf9 T3RE-5.23 than at the T3RE- 3.8.  
In addition to the conserved TH-dependent regulation of the Klf9 gene, we also 
found that GCs, acting mainly through the GR, upregulate Klf9 expression in tadpole 
and juvenile frog brain (Bonett, Hu et al. 2009). In Chapter 2, I showed that GC-
dependent regulation is evolutionarily conserved between frog and mouse. More 
importantly, I identified two functional GC response elements (GRE/MRE- 6.1 and 
GRE/MRE-5.3) in the mouse Klf9 gene. Between these two GRE/MREs, comparative 
sequence analysis revealed that only the GRE/MRE-5.3 is evolutionarily conserved 
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across tetrapods, and also showed a greater association of GR and transcriptionally 
active histone marks at the conserved GRE/MRE-5.3. Thus, studies in Chapter 2 led 
to the discovery of an evolutionarily conserved functional GRE/MRE that supports 
the conserved GC-dependent regulation of the frog and mouse Klf9 genes. 
In addition to the independent effects of TH and GC in regulating Klf9 expression, 
work from my thesis also found that TH and GC directly and synergistically 
upregulated transcription of the Klf9 gene in the hippocampus, and this synergistic 
regulation is conserved between frogs and rodents. Promoter reporter scans together 
with comparative genomic analysis identified an evolutionarily conserved ~180 bp 
sequence located -5.3 kb upstream of the TSS of the mouse Klf9 gene (centered at-5.9 
kb upstream of the TSS in Xenopus Klf9) that  supports synergistic transactivation by 
TH and GC, and I therefore called this the Klf9 synergy module. Interestingly, the 
evolutionarily conserved T3RE (mouse Klf9 T3RE-5.23) and GRE/MRE (mouse Klf9 
GRE/MRE-5.3) I identified is also located within this ~180 bp synergy module. There 
is also a highly conserved hormone response element HRE half site (HRE h1) that 
was predicted to be GRE/MRE half site by in silico analysis located 5 bp downstream 
of the predicted T3RE (composed of HRE h2 and HRE h3). Mutational analysis show 
that HRE h1, h2 and h3 function as a composite response element that supports TH 
and GC-dependent regulation, and that HRE h2 is the most important half site needed 
for synergistic activation (Chapter 3). The enrichment of HRE half sites and other 
conserved cis regulatory elements (Sp-1, NF-1 and NF-κB) within the Klf9 synergy 
module suggest that it is an important and more transcriptionally active regulatory 
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region. This may account for our findings that there is greater association of TR, GR 
and chromatin marks of active transcription at the at the Klf9 synergy module HREs 
than at the other identified HREs (T3RE- 3.8 and GRE/MRE- 6.1).  
The activity of the T3RE- 3.8 and GRE/MRE- 6.1 was mostly tested in neuronal 
cell types and it is possible that they may play more significant roles in hormone-
dependent regulation of the Klf9 gene in a cell type- specific manner. The additional 
T3RE-3.8 and GRE/MRE-6.1 in the mouse Klf9 gene arose later in evolution and 
perhaps due to the more complex organization and function of the mammalian brain, 
the evolution of additional HREs may confer an another level of hormone regulation 
that is separate and independent from the synergistic regulation that occurs at the Klf9 
synergy module. Given the importance of hormone-dependent regulation of the Klf9 
gene that occurs at the synergy module, additional HREs may have evolved in some 
lineages to refine and/ or reinforce hormone-dependent gene activation. 
To better understand the contribution of the composite response element and other 
conserved TF binding sites within the synergy in the hormone- dependent regulation 
of Klf9, additional mutational analysis of the HREs within the synergy module and in 
combination with the other HRE outside of the synergy module need to be performed.  
Since the HRE h1 and HRE h2 was not protected by the GR DNA binding domain in 
DNAseI footprinting assay, we need to test if GC-dependent activation at the HRE 
h1/HRE h2 occurs independent of GR binding to DNA (i.e protein-protein 
interaction). In support of this hypothesis, I found a predicted NFκB site that 
encompasses HRE h1 and HRE h2. Proinflammatory cytokine- activated  NFκB  TF 
dimers have been mostly shown to antagonize GR-dependent regulation of common 
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target genes through several mechanisms that include protein-protein interactions or 
tethering(Vallabhapurapu and Karin 2009). However, recent evidence suggests that 
GR and NFB TF are co-recruited to common target genes to synergistically 
upregulate their expression (Rao, McCalman et al. 2011). Therefore, it would be 
interesting to determine the interaction between the NFκB and TH and/or GC-
dependent signaling  in regulation of the Klf9 gene. This can be tested by an NFB 
siRNA knockdown or NFB overexpression systems and determining their effect on 
hormone-dependent gene expression of Klf9. By EMSA, we can also test if GR binds 
to the composite response element in the presence of the NFκB TF, or if TR 
association is affected by NFκB .  In the same manner, we can perform mutational 
analysis, knockdown or overexpression to determine  contributions or interactions of 
Sp1 and NF-1 with the hormone-dependent regulation of the Klf9 gene. 
 Combined mutational analysis of the HREs within and outside the mouse Klf9 
synergy module using a larger promoter fragment of the mouse Klf9 gene can help us 
better understand the contributions of the additional HREs and their interaction with 
the synergy module. We may be able to identify and separate the HREs that are 
important for the independent versus the synergistic response with TH and GC within 
a particular cell type. These studies may provide some of the evolutionary 






Molecular mechanisms of synergistic transcriptional regulation of the Klf9 gene 
by TR and GR 
Transcriptional synergy between TFs is an important mechanism for integrating 
multiple pathways and is regarded to be an important  means to ensure genes are 
expressed at the appropriate time and place (Courey 2001). There are several 
mechanisms for how two TFs can enhance each other’s function leading to 
transcriptional synergy that were described in Chapter 1 (Fig. 1.6). In the studies 
described in Chapter 3, I confirmed that two out of the four mechanisms described 
may, in part, explain the transcriptional synergy that occurs at the Klf9 gene. 
Scanning the mouse Klf9 locus by ChIP assays, I found TR association peaks at the 
synergy module, and that there is TH-dependent enhancement of GR association at 
the synergy module and at the GRE/MRE-6.1 which is consistent with the role of TR 
as a transcriptional switch (Mai, Janier et al. 2004; Shi 2009). Synergistic 
transcriptional regulation of Klf9 was also seen at the level of synergistic association 
of stalled RNA polymerase II (pol II) where TH plus GC treatment led to a peak in 
Pol II association at Klf9 the synergy module. There was a lower peak of stalled Pol II 
at the promoter but its association did not change with any of the hormone treatments 
suggesting that the Klf9 synergy module is a more important site for transcriptional 
regulation. Stalled RNA pol II is highly enriched among genes implicated in 
development and response to stimuli suggesting that Pol II stalling  keeps the gene 
poised and ready to afford a rapid transcriptional response to developmental and 
environmental signals (Muse, Gilchrist et al. 2007; Zeitlinger, Stark et al. 2007; 
Margaritis and Holstege 2008). Thus, the hormone- dependent and peak of Pol II 
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association at the synergy module may be a key mechanism behind the rapid and 
synergistic response of Klf9 to TH and GC. 
There are still several outstanding questions that need to be addressed to fully 
understand the role of Pol II in the transcriptional events mediated by TR and GR at 
the Klf9 synergy module. For example, there are several possibilities to account for 
the synergistic association of stalled Pol II at the synergy module that remains to be 
tested. Is the enhanced association of stalled Pol II at the synergy module due to 
synergistic recruitment of unphosphorylated Pol II, enhanced phosphorylation of Ser5 
or an increase in the stability and time of association of stalled Pol II at the synergy 
module? ChIP assays with unphosphorylated pol II, proteins that regulate Pol II 
phosphorylation, and the kinetics of their association need to be done to address these 
possibilities. 
In chapter 3, I also found that the peak in association of stalled Pol II at the 
synergy module was accompanied by hormone-dependent transcription at the 
enhancer region. My findings are consistent with a recent study that identified ~2,000 
activity regulated enhancers bound by pol II are transcribed into noncoding RNA or 
enhancer RNA (eRNA) that were less than 2 kb in length. Enhancer RNA synthesis 
was dependent on the presence of a promoter of the associated gene and correlated 
with induction of nearby genes (Kim, Hemberg et al. 2010).  My preliminary data 
suggest that the noncoding transcripts are short and transcribed towards the direction 
of the promoter. Using genome wide analysis using Chromatin interaction analysis 
with paired end tag sequencing (ChIA-PET ) (Li, Fullwood et al. 2010) to look at TH- 
dependent long range genomic interactions, Laurent Sachs and colleagues have 
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shown that there is a TH-dependent interaction between the synergy module and Klf9 
promoter which supports the role of the synergy module as a bona fide enhancer 
where the assembly of TR, GR, Pol II and other yet unidentified TFs is physically 
relayed to the Klf9 promoter to mediate synergistic transcription. 
The role of noncoding eRNAs in gene regulation is a fairly recent concept that 
remains to be further investigated. The eRNA I discovered at the synergy module 
showed a similar pattern but more robust hormone-dependent regulation as the Klf9 
mRNA consistent with the peak in Pol II association at the that region. It remains to 
be determined whether the eRNA plays a functional role in target gene regulation 
similar to what was found with the eRNAs of the β globin gene, the human growth 
hormone and other long noncoding RNAs identified through the GENCODE 
annotation of the human genome (Ling, Ainol et al. 2004; Ho, Elefant et al. 2006; 
Vernimmen, De Gobbi et al. 2007; Orom, Derrien et al. 2010). Since we also know 
that the synergy module communicates with Klf9 promoter by chromosomal looping, 
it would be interesting to determine if the eRNA influences the physical interaction 
between the synergy module and promoter. This could be tested by knocking down 
eRNA by siRNA or blocking eRNA transcription by insertion of a transcription 
termination signal close to the Klf9 synergy module. Once eRNA synthesis or 
expression is blocked, we can determine how this affects expression of the Klf9 
mRNA.  
Another important issue that needs to be addressed that may account for the 
synergistic regulation of the Klf9 gene is whether GC or TH plus GC affects the 
stability or formation of the loops that bridge the enhancer and the promoter. A key 
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player that is known to facilitate chromosomal looping and interacts with TR and GR 
during transcriptional regulation is the MED1/TRAP220 subunit of the Mediator 
complex (Ito and Roeder 2001; Park, Li et al. 2005; Chen and Roeder 2007). In this 
regard, we need to test if TRAP220 is recruited to the synergy module and if it 
facilitates the interaction of the Klf9 synergy module with the promoter in regulating 
Klf9 transcription. All these proposed studies will provide a better understanding of 
the molecular basis behind the transcriptional events that occur at the Klf9 synergy 
module.  
Using the Klf9 gene as a model, we can further explore the significance 
mechanisms of how TR functions as a transcriptional switch and how TR affects the 
association of other TFs at the synergy module. For example, using a dominant 
negative form of TR that is not able to bind hormone and therefore is a constitutive 
repressor, we can determine if the independent and synergistic regulation of Klf9 by 
TH and GC is dampened. More importantly, by overexpression of the dominant 
negative form of TR we can determine by ChIP assay if there are changes in the 
hormone- dependent association of GR, pol II isoforms and active chromatin marks 
across the Klf9 locus. We can also test if the dominant negative TR affects eRNA 
synthesis and looping.     
 
Functional Role of KLF9 in development 
The expression of KLF9 is strongly upregulated during postnatal development of 
frog and rodent brain (Denver, Ouellet et al. 1999; Denver and Williamson 2009) and 
it has been shown to play a role in TH-dependent actions on neuronal morphology 
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(Denver, Ouellet et al. 1999; Cayrou, Denver et al. 2002). Expression of Klf9 in frog 
brain and mouse hippocampus and cerebellum parallels the postnatal rise in plasma 
T3 concentration and TRβ expression in the brain (Porterfield and Hendrich 1993; 
Denver, Ouellet et al. 1999; Shi 2000; Morita, Kobayashi et al. 2003; Bagamasbad, 
Howdeshell et al. 2008; Denver and Williamson 2009). Forced expression of KLF9 in 
tadpole brain caused an increase in the number of Golgi stained cells (Bonett, Hu et 
al. 2009). In rodents, deficiency in KLF9 led to a decrease in dendritic branching in 
the Purkinje cells of the cerebellum (Morita, Kobayashi et al. 2003), delayed neuronal 
maturation and reduced neurogenesis-dependent LTP in the dentate gyrus (Scobie, 
Hall et al. 2009) that was accompanied by reduced activity in behavioral tests that 
define functions of  the cerebellum, hippocampus and amygdala (Morita, Kobayashi 
et al. 2003). The mechanism for how KLF9 functions to regulate neuronal 
morphology and function is poorly understood.  
One of the direct transcriptional targets of KLF9 that we identified in the frog 
brain is thyroid hormone receptor β (TRβ). The coordinate upregulation of  frog Klf9 
and TRβ that occurs during tadpole metamorphosis, and the discovery that the TRβA 
promoter has several potential binding sites for KLF9 (Ranjan, Wong et al. 1994) led 
us to hypothesize that Klf9, which is induced by TH with faster kinetics than TRβ, 
promoted TRβ upregulation by TH (autoinduction).  Indeed I found that Klf9 
expression is upregulated earlier than TRβA in XTC-2 cells and in the brain of 
premetamorphic tadpoles treated with TH.  More importantly, by ChIP assays I 
showed that KLF9 associates with the TRβA promoter in vivo in a TH and 
developmental stage-dependent manner. Furthermore, forced expression of KLF9 in 
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XTC-2 cells or tadpole brain in vivo accelerated and enhanced TRβA autoinduction  
(Bagamasbad, Howdeshell et al. 2008), Hu and Denver, unpublished data) supporting 
our hypothesis that KLF9 functions as an accessory TF necessary for TRβ 
autoinduction. TRβA autoinduction is hypothesized to be necessary for driving 
metamorphosis by  increasing tissue sensitivity to TH that consequently amplifies 
gene expression cascades activated by the TH (reviewed in (Bagamasbad and Denver 
2011)).  
 The pattern of TRβ expression in rat brain parallel those seen in the tadpole 
during metamorphosis where TRβ expression is low at birth and shows a dramatic 
increase during the first 2 weeks postnatally, that is coincident with rising plasma TH 
concentrations (Strait, Schwartz et al. 1990). The human TRβ promoter has two 
functional T3REs that mediate transactivation in transient transfection assays (Suzuki, 
Miyamoto et al. 1994) but to our knowledge, the occurrence and significance of TRβ 
autoinduction during mammalian development has not been investigated. Therefore it 
would be interesting to know if the role of KLF9 in TRβ autoinduction is conserved 
between frogs and rodents and to investigate the functional significance of TRβ 
autoinduction in shaping neuronal function and morphology.  
The physiological significance for the synergistic action of TH and GC in animal 
development is best exemplified by amphibian metamorphosis where GC have been 
shown to synergize with TH in promoting tail morphogenesis through the synergistic 
effect of TH and GC  in regulating TRβ and deiodinase expression (Bonett, Hoopfer 
et al. 2010). Evidence suggests that GC alone does not regulate TRβ expression but 
GC can synergize with TH to enhance TRβ expression (Bonett, Hoopfer et al. 2010). 
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Studies in this thesis have shown that Klf9 is a direct transcriptional target of TR and 
GR leading to synergistic levels of Klf9 expression and that KLF9 functions in TRβ 
autoinduction. These results when taken together suggest that perhaps the ability of 
GC to enhance TH-dependent TRβ expression may be, partly, a secondary effect that 
is mediated by the synergistic expression of Klf9 by TH and GC. My findings provide 
another dimension of how TH and GC synergize to accelerate metamorphosis. By 
creating a positive, feed forward loop where TR and GR synergistically increase Klf9 
expression which consequently enhances TRβ autoinduction, tissue sensitivity to TH 
can be synergistically amplified to accelerate the metamorphic process (Fig. 1.7).  
 Glucocorticoids have been found to regulate deiodinase expression in rat liver, 
kidney and brain in vivo (Van der Geyten and Darras 2005). Krüppel like factor 9 was 
also found to directly upregulate Type I deiodinase activity in mouse hepatocytes 
(Ohguchi, Tanaka et al. 2008). In tadpole tail, GC and TH synergistically upregulated 
Type II deiodinase expression (Bonett, Hoopfer et al. 2010). Thus, it is possible that 
the GC-dependent regulation of deiodinase expression is mediated through KLF9. We 
can hypothesize that similar to its role in TRβ regulation, KLF9 can regulate 
deiodinase expression in tadpole tissues and that the synergistic effect of GC and TH 
in Type II deiodinase expression during tadpole metamorphosis may be an indirect 
consequence of KLF9 induction. If so, this would further emphasize the functional 
significance of KLF9 as an intermediate that increases TH sensitivity of target tissue. 
The developmental consequence of the role of KLF9 as an intermediate of GC and 
TH transcriptional network can be tested by overexpressing wild type and dominant 
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negative forms of KLF9 in tadpole brain and determining if this accelerates 
spontaneous metamorphosis.  
 There is mounting evidence that KLF9 plays an important role in mediating 
hormone action in brain development and plasticity (Denver, Ouellet et al. 1999; 
Cayrou, Denver et al. 2002; Morita, Kobayashi et al. 2003; Lin, Bloodgood et al. 
2008; Scobie, Hall et al. 2009). I have established that Klf9 is also a direct target for 
GC- dependent induction in the brain. We have yet to determine if KLF9 is a 
mediator of the GC-dependent changes in neuronal morphology and function. For 
example, does the KLF9-null mouse exhibit altered response in stress induced 
changes in neuronal morphology, synaptic plasticity and behavior?  We also need to 
identify other KLF9 target genes so that we can further investigate if neuronal 
structure and function is differentially influenced by TH, GC or TH plus GC through 
pathways activated by KLF9.  
 Results of my microarray analysis showed that there are other genes 
synergistically regulated by TH and GC involved in shaping cell morphology through 
reorganization of the cytoskeleton. These results are preliminary but have great 
potential to better understand the molecular basis for GC and TH action in the 
hippocampus. We first need to verify if the hormone- regulated genes identified in the 
microarray exhibit a similar form of regulation in vivo. Among genes synergistically 
regulated by TH and GC, we can conduct extensive bioinformatic analysis to 
determine if the other genes possess a regulatory region similar to the Klf9 synergy 
module. More importantly, we can investigate if these other genes synergistically 
upregulated by TH and GC also play a role in hormone-dependent changes in 
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neuronal structure and function, and if there are interactions between these genes 
required to confer hormone dependent responses. These possibilities can be directly 
tested by hormone treatment of WT mouse in comparison with KLF9-null mouse and 
by hormone treatment of Klf9 siRNA knockdown or overexpression systems in 
neuronal cultures or tadpole brain. Through these studies we can determine the 
different changes in neuronal morphology and function that are mediated by the 
interaction of KLF9 with other hormone-regulated genes. The list of genes that we 
have generated with the microarray analysis in mouse hippocampal neurons are novel 
findings and the first study that has looked into the coordinate action of TH and GC in 
gene regulation in the hippocampus. 
Krüppel-like factor 9 has also been shown to play a role in different hormone- 
dependent physiological functions outside of the nervous system. Krüppel like factor 
9  was discovered to directly regulate the expression of peroxisome proliferator- 
activated receptor Ɣ (PPAR Ɣ) and mediate PPARƔ- dependent adipocyte 
differentiation (Pei, Yao et al. 2011). In hepatocytes, KLF9 together with the 
hepatocyte nuclear factor 4α (HNF4α) and GATA4 synergistically regulates the 
expression of mouse Type I deiodinase (Ohguchi, Tanaka et al. 2008).  In uterine 
epithelial cells, KLF9 was found to interact with the progesterone receptor (PR) 
where it enhances progesterone- dependent gene transcription (Zhang, Zhang et al. 
2002; Zhang, Zhang et al. 2003). In contrast, KLF9 was found to repress estrogen 
receptor (ER) expression and consequently inhibit estrogen- dependent signaling in 
endometrial epithelial cells (Velarde, Zeng et al. 2007). These studies indicate that 
KLF9 may be an important mediator that integrates estrogen and progesterone 
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signaling pathways during uterine development. Consistent with its role in 
progesterone and estrogen signaling,  KLF9 deficient female mice exhibit delayed 
uterine development, reduced embryo implantation, decrease in litter size and delayed 
parturition (Simmen, Eason et al. 2004; Zeng, Velarde et al. 2008). These findings 
indicate that KLF9 is involved and may play a central role in several hormone-
dependent regulatory pathways during development. Given that estrogen and 
progesterone also influence brain development and function, it would be interesting to 
determine if KLF9 functions as an intermediate in the cross- talk between TH- 
progesterone/estrogen, or GC- progesterone/estrogen in the brain.  
 
Concluding remarks 
Hormones, especially stress and thyroid hormone, are powerful signaling 
molecules that play crucial roles in animal development, particularly development of 
the nervous system. There is a large body of knowledge that documents the 
independent effects of TH and GC in the brain but studies that investigate their 
coordinate actions in neural development is lacking. The studies presented in this 
thesis describe an evolutionarily conserved mechanism for the synergistic actions of 
TH and GC in regulation of the Klf9 gene, which may function as an intermediate that 
coordinates actions of TH and GC in shaping neuronal morphology and function. 
Findings in this thesis provide a molecular basis for the synergistic actions of TH and 
GC in animal development. This recent and novel finding and the discovery of the 
Klf9 synergy module suggest that thyroid and stress hormone regulation of Klf9 arose 
early in the evolution of the tetrapod vertebrates, and may have been maintained 
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through evolutionary time because of a critical, adaptive role for KLF9 in promoting 
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Supplemental Methods, Tables and Figures for Chapter 2 
 
Supplemental Materials and Methods 
Genomic DNA fragments identified by ChIP-chip assay for MR [35] corresponding 
to two upstream regions of the human Klf9 gene (-5139 to -5771 bp and -3875 to -4211 
bp) were subcloned into pGL4.23 (Supplemental Table 1) for testing in HEK293-hMR+ 
cells. As a positive control we used a 626 bp fragment of the upstream region of the 
human glucocorticoid-induced leucine zipper (GILZ) gene (-1286 to -1912 bp) cloned 
into pGL4.23; this region of the GILZ gene was previously shown to contain at least two 
functional GRE/MREs [54]. We cultured and transfected HEK293-hMR+ cells as 
described previously [35]. We incubated cells for 5 h in the presence or absence of 10 nM 
ALDO with or without 1 M of the MR selective antagonist RU26752 (Sigma Chemical 
Co., St. Louis, MO). The vehicle DMSO was present in all wells at a final concentration 
of 0.01%. Luciferase activity in cell lysates was analyzed using the Dual Luciferase
 














PCR primers to amplify promoter fragments cloned into pGL4.23 vector 
hKlf9 GRE/MRE-5.5 Fragment1 
Forward: 5’ acatctcgagGCATGGGGGCCGTACAGAAGGGGGAACT 3’  
Reverse: 5’ acataagcttCGGCCAGGCTGTGCGGGAGGAGATG 3’  
 
hKlf9 GRE/MRE-4.0 Fragment2 
Forward: 5’ acagagctcGCCCCTGGGTGTTAGCTGTCATTAT 3’  
Reverse: 5’ acatctcgagCCAGGCGGGAAGGAAGGAGGAGAAC 3’  
 
hGILZ control -1286 to -1912 
Forward: 5’ acatctcgagAACATTGGGTTCCACCACATA 3’  
Reverse: 5’ acataagcttCAGGGAATTCTGATACCAGTTA 3’  
________________________________________________________________________ 








Supplemental Fig 2.1. Treatment with 3,5,3’-triiodothyronine (T3) caused dose and 
time-dependent increases in Klf9 mRNA in HT-22 cells.  Cells were treated with 30 
nM T3 for different times (A; F(5,23)=37.90, p<0.00; ANOVA), or with increasing doses 
of T3 for 4 h (B; EC50= 1.87 nM; (F(7,31)=77.09,  p<0.001; ANOVA) before harvest and 
analysis of Klf9 mRNA. In each experiment cells were treated with the hormone doses 
for the times indicated before cell harvest, RNA extraction and analysis by RTqPCR. 
Klf9 mRNA was normalized to the mRNA level of the housekeeping gene GAPDH. Bars 
represent the mean + SEM (n=4) and letters above the means indicate significant 
differences among hormone concentrations or time point (means with the same letter are 








Supplemental Fig 2.2. Identification of an aldosterone-responsive region of the 
human Klf9 gene centered at ~-5.5 kb relative to the transcription start site.  We co-
transfected HEK293-hMR+ cells with promoter-luciferase constructs containing 
fragments of the human Klf9 gene and the pRenilla plasmid, and measured luciferase 
activity after 5 h treatment with 10 nM aldosterone (ALDO) in the presence or absence of 
1 M of the MR-selective antagonist RU26752. Fragment 1 encompassed 632 bp from -
5771 to -5139 bp, and fragment 2 encompassed 336 bp from -4211 to -3875 bp upstream 
of the human Klf9 transcription start site. A 626 bp fragment of the upstream region the 
human glucocorticoid-induced leucine zipper gene (GILZ) that contains at least two 
GRE/MREs served as a positive control for hormone activation, and the pGL4.23 empty 
vector served as the negative control. Luciferase activity was measured using the Dual 
Luciferase Reporter Assay. Bars represent the mean + SEM (n=8) and letters above the 
means indicate significant differences among treatments (means with the same letter are 
not significantly different; fragment 1: F(2,41)=693.5, p<0.001; fragment 2: F(2,41)=10.92, 








Supplemental Figures for Chapter 3 
 
Supplemental Fig. 3.1. Corticosterone (CORT) synergizes with 3,5,3’-triiodothyronine (T3) 
to induce Klf9 heteronuclear RNA. HT-22 cells were treated with 30 nM T3, 100 nM CORT or 
T3 plus CORT for different times before harvest and RNA extraction. RNA samples were used to 
measure Klf9 heteronuclear RNA (hnRNA) by RTqPCR using Taqman assay targeted against the 
Klf9 intronic region. The Klf9 hnRNA were normalized to the mRNA level of the housekeeping 
gene GAPDH. Bars represent the mean + SEM and letters above the means indicate significant 
differences among treatments (means with the same letter are not significantly different; Tukey’s 
multiple comparison test; P<0.05). Dashed lines represent the additive effects of T3 plus CORT in 





Supplemental Fig. 3.2. The -6 to -5 kb genomic fragment of frog Klf9 gene shows synergistic 
transactivation in HT-22 cells. A series of 1 kilobase fragments covering from -7 kb to 0 kb 
upstream of the X. tropicalis Klf9 transcription start site were cloned into a luciferase vector and 
transfected into HT-22 cells.  Cells were treated with T3, CORT or T3 plus CORT for 4 h before 
harvest and analysis by dual luciferase assay. Bars represent the mean + SEM (n=4-5) fold 
induction and letters above the means indicate significant differences among hormone 
concentrations or time point (means with the same letter are not significantly different; Tukey’s 
multiple comparison test; P<0.05). Dashed lines represent the additive effects of T3 plus CORT 














Supplemental Fig. 3.3. Highly conserved transcription factor binding sites within the Klf9 
synergy module as identified by TESS and Match. Comparative sequence alignment of the 
~180 bp Klf9 synergy module across several tetrpod species showing conservation of the T3RE 
(yellow; HRE h2 and HRE h3), GRE/MRE (blue; mouse GRE/MRE-5.3) and other binding sites 
for estrogen receptor (ER half site, red), Sp1 (orange), NF-1 (pink) and NFkB as predicted by the 










Supplemental Fig. 3.4. Frog and mouse Klf9 synergy module support synergistic 
transactivation by T3 plus CORT in frog and mouse cell lines. (A) HT-22 cells were 
transfected with promoter luciferase constructs containing the mouse Klf9 179 bp synergy 
module, and corresponding site mutants (*). Cells were treated with 30 nM T3, 100 nM CORT or 
T3 plus CORT for 4 h before harvest and analysis by dual luciferase assay. Bars represent the 
mean + SEM (n=4-5) relative luciferase units. (B) XTC-2 cells were transfected with mouse and 
frog Klf9 synergy module promoter- luciferase constructs. Cells were treated with 5 nM T3, 100 
nM CORT or T3 plus CORT for 4 h before harvest and analysis by dual luciferase assay. Bars 
represent the mean + SEM (n=4-5) fold induction and letters above the means indicate significant 
differences among between hormone treatments (means with the same letter are not significantly 
different; Tukey’s multiple comparison test; P<0.05). Dashed lines represent the additive effects 













Supplemental Fig 3.5. Thyroid hormone receptor (TR) associates with the synergy module 
in neuroblastoma cells (N2a[TRβ1]). N2a[TRβ1] cells were treated with or without T3 (30 nM) 
for 24 h before harvest for ChIP assay. ChIP samples were analyzed by RTqPCR using TaqMan 
assays that targeted the synergy module.  Bars represent the mean ChIP signals (n=6/ treatment) 
for TR (anti-TR) and normal rabbit serum (NRS, negative control) expressed as a percentage of 
the input.  Asterisks indicate statistically significant differences between NRS (Control) and TR 










Supplemental Fig. 3.6. (CORT) synergizes with 3,5,3’-triiodothyronine (T3) to induce 
transcription at the Klf9 synergy module and at -3.8 kb TSS. HT-22 cells were treated  with 
30 nM T3, 100 nM CORT or T3 plus CORT for 4h before harvest and RNA extraction. RNA 
samples were treated with DNAseI and transcripts at the various regions upstream of the TSS 
were measured by RTqPCR using Taqman assays. RTqPCR without reverse transcriptase was 
used as a negative control and did not yield any amplicons for any of the assays. RNA transcripts 
were normalized to the mRNA level of the housekeeping gene GAPDH. Bars represent the mean 
+ SEM and letters above the means indicate significant differences among treatments (means 
with the same letter are not significantly different; Tukey’s multiple comparison test; P<0.05). 











Supplemental Fig. 3.7. Putative hormone response elements in the 5′-flanking region of the 
rat GHRH-R gene. Localizations of putative GREs and TRE in the 5′-flanking region of the rat 
GHRH-R gene are shown. The hexamer half-sites of hormone response elements are tentatively 
numbered from 1 through 9 (only 5-9 are shown).  GRE-3 (5 and 6) contains 7, 8, or 7 of 12 
nucleotides identical to the consensus GRE (GGTACAnnnTGTTCT), respectively. TRE-1, 
consists of half-sites 6 and 8, appears to be an inverted palindrom-like sequence, and TRE-2 
consists of half-sites 7 and 9 appears to be a palindromic TRE. Taken and modified from Nogami 





















Supplemental Fig. 3.8. Hormone dependent induction of frog Klf9 eRNA. XTC-2 cells were 
treated  with 5 nM T3, 100 nM CORT or T3 plus CORT for 4h before harvest and RNA 
extraction. RNA samples were treated with DNAseI and transcripts measured by RTqPCR using 
Taqman assays targeted to the frog Klf9 synergy module. RTqPCR without reverse transcriptase 
was used as a negative control and did not yield any amplicons for any of the assays. RNA 
transcripts were normalized to the mRNA level of the housekeeping gene rpL8. Bars represent 
the mean + SEM and letters above the means indicate significant differences among treatments 
(means with the same letter are not significantly different; Tukey’s multiple comparison test; 















Supplemental Tables for Chapter 4 
 
 
Supplemental Table 4.1. Complete list of genes upregulated by 4h of T3 treatment in HT-22 
cells.  
PROBE ID SYMBOL DEFINITION P value Fold 
chan
ge 
ILMN_1254031 Klf9 Mus musculus Kruppel-like factor 9 (Klf9), mRNA. 0 3.09 
ILMN_1220280 Tas1r1 Mus musculus taste receptor, type 1, member 1 
(Tas1r1), mRNA. 
0 2.68 
ILMN_1232601 Cyb561 Mus musculus cytochrome b-561 (Cyb561), mRNA. 0 2.61 
ILMN_2430906 2310051E17Rik PREDICTED: Mus musculus RIKEN cDNA 
2310051E17 gene (2310051E17Rik), mRNA. 
0.00009 2.23 
ILMN_1229547 Spon2 Mus musculus spondin 2, extracellular matrix protein 
(Spon2), mRNA. 
0 1.93 
ILMN_2616226 Dbp Mus musculus D site albumin promoter binding protein 
(Dbp), mRNA. 
0 1.79 
ILMN_2484932 C030002B11Rik  0 1.74 
ILMN_3127391 Npr3 Mus musculus natriuretic peptide receptor 3 (Npr3), 
transcript variant 1, mRNA. 
0 1.59 
ILMN_1217117 Cdon  0 1.51 
ILMN_2420341 9629514_325  0.02144 1.5 
ILMN_2457585 Trp53inp2 Mus musculus transformation related protein 53 
inducible nuclear protein 2 (Trp53inp2), mRNA. 
0 1.49 
ILMN_1243564 Plekha1 Mus musculus pleckstrin homology domain containing, 
family A (phosphoinositide binding specific) member 1 
(Plekha1), mRNA. 
0 1.48 
ILMN_1253191 E230024B12Rik  0 1.48 
ILMN_2708877 Plekha1 Mus musculus pleckstrin homology domain containing, 
family A (phosphoinositide binding specific) member 1 
(Plekha1), mRNA. 
0 1.47 
ILMN_2812215 Plekhg5 Mus musculus pleckstrin homology domain containing, 
family G (with RhoGef domain) member 5 (Plekhg5), 
mRNA. 
0.00009 1.46 
ILMN_2918002 Gbp3 Mus musculus guanylate nucleotide binding protein 3 
(Gbp3), mRNA. 
0.00276 1.46 





 0.01358 1.42 
ILMN_1255967 B430216N15Rik  0.01463 1.41 
ILMN_2772155 LOC100045780 PREDICTED: Mus musculus similar to 
metalloprotease-disintegrin meltrin beta 
(LOC100045780), mRNA. 
0.005 1.41 
ILMN_2966104 Htra1 Mus musculus HtrA serine peptidase 1 (Htra1), mRNA. 0 1.38 
ILMN_2746738 Htra1 Mus musculus HtrA serine peptidase 1 (Htra1), mRNA. 0 1.37 
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ILMN_2433213 Klf7  0 1.37 
ILMN_2482756 Usf2 Mus musculus upstream transcription factor 2 (Usf2), 
mRNA. 
0.00049 1.36 
ILMN_2702193 Mxra7 Mus musculus matrix-remodelling associated 7 (Mxra7), 
mRNA. 
0 1.36 
ILMN_2833163 BC064033 Mus musculus cDNA sequence BC064033 (BC064033), 
mRNA. 
0.01817 1.36 
ILMN_1229082 Klhl21 Mus musculus kelch-like 21 (Drosophila) (Klhl21), 
mRNA. 
0.00002 1.35 
ILMN_2618364 Flnc Mus musculus filamin C, gamma (Flnc), mRNA. 0.00994 1.35 
ILMN_2604333 Npr3  0 1.34 
ILMN_2485408 9626962_3  0.00001 1.34 
ILMN_1227465 9628654_5  0.00509 1.34 
ILMN_2976191 Stat5a Mus musculus signal transducer and activator of 
transcription 5A (Stat5a), mRNA. 
0.00005 1.34 
ILMN_2433848 Slco2a1  0 1.34 
ILMN_2685329 Hspg2 PREDICTED: Mus musculus perlecan (heparan sulfate 
proteoglycan 2) (Hspg2), mRNA. 
0 1.33 
ILMN_2510383 Tnfrsf25 Mus musculus tumor necrosis factor receptor 
superfamily, member 25 (Tnfrsf25), mRNA. 
0.00116 1.33 
ILMN_1253661 Plekhg5 Mus musculus pleckstrin homology domain containing, 
family G (with RhoGef domain) member 5 (Plekhg5), 
mRNA. 
0.02109 1.32 
ILMN_2625920 Aoc3 Mus musculus amine oxidase, copper containing 3 
(Aoc3), mRNA. 
0 1.32 
ILMN_2424299 Tnfrsf12a Mus musculus tumor necrosis factor receptor 
superfamily, member 12a (Tnfrsf12a), mRNA. 
0.00263 1.32 
ILMN_2422982 Synpo  0 1.32 
ILMN_1244513 Gbp3 Mus musculus guanylate binding protein 3 (Gbp3), 
mRNA. 
0 1.31 
ILMN_3091641 Dab2 Mus musculus disabled homolog 2 (Drosophila) (Dab2), 
transcript variant 2, mRNA. 
0.00184 1.31 
ILMN_2961216 Slco2a1 Mus musculus solute carrier organic anion transporter 
family, member 2a1 (Slco2a1), mRNA. 
0.00001 1.31 
ILMN_1220443 LOC381002 PREDICTED: Mus musculus hypothetical LOC381002 
(LOC381002), misc RNA. 
0.01517 1.31 
ILMN_2834344 2610029G23Rik Mus musculus RIKEN cDNA 2610029G23 gene 
(2610029G23Rik), mRNA. 
0.00842 1.3 
ILMN_2420956 Dysf Mus musculus dysferlin (Dysf), transcript variant 1, 
mRNA. 
0 1.29 
ILMN_2707308 Cct5 Mus musculus chaperonin containing Tcp1, subunit 5 
(epsilon) (Cct5), mRNA. 
0.0194 1.29 
ILMN_3156010 Pdzrn3 Mus musculus PDZ domain containing RING finger 3 
(Pdzrn3), mRNA. 
0.00001 1.29 
ILMN_1225880 Srm Mus musculus spermidine synthase (Srm), mRNA. 0.00764 1.29 
ILMN_2690122 Slc27a1  0.02185 1.29 
ILMN_2977903 BC057627 Mus musculus cDNA sequence BC057627 (BC057627), 
mRNA. 
0 1.29 
ILMN_1230423 Sh3pxd2b Mus musculus SH3 and PX domains 2B (Sh3pxd2b), 
mRNA. 
0.0012 1.29 
ILMN_2508910 Tpst2  0.00568 1.28 
ILMN_2520249 Hspg2  0.00556 1.28 
ILMN_2602185 40795 Mus musculus septin 9 (Sept9), mRNA. 0.00201 1.28 
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ILMN_2448651 Ampd3 Mus musculus adenosine monophosphate deaminase 3 
(Ampd3), mRNA. 
0.00002 1.28 
ILMN_1251426 Klf7 Mus musculus Kruppel-like factor 7 (ubiquitous) (Klf7), 
mRNA. 
0 1.27 
ILMN_2822579 Col4a2 Mus musculus collagen, type IV, alpha 2 (Col4a2), 
mRNA. 
0.03754 1.27 
ILMN_2712634 Nab1 Mus musculus Ngfi-A binding protein 1 (Nab1), 
mRNA. 
0.026 1.26 
ILMN_2466021 Hivep3  0.00052 1.26 
ILMN_2791272 Por Mus musculus P450 (cytochrome) oxidoreductase (Por), 
mRNA. 
0.00043 1.26 
ILMN_2543851 Sec62 Mus musculus SEC62 homolog (S. cerevisiae) (Sec62), 
mRNA. 
0.04672 1.26 
ILMN_2728118 Rrp12 Mus musculus ribosomal RNA processing 12 homolog 
(S. cerevisiae) (Rrp12), mRNA. 
0.02611 1.26 
ILMN_3162239 Prr7 Mus musculus proline rich 7 (synaptic) (Prr7), mRNA. 0.04194 1.25 
ILMN_1242125 Plekhg5 Mus musculus pleckstrin homology domain containing, 
family G (with RhoGef domain) member 5 (Plekhg5), 
mRNA. 
0.00914 1.25 
ILMN_1241890 Klf7  0.00267 1.25 
ILMN_2677921 Vasn Mus musculus vasorin (Vasn), mRNA. 0.00001 1.25 
ILMN_2931384 Lrrc59 Mus musculus leucine rich repeat containing 59 
(Lrrc59), mRNA. 
0.00388 1.25 
ILMN_2681776 Mapk6 Mus musculus mitogen-activated protein kinase 6 
(Mapk6), transcript variant 2, mRNA. 
0 1.25 
ILMN_3031099 Coq10b Mus musculus coenzyme Q10 homolog B (S. cerevisiae) 
(Coq10b), transcript variant 1, mRNA. 
0.00781 1.25 
ILMN_2526333 LOC381284  0.03845 1.25 
ILMN_2886981 Tm6sf1 Mus musculus transmembrane 6 superfamily member 1 
(Tm6sf1), mRNA. 
0.03805 1.25 
ILMN_2843782 Tpst2 Mus musculus protein-tyrosine sulfotransferase 2 
(Tpst2), mRNA. 
0.00003 1.24 
ILMN_3109360 Plec1 Mus musculus plectin 1 (Plec1), transcript variant 11, 
mRNA. 
0 1.24 
ILMN_1216597 Slc25a25 Mus musculus solute carrier family 25 (mitochondrial 
carrier, phosphate carrier), member 25 (Slc25a25), 
nuclear gene encoding mitochondrial protein, mRNA. 
0.00026 1.24 
ILMN_2496537 Npr3 Mus musculus natriuretic peptide receptor 3 (Npr3), 
transcript variant 2, mRNA. 
0.03378 1.24 
ILMN_2903351 Leo1 Mus musculus Leo1, Paf1/RNA polymerase II complex 
component, homolog (S. cerevisiae) (Leo1), mRNA. 
0.00009 1.24 
ILMN_2735118 Pprc1 Mus musculus peroxisome proliferative activated 
receptor, gamma, coactivator-related 1 (Pprc1), mRNA. 
0.04014 1.24 
ILMN_2714565 Rrm2  0.02662 1.24 
ILMN_2422014 LOC100040353 PREDICTED: Mus musculus similar to splicing 
coactivator subunit SRm300 (LOC100040353), mRNA. 
0.03244 1.24 
ILMN_2920200 Heg1 Mus musculus HEG homolog 1 (zebrafish) (Heg1), 
mRNA. 
0.0319 1.24 
ILMN_2743831 Pepd Mus musculus peptidase D (Pepd), mRNA. 0.04898 1.23 
ILMN_1237197 Nrp1 Mus musculus neuropilin 1 (Nrp1), mRNA. 0 1.23 
ILMN_2669912 Nrp1 Mus musculus neuropilin 1 (Nrp1), mRNA. 0.01505 1.23 
ILMN_2870487 Cpne2 Mus musculus copine II (Cpne2), mRNA. 0.00004 1.23 
ILMN_2961221 Slco2a1 Mus musculus solute carrier organic anion transporter 




ILMN_2920736 Bbc3 Mus musculus BCL2 binding component 3 (Bbc3), 
mRNA. 
0.00214 1.23 
ILMN_2622983 Dusp1 Mus musculus dual specificity phosphatase 1 (Dusp1), 
mRNA. 
0.03329 1.23 
ILMN_3023230 Jmjd3 Mus musculus jumonji domain containing 3 (Jmjd3), 
mRNA. 
0.04144 1.23 
ILMN_2908056 Tmbim1 Mus musculus transmembrane BAX inhibitor motif 
containing 1 (Tmbim1), mRNA. 
0.02362 1.23 
ILMN_2732317 Pik3r2 Mus musculus phosphatidylinositol 3-kinase, regulatory 
subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA. 
0.02466 1.22 
ILMN_2592554 Rexo1 Mus musculus REX1, RNA exonuclease 1 homolog (S. 
cerevisiae) (Rexo1), transcript variant 1, mRNA. 
0.03212 1.22 
ILMN_2644845 Trmt6 Mus musculus tRNA methyltransferase 6 homolog (S. 
cerevisiae) (Trmt6), mRNA. 
0.02571 1.22 
ILMN_2987863 Per2 Mus musculus period homolog 2 (Drosophila) (Per2), 
mRNA. 
0.01388 1.22 
ILMN_1243077 Peo1 Mus musculus progressive external ophthalmoplegia 1 
(human) (Peo1), mRNA. 
0.03554 1.22 
ILMN_3095624 Jmjd3 Mus musculus jumonji domain containing 3 (Jmjd3), 
mRNA. 
0.00816 1.22 
ILMN_2460062 Atl2 Mus musculus atlastin GTPase 2 (Atl2), transcript 
variant 1, mRNA. 
0.04075 1.22 
ILMN_1255871 Loxl1 Mus musculus lysyl oxidase-like 1 (Loxl1), mRNA. 0 1.22 
ILMN_2598103 Emp2 Mus musculus epithelial membrane protein 2 (Emp2), 
mRNA. 
0 1.22 
ILMN_1250969 LOC100047016 PREDICTED: Mus musculus similar to GCN1 general 
control of amino-acid synthesis 1-like 1 
(LOC100047016), mRNA. 
0.02208 1.22 
ILMN_2751072 Gna11  0.02043 1.22 
ILMN_2714031 Errfi1 Mus musculus ERBB receptor feedback inhibitor 1 
(Errfi1), mRNA. 
0.0324 1.21 
ILMN_1258148 Inppl1 Mus musculus inositol polyphosphate phosphatase-like 
1 (Inppl1), mRNA. 
0.02449 1.21 
ILMN_1220243 LOC385644  0.01038 1.21 
ILMN_2554000 5930429A15Rik  0.01087 1.21 
ILMN_2674822 Nt5c2 Mus musculus 5'-nucleotidase, cytosolic II (Nt5c2), 
mRNA. 
0.00835 1.21 
ILMN_3147112 Mapk6 Mus musculus mitogen-activated protein kinase 6 
(Mapk6), transcript variant 2, mRNA. 
0.00977 1.21 
ILMN_2596278 Tcfe2a  0.03226 1.21 
ILMN_2772027 2410016O06Rik  0.01228 1.21 
ILMN_3121255 Vegfa Mus musculus vascular endothelial growth factor A 
(Vegfa), transcript variant 1, mRNA. 
0.00156 1.21 
ILMN_2972325 2410016O06Rik Mus musculus RIKEN cDNA 2410016O06 gene 
(2410016O06Rik), mRNA. 
0.0064 1.21 
ILMN_2761046 Slc25a33 Mus musculus solute carrier family 25, member 33 
(Slc25a33), mRNA. 
0.01667 1.21 
ILMN_2614853 6720458F09Rik Mus musculus RIKEN cDNA 6720458F09 gene 
(6720458F09Rik), mRNA. 
0.00003 1.21 
ILMN_2729103 Adamts2 Mus musculus a disintegrin-like and metallopeptidase 
(reprolysin type) with thrombospondin type 1 motif, 2 
(Adamts2), mRNA. 
0.00034 1.2 
ILMN_2701534 Ampd2 Mus musculus adenosine monophosphate deaminase 2 
(isoform L) (Ampd2), mRNA. 
0.00213 1.2 
ILMN_3157483 Ets1 Mus musculus E26 avian leukemia oncogene 1, 5' 






















































Supplemental Table 4.2. Complete list of genes downregulated by 4h of T3 treatment in HT-
22 cells.  
 
PROBE ID SYMBOL DEFINITION P value Fold 
change 
ILMN_2606667 Ddx6 Mus musculus DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 6 (Ddx6), mRNA. 
0.0318 
-1.72 
ILMN_2654822 Chd4 Mus musculus chromodomain helicase DNA binding 







ILMN_1253178 Aldh3a1 Mus musculus aldehyde dehydrogenase family 3, 







ILMN_1230788 Tle1 Mus musculus transducin-like enhancer of split 1, 
homolog of Drosophila E(spl) (Tle1), mRNA. 
XM_984202 XM_984240 XM_984277 XM_984316 




ILMN_1237565 EG626367 PREDICTED: Mus musculus predicted gene, 
EG626367 (EG626367), misc RNA. 
0 
-1.44 
ILMN_1256844 EG668850 PREDICTED: Mus musculus predicted gene, 
EG668850 (EG668850), misc RNA. 
0 
-1.42 








ILMN_1243988 LOC269251  0.00022 
-1.41 
ILMN_3031781 Arid5b Mus musculus AT rich interactive domain 5B (MRF1-
like) (Arid5b), mRNA. 
0.01249 
-1.39 










ILMN_1219839 mtDNA_ND6  0 
-1.35 




ILMN_3038404 Tcf25 Mus musculus transcription factor 25 (basic helix-loop-
helix) (Tcf25), transcript variant 3, mRNA. 
0.0094 
-1.34 
ILMN_2710678 Nfic  0.04947 
-1.34 








ILMN_2874853 Eef1b2 Mus musculus eukaryotic translation elongation factor 
1 beta 2 (Eef1b2), mRNA. 
0.04617 
-1.31 
ILMN_1259322 Pdk4 Mus musculus pyruvate dehydrogenase kinase, 















PREDICTED: Mus musculus similar to ribosomal 













ILMN_1233064 Cdk2 Mus musculus cyclin-dependent kinase 2 (Cdk2), 
transcript variant 1, mRNA. 
0.00158 
-1.29 
ILMN_2819841 Rpl7a Mus musculus ribosomal protein L7a (Rpl7a), mRNA. 0 
-1.29 
ILMN_2497068 Zmynd11 Mus musculus zinc finger, MYND domain containing 
11 (Zmynd11), mRNA. 
0.01111 
-1.28 




ILMN_1232121 Zeb2 Mus musculus zinc finger E-box binding homeobox 2 





PREDICTED: Mus musculus hypothetical protein 







ILMN_1252004 Itpripl2 Mus musculus inositol 1,4,5-triphosphate receptor 
interacting protein-like 2 (Itpripl2), mRNA. 
0.00062 
-1.27 










PREDICTED: Mus musculus RIKEN cDNA 









ILMN_2688728 Pcyt1a Mus musculus phosphate cytidylyltransferase 1, 













ILMN_2692421 Ciz1 Mus musculus CDKN1A interacting zinc finger protein 
1 (Ciz1), mRNA. 
0.03611 
-1.25 
























ILMN_2846775 Cdkn1a Mus musculus cyclin-dependent kinase inhibitor 1A 
(P21) (Cdkn1a), mRNA. 
0.00161 
-1.24 
ILMN_2684909 Sirt6 Mus musculus sirtuin 6 (silent mating type information 




ILMN_2623112 Fam168a Mus musculus family with sequence similarity 168, 
member A (Fam168a), mRNA. 
0.00487 
-1.24 
ILMN_2525034 Cc1  0.04732 
-1.24 
ILMN_2936118 Rpl24 Mus musculus ribosomal protein L24 (Rpl24), mRNA. 0.00042 
-1.24 










ILMN_1239608 Arid4a Mus musculus AT rich interactive domain 4A (RBP1-
like) (Arid4a), mRNA. 
0.03768 
-1.24 
ILMN_1260532 Jarid1a PREDICTED: Mus musculus jumonji, AT rich 








Mus musculus RIKEN cDNA 2210010L05 gene 
(2210010L05Rik), transcript variant 1, mRNA. 
0.04662 
-1.23 




PREDICTED: Mus musculus RIKEN cDNA 






PREDICTED: Mus musculus similar to 
transmembrane protein 35 (LOC100046844), mRNA. 
0.02197 
-1.22 




ILMN_2769772 Pik3ip1 Mus musculus phosphoinositide-3-kinase interacting 
protein 1 (Pik3ip1), mRNA. 
0.00466 
-1.22 
ILMN_1212982 Zfp318 Mus musculus zinc finger protein 318 (Zfp318), 





PREDICTED: Mus musculus similar to ribosomal 
protein L35a (LOC100039532), mRNA. 
0.00044 
-1.22 




ILMN_1255869 Catnb  0.0391 
-1.22 
ILMN_3112873 Txnip Mus musculus thioredoxin interacting protein (Txnip), 
transcript variant 1, mRNA. 
0 
-1.22 
ILMN_1225552 Arsa Mus musculus arylsulfatase A (Arsa), mRNA. 0.00019 
-1.21 
ILMN_2650732 Taf15 Mus musculus TAF15 RNA polymerase II, TATA box 












ILMN_2717613 Cdk2  0.02192 
-1.21 
ILMN_2662803 Ptx3 Mus musculus pentraxin related gene (Ptx3), mRNA. 0.0473 
-1.21 
ILMN_2718030 Ank2 Mus musculus ankyrin 2, brain (Ank2), transcript 





PREDICTED: Mus musculus hypothetical protein 
LOC100047226 (LOC100047226), misc RNA. 
0.00046 
-1.21 




ILMN_1256285 Siat7b  0.03813 
-1.21 




ILMN_2632940 Sumo1  0.00075 
-1.2 














ILMN_1231586 Sertad2 Mus musculus SERTA domain containing 2 (Sertad2), 





















































Supplemental Table 4.3. Complete list of genes upregulated by 4h of CORT treatment in 
HT-22 cells.  
PROBE ID SYMBOL DEFINITION P value Fold 
change 
ILMN_2701664 Tsc22d3 Mus musculus TSC22 domain family, member 3 
(Tsc22d3), transcript variant 2, mRNA. 
0 8.82 
ILMN_3150811 Tsc22d3 Mus musculus TSC22 domain family, member 3 
(Tsc22d3), transcript variant 1, mRNA. 
0 5.41 
ILMN_1259322 Pdk4 Mus musculus pyruvate dehydrogenase kinase, isoenzyme 
4 (Pdk4), mRNA. 
0 5.02 
ILMN_2813484 Per1 Mus musculus period homolog 1 (Drosophila) (Per1), 
mRNA. 
0 4.64 
ILMN_2588249 S3-12 Mus musculus plasma membrane associated protein, S3-12 
(S3-12), mRNA. 
0 4.48 
ILMN_2987862 Per2 Mus musculus period homolog 2 (Drosophila) (Per2), 
mRNA. 
0 4.21 
ILMN_2770894 Map3k6  0 3.82 
ILMN_2768972 Fam107a Mus musculus family with sequence similarity 107, 
member A (Fam107a), mRNA. 
0 3.8 
ILMN_1232601 Cyb561 Mus musculus cytochrome b-561 (Cyb561), mRNA. 0 3.78 
ILMN_2712075 Lcn2 Mus musculus lipocalin 2 (Lcn2), mRNA. 0 3.74 
ILMN_2638923 Rn18s Mus musculus 18S RNA (Rn18s), non-coding RNA. 0 3.69 
ILMN_1226935 Orm1 Mus musculus orosomucoid 1 (Orm1), mRNA. 0 3.44 
ILMN_1219154 Mt2 Mus musculus metallothionein 2 (Mt2), mRNA. 0 3.4 
ILMN_2654074 Sesn1 Mus musculus sestrin 1 (Sesn1), mRNA. 0 3.35 
ILMN_1232884 Sphk1 Mus musculus sphingosine kinase 1 (Sphk1), transcript 
variant 1, mRNA. 
0 3.24 
ILMN_2813487 Per1 Mus musculus period homolog 1 (Drosophila) (Per1), 
mRNA. 
0 3.06 
ILMN_2987863 Per2 Mus musculus period homolog 2 (Drosophila) (Per2), 
mRNA. 
0 3.03 
ILMN_2822000 Slc10a6 Mus musculus solute carrier family 10 (sodium/bile acid 
cotransporter family), member 6 (Slc10a6), mRNA. 
0 3.03 
ILMN_3136744 Sesn1 Mus musculus sestrin 1 (Sesn1), mRNA. 0 3.02 





 0 2.98 
ILMN_1226712 Ccdc134 Mus musculus coiled-coil domain containing 134 
(Ccdc134), mRNA. 
0 2.92 
ILMN_2637714 Rasa3 Mus musculus RAS p21 protein activator 3 (Rasa3), 
mRNA. 
0 2.87 
ILMN_1255287 Mela  0 2.71 
ILMN_2718266 Fkbp5 Mus musculus FK506 binding protein 5 (Fkbp5), mRNA. 0 2.67 
ILMN_2793062 Rasl11b Mus musculus RAS-like, family 11, member B (Rasl11b), 
mRNA. 
0 2.54 
ILMN_2524986 Ear3 Mus musculus eosinophil-associated, ribonuclease A 
family, member 3 (Ear3), mRNA. 
0 2.5 
ILMN_1230073 Rn18s Mus musculus 18S RNA (Rn18s), non-coding RNA. 0 2.45 
ILMN_2765047 Chrd Mus musculus chordin (Chrd), mRNA. 0 2.43 
ILMN_2713055 Psca Mus musculus prostate stem cell antigen (Psca), mRNA. 0 2.41 
274 
 
ILMN_2706819 Rasl11b Mus musculus RAS-like, family 11, member B (Rasl11b), 
mRNA. 
0 2.4 
ILMN_2665545 Rin3 Mus musculus Ras and Rab interactor 3 (Rin3), mRNA. 0 2.36 
ILMN_2738345 Lims2 Mus musculus LIM and senescent cell antigen like 
domains 2 (Lims2), mRNA. 
0 2.36 
ILMN_3059476 Sesn1 Mus musculus sestrin 1 (Sesn1), mRNA. 0 2.35 
ILMN_1255766 Sh3bp2 Mus musculus SH3-domain binding protein 2 (Sh3bp2), 
mRNA. 
0 2.35 
ILMN_1243992 Ptrf  0 2.35 
ILMN_2979237 Gsta1 Mus musculus glutathione S-transferase, alpha 1 (Ya) 
(Gsta1), mRNA. 
0 2.32 
ILMN_2445165 Vdr Mus musculus vitamin D receptor (Vdr), mRNA. 0 2.32 
ILMN_2947292 Map3k6 Mus musculus mitogen-activated protein kinase kinase 
kinase 6 (Map3k6), mRNA. 
0 2.31 
ILMN_2776850 Gas7 Mus musculus growth arrest specific 7 (Gas7), mRNA. 0 2.28 
ILMN_2468473 B230343A1
0Rik 
 0 2.28 
ILMN_1224014 Tmem100 Mus musculus transmembrane protein 100 (Tmem100), 
mRNA. 
0 2.28 
ILMN_2605645 Gsn  0 2.25 
ILMN_2452855 1110003O08
Rik 
 0 2.23 
ILMN_1260061 D17H6S56E
-5 





PREDICTED: Mus musculus RIKEN cDNA 2310051E17 
gene (2310051E17Rik), mRNA. 
0 2.19 
ILMN_2772410 Anxa4  0 2.19 
ILMN_2733887 Mknk2 Mus musculus MAP kinase-interacting serine/threonine 
kinase 2 (Mknk2), mRNA. 
0 2.18 
ILMN_1254031 Klf9 Mus musculus Kruppel-like factor 9 (Klf9), mRNA. 0 2.17 
ILMN_1252259 LOC384836  0 2.16 
ILMN_2699621 Dlk2 Mus musculus delta-like 2 homolog (Drosophila) (Dlk2), 
mRNA. 
0 2.13 
ILMN_2666018 Mgp Mus musculus matrix Gla protein (Mgp), mRNA. 0 2.12 
ILMN_2727013 Nr1h4 Mus musculus nuclear receptor subfamily 1, group H, 
member 4 (Nr1h4), mRNA. 
0 2.11 
ILMN_2447100 D15Mit260  0 2.1 
ILMN_1259787 Osr1 Mus musculus odd-skipped related 1 (Drosophila) (Osr1), 
mRNA. 
0 2.08 
ILMN_2676052 Tef Mus musculus thyrotroph embryonic factor (Tef), 
transcript variant 1, mRNA. 
0 2.06 
ILMN_2692615 Tgm2 Mus musculus transglutaminase 2, C polypeptide (Tgm2), 
mRNA. 
0 2.05 
ILMN_2678714 Id4 Mus musculus inhibitor of DNA binding 4 (Id4), mRNA. 0 2.05 
ILMN_2755008 Nfkbiz Mus musculus nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor, zeta (Nfkbiz), mRNA. 
0 2.02 
ILMN_2450735 Rn18s Mus musculus 18S RNA (Rn18s), non-coding RNA. 0 2.01 
ILMN_2445166 Vdr Mus musculus vitamin D receptor (Vdr), mRNA. 0 2.01 
ILMN_2846255 Pgpep1 Mus musculus pyroglutamyl-peptidase I (Pgpep1), mRNA. 0 2 
ILMN_1224336 Spsb1 Mus musculus splA/ryanodine receptor domain and SOCS 




ILMN_1229315 Tns1 PREDICTED: Mus musculus tensin 1 (Tns1), mRNA. 0 1.98 
ILMN_2653567 Rhoj Mus musculus ras homolog gene family, member J (Rhoj), 
mRNA. 
0 1.96 
ILMN_2636624 Slc10a6 Mus musculus solute carrier family 10 (sodium/bile acid 
cotransporter family), member 6 (Slc10a6), mRNA. 
0 1.96 
ILMN_2669627 Vcan Mus musculus versican (Vcan), transcript variant 1, 
mRNA. 
0 1.95 
ILMN_2473531 Pik3r1 Mus musculus phosphatidylinositol 3-kinase, regulatory 
subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript 




 0 1.93 
ILMN_2757617 Il1rl1 Mus musculus interleukin 1 receptor-like 1 (Il1rl1), 




 0.00271 1.93 
ILMN_1213954 Sgk1 Mus musculus serum/glucocorticoid regulated kinase 1 
(Sgk1), mRNA. 
0 1.92 
ILMN_2480115 Rgs2  0.00001 1.92 
ILMN_3162452 Ppm2c Mus musculus protein phosphatase 2C, magnesium 
dependent, catalytic subunit (Ppm2c), nuclear gene 
encoding mitochondrial protein, transcript variant 1, 
mRNA. 
0 1.92 
ILMN_1246800 Serpina3n Mus musculus serine (or cysteine) peptidase inhibitor, 
clade A, member 3N (Serpina3n), mRNA. 
0 1.91 
ILMN_3157399 Tead4 Mus musculus TEA domain family member 4 (Tead4), 
transcript variant 2, mRNA. 
0 1.91 
ILMN_2776922 Glrx1  0.0001 1.91 
ILMN_1231997 Gsta1 Mus musculus glutathione S-transferase, alpha 1 (Ya) 
(Gsta1), mRNA. 
0 1.91 
ILMN_1218981 Aldh1a7 Mus musculus aldehyde dehydrogenase family 1, 
subfamily A7 (Aldh1a7), mRNA. 
0 1.9 
ILMN_1237939 Prkrir Mus musculus protein-kinase, interferon-inducible double 
stranded RNA dependent inhibitor, repressor of (P58 




 0 1.89 
ILMN_2702039 Cblb Mus musculus Casitas B-lineage lymphoma b (Cblb), 
mRNA. XM_001003462 XM_001003472 XM_001003476 
XM_001003639 XM_001003649 XM_156257 
XM_902056 XM_902058 XM_917535 XM_924994 
XM_924996 
0 1.89 
ILMN_1215275 Add1 Mus musculus adducin 1 (alpha) (Add1), transcript variant 
1, mRNA. 
0 1.89 
ILMN_2942674 Lims2 Mus musculus LIM and senescent cell antigen like 
domains 2 (Lims2), mRNA. 
0 1.89 
ILMN_3114641 Pik3r1 Mus musculus phosphatidylinositol 3-kinase, regulatory 
subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript 




 0 1.87 
ILMN_3009521 Foxred2 Mus musculus FAD-dependent oxidoreductase domain 
containing 2 (Foxred2), mRNA. 
0 1.87 
ILMN_1257117 Nol14 Mus musculus nucleolar protein 14 (Nol14), mRNA. 0 1.87 
ILMN_2622605 Srr Mus musculus serine racemase (Srr), mRNA. 0.00087 1.87 
ILMN_2737713 Edn1 Mus musculus endothelin 1 (Edn1), mRNA. 0 1.86 
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ILMN_2666622 Rgs2  0 1.86 
ILMN_2657636 Gsta1  0 1.86 
ILMN_1216522 Nfatc1 Mus musculus nuclear factor of activated T-cells, 
cytoplasmic, calcineurin-dependent 1 (Nfatc1), transcript 
variant 2, mRNA. 
0 1.86 
ILMN_1247996 LOC673501 PREDICTED: Mus musculus hypothetical protein 
LOC673501 (LOC673501), mRNA. 
0 1.85 
ILMN_1226587 EG668300 PREDICTED: Mus musculus predicted gene, EG668300 
(EG668300), mRNA. 
0 1.85 
ILMN_2763679 Sipa1l1 Mus musculus signal-induced proliferation-associated 1 
like 1 (Sipa1l1), mRNA. 
0 1.85 
ILMN_1225994 Vav2 Mus musculus vav 2 oncogene (Vav2), mRNA. 0 1.85 
ILMN_2675922 2310047A01
Rik 
PREDICTED: Mus musculus RIKEN cDNA 2310047A01 
gene (2310047A01Rik), mRNA. 
0 1.84 
ILMN_1224842 LOC385068  0 1.84 
ILMN_2766930 Faah Mus musculus fatty acid amide hydrolase (Faah), mRNA. 0 1.83 
ILMN_2473620 Rsn  0 1.81 
ILMN_2810645 Ehd2 Mus musculus EH-domain containing 2 (Ehd2), mRNA. 0 1.79 
ILMN_2645208 Arhgef3 Mus musculus Rho guanine nucleotide exchange factor 
(GEF) 3 (Arhgef3), mRNA. 
0 1.79 
ILMN_2611180 Ccdc3  0 1.79 
ILMN_2836749 Rasl12 Mus musculus RAS-like, family 12 (Rasl12), mRNA. 0 1.79 
ILMN_2772632 Saa3 Mus musculus serum amyloid A 3 (Saa3), mRNA. 0 1.79 
ILMN_1221805 Dtna Mus musculus dystrobrevin alpha (Dtna), transcript variant 
2, mRNA. 
0 1.79 
ILMN_2641816 Slurp1 Mus musculus secreted Ly6/Plaur domain containing 1 
(Slurp1), mRNA. 
0 1.78 
ILMN_2602821 Cdk5rap1 Mus musculus CDK5 regulatory subunit associated protein 




 0 1.78 
ILMN_2777535 LOC666053 PREDICTED: Mus musculus similar to protein tyrosine 
phosphatase-like protein PTPLB (LOC666053), misc 
RNA. 
0 1.77 
ILMN_2491125 Tbl1xr1 Mus musculus transducin (beta)-like 1X-linked receptor 1 
(Tbl1xr1), mRNA. 
0 1.77 
ILMN_2619697 B3gnt9 Mus musculus UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 9 (B3gnt9), mRNA. 
0 1.77 
ILMN_2599986 Tead4 Mus musculus TEA domain family member 4 (Tead4), 
transcript variant 2, mRNA. 
0 1.77 
ILMN_1249378 Bhlhb2 Mus musculus basic helix-loop-helix domain containing, 
class B2 (Bhlhb2), mRNA. 
0 1.76 
ILMN_2885277 Nnmt Mus musculus nicotinamide N-methyltransferase (Nnmt), 
mRNA. 
0 1.76 
ILMN_1252450 LOC380707  0 1.75 
ILMN_2515081 Trim59 Mus musculus tripartite motif-containing 59 (Trim59), 
mRNA. 
0 1.75 
ILMN_2868480 Ear4 Mus musculus eosinophil-associated, ribonuclease A 
family, member 4 (Ear4), mRNA. 
0.00001 1.75 
ILMN_2924831 Gas7 Mus musculus growth arrest specific 7 (Gas7), mRNA. 0 1.75 
ILMN_2420341 9629514_32
5 
 0 1.74 
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ILMN_2548664 Loxl4 Mus musculus lysyl oxidase-like 4 (Loxl4), mRNA. 0 1.74 
ILMN_1228919 St13 Mus musculus suppression of tumorigenicity 13 (St13), 
mRNA. 
0 1.74 
ILMN_2873750 Gldc Mus musculus glycine decarboxylase (Gldc), mRNA. 0 1.73 
ILMN_3083163 Cp Mus musculus ceruloplasmin (Cp), transcript variant 2, 
mRNA. 
0 1.73 
ILMN_1235932 Pdgfra Mus musculus platelet derived growth factor receptor, 
alpha polypeptide (Pdgfra), transcript variant 1, mRNA. 
0 1.72 
ILMN_1218206 Klf13 Mus musculus Kruppel-like factor 13 (Klf13), mRNA. 0 1.72 
ILMN_1241610 Adrb2 Mus musculus adrenergic receptor, beta 2 (Adrb2), 
mRNA. 
0 1.71 
ILMN_1258759 Col6a2  0 1.71 
ILMN_2672190 Id1 Mus musculus inhibitor of DNA binding 1 (Id1), mRNA. 0 1.71 
ILMN_1232396 Ear2 Mus musculus eosinophil-associated, ribonuclease A 
family, member 2 (Ear2), mRNA. 
0.00001 1.71 
ILMN_2909782 Rras2 Mus musculus related RAS viral (r-ras) oncogene homolog 
2 (Rras2), mRNA. 
0 1.71 
ILMN_2533916 LOC380655  0 1.71 
ILMN_1248849 Gsta2 Mus musculus glutathione S-transferase, alpha 2 (Yc2) 
(Gsta2), mRNA. 
0 1.71 





 0 1.69 
ILMN_1220063 EG666668 PREDICTED: Mus musculus predicted gene, EG666668 
(EG666668), mRNA. 
0 1.69 
ILMN_1227951 Gcnt2 Mus musculus glucosaminyl (N-acetyl) transferase 2, I-
branching enzyme (Gcnt2), transcript variant 3, mRNA. 
0 1.69 
ILMN_2638299 Slc29a1  0 1.69 
ILMN_2687032 Fbxo31 Mus musculus F-box protein 31 (Fbxo31), mRNA. 0 1.69 
ILMN_2707452 Ebf1 Mus musculus early B-cell factor 1 (Ebf1), mRNA. 0.00079 1.69 
ILMN_1222069 Bbx  0.0089 1.69 
ILMN_2734142 Snta1 Mus musculus syntrophin, acidic 1 (Snta1), mRNA. 0.00043 1.68 
ILMN_1247916 Lims2 Mus musculus LIM and senescent cell antigen like 




 0 1.68 
ILMN_1250550 scl0001259.
1_60 
 0 1.68 
ILMN_1241854 Lrrc59 Mus musculus leucine rich repeat containing 59 (Lrrc59), 
mRNA. 
0 1.68 
ILMN_2965903 Hdc Mus musculus histidine decarboxylase (Hdc), mRNA. 0 1.68 
ILMN_2459899 Adamtsl4 Mus musculus ADAMTS-like 4 (Adamtsl4), mRNA. 0 1.68 
ILMN_1236037 LOC627317 PREDICTED: Mus musculus similar to ribosomal protein 
L11 (LOC627317), misc RNA. 
0 1.68 
ILMN_3134632 Adam22 Mus musculus a disintegrin and metallopeptidase domain 
22 (Adam22), transcript variant 1, mRNA. 
0 1.68 
ILMN_1220173 Ppm2c Mus musculus protein phosphatase 2C, magnesium 
dependent, catalytic subunit (Ppm2c), nuclear gene 
encoding mitochondrial protein, transcript variant 1, 
mRNA. 
0 1.67 
ILMN_1254630 Ptpre Mus musculus protein tyrosine phosphatase, receptor type, 0 1.67 
278 
 
E (Ptpre), mRNA. 
ILMN_1260112 2400003C14
Rik 
Mus musculus RIKEN cDNA 2400003C14 gene 
(2400003C14Rik), mRNA. 
0.00002 1.67 
ILMN_2764143 Scap Mus musculus SREBF chaperone (Scap), mRNA. 0 1.67 
ILMN_2724469 4732473B16
Rik 
Mus musculus RIKEN cDNA 4732473B16 gene 
(4732473B16Rik), mRNA. 
0 1.67 
ILMN_1225995 Morc2a Mus musculus microrchidia 2A (Morc2a), mRNA. 0 1.66 
ILMN_1220530 Smc1a Mus musculus structural maintenance of chromosomes 1A 
(Smc1a), mRNA. 
0.00003 1.66 
ILMN_1223428 Eif3s8  0 1.66 
ILMN_2655336 Vcan Mus musculus versican (Vcan), transcript variant 1, 
mRNA. 
0 1.65 
ILMN_1235435 LOC666621 PREDICTED: Mus musculus similar to 40S ribosomal 
protein S2 (LOC666621), mRNA. 
0 1.65 
ILMN_2993334 Plekhf1 Mus musculus pleckstrin homology domain containing, 
family F (with FYVE domain) member 1 (Plekhf1), 
mRNA. 
0 1.65 
ILMN_2693019 Acpp Mus musculus acid phosphatase, prostate (Acpp), 
transcript variant 1, mRNA. 
0 1.65 
ILMN_2762326 Kif22 Mus musculus kinesin family member 22 (Kif22), mRNA. 0 1.64 
ILMN_2671601 Selk  0 1.64 
ILMN_2712731 Phf10 Mus musculus PHD finger protein 10 (Phf10), mRNA. 0.00005 1.64 
ILMN_1377923 Actb Mus musculus actin, beta (Actb), mRNA. 0 1.64 
ILMN_1232596 Pom121 Mus musculus nuclear pore membrane protein 121 
(Pom121), mRNA. 
0 1.64 
ILMN_2663230 Slco3a1 Mus musculus solute carrier organic anion transporter 
family, member 3a1 (Slco3a1), transcript variant 1, 
mRNA. 
0 1.64 
ILMN_2945551 Ptplb Mus musculus protein tyrosine phosphatase-like (proline 
instead of catalytic arginine), member b (Ptplb), mRNA. 
0 1.64 
ILMN_2520239 Cp  0 1.64 
ILMN_2698430 Bcl2l1 Mus musculus BCL2-like 1 (Bcl2l1), nuclear gene 
encoding mitochondrial protein, mRNA. 
0.00005 1.64 
ILMN_2629191 Cpm PREDICTED: Mus musculus carboxypeptidase M (Cpm), 
mRNA. 
0.00019 1.63 
ILMN_2439341 Vars Mus musculus valyl-tRNA synthetase (Vars), nuclear gene 
encoding mitochondrial protein, mRNA. 
0 1.63 





 0 1.63 
ILMN_1243179 Sec24d Mus musculus Sec24 related gene family, member D (S. 
cerevisiae) (Sec24d), mRNA. 
0.00031 1.63 
ILMN_2542885 Wdr89 PREDICTED: Mus musculus WD repeat domain 89, 
transcript variant 2 (Wdr89), mRNA. 
0 1.63 
ILMN_2683958 Col3a1 Mus musculus collagen, type III, alpha 1 (Col3a1), mRNA. 0.00027 1.63 
ILMN_1216689 Aplp2 Mus musculus amyloid beta (A4) precursor-like protein 2 
(Aplp2), transcript variant 3, mRNA. 
0 1.62 
ILMN_2677567 Galt Mus musculus galactose-1-phosphate uridyl transferase 
(Galt), mRNA. 
0 1.62 
ILMN_2961005 Ier5l Mus musculus immediate early response 5-like (Ier5l), 
mRNA. 
0 1.62 
ILMN_1222872 Wbscr16 Mus musculus Williams-Beuren syndrome chromosome 




ILMN_2534090 LOC216443  0 1.61 
ILMN_2594714 Ets2 Mus musculus E26 avian leukemia oncogene 2, 3' domain 
(Ets2), mRNA. 
0 1.61 
ILMN_2659062 Add1  0 1.61 
ILMN_2789239 Tgfbr3 Mus musculus transforming growth factor, beta receptor 




 0 1.61 
ILMN_1228942 Cd59a Mus musculus CD59a antigen (Cd59a), mRNA. 0 1.61 
ILMN_2773540 Thap4 Mus musculus THAP domain containing 4 (Thap4), 
mRNA. 
0 1.61 
ILMN_1238597 Omd Mus musculus osteomodulin (Omd), mRNA. 0.00002 1.61 
ILMN_3159720 Rin2 Mus musculus Ras and Rab interactor 2 (Rin2), mRNA. 0 1.61 
ILMN_1214120 1500005N04
Rik 
 0 1.6 
ILMN_2971479 Trp53inp1 Mus musculus transformation related protein 53 inducible 
nuclear protein 1 (Trp53inp1), mRNA. 
0.00239 1.6 
ILMN_2846254 Pgpep1 Mus musculus pyroglutamyl-peptidase I (Pgpep1), mRNA. 0 1.6 
ILMN_1220305 D19Bwg135
7e 
Mus musculus DNA segment, Chr 19, Brigham & 
Women's Genetics 1357 expressed (D19Bwg1357e), 
mRNA. 
0 1.6 
ILMN_2785454 Hist2h2ab Mus musculus histone cluster 2, H2ab (Hist2h2ab), 
mRNA. 
0 1.6 
ILMN_2659063 Add1 Mus musculus adducin 1 (alpha) (Add1), transcript variant 
2, mRNA. 
0.00001 1.6 
ILMN_2892441 Gsta4 Mus musculus glutathione S-transferase, alpha 4 (Gsta4), 
mRNA. 
0 1.59 
ILMN_1232416 Idb4  0.00002 1.59 
ILMN_1215969 Rcor1 Mus musculus REST corepressor 1 (Rcor1), mRNA. 0 1.59 
ILMN_2728729 Sdc4 Mus musculus syndecan 4 (Sdc4), mRNA. 0 1.59 





PREDICTED: Mus musculus similar to NFIL3/E4BP4 
transcription factor (LOC100046232), mRNA. 
0 1.59 
ILMN_2704619 Cc2d2a Mus musculus coiled-coil and C2 domain containing 2A 
(Cc2d2a), mRNA. 
0.00008 1.59 
ILMN_2611767 Gprc5b Mus musculus G protein-coupled receptor, family C, group 
5, member B (Gprc5b), mRNA. 
0 1.59 
ILMN_2678019 Psmd8 Mus musculus proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 8 (Psmd8), mRNA. XM_001002011 
0 1.59 
ILMN_2448651 Ampd3 Mus musculus adenosine monophosphate deaminase 3 
(Ampd3), mRNA. 
0.00017 1.59 
ILMN_2723639 Pacs1  0 1.59 
ILMN_1244096 Fam171a1 Mus musculus family with sequence similarity 171, 
member A1 (Fam171a1), mRNA. 
0 1.58 
ILMN_1254927 Ly6c1 Mus musculus lymphocyte antigen 6 complex, locus C1 
(Ly6c1), mRNA. 
0.00001 1.58 
ILMN_2598420 Rbm16 PREDICTED: Mus musculus RNA binding motif protein 




 0 1.58 





ILMN_1225544 Slc19a1 Mus musculus solute carrier family 19 (sodium/hydrogen 
exchanger), member 1 (Slc19a1), mRNA. 
0 1.58 
ILMN_2655577 Pold1 Mus musculus polymerase (DNA directed), delta 1, 
catalytic subunit (Pold1), mRNA. 
0 1.58 
ILMN_2825144 Fndc7 Mus musculus fibronectin type III domain containing 7 
(Fndc7), mRNA. 
0 1.58 
ILMN_2791272 Por Mus musculus P450 (cytochrome) oxidoreductase (Por), 
mRNA. 
0 1.58 
ILMN_2631098 Msh6 Mus musculus mutS homolog 6 (E. coli) (Msh6), mRNA. 0.00478 1.58 
ILMN_2728088 Cda Mus musculus cytidine deaminase (Cda), mRNA. 0 1.57 
ILMN_2733091 Baiap2 Mus musculus brain-specific angiogenesis inhibitor 1-
associated protein 2 (Baiap2), transcript variant 2, mRNA. 
0 1.57 
ILMN_2881263 Aifm1 Mus musculus apoptosis-inducing factor, mitochondrion-
associated 1 (Aifm1), nuclear gene encoding mitochondrial 
protein, mRNA. 
0 1.57 
ILMN_2781458 Tlcd1 Mus musculus TLC domain containing 1 (Tlcd1), mRNA. 0 1.57 
ILMN_1223807 EG382843 PREDICTED: Mus musculus predicted gene, EG382843 
(EG382843), mRNA. 
0 1.57 
ILMN_1229082 Klhl21 Mus musculus kelch-like 21 (Drosophila) (Klhl21), 
mRNA. 
0 1.57 
ILMN_2815506 Gamt Mus musculus guanidinoacetate methyltransferase (Gamt), 
mRNA. 
0 1.57 
ILMN_2766455 Lrrc8d Mus musculus leucine rich repeat containing 8D (Lrrc8d), 
mRNA. 
0 1.57 
ILMN_2764309 Dusp14 Mus musculus dual specificity phosphatase 14 (Dusp14), 
mRNA. 
0 1.57 
ILMN_2842366 Mrpl2 Mus musculus mitochondrial ribosomal protein L2 
(Mrpl2), nuclear gene encoding mitochondrial protein, 
mRNA. 
0 1.57 
ILMN_2502623 Zhx3 Mus musculus zinc fingers and homeoboxes 3 (Zhx3), 
mRNA. 
0 1.57 
ILMN_2714360 Cd34 Mus musculus CD34 antigen (Cd34), mRNA. 0.00004 1.57 
ILMN_1254655 Casp4 Mus musculus caspase 4, apoptosis-related cysteine 
peptidase (Casp4), mRNA. 
0 1.56 
ILMN_2651715 Axl Mus musculus AXL receptor tyrosine kinase (Axl), 
mRNA. 
0 1.56 
ILMN_2538852 LOC384307  0 1.56 
ILMN_1230788 Tle1 Mus musculus transducin-like enhancer of split 1, homolog 
of Drosophila E(spl) (Tle1), mRNA. XM_984202 
XM_984240 XM_984277 XM_984316 XM_984359 
XM_984397 XM_984426 XM_984456 XM_984492 
XM_984530 
0.00009 1.56 





Mus musculus RIKEN cDNA 1110067D22 gene 
(1110067D22Rik), mRNA. 
0 1.56 
ILMN_2525049 Fstl  0 1.56 
ILMN_2622089 5430432N15
Rik 
PREDICTED: Mus musculus RIKEN cDNA 5430432N15 
gene (5430432N15Rik), mRNA. 
0 1.56 
ILMN_2496817 Ulk2 Mus musculus Unc-51 like kinase 2 (C. elegans) (Ulk2), 
mRNA. 
0 1.55 
ILMN_2757682 Leng9 Mus musculus leukocyte receptor cluster (LRC) member 9 
(Leng9), mRNA. 
0 1.55 
ILMN_2631097 Msh6 Mus musculus mutS homolog 6 (E. coli) (Msh6), mRNA. 0 1.55 
ILMN_2498851 2310075M1
5Rik 
 0.00002 1.55 
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ILMN_1232447 Por Mus musculus P450 (cytochrome) oxidoreductase (Por), 
mRNA. 
0 1.55 
ILMN_2774646 Myd88  0 1.55 
ILMN_2981550 Capn1 Mus musculus calpain 1 (Capn1), mRNA. 0 1.55 
ILMN_2733778 Il4i1 Mus musculus interleukin 4 induced 1 (Il4i1), mRNA. 0 1.54 
ILMN_1257552 Tars Mus musculus threonyl-tRNA synthetase (Tars), mRNA. 0.00008 1.54 
ILMN_2585112 1200008A14
Rik 
 0 1.54 
ILMN_2428113 scl0001379.
1_70 
 0 1.54 
ILMN_1233129 Zbtb22 Mus musculus zinc finger and BTB domain containing 22 
(Zbtb22), mRNA. 
0 1.54 
ILMN_1224768 Ehd4 Mus musculus EH-domain containing 4 (Ehd4), mRNA. 0 1.54 
ILMN_1242767 Dok1 Mus musculus docking protein 1 (Dok1), mRNA. 0 1.54 
ILMN_1227465 9628654_5  0 1.53 
ILMN_2761169 3110050N22
Rik 
 0.00003 1.53 





Mus musculus RIKEN cDNA 2510003E04 gene 
(2510003E04Rik), mRNA. 
0.00024 1.53 
ILMN_2811705 Fbxo18 Mus musculus F-box protein 18 (Fbxo18), mRNA. 0 1.53 
ILMN_1233283 P2rx5 Mus musculus purinergic receptor P2X, ligand-gated ion 
channel, 5 (P2rx5), mRNA. 
0.00004 1.53 
ILMN_2669782 Phca Mus musculus phytoceramidase, alkaline (Phca), mRNA. 0 1.53 
ILMN_2664548 Pgls Mus musculus 6-phosphogluconolactonase (Pgls), mRNA. 0 1.53 
ILMN_2674407 Arpp19 Mus musculus cAMP-regulated phosphoprotein 19 
(Arpp19), mRNA. 
0 1.52 
ILMN_2599018 Clic4 Mus musculus chloride intracellular channel 4 
(mitochondrial) (Clic4), nuclear gene encoding 




PREDICTED: Mus musculus hypothetical protein 
LOC100044204 (LOC100044204), mRNA. 
0.00164 1.52 
ILMN_2744380 Npc2 Mus musculus Niemann Pick type C2 (Npc2), mRNA. 0 1.52 
ILMN_1246108 Hist1h2ah Mus musculus histone cluster 1, H2ah (Hist1h2ah), 
mRNA. 
0.0004 1.52 
ILMN_1256817 Slpi Mus musculus secretory leukocyte peptidase inhibitor 
(Slpi), mRNA. 
0.00001 1.52 
ILMN_2428961 Xpnpep1 Mus musculus X-prolyl aminopeptidase (aminopeptidase 
P) 1, soluble (Xpnpep1), mRNA. 
0 1.52 
ILMN_2526572 LOC545369 PREDICTED: Mus musculus similar to ribosomal protein 
L4 (LOC545369), misc RNA. 
0 1.52 
ILMN_2604029 Klf2 Mus musculus Kruppel-like factor 2 (lung) (Klf2), mRNA. 0 1.52 
ILMN_2638558 Pes1 Mus musculus pescadillo homolog 1, containing BRCT 
domain (zebrafish) (Pes1), mRNA. 
0 1.52 
ILMN_1238179 Ipmk Mus musculus inositol polyphosphate multikinase (Ipmk), 
mRNA. 
0 1.52 
ILMN_2589181 Eef2 Mus musculus eukaryotic translation elongation factor 2 
(Eef2), mRNA. 
0 1.51 
ILMN_2819679 Tmem50a Mus musculus transmembrane protein 50A (Tmem50a), 
mRNA. 
0 1.51 
ILMN_2474887 Whsc2 Mus musculus Wolf-Hirschhorn syndrome candidate 2 




ILMN_2531581 LOC381215  0.00014 1.51 
ILMN_2669690 Mpst Mus musculus mercaptopyruvate sulfurtransferase (Mpst), 




Mus musculus RIKEN cDNA 4831426I19 gene 
(4831426I19Rik), transcript variant 1, mRNA. 
0.00014 1.51 
ILMN_2881272 Aifm1 Mus musculus apoptosis-inducing factor, mitochondrion-
associated 1 (Aifm1), nuclear gene encoding mitochondrial 
protein, mRNA. 
0.00051 1.51 
ILMN_1240471 Retsat Mus musculus retinol saturase (all trans retinol 13,14 




Mus musculus RIKEN cDNA 5830457O10 gene 
(5830457O10Rik), mRNA. 
0 1.51 
ILMN_2647885 Bcl2l1 Mus musculus BCL2-like 1 (Bcl2l1), nuclear gene 
encoding mitochondrial protein, mRNA. 
0.00381 1.51 
ILMN_2521620 Phf15 Mus musculus PHD finger protein 15 (Phf15), mRNA. 0.00133 1.5 
ILMN_2628629 Cdh1 Mus musculus cadherin 1 (Cdh1), mRNA. 0 1.5 
ILMN_3008068 Scara5 Mus musculus scavenger receptor class A, member 5 
(putative) (Scara5), mRNA. 
0.00006 1.5 
ILMN_2759484 C3  0.00002 1.5 
ILMN_1241955 Dnali1  0 1.5 
ILMN_2982200 Mrpl13 Mus musculus mitochondrial ribosomal protein L13 
(Mrpl13), mRNA. 
0.0064 1.5 
ILMN_2641278 Mfn2 Mus musculus mitofusin 2 (Mfn2), nuclear gene encoding 
mitochondrial protein, mRNA. XM_919144 XM_919157 
XM_919164 
0 1.5 
ILMN_2748499 Fshprh1  0 1.5 
ILMN_3111575 Mef2b Mus musculus myocyte enhancer factor 2B (Mef2b), 
transcript variant 2, mRNA. 
0.00048 1.5 
ILMN_2536649 LOC665235 PREDICTED: Mus musculus similar to hCG1642689 
(LOC665235), misc RNA. 
0.00001 1.5 





Supplemental Table 4.4. Complete list of genes downregulated by 4h of CORT treatment in 
HT-22 cells.  
PROBE ID SYMBOL DEFINITION Pvalue Fold 
change  
ILMN_2710253 Cyr61 Mus musculus cysteine rich protein 61 (Cyr61), mRNA. 0 
-3.17 
ILMN_2754985 Phlda1 Mus musculus pleckstrin homology-like domain, family 
A, member 1 (Phlda1), mRNA. 
0 
-3.09 
ILMN_2662926 Egr1 Mus musculus early growth response 1 (Egr1), mRNA. 0 
-2.91 
ILMN_2794645 Cyr61 Mus musculus cysteine rich protein 61 (Cyr61), mRNA. 0 
-2.88 
ILMN_2483786 1110004P21Rik  0 
-2.43 
ILMN_1251193 A630084D02Rik  0 
-2.42 
ILMN_2937596 Ngfb Mus musculus nerve growth factor, beta (Ngfb), mRNA. 0 
-2.36 
ILMN_2660233 Ngfb Mus musculus nerve growth factor, beta (Ngfb), mRNA. 0 
-2.34 










ILMN_2752569 Paip1 Mus musculus polyadenylate binding protein-interacting 
protein 1 (Paip1), transcript variant 1, mRNA. 
0 
-2.17 
ILMN_1235571 Cyr61 Mus musculus cysteine rich protein 61 (Cyr61), mRNA. 0 
-2.16 
ILMN_1253178 Aldh3a1 Mus musculus aldehyde dehydrogenase family 3, 
subfamily A1 (Aldh3a1), mRNA. 
0 
-2.01 
ILMN_2551741 0610010I05Rik  0 
-1.98 
ILMN_2868220 Inhba Mus musculus inhibin beta-A (Inhba), mRNA. 0 
-1.92 
ILMN_2833706 Fgf7 Mus musculus fibroblast growth factor 7 (Fgf7), mRNA. 0 
-1.91 




ILMN_2451115 1500001E21Rik  0 
-1.83 




ILMN_2507810 mtDNA_ND5  0 
-1.79 
ILMN_2988299 Srf Mus musculus serum response factor (Srf), mRNA. 0 
-1.79 
ILMN_2683593 Fubp1  0 
-1.79 




ILMN_2550570 Fibp  0.00095 
-1.76 












ILMN_1232741 Fdps  0.00041 
-1.73 
ILMN_1216764 Ier3 Mus musculus immediate early response 3 (Ier3), mRNA. 0 
-1.72 
ILMN_2416218 5530400B01Rik  0 
-1.72 








ILMN_1247823 Lrp8 Mus musculus low density lipoprotein receptor-related 
protein 8, apolipoprotein e receptor (Lrp8), transcript 
variant 2, mRNA. 
0 
-1.71 








ILMN_2771176 Ccl7  0 
-1.7 




ILMN_2434853 mtDNA_ND2  0 
-1.68 
ILMN_2623867 Ostm1 Mus musculus osteopetrosis associated transmembrane 
protein 1 (Ostm1), mRNA. 
0 
-1.67 
ILMN_2511089 Ugcg  0 
-1.66 
ILMN_1236308 LOC268730  0 
-1.65 








ILMN_3131887 Spag9 Mus musculus sperm associated antigen 9 (Spag9), 
transcript variant 4, mRNA. 
0 
-1.65 
ILMN_3127066 Mark2 Mus musculus MAP/microtubule affinity-regulating 
kinase 2 (Mark2), transcript variant 1, mRNA. 
0 
-1.64 
ILMN_2557387 E430005I09Rik  0 
-1.64 
ILMN_2860804 Tfrc Mus musculus transferrin receptor (Tfrc), mRNA. 0 
-1.63 




ILMN_1232716 Cyp1b1 Mus musculus cytochrome P450, family 1, subfamily b, 
polypeptide 1 (Cyp1b1), mRNA. 
0 
-1.63 
ILMN_2965660 Apcdd1 Mus musculus adenomatosis polyposis coli down-
regulated 1 (Apcdd1), mRNA. 
0.00012 
-1.62 
ILMN_2904641 Snora65 Mus musculus small nucleolar RNA, H/ACA box 65 
(Snora65) on chromosome 2. 
0 
-1.62 




ILMN_2664129 Hist1h4h Mus musculus histone cluster 1, H4h (Hist1h4h), mRNA. 0 
-1.62 
ILMN_2592093 Ift20 Mus musculus intraflagellar transport 20 homolog 
(Chlamydomonas) (Ift20), mRNA. 
0 
-1.62 




ILMN_2640862 Lrig1 Mus musculus leucine-rich repeats and immunoglobulin-
like domains 1 (Lrig1), mRNA. 
0 
-1.61 
ILMN_1257107 LOC100043821 PREDICTED: Mus musculus hypothetical protein 
LOC100043821 (LOC100043821), mRNA. 
0 
-1.61 








ILMN_2734755 Col4a5  0 
-1.61 
















ILMN_1245733 Ddx49 Mus musculus DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 49 (Ddx49), mRNA. 
0 
-1.59 




ILMN_1230375 LOC383125  0 
-1.58 
ILMN_1250815 Wsb1 Mus musculus WD repeat and SOCS box-containing 1 
(Wsb1), transcript variant 2, mRNA. 
0 
-1.58 




ILMN_2619848 Tfrc Mus musculus transferrin receptor (Tfrc), mRNA. 0 
-1.57 
ILMN_2491831 D11Bwg0414e  0 
-1.57 
ILMN_3149024 Scoc Mus musculus short coiled-coil protein (Scoc), transcript 
variant 2, mRNA. 
0 
-1.57 
ILMN_1215167 Ddx5 Mus musculus DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 5 (Ddx5), mRNA. 
0.00001 
-1.57 
ILMN_2657911 Cnot4 Mus musculus CCR4-NOT transcription complex, subunit 





ILMN_1259905 Sfrs11 Mus musculus splicing factor, arginine/serine-rich 11 
(Sfrs11), transcript variant 1, mRNA. 
0 
-1.56 




ILMN_2747923 Slc40a1 Mus musculus solute carrier family 40 (iron-regulated 
transporter), member 1 (Slc40a1), mRNA. 
0.00254 
-1.56 
ILMN_1255925 Col8a1  0 
-1.56 




ILMN_2758073 Dmtf1 Mus musculus cyclin D binding myb-like transcription 
factor 1 (Dmtf1), mRNA. 
0 
-1.55 
ILMN_1229193 Msn  0 
-1.55 
ILMN_2683374 Asna1 Mus musculus arsA arsenite transporter, ATP-binding, 
homolog 1 (bacterial) (Asna1), mRNA. 
0 
-1.55 
ILMN_1234412 LOC674427 PREDICTED: Mus musculus similar to ribosomal protein 
L7a (LOC674427), misc RNA. 
0 
-1.55 
ILMN_2972478 Nlgn2 Mus musculus neuroligin 2 (Nlgn2), mRNA. 0 
-1.55 
ILMN_2825803 Parp14 Mus musculus poly (ADP-ribose) polymerase family, 




ILMN_2974069 Slc35a3 Mus musculus solute carrier family 35 (UDP-N-
acetylglucosamine (UDP-GlcNAc) transporter), member 
3 (Slc35a3), mRNA. 
0 
-1.55 




ILMN_2848463 Mthfsd Mus musculus methenyltetrahydrofolate synthetase 
domain containing (Mthfsd), mRNA. 
0.00001 
-1.55 
ILMN_1255317 Arnt  0 
-1.55 
ILMN_2585738 A730086L23Rik  0 
-1.54 




ILMN_2972585 Pvr Mus musculus poliovirus receptor (Pvr), mRNA. 0.00007 
-1.54 
ILMN_3147112 Mapk6 Mus musculus mitogen-activated protein kinase 6 
(Mapk6), transcript variant 2, mRNA. 
0 
-1.54 
ILMN_1231803 Dmtf1 Mus musculus cyclin D binding myb-like transcription 
factor 1 (Dmtf1), mRNA. 
0 
-1.53 
ILMN_1238820 LOC332788  0 
-1.53 








ILMN_1213322 Chd2 Mus musculus chromodomain helicase DNA binding 
protein 2 (Chd2), mRNA. 
0.00001 
-1.53 
ILMN_3153753 Cacnb3 Mus musculus calcium channel, voltage-dependent, beta 3 
subunit (Cacnb3), transcript variant 1, mRNA. 
0 
-1.53 




ILMN_1220813 Dtx3l Mus musculus deltex 3-like (Drosophila) (Dtx3l), mRNA. 0 
-1.53 




ILMN_3144289 Traf3 Mus musculus Tnf receptor-associated factor 3 (Traf3), 
transcript variant 1, mRNA. 
0 
-1.52 






ILMN_1230278 LOC100044702 PREDICTED: Mus musculus similar to LPS-induced 
CXC chemokine (LOC100044702), mRNA. 
0.00186 
-1.52 
ILMN_1248039 mtDNA_COXII  0 
-1.52 
ILMN_1214412 Antxr2 Mus musculus anthrax toxin receptor 2 (Antxr2), mRNA. 0 
-1.52 
ILMN_2794796 E2f4 Mus musculus E2F transcription factor 4 (E2f4), mRNA. 0 
-1.52 
ILMN_3157483 Ets1 Mus musculus E26 avian leukemia oncogene 1, 5' domain 
(Ets1), transcript variant 2, mRNA. 
0 
-1.52 




ILMN_3093089 Tardbp Mus musculus TAR DNA binding protein (Tardbp), 
transcript variant 2, mRNA. 
0 
-1.51 
ILMN_2757489 Ppp1r11 Mus musculus protein phosphatase 1, regulatory 
(inhibitor) subunit 11 (Ppp1r11), mRNA. 
0 
-1.51 
ILMN_2612407 Wdsub1 Mus musculus WD repeat, SAM and U-box domain 
containing 1 (Wdsub1), mRNA. 
0 
-1.51 
ILMN_2742599 Nfix Mus musculus nuclear factor I/X (Nfix), transcript variant 
2, mRNA. XM_921228 XM_921240 XM_921250 
XM_921261 XM_921270 XM_921288 XM_921293 
XM_921299 XM_921300 XM_921307 
0 
-1.51 
ILMN_2849753 Erich1 Mus musculus glutamate-rich 1 (Erich1), mRNA. 0 
-1.51 




ILMN_2742675 Rock1 Mus musculus Rho-associated coiled-coil containing 
protein kinase 1 (Rock1), mRNA. 
0 
-1.51 
ILMN_1222584 Sfrs11 Mus musculus splicing factor, arginine/serine-rich 11 
(Sfrs11), transcript variant 1, mRNA. 
0.00204 
-1.51 
ILMN_1258330 LOC384348  0 
-1.51 




ILMN_2942989 Mtpn Mus musculus myotrophin (Mtpn), mRNA. 0 
-1.51 








ILMN_1259340 1810073M12Rik  0 
-1.5 




ILMN_2552490 6720463L11Rik  0 
-1.5 
ILMN_2657338 D930038J03Rik  0 
-1.5 








ILMN_3031099 Coq10b Mus musculus coenzyme Q10 homolog B (S. cerevisiae) 
(Coq10b), transcript variant 1, mRNA. 
0 
-1.5 
ILMN_2768053 Supt16h Mus musculus suppressor of Ty 16 homolog (S. 
cerevisiae) (Supt16h), mRNA. 
0.00014 
-1.5 
ILMN_1253539 LOC432554 PREDICTED: Mus musculus similar to Ddx5 protein 









Supplemental Table 4.5. Complete list of genes upregulated by 4h of T3 plus CORT 
treatment in HT-22 cells.  
PROBE ID SYMBOL DEFINITION P value Fold 
change 
ILMN_1232601 Cyb561 Mus musculus cytochrome b-561 (Cyb561), mRNA. 0 10.52 
ILMN_2701664 Tsc22d3 Mus musculus TSC22 domain family, member 3 
(Tsc22d3), transcript variant 2, mRNA. 
0 7.25 
ILMN_1254031 Klf9 Mus musculus Kruppel-like factor 9 (Klf9), mRNA. 0 5.518 
ILMN_2430906 2310051E17Rik PREDICTED: Mus musculus RIKEN cDNA 
2310051E17 gene (2310051E17Rik), mRNA. 
0 5.245 
ILMN_1259322 Pdk4 Mus musculus pyruvate dehydrogenase kinase, 
isoenzyme 4 (Pdk4), mRNA. 
0 4.71 
ILMN_3150811 Tsc22d3 Mus musculus TSC22 domain family, member 3 
(Tsc22d3), transcript variant 1, mRNA. 
0 4.506 
ILMN_2813484 Per1 Mus musculus period homolog 1 (Drosophila) 
(Per1), mRNA. 
0 4.291 
ILMN_2987862 Per2 Mus musculus period homolog 2 (Drosophila) 
(Per2), mRNA. 
0 3.917 
ILMN_2524986 Ear3 Mus musculus eosinophil-associated, ribonuclease A 
family, member 3 (Ear3), mRNA. 
0 3.793 
ILMN_2638923 Rn18s Mus musculus 18S RNA (Rn18s), non-coding RNA. 0 3.65 
ILMN_1220280 Tas1r1 Mus musculus taste receptor, type 1, member 1 
(Tas1r1), mRNA. 
0 3.196 
ILMN_2770894 Map3k6   0 3.102 
ILMN_2822000 Slc10a6 Mus musculus solute carrier family 10 (sodium/bile 
acid cotransporter family), member 6 (Slc10a6), 
mRNA. 
0 3.064 
ILMN_2813487 Per1 Mus musculus period homolog 1 (Drosophila) 
(Per1), mRNA. 
0 3.008 
ILMN_2622983 Dusp1 Mus musculus dual specificity phosphatase 1 
(Dusp1), mRNA. 
0 2.93 
ILMN_2738345 Lims2 Mus musculus LIM and senescent cell antigen like 
domains 2 (Lims2), mRNA. 
0 2.913 
ILMN_2712075 Lcn2 Mus musculus lipocalin 2 (Lcn2), mRNA. 0 2.821 
ILMN_2588249 S3-12 Mus musculus plasma membrane associated protein, 
S3-12 (S3-12), mRNA. 
0 2.805 
ILMN_2768972 Fam107a Mus musculus family with sequence similarity 107, 
member A (Fam107a), mRNA. 
0 2.783 
ILMN_2654074 Sesn1 Mus musculus sestrin 1 (Sesn1), mRNA. 0 2.765 
ILMN_2637714 Rasa3 Mus musculus RAS p21 protein activator 3 (Rasa3), 
mRNA. 
0 2.758 
ILMN_2987863 Per2 Mus musculus period homolog 2 (Drosophila) 
(Per2), mRNA. 
0 2.683 
ILMN_1219154 Mt2 Mus musculus metallothionein 2 (Mt2), mRNA. 0 2.571 
ILMN_2517483 D15Bwg0759e   0 2.552 
ILMN_1226935 Orm1 Mus musculus orosomucoid 1 (Orm1), mRNA. 0 2.541 
ILMN_2616226 Dbp Mus musculus D site albumin promoter binding 
protein (Dbp), mRNA. 
0 2.516 
ILMN_2718266 Fkbp5 Mus musculus FK506 binding protein 5 (Fkbp5), 
mRNA. 
0 2.466 
ILMN_3136744 Sesn1 Mus musculus sestrin 1 (Sesn1), mRNA. 0 2.44 
ILMN_1255287 Mela   0 2.437 
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ILMN_1230073 Rn18s Mus musculus 18S RNA (Rn18s), non-coding RNA. 0 2.427 
ILMN_2942674 Lims2 Mus musculus LIM and senescent cell antigen like 
domains 2 (Lims2), mRNA. 
0 2.373 
ILMN_1260061 D17H6S56E-5 Mus musculus DNA segment, Chr 17, human 
D6S56E 5 (D17H6S56E-5), mRNA. 
0 2.368 
ILMN_1253191 E230024B12Rik   0 2.281 
ILMN_1232884 Sphk1 Mus musculus sphingosine kinase 1 (Sphk1), 
transcript variant 1, mRNA. 
0 2.273 
ILMN_2727013 Nr1h4 Mus musculus nuclear receptor subfamily 1, group 
H, member 4 (Nr1h4), mRNA. 
0 2.261 
ILMN_1255766 Sh3bp2 Mus musculus SH3-domain binding protein 2 
(Sh3bp2), mRNA. 
0 2.225 
ILMN_2868480 Ear4 Mus musculus eosinophil-associated, ribonuclease A 
family, member 4 (Ear4), mRNA. 
0 2.214 
ILMN_1243992 Ptrf   0 2.19 
ILMN_2605645 Gsn   0 2.184 
ILMN_3059476 Sesn1 Mus musculus sestrin 1 (Sesn1), mRNA. 0 2.144 
ILMN_1247996 LOC673501 PREDICTED: Mus musculus hypothetical protein 
LOC673501 (LOC673501), mRNA. 
0 2.133 
ILMN_2714031 Errfi1 Mus musculus ERBB receptor feedback inhibitor 1 
(Errfi1), mRNA. 
0 2.103 
ILMN_2665545 Rin3 Mus musculus Ras and Rab interactor 3 (Rin3), 
mRNA. 
0 2.08 
ILMN_1224842 LOC385068   0 2.076 
ILMN_1229082 Klhl21 Mus musculus kelch-like 21 (Drosophila) (Klhl21), 
mRNA. 
0 2.053 
ILMN_2452855 1110003O08Rik   0 2.029 
ILMN_2619697 B3gnt9 Mus musculus UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 9 (B3gnt9), mRNA. 
0 2.026 
ILMN_1255967 B430216N15Rik   0 2.022 
ILMN_1232396 Ear2 Mus musculus eosinophil-associated, ribonuclease A 
family, member 2 (Ear2), mRNA. 
0 2.022 
ILMN_2793062 Rasl11b Mus musculus RAS-like, family 11, member B 
(Rasl11b), mRNA. 
0 2.022 
ILMN_2733887 Mknk2 Mus musculus MAP kinase-interacting 
serine/threonine kinase 2 (Mknk2), mRNA. 
0 2.02 
ILMN_1260112 2400003C14Rik Mus musculus RIKEN cDNA 2400003C14 gene 
(2400003C14Rik), mRNA. 
0 2.004 
ILMN_2450735 Rn18s Mus musculus 18S RNA (Rn18s), non-coding RNA. 0 1.998 
ILMN_2947292 Map3k6 Mus musculus mitogen-activated protein kinase 
kinase kinase 6 (Map3k6), mRNA. 
0 1.996 
ILMN_2699621 Dlk2 Mus musculus delta-like 2 homolog (Drosophila) 
(Dlk2), mRNA. 
0 1.992 
ILMN_2420341 9629514_325   0 1.987 
ILMN_2765047 Chrd Mus musculus chordin (Chrd), mRNA. 0 1.975 
ILMN_2791272 Por Mus musculus P450 (cytochrome) oxidoreductase 
(Por), mRNA. 
0 1.964 
ILMN_2706819 Rasl11b Mus musculus RAS-like, family 11, member B 
(Rasl11b), mRNA. 
0 1.949 
ILMN_2763679 Sipa1l1 Mus musculus signal-induced proliferation-
associated 1 like 1 (Sipa1l1), mRNA. 
0 1.944 
ILMN_2772410 Anxa4   0.00009 1.942 
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ILMN_2445165 Vdr Mus musculus vitamin D receptor (Vdr), mRNA. 0 1.941 
ILMN_1218981 Aldh1a7 Mus musculus aldehyde dehydrogenase family 1, 
subfamily A7 (Aldh1a7), mRNA. 
0.00001 1.937 
ILMN_1252259 LOC384836   0 1.927 
ILMN_1232447 Por Mus musculus P450 (cytochrome) oxidoreductase 
(Por), mRNA. 
0 1.926 
ILMN_2473531 Pik3r1 Mus musculus phosphatidylinositol 3-kinase, 
regulatory subunit, polypeptide 1 (p85 alpha) 
(Pik3r1), transcript variant 1, mRNA. 
0 1.916 
ILMN_1213954 Sgk1 Mus musculus serum/glucocorticoid regulated 
kinase 1 (Sgk1), mRNA. 
0 1.916 
ILMN_2676052 Tef Mus musculus thyrotroph embryonic factor (Tef), 
transcript variant 1, mRNA. 
0 1.887 
ILMN_2653567 Rhoj Mus musculus ras homolog gene family, member J 
(Rhoj), mRNA. 
0 1.878 
ILMN_1237939 Prkrir Mus musculus protein-kinase, interferon-inducible 
double stranded RNA dependent inhibitor, repressor 
of (P58 repressor) (Prkrir), mRNA. 
0 1.875 
ILMN_2692615 Tgm2 Mus musculus transglutaminase 2, C polypeptide 
(Tgm2), mRNA. 
0 1.87 
ILMN_2447100 D15Mit260   0 1.865 
ILMN_2671601 Selk   0 1.85 
ILMN_2509988 Lbr   0 1.849 
ILMN_2464474 9430029L20Rik   0 1.846 
ILMN_1227465 9628654_5   0 1.845 
ILMN_1247916 Lims2 Mus musculus LIM and senescent cell antigen like 
domains 2 (Lims2), mRNA. 
0 1.827 
ILMN_2737713 Edn1 Mus musculus endothelin 1 (Edn1), mRNA. 0 1.825 
ILMN_2909782 Rras2 Mus musculus related RAS viral (r-ras) oncogene 
homolog 2 (Rras2), mRNA. 
0 1.814 
ILMN_2491125 Tbl1xr1 Mus musculus transducin (beta)-like 1X-linked 
receptor 1 (Tbl1xr1), mRNA. 
0 1.807 
ILMN_2544674 2310045K21Rik   0 1.804 
ILMN_2979237 Gsta1 Mus musculus glutathione S-transferase, alpha 1 
(Ya) (Gsta1), mRNA. 
0 1.79 
ILMN_2445166 Vdr Mus musculus vitamin D receptor (Vdr), mRNA. 0 1.771 
ILMN_2611180 Ccdc3   0 1.768 
ILMN_1241854 Lrrc59 Mus musculus leucine rich repeat containing 59 
(Lrrc59), mRNA. 
0 1.765 
ILMN_2675922 2310047A01Rik PREDICTED: Mus musculus RIKEN cDNA 
2310047A01 gene (2310047A01Rik), mRNA. 
0 1.763 
ILMN_1215275 Add1 Mus musculus adducin 1 (alpha) (Add1), transcript 
variant 1, mRNA. 
0 1.763 
ILMN_1256943 Ear3 Mus musculus eosinophil-associated, ribonuclease A 
family, member 3 (Ear3), mRNA. 
0.00098 1.759 
ILMN_1231096 2310036D22Rik   0.00064 1.755 
ILMN_2772632 Saa3 Mus musculus serum amyloid A 3 (Saa3), mRNA. 0 1.749 
ILMN_3114641 Pik3r1 Mus musculus phosphatidylinositol 3-kinase, 
regulatory subunit, polypeptide 1 (p85 alpha) 
(Pik3r1), transcript variant 2, mRNA. 
0 1.747 





ILMN_1226587 EG668300 PREDICTED: Mus musculus predicted gene, 
EG668300 (EG668300), mRNA. 
0.00001 1.736 
ILMN_2602597 Sh3rf1 Mus musculus SH3 domain containing ring finger 1 
(Sh3rf1), mRNA. 
0 1.733 
ILMN_2595359 Slc3a2 Mus musculus solute carrier family 3 (activators of 
dibasic and neutral amino acid transport), member 2 
(Slc3a2), mRNA. 
0.00005 1.727 
ILMN_2485408 9626962_3   0 1.727 
ILMN_2702039 Cblb Mus musculus Casitas B-lineage lymphoma b 
(Cblb), mRNA. XM_001003462 XM_001003472 
XM_001003476 XM_001003639 XM_001003649 
XM_156257 XM_902056 XM_902058 XM_917535 
XM_924994 XM_924996 
0 1.722 
ILMN_1226712 Ccdc134 Mus musculus coiled-coil domain containing 134 
(Ccdc134), mRNA. 
0 1.718 
ILMN_1224336 Spsb1 Mus musculus splA/ryanodine receptor domain and 
SOCS box containing 1 (Spsb1), mRNA. 
0 1.714 
ILMN_1216689 Aplp2 Mus musculus amyloid beta (A4) precursor-like 
protein 2 (Aplp2), transcript variant 3, mRNA. 
0 1.706 
ILMN_2742426 LOC100044204 PREDICTED: Mus musculus hypothetical protein 
LOC100044204 (LOC100044204), mRNA. 
0.00001 1.699 
ILMN_1259787 Osr1 Mus musculus odd-skipped related 1 (Drosophila) 
(Osr1), mRNA. 
0 1.697 
ILMN_2655577 Pold1 Mus musculus polymerase (DNA directed), delta 1, 
catalytic subunit (Pold1), mRNA. 
0 1.69 
ILMN_3009521 Foxred2 Mus musculus FAD-dependent oxidoreductase 
domain containing 2 (Foxred2), mRNA. 
0 1.689 
ILMN_1259355 Ccdc117 Mus musculus coiled-coil domain containing 117 
(Ccdc117), mRNA. 
0 1.687 
ILMN_2881272 Aifm1 Mus musculus apoptosis-inducing factor, 
mitochondrion-associated 1 (Aifm1), nuclear gene 
encoding mitochondrial protein, mRNA. 
0.00212 1.684 
ILMN_2669627 Vcan Mus musculus versican (Vcan), transcript variant 1, 
mRNA. 
0 1.683 
ILMN_2766455 Lrrc8d Mus musculus leucine rich repeat containing 8D 
(Lrrc8d), mRNA. 
0 1.681 
ILMN_2672190 Id1 Mus musculus inhibitor of DNA binding 1 (Id1), 
mRNA. 
0 1.68 
ILMN_1246800 Serpina3n Mus musculus serine (or cysteine) peptidase 
inhibitor, clade A, member 3N (Serpina3n), mRNA. 
0 1.678 
ILMN_2776922 Glrx1   0 1.674 
ILMN_2659063 Add1 Mus musculus adducin 1 (alpha) (Add1), transcript 
variant 2, mRNA. 
0 1.672 
ILMN_1254630 Ptpre Mus musculus protein tyrosine phosphatase, receptor 
type, E (Ptpre), mRNA. 
0 1.671 
ILMN_2712731 Phf10 Mus musculus PHD finger protein 10 (Phf10), 
mRNA. 
0 1.671 
ILMN_2636624 Slc10a6 Mus musculus solute carrier family 10 (sodium/bile 
acid cotransporter family), member 6 (Slc10a6), 
mRNA. 
0.00003 1.669 
ILMN_1223428 Eif3s8   0 1.668 
ILMN_1215969 Rcor1 Mus musculus REST corepressor 1 (Rcor1), mRNA. 0 1.664 
ILMN_1220173 Ppm2c Mus musculus protein phosphatase 2C, magnesium 
dependent, catalytic subunit (Ppm2c), nuclear gene 
encoding mitochondrial protein, transcript variant 1, 
mRNA. 
0 1.664 
ILMN_2663230 Slco3a1 Mus musculus solute carrier organic anion 0 1.658 
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transporter family, member 3a1 (Slco3a1), transcript 
variant 1, mRNA. 
ILMN_1236037 LOC627317 PREDICTED: Mus musculus similar to ribosomal 
protein L11 (LOC627317), misc RNA. 
0.00003 1.657 
ILMN_2764143 Scap Mus musculus SREBF chaperone (Scap), mRNA. 0 1.655 
ILMN_1225994 Vav2 Mus musculus vav 2 oncogene (Vav2), mRNA. 0 1.652 
ILMN_2752010 Mcm4 Mus musculus minichromosome maintenance 
deficient 4 homolog (S. cerevisiae) (Mcm4), mRNA. 
0 1.652 
ILMN_2502623 Zhx3 Mus musculus zinc fingers and homeoboxes 3 
(Zhx3), mRNA. 
0 1.649 
ILMN_3157399 Tead4 Mus musculus TEA domain family member 4 
(Tead4), transcript variant 2, mRNA. 
0 1.649 
ILMN_1215803 Slc38a4 Mus musculus solute carrier family 38, member 4 
(Slc38a4), mRNA. 
0.01414 1.649 
ILMN_2622605 Srr Mus musculus serine racemase (Srr), mRNA. 0.00715 1.647 
ILMN_1228919 St13 Mus musculus suppression of tumorigenicity 13 
(St13), mRNA. 
0 1.644 
ILMN_2748499 Fshprh1   0 1.643 
ILMN_2618745 Supv3l1 Mus musculus suppressor of var1, 3-like 1 (S. 
cerevisiae) (Supv3l1), mRNA. 
0 1.639 
ILMN_1225995 Morc2a Mus musculus microrchidia 2A (Morc2a), mRNA. 0 1.639 
ILMN_2842366 Mrpl2 Mus musculus mitochondrial ribosomal protein L2 
(Mrpl2), nuclear gene encoding mitochondrial 
protein, mRNA. 
0 1.638 
ILMN_1229416 1110034A24Rik   0.00006 1.637 
ILMN_2854943 Gprc5a Mus musculus G protein-coupled receptor, family C, 
group 5, member A (Gprc5a), mRNA. 
0 1.634 
ILMN_2682945 Psmd2 Mus musculus proteasome (prosome, macropain) 
26S subunit, non-ATPase, 2 (Psmd2), mRNA. 
0 1.633 
ILMN_2777535 LOC666053 PREDICTED: Mus musculus similar to protein 
tyrosine phosphatase-like protein PTPLB 
(LOC666053), misc RNA. 
0 1.631 
ILMN_1233813 Ss18 Mus musculus synovial sarcoma translocation, 
Chromosome 18 (Ss18), mRNA. 
0 1.629 
ILMN_1228942 Cd59a Mus musculus CD59a antigen (Cd59a), mRNA. 0.00023 1.625 
ILMN_2633777 Rab34 Mus musculus RAB34, member of RAS oncogene 
family (Rab34), mRNA. 
0 1.621 
ILMN_1240471 Retsat Mus musculus retinol saturase (all trans retinol 13,14 
reductase) (Retsat), mRNA. 
0 1.618 
ILMN_2885277 Nnmt Mus musculus nicotinamide N-methyltransferase 
(Nnmt), mRNA. 
0 1.614 
ILMN_1233129 Zbtb22 Mus musculus zinc finger and BTB domain 
containing 22 (Zbtb22), mRNA. 
0 1.61 
ILMN_1222071 C920004C08Rik   0 1.608 
ILMN_1221805 Dtna Mus musculus dystrobrevin alpha (Dtna), transcript 
variant 2, mRNA. 
0 1.607 
ILMN_2713055 Psca Mus musculus prostate stem cell antigen (Psca), 
mRNA. 
0 1.607 
ILMN_1218206 Klf13 Mus musculus Kruppel-like factor 13 (Klf13), 
mRNA. 
0 1.607 
ILMN_1230422 BC018507 PREDICTED: Mus musculus cDNA sequence 
BC018507, transcript variant 5 (BC018507), mRNA. 
0 1.596 





ILMN_3160881 Vrk3 Mus musculus vaccinia related kinase 3 (Vrk3), 
mRNA. 
0 1.595 
ILMN_1232055 9330175B01Rik   0 1.595 
ILMN_2971479 Trp53inp1 Mus musculus transformation related protein 53 
inducible nuclear protein 1 (Trp53inp1), mRNA. 
0.00004 1.594 
ILMN_2766930 Faah Mus musculus fatty acid amide hydrolase (Faah), 
mRNA. 
0 1.594 
ILMN_2588337 D930015E06Rik   0.00001 1.593 
ILMN_1220063 EG666668 PREDICTED: Mus musculus predicted gene, 
EG666668 (EG666668), mRNA. 
0 1.593 
ILMN_1230788 Tle1 Mus musculus transducin-like enhancer of split 1, 
homolog of Drosophila E(spl) (Tle1), mRNA. 
XM_984202 XM_984240 XM_984277 XM_984316 
XM_984359 XM_984397 XM_984426 XM_984456 
XM_984492 XM_984530 
0 1.593 
ILMN_1224014 Tmem100 Mus musculus transmembrane protein 100 
(Tmem100), mRNA. 
0 1.591 
ILMN_1224250 B230342M21Rik Mus musculus RIKEN cDNA B230342M21 gene 
(B230342M21Rik), mRNA. 
0 1.591 
ILMN_1228557 Id2 Mus musculus inhibitor of DNA binding 2 (Id2), 
mRNA. 
0.00003 1.59 
ILMN_2648937 Pdzrn3 Mus musculus PDZ domain containing RING finger 
3 (Pdzrn3), mRNA. 
0.00092 1.589 
ILMN_2602821 Cdk5rap1 Mus musculus CDK5 regulatory subunit associated 
protein 1 (Cdk5rap1), mRNA. 
0 1.582 
ILMN_2682947 Psmd2 Mus musculus proteasome (prosome, macropain) 
26S subunit, non-ATPase, 2 (Psmd2), mRNA. 
0 1.582 
ILMN_2533916 LOC380655   0 1.581 
ILMN_2595732 LOC100046232 PREDICTED: Mus musculus similar to 
NFIL3/E4BP4 transcription factor 
(LOC100046232), mRNA. 
0 1.581 
ILMN_2707452 Ebf1 Mus musculus early B-cell factor 1 (Ebf1), mRNA. 0 1.579 
ILMN_1228245 Prickle1 Mus musculus prickle like 1 (Drosophila) (Prickle1), 
mRNA. 
0 1.578 
ILMN_2944646 Cope Mus musculus coatomer protein complex, subunit 
epsilon (Cope), mRNA. 
0 1.578 
ILMN_2619594 Il11ra1 Mus musculus interleukin 11 receptor, alpha chain 1 
(Il11ra1), mRNA. 
0 1.577 
ILMN_2515081 Trim59 Mus musculus tripartite motif-containing 59 
(Trim59), mRNA. 
0 1.576 
ILMN_1243908 Sh3gl1 Mus musculus SH3-domain GRB2-like 1 (Sh3gl1), 
mRNA. 
0 1.576 
ILMN_2698430 Bcl2l1 Mus musculus BCL2-like 1 (Bcl2l1), nuclear gene 
encoding mitochondrial protein, mRNA. 
0 1.575 
ILMN_2490548 Tspan4 Mus musculus tetraspanin 4 (Tspan4), mRNA. 0 1.574 
ILMN_2881263 Aifm1 Mus musculus apoptosis-inducing factor, 
mitochondrion-associated 1 (Aifm1), nuclear gene 
encoding mitochondrial protein, mRNA. 
0 1.573 
ILMN_2955806 Arfip2 Mus musculus ADP-ribosylation factor interacting 
protein 2 (Arfip2), mRNA. 
0 1.572 
ILMN_2461582 4732460K03Rik PREDICTED: Mus musculus RIKEN cDNA 
4732460K03 gene, transcript variant 1 
(4732460K03Rik), mRNA. 
0 1.571 
ILMN_2704619 Cc2d2a Mus musculus coiled-coil and C2 domain containing 
2A (Cc2d2a), mRNA. 
0 1.571 





ILMN_2636832 Cyb5r3 Mus musculus cytochrome b5 reductase 3 (Cyb5r3), 
mRNA. 
0 1.57 
ILMN_2774646 Myd88   0 1.569 
ILMN_2644845 Trmt6 Mus musculus tRNA methyltransferase 6 homolog 
(S. cerevisiae) (Trmt6), mRNA. 
0 1.569 
ILMN_2631097 Msh6 Mus musculus mutS homolog 6 (E. coli) (Msh6), 
mRNA. 
0 1.568 
ILMN_2687032 Fbxo31 Mus musculus F-box protein 31 (Fbxo31), mRNA. 0 1.567 
ILMN_2811705 Fbxo18 Mus musculus F-box protein 18 (Fbxo18), mRNA. 0.00018 1.567 
ILMN_2776585 Slc1a5 Mus musculus solute carrier family 1 (neutral amino 
acid transporter), member 5 (Slc1a5), mRNA. 
0.00002 1.564 
ILMN_2511971 Whsc1l1 Mus musculus Wolf-Hirschhorn syndrome candidate 





  0 1.563 
ILMN_1257501 Pet112l Mus musculus PET112-like (yeast) (Pet112l), 
mRNA. 
0.00002 1.559 
ILMN_2982200 Mrpl13 Mus musculus mitochondrial ribosomal protein L13 
(Mrpl13), mRNA. 
0 1.559 
ILMN_2473620 Rsn   0 1.558 
ILMN_2764205 Tor1a Mus musculus torsin family 1, member A (torsin A) 
(Tor1a), mRNA. 
0 1.557 
ILMN_2644920 Plekhf1 Mus musculus pleckstrin homology domain 
containing, family F (with FYVE domain) member 1 
(Plekhf1), mRNA. 
0 1.556 
ILMN_2489314 2500002G23Rik   0 1.555 
ILMN_3134632 Adam22 Mus musculus a disintegrin and metallopeptidase 
domain 22 (Adam22), transcript variant 1, mRNA. 
0 1.553 
ILMN_2448651 Ampd3 Mus musculus adenosine monophosphate deaminase 
3 (Ampd3), mRNA. 
0 1.551 
ILMN_2762326 Kif22 Mus musculus kinesin family member 22 (Kif22), 
mRNA. 
0 1.551 
ILMN_1250036 Tmem201 Mus musculus transmembrane protein 201 
(Tmem201), transcript variant 1, mRNA. 
0 1.549 
ILMN_3162452 Ppm2c Mus musculus protein phosphatase 2C, magnesium 
dependent, catalytic subunit (Ppm2c), nuclear gene 
encoding mitochondrial protein, transcript variant 1, 
mRNA. 
0 1.548 
ILMN_2819530 D15Ertd682e Mus musculus DNA segment, Chr 15, ERATO Doi 
682, expressed (D15Ertd682e), mRNA. 
0 1.548 
ILMN_2547078 Zc3h13 Mus musculus zinc finger CCCH type containing 13 
(Zc3h13), mRNA. 
0.00001 1.547 
ILMN_2845839 1700065O13Rik Mus musculus RIKEN cDNA 1700065O13 gene 
(1700065O13Rik), mRNA. 
0.00053 1.547 
ILMN_3156010 Pdzrn3 Mus musculus PDZ domain containing RING finger 
3 (Pdzrn3), mRNA. 
0 1.545 
ILMN_1254927 Ly6c1 Mus musculus lymphocyte antigen 6 complex, locus 
C1 (Ly6c1), mRNA. 
0 1.544 
ILMN_3023230 Jmjd3 Mus musculus jumonji domain containing 3 (Jmjd3), 
mRNA. 
0 1.544 
ILMN_2631098 Msh6 Mus musculus mutS homolog 6 (E. coli) (Msh6), 
mRNA. 
0 1.543 
ILMN_2861176 Calr Mus musculus calreticulin (Calr), mRNA. 0 1.542 





ILMN_2496817 Ulk2 Mus musculus Unc-51 like kinase 2 (C. elegans) 
(Ulk2), mRNA. 
0 1.539 
ILMN_1222872 Wbscr16 Mus musculus Williams-Beuren syndrome 
chromosome region 16 homolog (human) 
(Wbscr16), mRNA. 
0 1.539 
ILMN_2631192 Vps26b Mus musculus vacuolar protein sorting 26 homolog 
B (yeast) (Vps26b), mRNA. 
0 1.539 
ILMN_1222356 1110067D22Rik Mus musculus RIKEN cDNA 1110067D22 gene 
(1110067D22Rik), mRNA. 
0 1.538 
ILMN_1243564 Plekha1 Mus musculus pleckstrin homology domain 
containing, family A (phosphoinositide binding 
specific) member 1 (Plekha1), mRNA. 
0 1.538 
ILMN_2455637 Top1mt Mus musculus DNA topoisomerase 1, mitochondrial 
(Top1mt), nuclear gene encoding mitochondrial 
protein, mRNA. 
0 1.538 
ILMN_2709681 Hdlbp Mus musculus high density lipoprotein (HDL) 
binding protein (Hdlbp), mRNA. 
0 1.537 
ILMN_1238179 Ipmk Mus musculus inositol polyphosphate multikinase 
(Ipmk), mRNA. 
0 1.537 
ILMN_2422333 Trap1 Mus musculus TNF receptor-associated protein 1 
(Trap1), mRNA. 
0.00029 1.537 
ILMN_2971721 2410025L10Rik Mus musculus RIKEN cDNA 2410025L10 gene 
(2410025L10Rik), mRNA. 
0 1.535 
ILMN_1216116 Smarcd2 Mus musculus SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, subfamily d, 
member 2 (Smarcd2), mRNA. 
0 1.533 
ILMN_3051252 BC026590 Mus musculus cDNA sequence BC026590 
(BC026590), mRNA. 
0 1.533 
ILMN_1233283 P2rx5 Mus musculus purinergic receptor P2X, ligand-gated 
ion channel, 5 (P2rx5), mRNA. 
0 1.533 
ILMN_1217144 Tbc1d5 Mus musculus TBC1 domain family, member 5 
(Tbc1d5), mRNA. 
0 1.532 
ILMN_2599412 Kti12 Mus musculus KTI12 homolog, chromatin 
associated (S. cerevisiae) (Kti12), mRNA. 
0 1.531 
ILMN_2933399 Ppp1r10 Mus musculus protein phosphatase 1, regulatory 
subunit 10 (Ppp1r10), mRNA. 
0 1.53 
ILMN_1228501 Tob2 Mus musculus transducer of ERBB2, 2 (Tob2), 
mRNA. 
0 1.526 
ILMN_2497581 Uhrf1 Mus musculus ubiquitin-like, containing PHD and 
RING finger domains, 1 (Uhrf1), mRNA. 
0.0001 1.526 
ILMN_2439341 Vars Mus musculus valyl-tRNA synthetase (Vars), 
nuclear gene encoding mitochondrial protein, 
mRNA. 
0 1.526 
ILMN_2647885 Bcl2l1 Mus musculus BCL2-like 1 (Bcl2l1), nuclear gene 
encoding mitochondrial protein, mRNA. 
0.00001 1.524 
ILMN_1243179 Sec24d Mus musculus Sec24 related gene family, member D 
(S. cerevisiae) (Sec24d), mRNA. 
0 1.523 
ILMN_1234112 Tomm70a Mus musculus translocase of outer mitochondrial 
membrane 70 homolog A (yeast) (Tomm70a), 
mRNA. 
0 1.523 
ILMN_1214918 LOC546015 PREDICTED: Mus musculus similar to ribosomal 
protein S9 (LOC546015), misc RNA. 
0 1.522 
ILMN_2678714 Id4 Mus musculus inhibitor of DNA binding 4 (Id4), 
mRNA. 
0.00015 1.52 
ILMN_2443831 Uba1 Mus musculus ubiquitin-like modifier activating 
enzyme 1 (Uba1), mRNA. 
0.00003 1.519 
ILMN_1252450 LOC380707   0 1.519 
ILMN_2727309 LOC100044204 PREDICTED: Mus musculus hypothetical protein 




ILMN_2677567 Galt Mus musculus galactose-1-phosphate uridyl 
transferase (Galt), mRNA. 
0 1.514 
ILMN_2599018 Clic4 Mus musculus chloride intracellular channel 4 
(mitochondrial) (Clic4), nuclear gene encoding 
mitochondrial protein, mRNA. 
0 1.513 
ILMN_2820379 Rnf135 Mus musculus ring finger protein 135 (Rnf135), 
mRNA. 
0 1.511 
ILMN_1249269 5830457O10Rik Mus musculus RIKEN cDNA 5830457O10 gene 
(5830457O10Rik), mRNA. 
0 1.511 
ILMN_2985111 Chfr Mus musculus checkpoint with forkhead and ring 
finger domains (Chfr), mRNA. 
0 1.51 
ILMN_1243679 Cep55 Mus musculus centrosomal protein 55 (Cep55), 
mRNA. 
0.00004 1.51 
ILMN_2746328 BC003993 Mus musculus cDNA sequence BC003993 
(BC003993), mRNA. 
0.00044 1.509 
ILMN_2789239 Tgfbr3 Mus musculus transforming growth factor, beta 
receptor III (Tgfbr3), mRNA. 
0 1.509 
ILMN_2773862 C730025P13Rik Mus musculus RIKEN cDNA C730025P13 gene 
(C730025P13Rik), mRNA. 
0 1.509 
ILMN_2794686 Fam152b Mus musculus family with sequence similarity 152, 
member B (Fam152b), mRNA. 
0 1.509 
ILMN_2761169 3110050N22Rik   0.00048 1.508 
ILMN_2589181 Eef2 Mus musculus eukaryotic translation elongation 
factor 2 (Eef2), mRNA. 
0 1.508 
ILMN_2515982 Ugt1a6b Mus musculus UDP glucuronosyltransferase 1 
family, polypeptide A6B (Ugt1a6b), mRNA. 
0 1.508 
ILMN_1225363 E430025E21Rik Mus musculus RIKEN cDNA E430025E21 gene 
(E430025E21Rik), mRNA. 
0 1.507 
ILMN_2695150 Smc5l1   0.00235 1.505 
ILMN_1223015 Dedd2 Mus musculus death effector domain-containing 
DNA binding protein 2 (Dedd2), mRNA. 
0 1.504 
ILMN_2678019 Psmd8 Mus musculus proteasome (prosome, macropain) 
26S subunit, non-ATPase, 8 (Psmd8), mRNA. 
XM_001002011 
0 1.504 
ILMN_1257117 Nol14 Mus musculus nucleolar protein 14 (Nol14), mRNA. 0 1.504 
ILMN_2773540 Thap4 Mus musculus THAP domain containing 4 (Thap4), 
mRNA. 
0 1.501 
ILMN_2724469 4732473B16Rik Mus musculus RIKEN cDNA 4732473B16 gene 
(4732473B16Rik), mRNA. 
0.0001 1.501 


















Supplemental Table 4.6. Complete list of genes downregulated by 4h of T3 plus CORT 
treatment in HT-22 cells.  
PROBE ID SYMBOL DEFINITION P value Fold 
change 
ILMN_2754985 Phlda1 Mus musculus pleckstrin homology-like domain, family 
A, member 1 (Phlda1), mRNA. 
0 
-2.883 




ILMN_2771176 Ccl7   0 
-2.687 




ILMN_2660233 Ngfb Mus musculus nerve growth factor, beta (Ngfb), mRNA. 0 
-2.653 




  0 
-2.259 
ILMN_1253178 Aldh3a1 Mus musculus aldehyde dehydrogenase family 3, 
subfamily A1 (Aldh3a1), mRNA. 
0 
-2.244 
ILMN_2662926 Egr1 Mus musculus early growth response 1 (Egr1), mRNA. 0 
-2.137 
ILMN_2833706 Fgf7 Mus musculus fibroblast growth factor 7 (Fgf7), mRNA. 0 
-2.124 




ILMN_2759365 Angptl4 Mus musculus angiopoietin-like 4 (Angptl4), mRNA. 0 
-2.099 
ILMN_2752569 Paip1 Mus musculus polyadenylate binding protein-interacting 
protein 1 (Paip1), transcript variant 1, mRNA. 
0 
-2.068 
ILMN_2794645 Cyr61 Mus musculus cysteine rich protein 61 (Cyr61), mRNA. 0.00002 
-2.044 
















  0.00001 
-1.993 




ILMN_2710253 Cyr61 Mus musculus cysteine rich protein 61 (Cyr61), mRNA. 0 
-1.94 












ILMN_2623793 Zfhx3 Mus musculus zinc finger homeobox 3 (Zfhx3), mRNA. 0 
-1.821 
ILMN_1255925 Col8a1   0 
-1.813 






  0 
-1.783 
ILMN_2511089 Ugcg   0 
-1.776 






ILMN_2840091 Ugcg Mus musculus UDP-glucose ceramide 





  0 
-1.736 




ILMN_1232716 Cyp1b1 Mus musculus cytochrome P450, family 1, subfamily b, 
polypeptide 1 (Cyp1b1), mRNA. 
0 
-1.735 
ILMN_2683593 Fubp1   0 
-1.731 
ILMN_2734755 Col4a5   0 
-1.724 
ILMN_2937136 Tceal1 Mus musculus transcription elongation factor A (SII)-like 
1 (Tceal1), mRNA. 
0 
-1.72 






PREDICTED: Mus musculus similar to LPS-induced 





  0.00002 
-1.689 




ILMN_2434853 mtDNA_ND2   0 
-1.68 
ILMN_1217489 LOC671878 PREDICTED: Mus musculus similar to spermine 













ILMN_1220813 Dtx3l Mus musculus deltex 3-like (Drosophila) (Dtx3l), mRNA. 0 
-1.661 
ILMN_3115472 Aqp5 Mus musculus aquaporin 5 (Aqp5), mRNA. 0 
-1.659 
ILMN_1222584 Sfrs11 Mus musculus splicing factor, arginine/serine-rich 11 

















ILMN_2657911 Cnot4 Mus musculus CCR4-NOT transcription complex, 
subunit 4 (Cnot4), mRNA. 
0 
-1.652 
ILMN_2816180 Lbh Mus musculus limb-bud and heart (Lbh), mRNA. 0 
-1.649 
ILMN_2550570 Fibp   0.00365 
-1.647 
ILMN_2868220 Inhba Mus musculus inhibin beta-A (Inhba), mRNA. 0 
-1.647 
ILMN_2742599 Nfix Mus musculus nuclear factor I/X (Nfix), transcript variant 
2, mRNA. XM_921228 XM_921240 XM_921250 
XM_921261 XM_921270 XM_921288 XM_921293 
XM_921299 XM_921300 XM_921307 
0 
-1.644 






  0 
-1.64 














ILMN_2507810 mtDNA_ND5   0 
-1.635 










  0 
-1.626 
ILMN_2775937 Plat   0 
-1.624 




ILMN_2640862 Lrig1 Mus musculus leucine-rich repeats and immunoglobulin-
like domains 1 (Lrig1), mRNA. 
0 
-1.622 
ILMN_1232741 Fdps   0.00235 
-1.621 
ILMN_1236123 Tomm6 Mus musculus translocase of outer mitochondrial 
membrane 6 homolog (yeast) (Tomm6), nuclear gene 
encoding mitochondrial protein, mRNA. 
0 
-1.62 
ILMN_2972478 Nlgn2 Mus musculus neuroligin 2 (Nlgn2), mRNA. 0 
-1.62 
ILMN_2643241 Accn2 Mus musculus amiloride-sensitive cation channel 2, 
neuronal (Accn2), mRNA. 
0 
-1.62 
ILMN_2696592 C77080   0 
-1.619 
ILMN_2848463 Mthfsd Mus musculus methenyltetrahydrofolate synthetase 
domain containing (Mthfsd), mRNA. 
0.00004 
-1.619 
ILMN_1230152 Adamts4   0 
-1.618 




ILMN_1259905 Sfrs11 Mus musculus splicing factor, arginine/serine-rich 11 
(Sfrs11), transcript variant 1, mRNA. 
0 
-1.615 




ILMN_2965660 Apcdd1 Mus musculus adenomatosis polyposis coli down-
regulated 1 (Apcdd1), mRNA. 
0 
-1.601 






PREDICTED: Mus musculus RIKEN cDNA 
A930002H24 gene (A930002H24Rik), mRNA. 
0 
-1.599 
ILMN_2760979 Tgfbr2 Mus musculus transforming growth factor, beta receptor 
II (Tgfbr2), transcript variant 1, mRNA. 
0 
-1.597 












ILMN_2623776 Eps8 Mus musculus epidermal growth factor receptor pathway 
substrate 8 (Eps8), mRNA. 
0 
-1.59 








ILMN_1213376 Cfl1 Mus musculus cofilin 1, non-muscle (Cfl1), mRNA. 0 
-1.586 








21 LOC100043821 (LOC100043821), mRNA. 




ILMN_1213322 Chd2 Mus musculus chromodomain helicase DNA binding 
protein 2 (Chd2), mRNA. 
0 
-1.58 
ILMN_3131887 Spag9 Mus musculus sperm associated antigen 9 (Spag9), 





  0 
-1.572 
ILMN_2819841 Rpl7a Mus musculus ribosomal protein L7a (Rpl7a), mRNA. 0 
-1.57 
ILMN_1229193 Msn   0 
-1.569 
ILMN_2495703 Clip2 Mus musculus CAP-GLY domain containing linker 





PREDICTED: Mus musculus similar to Deltex3 
(LOC100045005), misc RNA. 
0 
-1.568 
ILMN_1234412 LOC674427 PREDICTED: Mus musculus similar to ribosomal protein 
L7a (LOC674427), misc RNA. 
0 
-1.566 
ILMN_2942989 Mtpn Mus musculus myotrophin (Mtpn), mRNA. 0 
-1.566 




ILMN_1246841 Relb Mus musculus avian reticuloendotheliosis viral (v-rel) 
oncogene related B (Relb), mRNA. 
0 
-1.562 




ILMN_2617265 Ipo13 Mus musculus importin 13 (Ipo13), mRNA. 0 
-1.555 




ILMN_2757870 Psmb10 Mus musculus proteasome (prosome, macropain) subunit, 
beta type 10 (Psmb10), mRNA. 
0 
-1.55 




ILMN_1219807 Hoxd4 Mus musculus homeo box D4 (Hoxd4), mRNA. 0.00081 
-1.548 








ILMN_2747381 Ddx24 Mus musculus DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 24 (Ddx24), mRNA. 
0 
-1.542 
ILMN_1235173 LOC386218   0 
-1.54 








ILMN_3153753 Cacnb3 Mus musculus calcium channel, voltage-dependent, beta 
3 subunit (Cacnb3), transcript variant 1, mRNA. 
0 
-1.534 










ILMN_2758073 Dmtf1 Mus musculus cyclin D binding myb-like transcription 
factor 1 (Dmtf1), mRNA. 
0 
-1.53 
ILMN_2625351 Sh3bgrl3 Mus musculus SH3 domain binding glutamic acid-rich 
protein-like 3 (Sh3bgrl3), mRNA. 
0 
-1.529 
ILMN_2440530 Vat1 Mus musculus vesicle amine transport protein 1 homolog 









ILMN_1216764 Ier3 Mus musculus immediate early response 3 (Ier3), mRNA. 0 
-1.526 
ILMN_1249547 Zfp292 PREDICTED: Mus musculus zinc finger protein 292, 
transcript variant 4 (Zfp292), mRNA. 
0 
-1.525 










  0.00001 
-1.523 
ILMN_2974720 Igf2bp2 Mus musculus insulin-like growth factor 2 mRNA 
binding protein 2 (Igf2bp2), mRNA. 
0 
-1.523 
ILMN_2629601 Slc4a7   0 
-1.521 




ILMN_2520249 Hspg2   0 
-1.52 








ILMN_1259610 Cd276 Mus musculus CD276 antigen (Cd276), mRNA. 0 
-1.519 
ILMN_2768053 Supt16h Mus musculus suppressor of Ty 16 homolog (S. 
cerevisiae) (Supt16h), mRNA. 
0.0001 
-1.518 




ILMN_2424299 Tnfrsf12a Mus musculus tumor necrosis factor receptor 
superfamily, member 12a (Tnfrsf12a), mRNA. 
0 
-1.517 
ILMN_1235732 Cdsn Mus musculus corneodesmosin (Cdsn), mRNA. 0 
-1.514 
ILMN_1247823 Lrp8 Mus musculus low density lipoprotein receptor-related 
protein 8, apolipoprotein e receptor (Lrp8), transcript 
variant 2, mRNA. 
0 
-1.514 
ILMN_2825803 Parp14 Mus musculus poly (ADP-ribose) polymerase family, 










  0 
-1.51 




ILMN_2778151 Sox9   0 
-1.506 
ILMN_1225373 C1qbp Mus musculus complement component 1, q 
subcomponent binding protein (C1qbp), nuclear gene 
encoding mitochondrial protein, mRNA. 
0 
-1.505 








ILMN_2731057 Psme2 Mus musculus proteasome (prosome, macropain) 28 
subunit, beta (Psme2), transcript variant 1, mRNA. 
0 
-1.504 








Supplemental Table 4.7. T3 regulated genes that are found in the thyroid hormone 
and thyroid hormone receptor interaction pathway generated by the Ingenuity 
knowledge base (Illimuna) 
 




Mus musculus chromodomain helicase 
DNA binding protein 4 (Chd4), mRNA. 
0.0072 -1.49 
ILMN_1259322 Pdk4 
Mus musculus pyruvate dehydrogenase 
kinase, isoenzyme 4 (Pdk4), mRNA. 
0 -1.31 
ILMN_1233064 Cdk2 
Mus musculus cyclin-dependent kinase 2 
(Cdk2), transcript variant 1, mRNA. 
0.00158 -1.29 
ILMN_2819841 Rpl7a 




Mus musculus K(lysine) acetyltransferase 
2B (Kat2b), mRNA. 
0.00415 -1.25 
ILMN_2846775 Cdkn1a 
Mus musculus cyclin-dependent kinase 






Mus musculus P450 (cytochrome) 
oxidoreductase (Por), mRNA. 
0.00043 1.26 
ILMN_2976191 Stat5a 
Mus musculus signal transducer and 































Supplemental Table 4.8. CORT regulated genes that are found in the glucocorticoid 
and glucocorticoid receptor interaction pathway generated by the Ingenuity 












Mus musculus aldehyde dehydrogenase family 3, 
subfamily A1 (Aldh3a1), mRNA. 
0 -2.01 
ILMN_2840091 Ugcg 
Mus musculus UDP-glucose ceramide 
glucosyltransferase (Ugcg), mRNA. 
0 -1.72 
ILMN_2479290 Fas 
Mus musculus Fas (TNF receptor superfamily 
member 6) (Fas), mRNA. 
0 -1.71 
ILMN_3122961 Gbp2 




Mus musculus pleckstrin homology domain 
containing, family F (with FYVE domain) member 1 
(Plekhf1), mRNA. 
0 1.65 
ILMN_2764143 Scap Mus musculus SREBF chaperone (Scap), mRNA. 0 1.67 
ILMN_1241610 Adrb2 




Mus musculus suppression of tumorigenicity 13 
(St13), mRNA. 
0 1.74 
ILMN_2737713 Edn1 Mus musculus endothelin 1 (Edn1), mRNA. 0 1.86 
ILMN_1213954 Sgk1 
Mus musculus serum/glucocorticoid regulated kinase 
1 (Sgk1), mRNA. 
0 1.92 
ILMN_2733887 Mknk2 
Mus musculus MAP kinase-interacting 
serine/threonine kinase 2 (Mknk2), mRNA. 
0 2.18 
ILMN_2718266 Fkbp5 












Mus musculus period homolog 1 (Drosophila) 
(Per1), mRNA. 
0 3.06 
ILMN_1219154 Mt2 Mus musculus metallothionein 2 (Mt2), mRNA. 0 3.4 












Supplemental Table 5.1. The X. laevis TrβΑ promoter divided into seven segments for analysis, and 
location of GC-rich sequences.  
________________________________________________________________________  













D) -432/-266 No GC box  
gctgtaacatgccatagtcattatttagtgggctggtggggagctgagtgggtccttgtgtacttggaatgccagggcctattttga  
atcccagtccagacctgcagacacacacaaacccccaatcctgcaactgccccacagcccttatgggtcttcactcaggc  














GC boxes are indicated in boldtype capitals. TRE half sites are boldtype lowercase underlined. The transcription 
start site is the capital, boldtype, shaded ‘G’ in fragment F (based on 58). Genbank Accession # U04675. 
